{"docstore/data": {"b7c79611-c6bb-45cf-83e5-a5be2f4daafb": {"__data__": {"id_": "b7c79611-c6bb-45cf-83e5-a5be2f4daafb", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n20-May -2020  \nMcKesson Corp.   (MCK ) \nQ4 2020 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n20-May -2020  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f04ed7c-eb87-47e3-a52f-ff5878599c6f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de3e1eedd43b29775f30bdb76e80679bb618e2d131646ff1cef383fa14105d61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7eb581cb-a932-4cd0-8fe2-bda5a78fb20b", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n20-May -2020  \nMcKesson Corp.   (MCK ) \nQ4 2020 Earnings Call    ", "original_text": "(MCK ) \nQ4 2020 Earnings Call    "}, "hash": "4725bdac0325d931a56dbe2de711131db46fcb4504171c0ac71a1d340ecb5024", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n20-May -2020  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7eb581cb-a932-4cd0-8fe2-bda5a78fb20b": {"__data__": {"id_": "7eb581cb-a932-4cd0-8fe2-bda5a78fb20b", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n20-May -2020  \nMcKesson Corp.   (MCK ) \nQ4 2020 Earnings Call    ", "original_text": "(MCK ) \nQ4 2020 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f04ed7c-eb87-47e3-a52f-ff5878599c6f", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de3e1eedd43b29775f30bdb76e80679bb618e2d131646ff1cef383fa14105d61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7c79611-c6bb-45cf-83e5-a5be2f4daafb", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n20-May -2020  \nMcKesson Corp.   (MCK ) \nQ4 2020 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n20-May -2020  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "049e9e165a206257a7e9ed23e9d061ad4b8d3e0db6d3f5d99301f7ac7a01bf2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c89c7fd-c275-4d4f-8d5e-77a1634e7979", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "6b93ead48bb721466bfda53acb77ec8a7629ed926f1b255170d556e1b392b0dc", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call    ", "start_char_idx": 166, "end_char_idx": 199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c89c7fd-c275-4d4f-8d5e-77a1634e7979": {"__data__": {"id_": "6c89c7fd-c275-4d4f-8d5e-77a1634e7979", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0301edfe5ad2a10ad324522d7f7f1613acfc254c83cf1d77e1b1f46fab9d9419", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7eb581cb-a932-4cd0-8fe2-bda5a78fb20b", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n20-May -2020  \nMcKesson Corp.   (MCK ) \nQ4 2020 Earnings Call    ", "original_text": "(MCK ) \nQ4 2020 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e6f652bce99428d5820d6741626f7d569b7c306431c96f2f10785638f46a576", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b01e0b1-88b6-456b-b1d0-8259df38a901", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n"}, "hash": "3e08bddeb5bdae41f8ba1242dcb4bb26964e6cc9bfda53092a9af289f1c9b0bd", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b01e0b1-88b6-456b-b1d0-8259df38a901": {"__data__": {"id_": "1b01e0b1-88b6-456b-b1d0-8259df38a901", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0301edfe5ad2a10ad324522d7f7f1613acfc254c83cf1d77e1b1f46fab9d9419", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c89c7fd-c275-4d4f-8d5e-77a1634e7979", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5c6d6261cf341be62f8edcdee49d6ef26d0260cc60052f1f34644fb2c665d06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba6ca4ba-1d79-4842-8103-6af0fb3f2e59", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "5a1da18844b9a09364c9fdd2296e4aa124c8fab0b1ad2a3335f9b35d992b736d", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba6ca4ba-1d79-4842-8103-6af0fb3f2e59": {"__data__": {"id_": "ba6ca4ba-1d79-4842-8103-6af0fb3f2e59", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0301edfe5ad2a10ad324522d7f7f1613acfc254c83cf1d77e1b1f46fab9d9419", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b01e0b1-88b6-456b-b1d0-8259df38a901", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b0025790e3221d55a4b65b624c5cb003dfa5dcc4ee72763c836f4a0cd0f79cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2f3facc-2575-456d-bffa-026d8e805347", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n "}, "hash": "71759cc3c037acce4313c99d3cd56066e567edd693906fb34e23f83234ba7b12", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 283, "end_char_idx": 352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2f3facc-2575-456d-bffa-026d8e805347": {"__data__": {"id_": "d2f3facc-2575-456d-bffa-026d8e805347", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0301edfe5ad2a10ad324522d7f7f1613acfc254c83cf1d77e1b1f46fab9d9419", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba6ca4ba-1d79-4842-8103-6af0fb3f2e59", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94f0bded5c7e948da54faaa8f010514bef819fa70e2e0f97bced879667573abd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75c002fc-ed2f-4cb1-a04e-c1b143ed5df7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "54a5928c35b63a76d3b3a629e28f5555c0eb0f79f892204098d4dc06179ca343", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "start_char_idx": 352, "end_char_idx": 442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75c002fc-ed2f-4cb1-a04e-c1b143ed5df7": {"__data__": {"id_": "75c002fc-ed2f-4cb1-a04e-c1b143ed5df7", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0301edfe5ad2a10ad324522d7f7f1613acfc254c83cf1d77e1b1f46fab9d9419", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2f3facc-2575-456d-bffa-026d8e805347", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d699fd833b0b66bd7c2adcb93d1243f1714f9481a213454ca2a3f872d3b2f277", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae3c70d5-727f-4581-8ede-05ed486b3cb5", "node_type": "1", "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n"}, "hash": "9dd96812bd760fb7626253e04931f0e319afb53adf358f887e45b2e1b1ce291e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 442, "end_char_idx": 844, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae3c70d5-727f-4581-8ede-05ed486b3cb5": {"__data__": {"id_": "ae3c70d5-727f-4581-8ede-05ed486b3cb5", "embedding": null, "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0301edfe5ad2a10ad324522d7f7f1613acfc254c83cf1d77e1b1f46fab9d9419", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75c002fc-ed2f-4cb1-a04e-c1b143ed5df7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e15bc50cb5129440523e1e7117ceaa8d5ad2d2c0525a92e91264db49a924881", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe025f49-d8d5-439b-bf5d-ef2be25c9906", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n"}, "hash": "f70b29625921d70bb5846bbcc11ee2c63f862909aee6ee46d140f0ddf5e9fffa", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "start_char_idx": 844, "end_char_idx": 911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe025f49-d8d5-439b-bf5d-ef2be25c9906": {"__data__": {"id_": "fe025f49-d8d5-439b-bf5d-ef2be25c9906", "embedding": null, "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0301edfe5ad2a10ad324522d7f7f1613acfc254c83cf1d77e1b1f46fab9d9419", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae3c70d5-727f-4581-8ede-05ed486b3cb5", "node_type": "1", "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a17c13d7f9fd1346dd4cc9ea4cb61ea8339579c568ede4a3e656bfd5c5a6d869", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbfeb5f4-0307-4c08-9f5b-6b0b5df52191", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "91d46f46a20b245c15c43373940ff9f37aaf552289b46734430e1c98606e2c01", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "start_char_idx": 911, "end_char_idx": 1156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbfeb5f4-0307-4c08-9f5b-6b0b5df52191": {"__data__": {"id_": "cbfeb5f4-0307-4c08-9f5b-6b0b5df52191", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0301edfe5ad2a10ad324522d7f7f1613acfc254c83cf1d77e1b1f46fab9d9419", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe025f49-d8d5-439b-bf5d-ef2be25c9906", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b0990be691034c20f4c2189d11477061b29484d4610b3229ee6454ed91f959e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7ae38a6-0baf-48ec-a00b-75d539f5994a", "node_type": "1", "metadata": {"window": "LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  "}, "hash": "dd4202a862497bafe01436103bd68730017a420ce4e091e1b18c3ab4d4e91cf3", "class_name": "RelatedNodeInfo"}}, "text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 1156, "end_char_idx": 1208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7ae38a6-0baf-48ec-a00b-75d539f5994a": {"__data__": {"id_": "f7ae38a6-0baf-48ec-a00b-75d539f5994a", "embedding": null, "metadata": {"window": "LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0301edfe5ad2a10ad324522d7f7f1613acfc254c83cf1d77e1b1f46fab9d9419", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbfeb5f4-0307-4c08-9f5b-6b0b5df52191", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "931bf916722b21055a386c1bb87236bd45333eeda39234d9a65494d27ef00969", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71382120-b4fe-48f5-9778-c2dfffe2bcb2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss. ", "original_text": "McKesson Corp.  "}, "hash": "40933ae14387e6dc8f3d2c6d289f50a3e750116b76c90d7c87ada4ed9485576f", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "start_char_idx": 1208, "end_char_idx": 1375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71382120-b4fe-48f5-9778-c2dfffe2bcb2": {"__data__": {"id_": "71382120-b4fe-48f5-9778-c2dfffe2bcb2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7ae38a6-0baf-48ec-a00b-75d539f5994a", "node_type": "1", "metadata": {"window": "LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Eric Percher  \nAnalyst, Nephron  Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Ricky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nKevin  Caliendo  \nAnalyst, UBS Securities LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "faa289b8cfd8cf2fc7462ffe623f9763c2021d6d68d02da62929f64e02a2ccca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c6612d8-4df3-4351-ae32-73474482bf42", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call. "}, "hash": "4e33a18a04922184d4d202466759b6e36d806c1aa3cf94000acd40ad0dc1c097", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c6612d8-4df3-4351-ae32-73474482bf42": {"__data__": {"id_": "6c6612d8-4df3-4351-ae32-73474482bf42", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71382120-b4fe-48f5-9778-c2dfffe2bcb2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "084e5705cad8def207408a78193417e359f874ce4c277d0b102c63bbfec826dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60cbaf52-4cd0-4fd4-b150-daa547d35fec", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. "}, "hash": "3f17084aaa92456960fc08ee6789ef4bf62d916a9a4a840a06e6f14fcc5932ab", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call. ", "start_char_idx": 16, "end_char_idx": 268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60cbaf52-4cd0-4fd4-b150-daa547d35fec": {"__data__": {"id_": "60cbaf52-4cd0-4fd4-b150-daa547d35fec", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c6612d8-4df3-4351-ae32-73474482bf42", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f422f49453f4f63dea5db9da490176fa07dc8eb50f2738f758b72efb0b086b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d8cfd31-6d03-4de8-a6a5-1bc39788ceb4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana. ", "original_text": "At this time, I'd like \nto turn the call over to Holly Weiss. "}, "hash": "afcbb781dfc735ece434ebb7d456296b9c7627ed1c0753947a43bfbd15923584", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded. ", "start_char_idx": 268, "end_char_idx": 306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d8cfd31-6d03-4de8-a6a5-1bc39788ceb4": {"__data__": {"id_": "6d8cfd31-6d03-4de8-a6a5-1bc39788ceb4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana. ", "original_text": "At this time, I'd like \nto turn the call over to Holly Weiss. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60cbaf52-4cd0-4fd4-b150-daa547d35fec", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5bdb632c446b9bec6ef7ff11b812dffc3c7e6cbf9bedfdd3169c229ae7e20aed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18ba7561-ad5b-4869-8af1-4f26cb0745a6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall. ", "original_text": "Please go ahead.  \n "}, "hash": "b02069d4c5314aa8ef7b4129fb0ae3f185de7f1f0b4b20365d7d090434c102b9", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I'd like \nto turn the call over to Holly Weiss. ", "start_char_idx": 306, "end_char_idx": 368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18ba7561-ad5b-4869-8af1-4f26cb0745a6": {"__data__": {"id_": "18ba7561-ad5b-4869-8af1-4f26cb0745a6", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall. ", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d8cfd31-6d03-4de8-a6a5-1bc39788ceb4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana. ", "original_text": "At this time, I'd like \nto turn the call over to Holly Weiss. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94981fd952cb0c16366faa06258a85ff872e0b60ab9cfb973570710bf11a0a13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "918a3d8c-6e42-4eb9-b940-78b64d4e4d59", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n"}, "hash": "c018c8fc53e6d77720ba9912e0d29198c3540ccc7efeec2227e7e58a4bdcda86", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 368, "end_char_idx": 388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "918a3d8c-6e42-4eb9-b940-78b64d4e4d59": {"__data__": {"id_": "918a3d8c-6e42-4eb9-b940-78b64d4e4d59", "embedding": null, "metadata": {"window": "Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18ba7561-ad5b-4869-8af1-4f26cb0745a6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall. ", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb5d7261e693414e2fe63da120ab24bca795619f9eb01e3bb826398ca67d8466", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "167fa8c0-0058-43c9-a472-c2d476b54db3", "node_type": "1", "metadata": {"window": "At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n", "original_text": "Thank you, Lashana. "}, "hash": "9a89858b5b8f3899491fbd2c5b2df9e1f800ac9376ad4ae4eec62cbc45fafc92", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "start_char_idx": 388, "end_char_idx": 734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "167fa8c0-0058-43c9-a472-c2d476b54db3": {"__data__": {"id_": "167fa8c0-0058-43c9-a472-c2d476b54db3", "embedding": null, "metadata": {"window": "At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n", "original_text": "Thank you, Lashana. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "918a3d8c-6e42-4eb9-b940-78b64d4e4d59", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfeddfbe2319305ab3feab7a53a64a0e28913988fa351cb269f2345b19947a66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f7849c6-570f-4d1c-9b36-caaf1711bbf4", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "original_text": "Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall. "}, "hash": "5434cb3875240fa94e49b2c6c7bd3ec60623c870eb97237b9ee77c880066cd03", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Lashana. ", "start_char_idx": 734, "end_char_idx": 754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f7849c6-570f-4d1c-9b36-caaf1711bbf4": {"__data__": {"id_": "4f7849c6-570f-4d1c-9b36-caaf1711bbf4", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "original_text": "Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "167fa8c0-0058-43c9-a472-c2d476b54db3", "node_type": "1", "metadata": {"window": "At this time, I'd like \nto turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n", "original_text": "Thank you, Lashana. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1974d3edc6fadb5e02731d0d53ee3d0011bd94ac4c2dd6ea2501ac8eb1a99b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9419074-4897-4d89-9dcc-ba2ab64a4eca", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n"}, "hash": "96b0481b70b19a6ec2743a97e8078b0037c31978dfe045d0c62dc4d06e7ca025", "class_name": "RelatedNodeInfo"}}, "text": "Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall. ", "start_char_idx": 754, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9419074-4897-4d89-9dcc-ba2ab64a4eca": {"__data__": {"id_": "a9419074-4897-4d89-9dcc-ba2ab64a4eca", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f7849c6-570f-4d1c-9b36-caaf1711bbf4", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "original_text": "Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6bef7130587d765818432a55cfd0d06a8506398fa4e37bb3d2a95806bf7323b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dc63cda-b3c1-4ba6-a36a-7f3fcba146f1", "node_type": "1", "metadata": {"window": "Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n"}, "hash": "aa1cdcc4e5c74fb9626bc9d883bd94cc03aafcaadf65a75ef85fca69f12358e2", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "start_char_idx": 845, "end_char_idx": 958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dc63cda-b3c1-4ba6-a36a-7f3fcba146f1": {"__data__": {"id_": "2dc63cda-b3c1-4ba6-a36a-7f3fcba146f1", "embedding": null, "metadata": {"window": "Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9419074-4897-4d89-9dcc-ba2ab64a4eca", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ff8af87d15d0c240c1c9cb007b8f35b203fa2be34fb8423b3aa67ff1d907119", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e34e6a44-5c14-4080-9936-faaac68ad6f0", "node_type": "1", "metadata": {"window": "Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. "}, "hash": "63a92e4e6e71fc840ff247a36572e173456e4bedf0cacf6037a22d39806df343", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n", "start_char_idx": 958, "end_char_idx": 1057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e34e6a44-5c14-4080-9936-faaac68ad6f0": {"__data__": {"id_": "e34e6a44-5c14-4080-9936-faaac68ad6f0", "embedding": null, "metadata": {"window": "Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dc63cda-b3c1-4ba6-a36a-7f3fcba146f1", "node_type": "1", "metadata": {"window": "Thank you, Lashana.  Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbed05d416c7b3078471ffa7063f424243e2ea07017b2359d1ebdca6df2475c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cecb67d2-af9c-40aa-b83b-8b1148e4d91a", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n"}, "hash": "b7416b3214344b8aab6e98f07d24d25c03a0bf9a836e1973faf63e10c3c6d562", "class_name": "RelatedNodeInfo"}}, "text": "Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "start_char_idx": 1057, "end_char_idx": 1185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cecb67d2-af9c-40aa-b83b-8b1148e4d91a": {"__data__": {"id_": "cecb67d2-af9c-40aa-b83b-8b1148e4d91a", "embedding": null, "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e34e6a44-5c14-4080-9936-faaac68ad6f0", "node_type": "1", "metadata": {"window": "Good morning and welcome everyone to McKesson's Fourth Quarter Fiscal 2020 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd560e0e87c1024a0ba8b110aad0128d5499880e2f26774b72cd3623498f75be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91dc043f-6fb6-4022-bd27-09d8ee8bfc8e", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. "}, "hash": "abfb93e9d4ffd74c8fea96c98f67ed952cc5bb991073e870c8b4d946dc9eaca3", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "start_char_idx": 1185, "end_char_idx": 1501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91dc043f-6fb6-4022-bd27-09d8ee8bfc8e": {"__data__": {"id_": "91dc043f-6fb6-4022-bd27-09d8ee8bfc8e", "embedding": null, "metadata": {"window": "Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cecb67d2-af9c-40aa-b83b-8b1148e4d91a", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "753b2c182e065df0e443000256c2829e8655b0a8ea298118afd8b46591565572", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "934877dc-a8a7-418c-beab-7e10dae5755d", "node_type": "1", "metadata": {"window": "Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody. ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n"}, "hash": "d11849fcfcb98b4e6f4f6c4c62185d8401b690c5342def752e829a9a498d454c", "class_name": "RelatedNodeInfo"}}, "text": "During this call, we will discuss non -GAAP financial measures. ", "start_char_idx": 1501, "end_char_idx": 1565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "934877dc-a8a7-418c-beab-7e10dae5755d": {"__data__": {"id_": "934877dc-a8a7-418c-beab-7e10dae5755d", "embedding": null, "metadata": {"window": "Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody. ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91dc043f-6fb6-4022-bd27-09d8ee8bfc8e", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we'll move to a question -and-answer session.  \n \n Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aadbdd5c6e0a1f030c55bddf61e6ac57497ea445d9ecef77ba08fb419aebb628", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58e6a65a-297a-4f7d-9452-e8c07fb3efd1", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today. ", "original_text": "With that, let me turn it over to Bri an. \n "}, "hash": "b08c050dd6484c3baf11fa93609d0cf08d1cd63ac501f3ed0363a0a02c607579", "class_name": "RelatedNodeInfo"}}, "text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "start_char_idx": 1565, "end_char_idx": 1819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58e6a65a-297a-4f7d-9452-e8c07fb3efd1": {"__data__": {"id_": "58e6a65a-297a-4f7d-9452-e8c07fb3efd1", "embedding": null, "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today. ", "original_text": "With that, let me turn it over to Bri an. \n ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "934877dc-a8a7-418c-beab-7e10dae5755d", "node_type": "1", "metadata": {"window": "Today's discus sion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody. ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b86af6bfb7478c2e7c9821a3ff6e1fdc8fd31a37ca659bc35f4770943d21371", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23742ecd-5838-4c06-b187-e877717c6f20", "node_type": "1", "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "59f8dc9b40a27d890c82daff138301e4842206f32798f3ad691fb4529ce91551", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it over to Bri an. \n ", "start_char_idx": 1819, "end_char_idx": 1863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23742ecd-5838-4c06-b187-e877717c6f20": {"__data__": {"id_": "23742ecd-5838-4c06-b187-e877717c6f20", "embedding": null, "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58e6a65a-297a-4f7d-9452-e8c07fb3efd1", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC  filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today. ", "original_text": "With that, let me turn it over to Bri an. \n ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3037e845da1a76203b732533a685e25a958447a021edea36f5a1176b204156f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f77f5c64-25f5-4fd3-aa4b-cb69bed4295d", "node_type": "1", "metadata": {"window": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year. ", "original_text": "Thank you, Holly, and good morning, everybody. "}, "hash": "8d722a94825e5d0217062ad55c7333f8028c63c8a2d283cd4e8ef7dcb9c375da", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 1863, "end_char_idx": 2205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f77f5c64-25f5-4fd3-aa4b-cb69bed4295d": {"__data__": {"id_": "f77f5c64-25f5-4fd3-aa4b-cb69bed4295d", "embedding": null, "metadata": {"window": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year. ", "original_text": "Thank you, Holly, and good morning, everybody. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23742ecd-5838-4c06-b187-e877717c6f20", "node_type": "1", "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b0c2d327e78afd46ded1f0a3844e943ec9558ef35cac94692153c7e7ecbd5e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b67a567e-eb2e-4624-8907-7744792a16cb", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n", "original_text": "Appreciate you being with us on the call today. "}, "hash": "5f7a022a97361084a5ad4337843a9017c4792e8642f5d8bfb51c6d49de0f8fda", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Holly, and good morning, everybody. ", "start_char_idx": 2205, "end_char_idx": 2252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b67a567e-eb2e-4624-8907-7744792a16cb": {"__data__": {"id_": "b67a567e-eb2e-4624-8907-7744792a16cb", "embedding": null, "metadata": {"window": "With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n", "original_text": "Appreciate you being with us on the call today. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f77f5c64-25f5-4fd3-aa4b-cb69bed4295d", "node_type": "1", "metadata": {"window": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year. ", "original_text": "Thank you, Holly, and good morning, everybody. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e83ba192972fce93f89e75a1caf7fe7be8d0c4560abc8ed86cf6eaa7def831c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d26dfc13-da6f-4414-9b29-d066e3fdb1fe", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes. ", "original_text": "I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n"}, "hash": "9e0c8f39ce0ad899a8a8fe585cd8c2f4d4283b8af6d548cb611c4b7ff6aa2050", "class_name": "RelatedNodeInfo"}}, "text": "Appreciate you being with us on the call today. ", "start_char_idx": 2252, "end_char_idx": 2300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d26dfc13-da6f-4414-9b29-d066e3fdb1fe": {"__data__": {"id_": "d26dfc13-da6f-4414-9b29-d066e3fdb1fe", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes. ", "original_text": "I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b67a567e-eb2e-4624-8907-7744792a16cb", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Bri an. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n", "original_text": "Appreciate you being with us on the call today. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45d1567cf3f2bfa8176f2194622dc9f3f3ee65d2c6e15a08e24894221d7ee1b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e21a9c87-2898-4ad0-b0ed-24bda083b839", "node_type": "1", "metadata": {"window": "Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter. ", "original_text": "Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year. "}, "hash": "bc3e66a7a9287b5cdca7f0ba56d2b7cfff846436d8725f35e50afd6c9805c9d0", "class_name": "RelatedNodeInfo"}}, "text": "I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n", "start_char_idx": 2300, "end_char_idx": 2458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e21a9c87-2898-4ad0-b0ed-24bda083b839": {"__data__": {"id_": "e21a9c87-2898-4ad0-b0ed-24bda083b839", "embedding": null, "metadata": {"window": "Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter. ", "original_text": "Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d26dfc13-da6f-4414-9b29-d066e3fdb1fe", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes. ", "original_text": "I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3db5df29024c7c96563d0e897ea43cc6263623872b38fb99004316e64c2010e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef4a4182-d3cc-4e0e-bf15-9f597d9def30", "node_type": "1", "metadata": {"window": "Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n", "original_text": "Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n"}, "hash": "b3832250b46a7edefb44a3910ac939d871e42f7a9189ce8ccb1137e5d3d0d4da", "class_name": "RelatedNodeInfo"}}, "text": "Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year. ", "start_char_idx": 2458, "end_char_idx": 2701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef4a4182-d3cc-4e0e-bf15-9f597d9def30": {"__data__": {"id_": "ef4a4182-d3cc-4e0e-bf15-9f597d9def30", "embedding": null, "metadata": {"window": "Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n", "original_text": "Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e21a9c87-2898-4ad0-b0ed-24bda083b839", "node_type": "1", "metadata": {"window": "Thank you, Holly, and good morning, everybody.  Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter. ", "original_text": "Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bea8d9334f9dd73807a7b57347be2b4b0bcabddb76631b58c21ef298107cc85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f0ffc90-2ac4-45ce-8584-48abc6785d6d", "node_type": "1", "metadata": {"window": "I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world. ", "original_text": "Today, my remarks will echo similar themes. "}, "hash": "cebf8210a45d1a3a2dee7fcd5d409ecc3162d5d63051b709bd01b882ecb3773b", "class_name": "RelatedNodeInfo"}}, "text": "Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n", "start_char_idx": 2701, "end_char_idx": 2968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f0ffc90-2ac4-45ce-8584-48abc6785d6d": {"__data__": {"id_": "5f0ffc90-2ac4-45ce-8584-48abc6785d6d", "embedding": null, "metadata": {"window": "I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world. ", "original_text": "Today, my remarks will echo similar themes. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef4a4182-d3cc-4e0e-bf15-9f597d9def30", "node_type": "1", "metadata": {"window": "Appreciate you being with us on the call today.  I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n", "original_text": "Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b522d69b98b5fbeb0de0d3be503e3a42cce48f9f08613caca988d813ad1bee9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7d926d5-dfa1-45d3-bc70-e637e1f9e2fc", "node_type": "1", "metadata": {"window": "Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world.  Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the ", "original_text": "I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter. "}, "hash": "3ea94fd26f60a5adbbe284cd5b944c48da9f1986dbdb4caa98d4862a2c79b5f7", "class_name": "RelatedNodeInfo"}}, "text": "Today, my remarks will echo similar themes. ", "start_char_idx": 2968, "end_char_idx": 3012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7d926d5-dfa1-45d3-bc70-e637e1f9e2fc": {"__data__": {"id_": "c7d926d5-dfa1-45d3-bc70-e637e1f9e2fc", "embedding": null, "metadata": {"window": "Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world.  Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the ", "original_text": "I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f0ffc90-2ac4-45ce-8584-48abc6785d6d", "node_type": "1", "metadata": {"window": "I sincerely hope \nthat you and your families and your communities are staying healthy and  safe as we navigate through these really \nextraordinary times.  \n \n Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world. ", "original_text": "Today, my remarks will echo similar themes. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d90061e46e594f9c4532dcd3d586e92d5e6123ee2c39af07ef4fd2a7e24c52c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c30427c6-fd10-46fb-a44b-250b4c11b3a9", "node_type": "1", "metadata": {"window": "Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world.  Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the ", "original_text": "I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n"}, "hash": "09e3e4946c9a213e6a4b94a5f00f579c953620a9a20949622f835cf4c5f88c59", "class_name": "RelatedNodeInfo"}}, "text": "I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter. ", "start_char_idx": 3012, "end_char_idx": 3309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c30427c6-fd10-46fb-a44b-250b4c11b3a9": {"__data__": {"id_": "c30427c6-fd10-46fb-a44b-250b4c11b3a9", "embedding": null, "metadata": {"window": "Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world.  Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the ", "original_text": "I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7d926d5-dfa1-45d3-bc70-e637e1f9e2fc", "node_type": "1", "metadata": {"window": "Today, we reported a strong finish to our fiscal 2020, with the trends we saw in the fourth quarter prior to the \nCOVID -19 pandemic reflecting a continuation of the momentum we experienced comi ng into and really \nthroughout our fiscal year.  Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world.  Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the ", "original_text": "I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "626b8e590f0271f98ccd56b327e6dee4c92916d68adec257d6aa3c90ed4be72a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bc48dec-0e91-46aa-8b0f-5b6fe1b4814d", "node_type": "1", "metadata": {"window": "Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world.  Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the ", "original_text": "Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world. "}, "hash": "7ae371b8fdaf292b392ff8ba96501d15798ee1f5241db1c2d2805395d8d4783a", "class_name": "RelatedNodeInfo"}}, "text": "I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n", "start_char_idx": 3309, "end_char_idx": 3437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bc48dec-0e91-46aa-8b0f-5b6fe1b4814d": {"__data__": {"id_": "1bc48dec-0e91-46aa-8b0f-5b6fe1b4814d", "embedding": null, "metadata": {"window": "Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world.  Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the ", "original_text": "Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c30427c6-fd10-46fb-a44b-250b4c11b3a9", "node_type": "1", "metadata": {"window": "Throughout McKesson's 187 -year history, we've demonstrated time and time again our \nability to adapt and swiftly respond to the evolving needs of our customers, particularly in trying times, and the \nresiliency and the long -term strength of our business model.  \n \n Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world.  Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the ", "original_text": "I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "534052d3f30c6a037a438356f4183044297b5907691bccf0892961db29b2c62e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b06fb94-6db2-49c4-a989-1a7278649f33", "node_type": "1", "metadata": {"window": "I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world.  Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the ", "original_text": "Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the "}, "hash": "f7cb054799d5eec0c9f76790563dffde72856bc76a9f1a6a412e9741e343a3ab", "class_name": "RelatedNodeInfo"}}, "text": "Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world. ", "start_char_idx": 3437, "end_char_idx": 3726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b06fb94-6db2-49c4-a989-1a7278649f33": {"__data__": {"id_": "3b06fb94-6db2-49c4-a989-1a7278649f33", "embedding": null, "metadata": {"window": "I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world.  Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the ", "original_text": "Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3aed8e79b0ec41e8ea1145372e3e99a6ad223ac21b259f4552f75b73e602a7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bc48dec-0e91-46aa-8b0f-5b6fe1b4814d", "node_type": "1", "metadata": {"window": "Today, my remarks will echo similar themes.  I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world.  Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the ", "original_text": "Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world. ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33402ce1ca2dd1f1b56f9de6c842f1903ad32c807841b3b7b9960a96d79d2b81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df350493-aeea-4491-b73a-e1305a77d5cb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic. ", "original_text": "McKesson Corp.  "}, "hash": "03687b83c80c1b94e0f3dd37e5ac21beaed14b157aff149e0fa15fa84e02ed12", "class_name": "RelatedNodeInfo"}}, "text": "Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the ", "start_char_idx": 3726, "end_char_idx": 3895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df350493-aeea-4491-b73a-e1305a77d5cb": {"__data__": {"id_": "df350493-aeea-4491-b73a-e1305a77d5cb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b06fb94-6db2-49c4-a989-1a7278649f33", "node_type": "1", "metadata": {"window": "I want to walk you through McKesson's response to the COVID -19 \npandemic and the essential role we play in the healthcare supply chain, the progress we've made th is year \nagainst our strategic priorities and our FY 2020 results, including the impact COVID -19 had on our fiscal fourth \nquarter.  I also want to talk about why I'm confident that McKesson remains well positioned now and especially \nover the longer term.  \n \n Before I begin, I want to acknowledge and really sincerely thank all those who are working so tirelessly to keep us \nhealthy and safe during this crisis, including our customers and all frontline healthcare professionals, nurses, \nphysicians, first responder s literally around the world.  Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the ", "original_text": "Thank you to each and every one of our 80,000 McKesson \nassociates for their passion, their energy, in many cases, courage these past several months, working around the ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16894019f374909551dcec0314da47e4c4413cd3457d94b25eb05d317e86bc4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfd6fb47-8e86-45e1-87c1-9387eba9bb60", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n"}, "hash": "b6244a68a2cea7ac04ceadaace295561d46888a7bf1e5a531e3be66400fa496a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfd6fb47-8e86-45e1-87c1-9387eba9bb60": {"__data__": {"id_": "bfd6fb47-8e86-45e1-87c1-9387eba9bb60", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df350493-aeea-4491-b73a-e1305a77d5cb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72ee8eb9b054f7a1a9fce1c0f457fb95a84eb500e349aa46c64ff6e0137b5eaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4461a94-1342-4a28-a2a2-d5dd161e12bd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe. ", "original_text": "I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n"}, "hash": "1a16f6f8f9dba305330fc060335aa832d12e820debce7c70a9ddce592adfe4fa", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n", "start_char_idx": 16, "end_char_idx": 309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4461a94-1342-4a28-a2a2-d5dd161e12bd": {"__data__": {"id_": "f4461a94-1342-4a28-a2a2-d5dd161e12bd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe. ", "original_text": "I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfd6fb47-8e86-45e1-87c1-9387eba9bb60", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9cbf90c20eb3e2df087854b0a1040262a73b298bdc599e1fd7d9edb3826e1b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81160bc7-49b7-4336-bcb8-91af7b635970", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand. ", "original_text": "As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic. "}, "hash": "ba58cf3c9ddcba5a4e9c4c39355f6e83974879d72d973fb872f61c904a33e9be", "class_name": "RelatedNodeInfo"}}, "text": "I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n", "start_char_idx": 309, "end_char_idx": 793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81160bc7-49b7-4336-bcb8-91af7b635970": {"__data__": {"id_": "81160bc7-49b7-4336-bcb8-91af7b635970", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand. ", "original_text": "As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4461a94-1342-4a28-a2a2-d5dd161e12bd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe. ", "original_text": "I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0cf19deaa2b137dda8b3c4be1c47f8986a41c549fdaa298dcf6c2319161b6b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b587278-45eb-4547-9052-49df994a0877", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n", "original_text": "Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n"}, "hash": "16ed0d47cb101369bd479d5d2e956afe81ce453e802b53991e0b175c0c3496f2", "class_name": "RelatedNodeInfo"}}, "text": "As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic. ", "start_char_idx": 793, "end_char_idx": 944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b587278-45eb-4547-9052-49df994a0877": {"__data__": {"id_": "5b587278-45eb-4547-9052-49df994a0877", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n", "original_text": "Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81160bc7-49b7-4336-bcb8-91af7b635970", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand. ", "original_text": "As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bab09fae8318c2e72d1d3afa5aee367355ab957d2b732a373a29aae0f23e76c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4a8cd3f-963d-48a2-ab04-635fdd79b4e4", "node_type": "1", "metadata": {"window": "I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead. ", "original_text": "Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe. "}, "hash": "21397994919bf2a86ea7eac0725fbc382ec653c6e1bcf44a509bdc3ed2a12957", "class_name": "RelatedNodeInfo"}}, "text": "Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n", "start_char_idx": 944, "end_char_idx": 1149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4a8cd3f-963d-48a2-ab04-635fdd79b4e4": {"__data__": {"id_": "b4a8cd3f-963d-48a2-ab04-635fdd79b4e4", "embedding": null, "metadata": {"window": "I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead. ", "original_text": "Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b587278-45eb-4547-9052-49df994a0877", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n", "original_text": "Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6807155083b029d16d52f7e57bc3f80fa06466b070f5d293b30acd2e2aac88df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2df7a84-d61b-4661-a0b3-ef371d41c733", "node_type": "1", "metadata": {"window": "As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n", "original_text": "We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand. "}, "hash": "7d754bc79b7a37b7e06c7b2c0f1ed61c79eb93b68f1b3ac1f52ff4fc2f69a005", "class_name": "RelatedNodeInfo"}}, "text": "Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe. ", "start_char_idx": 1149, "end_char_idx": 1315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2df7a84-d61b-4661-a0b3-ef371d41c733": {"__data__": {"id_": "b2df7a84-d61b-4661-a0b3-ef371d41c733", "embedding": null, "metadata": {"window": "As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n", "original_text": "We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4a8cd3f-963d-48a2-ab04-635fdd79b4e4", "node_type": "1", "metadata": {"window": "I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead. ", "original_text": "Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58e36901339f9d0199cc770b6c1e6df4ccc6b1dfb84cfe8e4a67163ef093b6c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ad8dc75-93e9-473e-9ea5-93ae549e614d", "node_type": "1", "metadata": {"window": "Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products. ", "original_text": "This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n"}, "hash": "a172c0bea26f81830ac2811b8b7bd31dc37904ab368c7677e4f2397a6a4ac001", "class_name": "RelatedNodeInfo"}}, "text": "We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand. ", "start_char_idx": 1315, "end_char_idx": 1574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ad8dc75-93e9-473e-9ea5-93ae549e614d": {"__data__": {"id_": "8ad8dc75-93e9-473e-9ea5-93ae549e614d", "embedding": null, "metadata": {"window": "Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products. ", "original_text": "This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2df7a84-d61b-4661-a0b3-ef371d41c733", "node_type": "1", "metadata": {"window": "As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic.  Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n", "original_text": "We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50f33b20557f6f9e54fe0cbb59f4f4a88b79ddc4566b7b440b933946e28a4f73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3f4cdac-f739-482d-83ee-20345c1cc121", "node_type": "1", "metadata": {"window": "Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US. ", "original_text": "In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead. "}, "hash": "e11ad97f5f60ca1acc964419056474ad9e6340bddd7e7124a1a4cb1e439cdd76", "class_name": "RelatedNodeInfo"}}, "text": "This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n", "start_char_idx": 1574, "end_char_idx": 1771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3f4cdac-f739-482d-83ee-20345c1cc121": {"__data__": {"id_": "f3f4cdac-f739-482d-83ee-20345c1cc121", "embedding": null, "metadata": {"window": "Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US. ", "original_text": "In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ad8dc75-93e9-473e-9ea5-93ae549e614d", "node_type": "1", "metadata": {"window": "Our response has been guided by the key principles of protecting health \nand sa fety for the healthcare supply chain, for our customers and for our employees and the communities in \nwhich we all live.  \n \n Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products. ", "original_text": "This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5326b14a840cb0944caf39aa95332dc25f5015334de3c8bcf163ad088bf5f849", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f3aca91-aa79-4398-a6e4-ee6f5bf59896", "node_type": "1", "metadata": {"window": "We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n", "original_text": "M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n"}, "hash": "6b3d8b12418756eb9e365432cb90535a5998546a28a0652e8a05427c379dedc4", "class_name": "RelatedNodeInfo"}}, "text": "In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead. ", "start_char_idx": 1771, "end_char_idx": 2064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f3aca91-aa79-4398-a6e4-ee6f5bf59896": {"__data__": {"id_": "0f3aca91-aa79-4398-a6e4-ee6f5bf59896", "embedding": null, "metadata": {"window": "We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n", "original_text": "M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3f4cdac-f739-482d-83ee-20345c1cc121", "node_type": "1", "metadata": {"window": "Early on, we enacted our business continuity and disaster recovery plans across the organization in order to \nmaintain high -functioning operations around the globe.  We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US. ", "original_text": "In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "69768b861e7c2b2df2e0c74df0b52689d4a1577fb8f111a57e480b5f2e800803", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de23220b-30a5-4ef3-974d-4e1037ff7f65", "node_type": "1", "metadata": {"window": "This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on. ", "original_text": "As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products. "}, "hash": "bc478fa8310a18a5d8aa12d7fdfaf6d71b87657ce8fc8f4cb8915146809cf22f", "class_name": "RelatedNodeInfo"}}, "text": "M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n", "start_char_idx": 2064, "end_char_idx": 2275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de23220b-30a5-4ef3-974d-4e1037ff7f65": {"__data__": {"id_": "de23220b-30a5-4ef3-974d-4e1037ff7f65", "embedding": null, "metadata": {"window": "This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on. ", "original_text": "As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f3aca91-aa79-4398-a6e4-ee6f5bf59896", "node_type": "1", "metadata": {"window": "We assembled a Critical Care Drug Task Force comprised \nof our sourcing specialists and individuals with clinical backgrounds in health systems pharmacy to review \nguidelines and protocols, and to forecast changing pharmaceutical  and medical product demand.  This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n", "original_text": "M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d582e5e5d908d61d2f474635d4cf1118e894bf40bcdcddcdabba57a12700a412", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30a88c4d-9d6c-4e86-9a1a-61e587231664", "node_type": "1", "metadata": {"window": "In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n", "original_text": "We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US. "}, "hash": "dd35b15594c4cedf4e1138fb2a18c3fe776d0530065cb1f847b292ff18b8d450", "class_name": "RelatedNodeInfo"}}, "text": "As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products. ", "start_char_idx": 2275, "end_char_idx": 2471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30a88c4d-9d6c-4e86-9a1a-61e587231664": {"__data__": {"id_": "30a88c4d-9d6c-4e86-9a1a-61e587231664", "embedding": null, "metadata": {"window": "In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n", "original_text": "We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de23220b-30a5-4ef3-974d-4e1037ff7f65", "node_type": "1", "metadata": {"window": "This task force \nin conjunction with guidance from our government partners is working to predict, allocate and extend supply \navailability to serve the rapidly changing needs of our customers.  \n \n In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on. ", "original_text": "As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e80a57e4b5cc26dd302fbd187a6bbb0ee24b0f765d6a95ec8840ad339d77f778", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3df04fc2-35fb-482b-8a7b-922aa3487c6d", "node_type": "1", "metadata": {"window": "M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities. ", "original_text": "Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n"}, "hash": "28697b00549de8f11be2ca59fbf456788ad11549d88bc8a3d5effc528d451447", "class_name": "RelatedNodeInfo"}}, "text": "We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US. ", "start_char_idx": 2471, "end_char_idx": 2570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3df04fc2-35fb-482b-8a7b-922aa3487c6d": {"__data__": {"id_": "3df04fc2-35fb-482b-8a7b-922aa3487c6d", "embedding": null, "metadata": {"window": "M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities. ", "original_text": "Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30a88c4d-9d6c-4e86-9a1a-61e587231664", "node_type": "1", "metadata": {"window": "In addition, our ClarusONE and our global sourcing teams in London are working closely with manufacturers to \nunderstand their plans and to create new capacity or scale -up production, so that we can be prepared to swiftly \nreact as a supply chain in the coming weeks, months and years ahead.  M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n", "original_text": "We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "791f408a51c8f470d510ad5a6ba4ec7d2105d4424baeba42c8cf37887e8c45eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9990b860-8b84-4611-96df-dde611022e97", "node_type": "1", "metadata": {"window": "As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees. ", "original_text": "In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on. "}, "hash": "9d8b4bff1e721e1c702ae8273362cbf50f31a1014e62994c223458b8a0a697f1", "class_name": "RelatedNodeInfo"}}, "text": "Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n", "start_char_idx": 2570, "end_char_idx": 2855, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9990b860-8b84-4611-96df-dde611022e97": {"__data__": {"id_": "9990b860-8b84-4611-96df-dde611022e97", "embedding": null, "metadata": {"window": "As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees. ", "original_text": "In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3df04fc2-35fb-482b-8a7b-922aa3487c6d", "node_type": "1", "metadata": {"window": "M cKesson is partnering with government \nagencies at the federal, state and local level, along with other industry leaders to creatively solve for the most \ncomplex and pressing issues this crisis presents.  \n \n As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities. ", "original_text": "Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb905ef677a3a8a0cf23748579cdfd21f9022456632e2ffdee2eaf7cbfb036eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a2a01ae-f9e6-412f-9c5f-1a44cafb732d", "node_type": "1", "metadata": {"window": "We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n", "original_text": "We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n"}, "hash": "8f3bab6853a8b3f3a280904d1716cbe3189477d451f0dc5f51924598f44b8d02", "class_name": "RelatedNodeInfo"}}, "text": "In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on. ", "start_char_idx": 2855, "end_char_idx": 2994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a2a01ae-f9e6-412f-9c5f-1a44cafb732d": {"__data__": {"id_": "0a2a01ae-f9e6-412f-9c5f-1a44cafb732d", "embedding": null, "metadata": {"window": "We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n", "original_text": "We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9990b860-8b84-4611-96df-dde611022e97", "node_type": "1", "metadata": {"window": "As demand surges for personal protective equipment o r PPE, McKesson is doing everything within our power to \nidentify new sources, manufacturers and markets for these critically needed products.  We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees. ", "original_text": "In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2840b0111c1280c7782af87b80cf12e7c58ffbd4e36cc5ee10c605f129922029", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef86c74d-efad-44d0-9246-e71f7121c276", "node_type": "1", "metadata": {"window": "Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities. ", "original_text": "We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities. "}, "hash": "505ffca7a2c40c4795f49a283c5261cd4fea7b4ac12a97932aebba3bde72c561", "class_name": "RelatedNodeInfo"}}, "text": "We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n", "start_char_idx": 2994, "end_char_idx": 3328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef86c74d-efad-44d0-9246-e71f7121c276": {"__data__": {"id_": "ef86c74d-efad-44d0-9246-e71f7121c276", "embedding": null, "metadata": {"window": "Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities. ", "original_text": "We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a2a01ae-f9e6-412f-9c5f-1a44cafb732d", "node_type": "1", "metadata": {"window": "We are very proud of our \npartnership with Walmart to produce and deliver medical gowns to the US.  Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n", "original_text": "We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a69014babfc0ccec15a259d2875d1e91ecb0a8b4f0a47e68ecd32eae692fffc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a2568c0-ce18-4f12-924f-16904eeaa4e8", "node_type": "1", "metadata": {"window": "In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities.  So we made special payments to reward the hard work of our associates on the frontline ", "original_text": "We've undertaken multiple measures to protect and promote the \nwellbeing of our employees. "}, "hash": "dd9d45f5345fe20309361603e4915425ad529b2d8ac22adf5b89b77b31bf0c3b", "class_name": "RelatedNodeInfo"}}, "text": "We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities. ", "start_char_idx": 3328, "end_char_idx": 3487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a2568c0-ce18-4f12-924f-16904eeaa4e8": {"__data__": {"id_": "4a2568c0-ce18-4f12-924f-16904eeaa4e8", "embedding": null, "metadata": {"window": "In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities.  So we made special payments to reward the hard work of our associates on the frontline ", "original_text": "We've undertaken multiple measures to protect and promote the \nwellbeing of our employees. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef86c74d-efad-44d0-9246-e71f7121c276", "node_type": "1", "metadata": {"window": "Our two companie s have collaborated \nin an entirely new way by bringing expert teams together and moving with remarkable speed, which has led to 2 \nmillion additional medical gowns in our country supply to date, and we expect roughly 10 million will be added by \nthe end of J une. \n \n In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities. ", "original_text": "We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9dd26aa7f1c2e9ba9bf832844c4c088d5dbf404ec6e0fdb44131af7e7ae180f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a81f0956-afc5-40a7-9120-02a163fdffaf", "node_type": "1", "metadata": {"window": "We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities.  So we made special payments to reward the hard work of our associates on the frontline ", "original_text": "These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n"}, "hash": "4247f75004097e8cddc37eebfa26407e64d75913312f0388609e8367279ba903", "class_name": "RelatedNodeInfo"}}, "text": "We've undertaken multiple measures to protect and promote the \nwellbeing of our employees. ", "start_char_idx": 3487, "end_char_idx": 3578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a81f0956-afc5-40a7-9120-02a163fdffaf": {"__data__": {"id_": "a81f0956-afc5-40a7-9120-02a163fdffaf", "embedding": null, "metadata": {"window": "We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities.  So we made special payments to reward the hard work of our associates on the frontline ", "original_text": "These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a2568c0-ce18-4f12-924f-16904eeaa4e8", "node_type": "1", "metadata": {"window": "In Europe and Canada, our retail pharmacies have remained open, providing the essential community -based care \nthat our customers rely on.  We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities.  So we made special payments to reward the hard work of our associates on the frontline ", "original_text": "We've undertaken multiple measures to protect and promote the \nwellbeing of our employees. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a760ef66121e00395486034310269b8ab2be6c6f100073933fbe8785df6537b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3b8a761-8a4c-4b8b-932f-1b7e0b79ddfc", "node_type": "1", "metadata": {"window": "We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities.  So we made special payments to reward the hard work of our associates on the frontline ", "original_text": "Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities. "}, "hash": "045fc76df1142c648b7d521bb68275217baf263b7983d6093160c92558c469a8", "class_name": "RelatedNodeInfo"}}, "text": "These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n", "start_char_idx": 3578, "end_char_idx": 3850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3b8a761-8a4c-4b8b-932f-1b7e0b79ddfc": {"__data__": {"id_": "e3b8a761-8a4c-4b8b-932f-1b7e0b79ddfc", "embedding": null, "metadata": {"window": "We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities.  So we made special payments to reward the hard work of our associates on the frontline ", "original_text": "Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a81f0956-afc5-40a7-9120-02a163fdffaf", "node_type": "1", "metadata": {"window": "We implemented several changes in our retail pharmacies to ensure our customers \nfeel comfortable and safe, includ ing limiting the number of customers in stores, installing protective shields at \npharmacy counters, dedicating shopping times for seniors and for first responders, and regularly disinfecting all \nhigh-touch areas.  \n \n We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities.  So we made special payments to reward the hard work of our associates on the frontline ", "original_text": "These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e19a09a0ae8ec53d3ab97ec7e1b61fa1a6653ea13bed6d6bb58bf962716bef0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da7dcadc-fa57-4f9c-af5d-72b1baa5f8dc", "node_type": "1", "metadata": {"window": "We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities.  So we made special payments to reward the hard work of our associates on the frontline ", "original_text": "So we made special payments to reward the hard work of our associates on the frontline "}, "hash": "886ae9ffbbe7ad71613d83eed8cdf6b5f96969481af395c090ff65b5867ec4c6", "class_name": "RelatedNodeInfo"}}, "text": "Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities. ", "start_char_idx": 3850, "end_char_idx": 3988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da7dcadc-fa57-4f9c-af5d-72b1baa5f8dc": {"__data__": {"id_": "da7dcadc-fa57-4f9c-af5d-72b1baa5f8dc", "embedding": null, "metadata": {"window": "We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities.  So we made special payments to reward the hard work of our associates on the frontline ", "original_text": "So we made special payments to reward the hard work of our associates on the frontline ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a119bc03acb4cb7d60dc9e77eea61d24f48f1d901522d7569a9f1801ad72c57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3b8a761-8a4c-4b8b-932f-1b7e0b79ddfc", "node_type": "1", "metadata": {"window": "We're also expanding our pharmacy services  to include virtual health offerings, home delivery in certain markets \nand increased online pharmacy capabilities.  We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities.  So we made special payments to reward the hard work of our associates on the frontline ", "original_text": "Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities. ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85ac9186aaf58a1a4f044d8354b2447cc363de3545a40bb85e58f9f53a7201f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c2953b5-ba40-4078-b12e-dc29392b20d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "622d34630c117c5c9f8a174ce4078393d3e23a8edac0a544560ca0a396c206a3", "class_name": "RelatedNodeInfo"}}, "text": "So we made special payments to reward the hard work of our associates on the frontline ", "start_char_idx": 3988, "end_char_idx": 4075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c2953b5-ba40-4078-b12e-dc29392b20d1": {"__data__": {"id_": "7c2953b5-ba40-4078-b12e-dc29392b20d1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da7dcadc-fa57-4f9c-af5d-72b1baa5f8dc", "node_type": "1", "metadata": {"window": "We've undertaken multiple measures to protect and promote the \nwellbeing of our employees.  These include comprehensive sanitation protocols fo r our distribution centers and \noffice facilities, work -from-home technology for our office -based employees, enhanced medical benefits, including \ntelemedicine and wellness offerings and emergency paid sick leave.  \n \n Some of our very first actions were to reco gnize the stress that this situation would put on our frontline workers \nand our communities.  So we made special payments to reward the hard work of our associates on the frontline ", "original_text": "So we made special payments to reward the hard work of our associates on the frontline ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9c49e1cf6e02d5f3738d73c93762a84a48b0292264dcb88ade6a88ea779ba13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1fa504d-fcb8-4cc4-b5f9-4aada49d7dbe", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families. "}, "hash": "6a93871569bf5066e7de1ee9c6460683ddde78ae091e59887c200ccab672154c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1fa504d-fcb8-4cc4-b5f9-4aada49d7dbe": {"__data__": {"id_": "e1fa504d-fcb8-4cc4-b5f9-4aada49d7dbe", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c2953b5-ba40-4078-b12e-dc29392b20d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52ace4dde6fea7c931ecd137b4fc18a37d87a55de413bb9e4b5aef08009e403f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbfd708e-bfb5-4b72-9612-f4db6ccfdd5c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n", "original_text": "We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities. "}, "hash": "610086d0e193a9c7b7cbae073d4a4f3cea7b24c623759f9fde82066809e81d4a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families. ", "start_char_idx": 16, "end_char_idx": 243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbfd708e-bfb5-4b72-9612-f4db6ccfdd5c": {"__data__": {"id_": "dbfd708e-bfb5-4b72-9612-f4db6ccfdd5c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n", "original_text": "We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1fa504d-fcb8-4cc4-b5f9-4aada49d7dbe", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ef31c69ead0ba96ba0c7591d2e760ec8178fa335003ce6f4efd84128e832ca7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d0795d6-2f36-4928-97e0-f2b61329b32e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business. ", "original_text": "And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n"}, "hash": "b446d48a5dd23dfa9ab47aecaf475b0e448e2b72cec963ad82786b5ee5a892ce", "class_name": "RelatedNodeInfo"}}, "text": "We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities. ", "start_char_idx": 243, "end_char_idx": 374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d0795d6-2f36-4928-97e0-f2b61329b32e": {"__data__": {"id_": "3d0795d6-2f36-4928-97e0-f2b61329b32e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business. ", "original_text": "And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbfd708e-bfb5-4b72-9612-f4db6ccfdd5c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n", "original_text": "We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94290289490efa4d576a8bb1cd1bbe64165992dc66e5bf25665ac4846f4868d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c89b3690-432b-40ec-9889-05aee1686fe4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n", "original_text": "Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n"}, "hash": "a1c24b4c15a8f8de0dacd85012ba3fef20acf3e327d760e31c20d9dd41b3fc96", "class_name": "RelatedNodeInfo"}}, "text": "And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n", "start_char_idx": 374, "end_char_idx": 603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c89b3690-432b-40ec-9889-05aee1686fe4": {"__data__": {"id_": "c89b3690-432b-40ec-9889-05aee1686fe4", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n", "original_text": "Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d0795d6-2f36-4928-97e0-f2b61329b32e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business. ", "original_text": "And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c087497f8d404537c430e8e243ce3ceb2a52526cd3c7998c8fb01b64ba626b04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96c979e5-f766-41d5-9c0a-56e7cf8ac5c1", "node_type": "1", "metadata": {"window": "We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December. ", "original_text": "Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n"}, "hash": "2cbcbacae8157d329db2064d2c93ccc96f2905060f95a0750466afbd88293af2", "class_name": "RelatedNodeInfo"}}, "text": "Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n", "start_char_idx": 603, "end_char_idx": 790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96c979e5-f766-41d5-9c0a-56e7cf8ac5c1": {"__data__": {"id_": "96c979e5-f766-41d5-9c0a-56e7cf8ac5c1", "embedding": null, "metadata": {"window": "We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December. ", "original_text": "Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c89b3690-432b-40ec-9889-05aee1686fe4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n", "original_text": "Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25764da825cfdbbddcf963270141e445c88b33d0bdc68097bb104b8994312dc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41068803-b2c0-4461-b178-b0a0d0f62480", "node_type": "1", "metadata": {"window": "And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization. ", "original_text": "In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business. "}, "hash": "ee091fc183a85607a634efb5e8170f166f634250c86290d4c1c74454b2826eac", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n", "start_char_idx": 790, "end_char_idx": 1039, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41068803-b2c0-4461-b178-b0a0d0f62480": {"__data__": {"id_": "41068803-b2c0-4461-b178-b0a0d0f62480", "embedding": null, "metadata": {"window": "And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization. ", "original_text": "In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96c979e5-f766-41d5-9c0a-56e7cf8ac5c1", "node_type": "1", "metadata": {"window": "We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December. ", "original_text": "Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f14a69ae2ad1d767e436e8adeb294288fcf989b91a164033f5bf5af1904fb157", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fe51ca0-12e9-43b0-9b2d-30a514a613ec", "node_type": "1", "metadata": {"window": "Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n", "original_text": "Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n"}, "hash": "b802385b212cd80fe5bcae162bdcc1e30b6b7a4e91f21ec84aa850e083765cc1", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business. ", "start_char_idx": 1039, "end_char_idx": 1147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fe51ca0-12e9-43b0-9b2d-30a514a613ec": {"__data__": {"id_": "9fe51ca0-12e9-43b0-9b2d-30a514a613ec", "embedding": null, "metadata": {"window": "Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n", "original_text": "Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41068803-b2c0-4461-b178-b0a0d0f62480", "node_type": "1", "metadata": {"window": "And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization. ", "original_text": "In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9376cce8b311f24208f216d499e274eef943c1446e663c9a75c23b3b96775946", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc3209d2-b9b6-4255-b420-a2526bdade4d", "node_type": "1", "metadata": {"window": "Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S. ", "original_text": "Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December. "}, "hash": "b53c10cc18555d3dad18d17efb7ba5351fa05de36e39309b45dd3266fad76e74", "class_name": "RelatedNodeInfo"}}, "text": "Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n", "start_char_idx": 1147, "end_char_idx": 1333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc3209d2-b9b6-4255-b420-a2526bdade4d": {"__data__": {"id_": "fc3209d2-b9b6-4255-b420-a2526bdade4d", "embedding": null, "metadata": {"window": "Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S. ", "original_text": "Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fe51ca0-12e9-43b0-9b2d-30a514a613ec", "node_type": "1", "metadata": {"window": "Our approach to address the pandemic underscores our value system and how we carry out our vision to improve \ncare in every setting, one product, one partner, one patient at  a time.  \n \n Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n", "original_text": "Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c092611a30492acbcd2b191b5c055c8863d5a92ffdd2feb7eba9125bd0d8de4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7428bb5f-4b2e-45b0-a3c9-5f66c8b993cb", "node_type": "1", "metadata": {"window": "In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S. ", "original_text": "I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization. "}, "hash": "2c15039a80458dc8d1176704176a7913bdba1f1ffadb7c7114889ae608945f11", "class_name": "RelatedNodeInfo"}}, "text": "Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December. ", "start_char_idx": 1333, "end_char_idx": 1502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7428bb5f-4b2e-45b0-a3c9-5f66c8b993cb": {"__data__": {"id_": "7428bb5f-4b2e-45b0-a3c9-5f66c8b993cb", "embedding": null, "metadata": {"window": "In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S. ", "original_text": "I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc3209d2-b9b6-4255-b420-a2526bdade4d", "node_type": "1", "metadata": {"window": "Turning now to our financial performance, we're going to review our fiscal 2020 results, our fiscal 2021 outlook \nand why we're so confident in McKesson's long -term future, despite the near -term uncertainties that are really \nfacing everyone.  \n \n In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S. ", "original_text": "Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f13c02ba37c715803c7117e05ccb760ea14edd723f93410f647cbd4a4e5eb86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ddb71c9-b39f-4895-b267-b078b4aef7a2", "node_type": "1", "metadata": {"window": "Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears. ", "original_text": "I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n"}, "hash": "3b6eaf858632a9337b8fe57c2d11ecb3c8f818d62a7b062068ff71331c073843", "class_name": "RelatedNodeInfo"}}, "text": "I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization. ", "start_char_idx": 1502, "end_char_idx": 1731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ddb71c9-b39f-4895-b267-b078b4aef7a2": {"__data__": {"id_": "1ddb71c9-b39f-4895-b267-b078b4aef7a2", "embedding": null, "metadata": {"window": "Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears. ", "original_text": "I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7428bb5f-4b2e-45b0-a3c9-5f66c8b993cb", "node_type": "1", "metadata": {"window": "In fiscal 2020, McKesson delivered strong revenue and adjusted operating profit growth across the business.  Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S. ", "original_text": "I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "acd4494ebb936b647a728c94a83117eeebfb49b5bbf448325eda0f80e5fc974d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a10be71-e4dd-4be9-8778-9c5db82f12e0", "node_type": "1", "metadata": {"window": "Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n", "original_text": "In our U.S. "}, "hash": "8b9ad56cdd3991d862f91f50777dbe760fe8e93703cc6d29176061a9afc124f4", "class_name": "RelatedNodeInfo"}}, "text": "I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n", "start_char_idx": 1731, "end_char_idx": 1860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a10be71-e4dd-4be9-8778-9c5db82f12e0": {"__data__": {"id_": "4a10be71-e4dd-4be9-8778-9c5db82f12e0", "embedding": null, "metadata": {"window": "Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n", "original_text": "In our U.S. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ddb71c9-b39f-4895-b267-b078b4aef7a2", "node_type": "1", "metadata": {"window": "Our \nfiscal 2020 adjusted earnings per diluted share result of $14.95, which was up 10% versus the prior year, reflects \ncontinuing momentum and transform ation within our business.  \n \n Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears. ", "original_text": "I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29dca5999bae9dc91380954597bf2b7752f5201d9346a9066a358ccc40cbb3ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "514d4865-431a-4183-a456-e6a55faba191", "node_type": "1", "metadata": {"window": "I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n", "original_text": "Pharmaceutical Specialty and Solutions (sic) [U.S. "}, "hash": "238ae1db48316471021126d357fcb237a86ec03b28e5a7e4c89f6dd7ac4417b5", "class_name": "RelatedNodeInfo"}}, "text": "In our U.S. ", "start_char_idx": 1860, "end_char_idx": 1872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "514d4865-431a-4183-a456-e6a55faba191": {"__data__": {"id_": "514d4865-431a-4183-a456-e6a55faba191", "embedding": null, "metadata": {"window": "I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n", "original_text": "Pharmaceutical Specialty and Solutions (sic) [U.S. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a10be71-e4dd-4be9-8778-9c5db82f12e0", "node_type": "1", "metadata": {"window": "Coming into the CEO role a little over a year ago, I focused the organization around three strategic priorities, \nwhich I shared during our Analyst Meeting in December.  I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n", "original_text": "In our U.S. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a0e4a1b329a097ada70ef68da5bdab27c2521e874b7066211f1f76258b5744", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6ce3d14-0b54-415f-b06f-f82218ef95ae", "node_type": "1", "metadata": {"window": "I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business. ", "original_text": "Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears. "}, "hash": "661e44dd8c896d4c923eb9bb0b3557068c0557c1b61a0d1fe808b84bc1a85139", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical Specialty and Solutions (sic) [U.S. ", "start_char_idx": 1872, "end_char_idx": 1923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6ce3d14-0b54-415f-b06f-f82218ef95ae": {"__data__": {"id_": "d6ce3d14-0b54-415f-b06f-f82218ef95ae", "embedding": null, "metadata": {"window": "I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business. ", "original_text": "Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "514d4865-431a-4183-a456-e6a55faba191", "node_type": "1", "metadata": {"window": "I'd remind you, these priorities were growing our core US \npharma business, investing in the areas where we have differentiated capability and growth prospects, and \nsimplifying the business and better aligning the organization.  I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n", "original_text": "Pharmaceutical Specialty and Solutions (sic) [U.S. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ec872449433ad21004f03ff995cf38d4ccb526b2f59c5791a633383d220013e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db2abff1-79f5-4bd0-a115-10c7c19b2cca", "node_type": "1", "metadata": {"window": "In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n", "original_text": "And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n"}, "hash": "24855ea305aeb9a2a9dd020d2fbdc11a6f002796a3992c621600e016fb7d05b7", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears. ", "start_char_idx": 1923, "end_char_idx": 2097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db2abff1-79f5-4bd0-a115-10c7c19b2cca": {"__data__": {"id_": "db2abff1-79f5-4bd0-a115-10c7c19b2cca", "embedding": null, "metadata": {"window": "In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n", "original_text": "And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6ce3d14-0b54-415f-b06f-f82218ef95ae", "node_type": "1", "metadata": {"window": "I'm extremely pleased with the meaningful progress \nwe made in executing against these str ategic priorities in fiscal 2020.  \n \n In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business. ", "original_text": "Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b208065937dc85c8a16a01ade5c84a413dd0d8d3adf731d60c66ab6e3f35bb77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3bd19a7-c268-4884-8e2d-a8a3f7c4390f", "node_type": "1", "metadata": {"window": "Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth. ", "original_text": "We believe our strong value proposition and superior customer service quality are foundational to this success. \n"}, "hash": "435da4eb8a4c41b8dc1f3fee3cd94f476621e54858955859cb0c0a5211bf6dce", "class_name": "RelatedNodeInfo"}}, "text": "And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n", "start_char_idx": 2097, "end_char_idx": 2325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3bd19a7-c268-4884-8e2d-a8a3f7c4390f": {"__data__": {"id_": "a3bd19a7-c268-4884-8e2d-a8a3f7c4390f", "embedding": null, "metadata": {"window": "Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth. ", "original_text": "We believe our strong value proposition and superior customer service quality are foundational to this success. \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db2abff1-79f5-4bd0-a115-10c7c19b2cca", "node_type": "1", "metadata": {"window": "In our U.S.  Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n", "original_text": "And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d2b7cd4c33ca5af916d37ed25515977a3a406306462de340613e33f420b810a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8302cde-db53-4648-b72c-43e7137ff62a", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n", "original_text": "Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business. "}, "hash": "5a16626a26706bc89481cf6b1cb342cc4305d331d56affee27fea03c7c610ed3", "class_name": "RelatedNodeInfo"}}, "text": "We believe our strong value proposition and superior customer service quality are foundational to this success. \n", "start_char_idx": 2325, "end_char_idx": 2438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8302cde-db53-4648-b72c-43e7137ff62a": {"__data__": {"id_": "d8302cde-db53-4648-b72c-43e7137ff62a", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n", "original_text": "Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3bd19a7-c268-4884-8e2d-a8a3f7c4390f", "node_type": "1", "metadata": {"window": "Pharmaceutical Specialty and Solutions (sic) [U.S.  Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth. ", "original_text": "We believe our strong value proposition and superior customer service quality are foundational to this success. \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "173ee6d87254d88238fbd1e65254b8bdc49183e1fe3a389c731488ffdd74eec0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9dd4f86-e787-46f9-993c-eb42f0139467", "node_type": "1", "metadata": {"window": "And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed. ", "original_text": "We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n"}, "hash": "62b9f484de8b60202b1b0f5305cdffd11b38be2870ea2b7711e6db3c540b600e", "class_name": "RelatedNodeInfo"}}, "text": "Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business. ", "start_char_idx": 2438, "end_char_idx": 2575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9dd4f86-e787-46f9-993c-eb42f0139467": {"__data__": {"id_": "a9dd4f86-e787-46f9-993c-eb42f0139467", "embedding": null, "metadata": {"window": "And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed. ", "original_text": "We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8302cde-db53-4648-b72c-43e7137ff62a", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions] (00:09:05) \nsegment, we finished the year with the highest level of adjusted operating profit growth in our last four f iscal \nyears.  And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n", "original_text": "Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c73a6593d5836fa89a8bdd82629e79b7f8f99dd41320fbddfe61620ef7c0a0d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "075d7018-7429-4294-92a1-db92e6080569", "node_type": "1", "metadata": {"window": "We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment . ", "original_text": "We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth. "}, "hash": "0807965d3ac3fe5f28561c8d4e38bb4e887dddfda418f61ab8e1bebe49c68a17", "class_name": "RelatedNodeInfo"}}, "text": "We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n", "start_char_idx": 2575, "end_char_idx": 2735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "075d7018-7429-4294-92a1-db92e6080569": {"__data__": {"id_": "075d7018-7429-4294-92a1-db92e6080569", "embedding": null, "metadata": {"window": "We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment . ", "original_text": "We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9dd4f86-e787-46f9-993c-eb42f0139467", "node_type": "1", "metadata": {"window": "And we, again, this year successfully renewed large customers while being disciplined in our approach to \nthe market, most recently, having been selected by the VA to continue to serve as their prime pharmaceutical \nvendor.  \n \n We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed. ", "original_text": "We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72695d19862d0c3574914818f0ee9fafeda54c8742811981d9ab53c17acfb828", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f1ff1c5-85f6-4830-b2a1-497e332e527f", "node_type": "1", "metadata": {"window": "Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n", "original_text": "In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n"}, "hash": "7a037f94212510ee67eb01490a7c01586fdd95e44ada537d6ccc381efff4e628", "class_name": "RelatedNodeInfo"}}, "text": "We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth. ", "start_char_idx": 2735, "end_char_idx": 2856, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f1ff1c5-85f6-4830-b2a1-497e332e527f": {"__data__": {"id_": "2f1ff1c5-85f6-4830-b2a1-497e332e527f", "embedding": null, "metadata": {"window": "Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n", "original_text": "In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "075d7018-7429-4294-92a1-db92e6080569", "node_type": "1", "metadata": {"window": "We believe our strong value proposition and superior customer service quality are foundational to this success. \n Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment . ", "original_text": "We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb3ef18616af887a16cc74098f03816ea7f604a4bda6a95f8e865e0277e238dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5282f2d-624a-4b2a-9f3f-8850d381cf66", "node_type": "1", "metadata": {"window": "We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n Our third strategic priority is centered around simplifying the business and aligning the organization. ", "original_text": "We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed. "}, "hash": "a8403f1b23367030fe20e20d26857139b423b6455150894d367bd6608dedb10e", "class_name": "RelatedNodeInfo"}}, "text": "In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n", "start_char_idx": 2856, "end_char_idx": 3068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5282f2d-624a-4b2a-9f3f-8850d381cf66": {"__data__": {"id_": "c5282f2d-624a-4b2a-9f3f-8850d381cf66", "embedding": null, "metadata": {"window": "We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n Our third strategic priority is centered around simplifying the business and aligning the organization. ", "original_text": "We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f1ff1c5-85f6-4830-b2a1-497e332e527f", "node_type": "1", "metadata": {"window": "Our cost and working capital efficiencies underpin this growth and further fuel the strategic investments we're \nmaking in the business.  We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n", "original_text": "In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "303e47f46d2ee012d3349dd342bdc33e891c1269f1583e3061da524eed505046", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83739e53-e2a6-4b63-be4f-5eb8d2660cd5", "node_type": "1", "metadata": {"window": "We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n Our third strategic priority is centered around simplifying the business and aligning the organization.  We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n ", "original_text": "And we continue to prioritize specialty as a key area of future growth and investment . "}, "hash": "8aa34f393ae20af6c31c101293123afaba6005239a1d2a76bd1175120e6cd8ab", "class_name": "RelatedNodeInfo"}}, "text": "We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed. ", "start_char_idx": 3068, "end_char_idx": 3295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83739e53-e2a6-4b63-be4f-5eb8d2660cd5": {"__data__": {"id_": "83739e53-e2a6-4b63-be4f-5eb8d2660cd5", "embedding": null, "metadata": {"window": "We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n Our third strategic priority is centered around simplifying the business and aligning the organization.  We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n ", "original_text": "And we continue to prioritize specialty as a key area of future growth and investment . ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5282f2d-624a-4b2a-9f3f-8850d381cf66", "node_type": "1", "metadata": {"window": "We view our investments  in data and analytics as investments in foundational capability, \nleveraging our scale to deliver greater value for our customers.  \n \n We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n Our third strategic priority is centered around simplifying the business and aligning the organization. ", "original_text": "We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "38f3e09bc0afc0dee9323155d022626cc466b240b3411d83337cd3dfb554715d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37766d81-be37-4a5b-9eb9-5c6566ee589a", "node_type": "1", "metadata": {"window": "In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n Our third strategic priority is centered around simplifying the business and aligning the organization.  We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n ", "original_text": "We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n"}, "hash": "e7663e1e0091bc2daeaabcad8fd7705f8ec2b2197dea4486918a5ef4b2c9f081", "class_name": "RelatedNodeInfo"}}, "text": "And we continue to prioritize specialty as a key area of future growth and investment . ", "start_char_idx": 3295, "end_char_idx": 3383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37766d81-be37-4a5b-9eb9-5c6566ee589a": {"__data__": {"id_": "37766d81-be37-4a5b-9eb9-5c6566ee589a", "embedding": null, "metadata": {"window": "In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n Our third strategic priority is centered around simplifying the business and aligning the organization.  We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n ", "original_text": "We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83739e53-e2a6-4b63-be4f-5eb8d2660cd5", "node_type": "1", "metadata": {"window": "We're also making investments into areas where we believe we have differentiated capability and opportunity for \ngrowth.  In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n Our third strategic priority is centered around simplifying the business and aligning the organization.  We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n ", "original_text": "And we continue to prioritize specialty as a key area of future growth and investment . ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e37071d7d55578211063e49ff48c1dc803306393796e3e1c027a8d7334ab3e07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "019006a5-44b3-43c3-b449-8cd839cbe692", "node_type": "1", "metadata": {"window": "We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n Our third strategic priority is centered around simplifying the business and aligning the organization.  We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n ", "original_text": "Our third strategic priority is centered around simplifying the business and aligning the organization. "}, "hash": "6ae482abde002d9d7163021a3d110602f16cb88e037c03126f781e7049e3e21a", "class_name": "RelatedNodeInfo"}}, "text": "We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n", "start_char_idx": 3383, "end_char_idx": 3556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "019006a5-44b3-43c3-b449-8cd839cbe692": {"__data__": {"id_": "019006a5-44b3-43c3-b449-8cd839cbe692", "embedding": null, "metadata": {"window": "We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n Our third strategic priority is centered around simplifying the business and aligning the organization.  We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n ", "original_text": "Our third strategic priority is centered around simplifying the business and aligning the organization. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37766d81-be37-4a5b-9eb9-5c6566ee589a", "node_type": "1", "metadata": {"window": "In a lignment with our strategic growth initiatives, we're expanding our manufacturer value proposition to \ndrive more innovation, better patient outcomes and additional uptake for our manufacturer partners.  \n \n We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n Our third strategic priority is centered around simplifying the business and aligning the organization.  We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n ", "original_text": "We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6eed47bfdc89dae2a500368b1eff1fd18de8a7070a4be8a62441306859c8d4c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62a3d3c2-2a8f-4dc4-b392-a7bd4d69d94d", "node_type": "1", "metadata": {"window": "And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n Our third strategic priority is centered around simplifying the business and aligning the organization.  We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n ", "original_text": "We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n "}, "hash": "cacaf2a36337dff8b11c3baf6cf3461cad8ffc7f19c7678e4866678c6e7dd43c", "class_name": "RelatedNodeInfo"}}, "text": "Our third strategic priority is centered around simplifying the business and aligning the organization. ", "start_char_idx": 3556, "end_char_idx": 3660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62a3d3c2-2a8f-4dc4-b392-a7bd4d69d94d": {"__data__": {"id_": "62a3d3c2-2a8f-4dc4-b392-a7bd4d69d94d", "embedding": null, "metadata": {"window": "And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n Our third strategic priority is centered around simplifying the business and aligning the organization.  We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n ", "original_text": "We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49cee5880d0a76038f0a7d2f03be77222b9ce997845867a0283106623f1d6c70", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "019006a5-44b3-43c3-b449-8cd839cbe692", "node_type": "1", "metadata": {"window": "We're harnessing our decades of experience in patient  access and adherence programs and combining it with the \nconnectivity and reach of CoverMyMeds within our MRxTS business to deliver new capabilities at accelerated \nspeed.  And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n Our third strategic priority is centered around simplifying the business and aligning the organization.  We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n ", "original_text": "Our third strategic priority is centered around simplifying the business and aligning the organization. ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31ebc6b8d5d7fad9db224dfb0c8c2f4c8f86c118f9d3b01b6012df740b88b56d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae07db96-fb7a-4acf-8c4b-9541c78b5dc6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers. ", "original_text": "McKesson Corp.  "}, "hash": "e90d336a43e93866056b08a3873d663d3e391bcc2ad455c062ea22b3187448c6", "class_name": "RelatedNodeInfo"}}, "text": "We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n ", "start_char_idx": 3660, "end_char_idx": 3807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae07db96-fb7a-4acf-8c4b-9541c78b5dc6": {"__data__": {"id_": "ae07db96-fb7a-4acf-8c4b-9541c78b5dc6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62a3d3c2-2a8f-4dc4-b392-a7bd4d69d94d", "node_type": "1", "metadata": {"window": "And we continue to prioritize specialty as a key area of future growth and investment .  We have been \nbuilding and investing in our portfolio of differentiated specialty assets for more than a decade, which gives us \ngreat expertise in areas like oncology.  \n \n Our third strategic priority is centered around simplifying the business and aligning the organization.  We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n ", "original_text": "We are \nbecoming a more focused, more aligned and more agile company, a foundation that served us well during our \nCOVID -19 pandemic response.  \n ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "725eb568914f8e58627b4b0aadfa3db2be4cc1879ae2d2fd7a35ac6af4df62ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cba5881-dd10-4460-9bc1-12ecf6265170", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe. "}, "hash": "885d753194b260a046c7da82991038401b305c851c572236438f73810fdede27", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cba5881-dd10-4460-9bc1-12ecf6265170": {"__data__": {"id_": "9cba5881-dd10-4460-9bc1-12ecf6265170", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae07db96-fb7a-4acf-8c4b-9541c78b5dc6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "942d992f774679cd0aeaa7d048b9bcd677f82ac1bf9ffc78d020f31127d18735", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8015caaf-488f-4a42-97bb-3c85813f912d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team. ", "original_text": "Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n"}, "hash": "18dd14a647db430a96277330879ae560e1b171ef72716f0fd73379722baef4af", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe. ", "start_char_idx": 16, "end_char_idx": 355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8015caaf-488f-4a42-97bb-3c85813f912d": {"__data__": {"id_": "8015caaf-488f-4a42-97bb-3c85813f912d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team. ", "original_text": "Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cba5881-dd10-4460-9bc1-12ecf6265170", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c7b07dd0e5e0cdf074a37e52467215b2bda41a2e2ef552221b39e2f6e5f7fd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c729807-428c-40cc-8d22-556ae4a06bb2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n", "original_text": "Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers. "}, "hash": "683d0f8cbd5b4b5e001dc5f474da018dd7b414a81493fc51e1d5606944a6f5cc", "class_name": "RelatedNodeInfo"}}, "text": "Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n", "start_char_idx": 355, "end_char_idx": 518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c729807-428c-40cc-8d22-556ae4a06bb2": {"__data__": {"id_": "8c729807-428c-40cc-8d22-556ae4a06bb2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n", "original_text": "Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8015caaf-488f-4a42-97bb-3c85813f912d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team. ", "original_text": "Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52cf6cdc0e703ed0ad53d329c4157e28da181d00b86dbdefe5ce0ece937cbcea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7376695-be65-4906-8e83-ad734c867405", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare. ", "original_text": "This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n"}, "hash": "de36aea04975df647fdcdd244d5ddb522a3380097cf29ae005c9832696b95c43", "class_name": "RelatedNodeInfo"}}, "text": "Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers. ", "start_char_idx": 518, "end_char_idx": 657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7376695-be65-4906-8e83-ad734c867405": {"__data__": {"id_": "e7376695-be65-4906-8e83-ad734c867405", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare. ", "original_text": "This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c729807-428c-40cc-8d22-556ae4a06bb2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n", "original_text": "Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2a3cbe425023995c1f0e57be93c9b8537a2652782fdce9c6934fbb9db968838", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bd6deaa-fb4b-4720-9531-d42f5225b07a", "node_type": "1", "metadata": {"window": "Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n", "original_text": "We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team. "}, "hash": "6274fa644d8373e094c817d8cff277333bc9e0ac133f7d6efb6b39cba59d5481", "class_name": "RelatedNodeInfo"}}, "text": "This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n", "start_char_idx": 657, "end_char_idx": 832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bd6deaa-fb4b-4720-9531-d42f5225b07a": {"__data__": {"id_": "4bd6deaa-fb4b-4720-9531-d42f5225b07a", "embedding": null, "metadata": {"window": "Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n", "original_text": "We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7376695-be65-4906-8e83-ad734c867405", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare. ", "original_text": "This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2dabaf23be8d40f31d10efc92eedbf6e3f038feedee2543116ef1858565abb4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b1e0292-c967-4eac-a77a-f21bb50d8c1c", "node_type": "1", "metadata": {"window": "Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties. ", "original_text": "Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n"}, "hash": "b69c472a8eea2072ff89ac103b13814f0c24c7dd781afc0b188575d7c9e3dbbf", "class_name": "RelatedNodeInfo"}}, "text": "We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team. ", "start_char_idx": 832, "end_char_idx": 1005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b1e0292-c967-4eac-a77a-f21bb50d8c1c": {"__data__": {"id_": "9b1e0292-c967-4eac-a77a-f21bb50d8c1c", "embedding": null, "metadata": {"window": "Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties. ", "original_text": "Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bd6deaa-fb4b-4720-9531-d42f5225b07a", "node_type": "1", "metadata": {"window": "Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n", "original_text": "We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a75e48cbe833f260df390c04da5cdf6c4b428978e7216f866763d25d49152db3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cb6ea31-d193-4ba8-9b9f-b1a26a0308be", "node_type": "1", "metadata": {"window": "This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments. ", "original_text": "One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare. "}, "hash": "348dd8be9827543b6e1d270ba44da7d25370f337b91e4b8c6ae038f4a33ee78e", "class_name": "RelatedNodeInfo"}}, "text": "Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n", "start_char_idx": 1005, "end_char_idx": 1198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cb6ea31-d193-4ba8-9b9f-b1a26a0308be": {"__data__": {"id_": "3cb6ea31-d193-4ba8-9b9f-b1a26a0308be", "embedding": null, "metadata": {"window": "This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments. ", "original_text": "One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b1e0292-c967-4eac-a77a-f21bb50d8c1c", "node_type": "1", "metadata": {"window": "Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers.  This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties. ", "original_text": "Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21f6317254c07ba767a29d3cd656d6a6457434e206261d03b14d77a7bff4dc9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35af83e2-6379-4dcd-b85b-2fd99ede99d8", "node_type": "1", "metadata": {"window": "We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n", "original_text": "This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n"}, "hash": "176abf746d33cd3929242d531ec5de94d9867e2dec770b4539d19c94c017b07a", "class_name": "RelatedNodeInfo"}}, "text": "One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare. ", "start_char_idx": 1198, "end_char_idx": 1349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35af83e2-6379-4dcd-b85b-2fd99ede99d8": {"__data__": {"id_": "35af83e2-6379-4dcd-b85b-2fd99ede99d8", "embedding": null, "metadata": {"window": "We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n", "original_text": "This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cb6ea31-d193-4ba8-9b9f-b1a26a0308be", "node_type": "1", "metadata": {"window": "This strategic change, combined with the continued execution of actions taken in the prior \nyear, translated into good profit growth for the  Canadian business this year.  \n \n We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments. ", "original_text": "One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e1750f52c8f5e937927dbeb548507d1333022bb8bf6f19f8c9939477ff5efb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "caca2e71-dcb8-4c2e-bb02-0330c0fdaf08", "node_type": "1", "metadata": {"window": "Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S. ", "original_text": "Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties. "}, "hash": "e79edae56cd450c081cda970a24efe5bc12eecd047506c1d065220b7c8a54fb0", "class_name": "RelatedNodeInfo"}}, "text": "This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n", "start_char_idx": 1349, "end_char_idx": 1560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "caca2e71-dcb8-4c2e-bb02-0330c0fdaf08": {"__data__": {"id_": "caca2e71-dcb8-4c2e-bb02-0330c0fdaf08", "embedding": null, "metadata": {"window": "Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S. ", "original_text": "Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35af83e2-6379-4dcd-b85b-2fd99ede99d8", "node_type": "1", "metadata": {"window": "We also invested a significant amount of time in our culture transformation and leveraged our corporate \nheadquarters relocation to Texas to strengthen our management team.  Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n", "original_text": "This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "921a0cda2da4257d1af4f53c8bc52070ec5e331e0fd6420fee1bfcd33ca3461c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f2e6b80-6f14-4cc2-a011-88071fc600f0", "node_type": "1", "metadata": {"window": "One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S.  and Specialty Solutions (sic) [U.S. ", "original_text": "I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments. "}, "hash": "8680c4ec02add9fbad510fbea3e218cc171bbc5060f77ad23deb3df161cbe6eb", "class_name": "RelatedNodeInfo"}}, "text": "Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties. ", "start_char_idx": 1560, "end_char_idx": 1730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f2e6b80-6f14-4cc2-a011-88071fc600f0": {"__data__": {"id_": "4f2e6b80-6f14-4cc2-a011-88071fc600f0", "embedding": null, "metadata": {"window": "One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S.  and Specialty Solutions (sic) [U.S. ", "original_text": "I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "caca2e71-dcb8-4c2e-bb02-0330c0fdaf08", "node_type": "1", "metadata": {"window": "Five new members have joined my \nmanagement team this year, and I could not be more pleased with how quickly the team has united together to \nexecute our strategic and cultural priorities.  \n \n One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S. ", "original_text": "Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "706a3a16c4264974a91004a3669314ffbc0f80b915d638b67243b4a41e02f9c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59172798-b18e-4f1f-a0cf-aa1cf26c2b0f", "node_type": "1", "metadata": {"window": "This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S.  and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment. ", "original_text": "We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n"}, "hash": "d616a6ae54974241280ac26e4368ae918b42339a8763f2e829678f375073194e", "class_name": "RelatedNodeInfo"}}, "text": "I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments. ", "start_char_idx": 1730, "end_char_idx": 1882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59172798-b18e-4f1f-a0cf-aa1cf26c2b0f": {"__data__": {"id_": "59172798-b18e-4f1f-a0cf-aa1cf26c2b0f", "embedding": null, "metadata": {"window": "This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S.  and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment. ", "original_text": "We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f2e6b80-6f14-4cc2-a011-88071fc600f0", "node_type": "1", "metadata": {"window": "One of the most visible accomplishments we made in fiscal 2020 towards simplifying the business was the \ncompletion of our  exit of Change Healthcare.  This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S.  and Specialty Solutions (sic) [U.S. ", "original_text": "I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "451515d0a61137e12b0ea1507c8cd35c467c4762c1fba08fb542260913e5f236", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5c13d19-1e0d-44b9-a9c6-bd359f0d29fd", "node_type": "1", "metadata": {"window": "Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S.  and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home. ", "original_text": "I'll start in the U.S. "}, "hash": "18d27f92d38de61b62285e5d51e9c5f5593ee542b57bd1ca5f62a0be3e1927db", "class_name": "RelatedNodeInfo"}}, "text": "We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n", "start_char_idx": 1882, "end_char_idx": 2032, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5c13d19-1e0d-44b9-a9c6-bd359f0d29fd": {"__data__": {"id_": "b5c13d19-1e0d-44b9-a9c6-bd359f0d29fd", "embedding": null, "metadata": {"window": "Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S.  and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home. ", "original_text": "I'll start in the U.S. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59172798-b18e-4f1f-a0cf-aa1cf26c2b0f", "node_type": "1", "metadata": {"window": "This is a significant milestone in our company's history that was \nnearly four years in the making, and we're pleased to deliver on our commitment to create shareholder value \nthrough a tax -efficient exit.  \n \n Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S.  and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment. ", "original_text": "We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5cdc9ea56440735f4d2c5589265d013342cf635d429568410ddca4137933c70b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6454d9c-6445-4973-8eb9-7b294d096b37", "node_type": "1", "metadata": {"window": "I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S.  and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n", "original_text": "and Specialty Solutions (sic) [U.S. "}, "hash": "e973bea3922e591c4ba75bc40a1c444bab70cca632f6b3995a0d0a912fb8d816", "class_name": "RelatedNodeInfo"}}, "text": "I'll start in the U.S. ", "start_char_idx": 2032, "end_char_idx": 2055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6454d9c-6445-4973-8eb9-7b294d096b37": {"__data__": {"id_": "e6454d9c-6445-4973-8eb9-7b294d096b37", "embedding": null, "metadata": {"window": "I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S.  and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n", "original_text": "and Specialty Solutions (sic) [U.S. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5c13d19-1e0d-44b9-a9c6-bd359f0d29fd", "node_type": "1", "metadata": {"window": "Let me turn now to the trends that we're currently seeing on our business and how we're planning ahead for fiscal \n2021 in light of these near -term macro uncertainties.  I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S.  and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home. ", "original_text": "I'll start in the U.S. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "104d1da775afee89131510dce108b853ea35584756fe54399b29b8625acfc414", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a26c0bb0-5b4c-4ae5-bc1b-bf26b7194f14", "node_type": "1", "metadata": {"window": "We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S.  and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets. ", "original_text": "Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment. "}, "hash": "bd5ff9cd34b38ba29bbdb659bfa25ead6ac17f92f18d5bbb24ee83c10c131dc8", "class_name": "RelatedNodeInfo"}}, "text": "and Specialty Solutions (sic) [U.S. ", "start_char_idx": 2055, "end_char_idx": 2091, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a26c0bb0-5b4c-4ae5-bc1b-bf26b7194f14": {"__data__": {"id_": "a26c0bb0-5b4c-4ae5-bc1b-bf26b7194f14", "embedding": null, "metadata": {"window": "We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S.  and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets. ", "original_text": "Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6454d9c-6445-4973-8eb9-7b294d096b37", "node_type": "1", "metadata": {"window": "I'll discuss these trends really in kind of more real -time \ngranularity than we typically would and then Britt w ill further elaborate on my comments.  We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S.  and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n", "original_text": "and Specialty Solutions (sic) [U.S. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1ed9efddee95b3d3c91106efdaa3cb077bf154bc0baaa59d2cc1b4770044ada", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6533b011-b609-4371-86db-5a9962bf3a7e", "node_type": "1", "metadata": {"window": "I'll start in the U.S.  and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n", "original_text": "We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home. "}, "hash": "7f77734354c3f42a211f7e27d77cf0969ee1375f99272def4ee01a25263282d2", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment. ", "start_char_idx": 2091, "end_char_idx": 2153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6533b011-b609-4371-86db-5a9962bf3a7e": {"__data__": {"id_": "6533b011-b609-4371-86db-5a9962bf3a7e", "embedding": null, "metadata": {"window": "I'll start in the U.S.  and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n", "original_text": "We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a26c0bb0-5b4c-4ae5-bc1b-bf26b7194f14", "node_type": "1", "metadata": {"window": "We really want to help \nyou understand how the rapidly evolving environment impacted not just our FY 2020 results, but also our FY 2021 \noutlook.  \n \n I'll start in the U.S.  and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets. ", "original_text": "Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "efbfbad75972d08db7690b6565a7d7c5e8f2cad18530a17a0595ebbd64c37d95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a510d8be-4530-4358-8b8e-e37a3305ed92", "node_type": "1", "metadata": {"window": "and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect. ", "original_text": "In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n"}, "hash": "eb4c3f4cd335e3ba38266f63b030f2b8f5059bee12b1b1ca38594395bee9c70c", "class_name": "RelatedNodeInfo"}}, "text": "We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home. ", "start_char_idx": 2153, "end_char_idx": 2281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a510d8be-4530-4358-8b8e-e37a3305ed92": {"__data__": {"id_": "a510d8be-4530-4358-8b8e-e37a3305ed92", "embedding": null, "metadata": {"window": "and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect. ", "original_text": "In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6533b011-b609-4371-86db-5a9962bf3a7e", "node_type": "1", "metadata": {"window": "I'll start in the U.S.  and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n", "original_text": "We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67a0ddf00bb04e0c29c97e306ed6099cc6dea7662cdc217e4a7fc2d3ead2c2cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db0ea668-7b93-4dfb-8fcb-9283ddc5fa29", "node_type": "1", "metadata": {"window": "Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers. ", "original_text": "More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets. "}, "hash": "aef0203e517b042409a19d87d03e86fef224be624f5b17b10e1530a05486fc26", "class_name": "RelatedNodeInfo"}}, "text": "In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n", "start_char_idx": 2281, "end_char_idx": 2409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db0ea668-7b93-4dfb-8fcb-9283ddc5fa29": {"__data__": {"id_": "db0ea668-7b93-4dfb-8fcb-9283ddc5fa29", "embedding": null, "metadata": {"window": "Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers. ", "original_text": "More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a510d8be-4530-4358-8b8e-e37a3305ed92", "node_type": "1", "metadata": {"window": "and Specialty Solutions (sic) [U.S.  Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect. ", "original_text": "In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "987c00b76b4c2a9802ff36c0979d18727a1cd247c63467d20ec0265e4b636903", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a022dc64-989c-4bcc-a73a-ac95738f99b9", "node_type": "1", "metadata": {"window": "We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n", "original_text": "In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n"}, "hash": "9ce6839fe087ad5860598efc6c835e846a01e4f12f7b850e0453104a169bf111", "class_name": "RelatedNodeInfo"}}, "text": "More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets. ", "start_char_idx": 2409, "end_char_idx": 2512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a022dc64-989c-4bcc-a73a-ac95738f99b9": {"__data__": {"id_": "a022dc64-989c-4bcc-a73a-ac95738f99b9", "embedding": null, "metadata": {"window": "We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n", "original_text": "In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db0ea668-7b93-4dfb-8fcb-9283ddc5fa29", "node_type": "1", "metadata": {"window": "Pharmaceutical  and Specialty Solutions] (00:13:01) \nsegment.  We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers. ", "original_text": "More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e1219188d92d2eb62141f13c32bfd68b08061d9767756cc43c1d57e5c0ac012", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85498caa-4623-4572-b8dd-1162d99cb016", "node_type": "1", "metadata": {"window": "In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed. ", "original_text": "In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect. "}, "hash": "f9486850a8f55bd0180231fe8cb46bbfed0f9cb82f61d8409e16e3b067d72e28", "class_name": "RelatedNodeInfo"}}, "text": "In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n", "start_char_idx": 2512, "end_char_idx": 2758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85498caa-4623-4572-b8dd-1162d99cb016": {"__data__": {"id_": "85498caa-4623-4572-b8dd-1162d99cb016", "embedding": null, "metadata": {"window": "In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed. ", "original_text": "In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a022dc64-989c-4bcc-a73a-ac95738f99b9", "node_type": "1", "metadata": {"window": "We saw increased demand in pharmaceutical sales during the month of March as consumers prepared \nfor an extended stay -at-home.  In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n", "original_text": "In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0e1c8cb6f07ceb652d1a2c6a7eb713018aa93e40014e9239fdc5b145da9d1fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41840264-35ff-4881-82bd-74f1d09e3d0e", "node_type": "1", "metadata": {"window": "More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed.  With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n ", "original_text": "In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers. "}, "hash": "7fb056de1f3777b2b0cd126c10aed4998e671e164b1c57a693d49144d13c9943", "class_name": "RelatedNodeInfo"}}, "text": "In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect. ", "start_char_idx": 2758, "end_char_idx": 2982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41840264-35ff-4881-82bd-74f1d09e3d0e": {"__data__": {"id_": "41840264-35ff-4881-82bd-74f1d09e3d0e", "embedding": null, "metadata": {"window": "More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed.  With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n ", "original_text": "In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85498caa-4623-4572-b8dd-1162d99cb016", "node_type": "1", "metadata": {"window": "In turn, pharmaceutical sales declined below pre -pandemic levels in April, \ncoincidin g with the start of our fiscal year.  \n \n More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed. ", "original_text": "In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72b374dafb360b856a90e790fb404507414828024e8654f2faa35885c95fcee9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ad62c32-a357-4e42-95f7-d6ca8f648abf", "node_type": "1", "metadata": {"window": "In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed.  With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n ", "original_text": "And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n"}, "hash": "64f16590813b1abcfbab8de64d94c88ace2e1378f59648856da7fd62ead09fa3", "class_name": "RelatedNodeInfo"}}, "text": "In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers. ", "start_char_idx": 2982, "end_char_idx": 3172, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ad62c32-a357-4e42-95f7-d6ca8f648abf": {"__data__": {"id_": "2ad62c32-a357-4e42-95f7-d6ca8f648abf", "embedding": null, "metadata": {"window": "In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed.  With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n ", "original_text": "And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41840264-35ff-4881-82bd-74f1d09e3d0e", "node_type": "1", "metadata": {"window": "More pronounced was the decline in specialty provider volumes, primarily in the non -oncology markets.  In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed.  With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n ", "original_text": "In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "413e4d60a2983bc6264d65e91747cb60772106faef70110011cb17f59df025c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ed6816c-dae1-4767-9229-89f747e38d6b", "node_type": "1", "metadata": {"window": "In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed.  With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n ", "original_text": "While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed. "}, "hash": "cee32dbbee57177796bebc12912f02d3ceb992a4cab784785cd1cf7a3241dbcb", "class_name": "RelatedNodeInfo"}}, "text": "And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n", "start_char_idx": 3172, "end_char_idx": 3353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ed6816c-dae1-4767-9229-89f747e38d6b": {"__data__": {"id_": "4ed6816c-dae1-4767-9229-89f747e38d6b", "embedding": null, "metadata": {"window": "In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed.  With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n ", "original_text": "While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ad62c32-a357-4e42-95f7-d6ca8f648abf", "node_type": "1", "metadata": {"window": "In \noncology, as evidenced by US oncology practices, despite a decline in routine office visits such as consults and \nfollow -ups, we are seeing relative signs of stability in oncology volumes as patients remain on their treatment \nregimens.  \n \n In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed.  With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n ", "original_text": "And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b67d1ec7ae83d8db2878f476cbf5887e589442880c52ebe8bf7192e87b36cf3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb583725-963a-4577-a27f-a25d35291f6e", "node_type": "1", "metadata": {"window": "In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed.  With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n ", "original_text": "With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n "}, "hash": "dff48f1006663058f984537625d9f980a3eef2cfb946b7bb1ecac692e1e640e6", "class_name": "RelatedNodeInfo"}}, "text": "While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed. ", "start_char_idx": 3353, "end_char_idx": 3605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb583725-963a-4577-a27f-a25d35291f6e": {"__data__": {"id_": "cb583725-963a-4577-a27f-a25d35291f6e", "embedding": null, "metadata": {"window": "In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed.  With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n ", "original_text": "With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ba158130-c643-44e1-9024-e87d5258ad90", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353c842af23ecb685d72c95a8c20db517b78dbcf6b6c8a4ac216b578ee422b67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ed6816c-dae1-4767-9229-89f747e38d6b", "node_type": "1", "metadata": {"window": "In our medical business, our alternate site customers are facing significant headwinds, with providers and surgery \ncenters seeing sha rp declines in office visits due to shelter -in-place guidelines that have taken effect.  In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed.  With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n ", "original_text": "While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed. ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01514d9b6d7a96d4b02c33474a04966b500f8c5bdecab29421b5a0faf599eb02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4931c29c-e08c-4027-b2a9-c690cf4dff8f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009. ", "original_text": "McKesson Corp.  "}, "hash": "43947187674d7dfc6c701f62bd76f46170d5c62723e997875e45fc464c09a1ae", "class_name": "RelatedNodeInfo"}}, "text": "With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n ", "start_char_idx": 3605, "end_char_idx": 3746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4931c29c-e08c-4027-b2a9-c690cf4dff8f": {"__data__": {"id_": "4931c29c-e08c-4027-b2a9-c690cf4dff8f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb583725-963a-4577-a27f-a25d35291f6e", "node_type": "1", "metadata": {"window": "In our \ntechnology, our MRxTS business, we're seeing lower prior authorization volumes as a result of provider office \nclosures and relaxed and sometimes extended require ments from payers.  And in Canada and Europe, our retail \npharmacy operations are navigating how to adapt to changing consumer needs as retail traffic is impacted by \nsocial distancing guidelines.  \n \n While it is still early in the quarter, we are currently seei ng positive indicators and encouraging signs across all of \nour businesses that activities are beginning to pick up in the communities where shelter -in-place guidelines are \nbeing relaxed.  With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n ", "original_text": "With this as our environmental backdrop, we carefully and thoughtfull y constructed our fiscal 2021 \noutlook based on what we know today.  \n ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b6541d20356beb8a4a859694fea6f5d0cc1daa59d36a7bc9c6d78f6b1478a2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f63b4a6-c656-4f57-ab27-195ac1acdd5d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions. "}, "hash": "76e706a8025e40513877f4e886757798d5ab90d3dfa6e06a4b9625e6a9740d95", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f63b4a6-c656-4f57-ab27-195ac1acdd5d": {"__data__": {"id_": "2f63b4a6-c656-4f57-ab27-195ac1acdd5d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4931c29c-e08c-4027-b2a9-c690cf4dff8f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77bf73d078b305217c64f1376d661ffe6e3efef42485f96192596bce09f38d0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e0ff743-eeab-42a2-9192-659b218a417b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength. ", "original_text": "Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n"}, "hash": "fb25826ac373a133859ba29904dc9667287d0ac4a0e937096407e1efef8b300d", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions. ", "start_char_idx": 16, "end_char_idx": 333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e0ff743-eeab-42a2-9192-659b218a417b": {"__data__": {"id_": "7e0ff743-eeab-42a2-9192-659b218a417b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength. ", "original_text": "Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f63b4a6-c656-4f57-ab27-195ac1acdd5d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83da1769452b72961c2dc23f42ec6789bee01107385531b75416098ed080fd12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9215cf5a-1823-499b-a5dd-cd7b4126da0f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n", "original_text": "We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009. "}, "hash": "245030a6c6527c3f029adbccdd26bc23cea821e0457a0618648d6501a278d1a6", "class_name": "RelatedNodeInfo"}}, "text": "Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n", "start_char_idx": 333, "end_char_idx": 501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9215cf5a-1823-499b-a5dd-cd7b4126da0f": {"__data__": {"id_": "9215cf5a-1823-499b-a5dd-cd7b4126da0f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n", "original_text": "We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e0ff743-eeab-42a2-9192-659b218a417b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength. ", "original_text": "Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffdf72ec3912f1a858bee78d42e17277eeddf844f4a8cff6fb8252f27d020f3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd873e80-31db-4440-a825-8c5f9890ad5d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth. ", "original_text": "I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell. "}, "hash": "f22e878a079cf38d4a648ccc251f640bec6dc679b862039db6bd68bca536395b", "class_name": "RelatedNodeInfo"}}, "text": "We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009. ", "start_char_idx": 501, "end_char_idx": 632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd873e80-31db-4440-a825-8c5f9890ad5d": {"__data__": {"id_": "cd873e80-31db-4440-a825-8c5f9890ad5d", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth. ", "original_text": "I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9215cf5a-1823-499b-a5dd-cd7b4126da0f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n", "original_text": "We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c03058f907c4d4ed52c448e8f4d7ae91db51ef1317f17a2da0cb4c45408c514", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03ddb6fa-b1e7-4d70-8b6c-983602e51c27", "node_type": "1", "metadata": {"window": "Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives. ", "original_text": "We operate from a position of financial strength. "}, "hash": "3c0e44047afe93c9c965e3690ea5f8b5c852b4a840b403ee7d598266e08e3e82", "class_name": "RelatedNodeInfo"}}, "text": "I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell. ", "start_char_idx": 632, "end_char_idx": 726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03ddb6fa-b1e7-4d70-8b6c-983602e51c27": {"__data__": {"id_": "03ddb6fa-b1e7-4d70-8b6c-983602e51c27", "embedding": null, "metadata": {"window": "Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives. ", "original_text": "We operate from a position of financial strength. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd873e80-31db-4440-a825-8c5f9890ad5d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth. ", "original_text": "I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e6c1251c2353776092f6575e17b2e84998be67c45643eda68b0e1e04ea1c5c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a51764fd-9db6-4cc5-af38-5fcb0834ba1f", "node_type": "1", "metadata": {"window": "We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n", "original_text": "Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n"}, "hash": "973e9e2395f8eb40c345a851bbb1cd2e79ea6f7b4d5c897c385b7558c27655f7", "class_name": "RelatedNodeInfo"}}, "text": "We operate from a position of financial strength. ", "start_char_idx": 726, "end_char_idx": 776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a51764fd-9db6-4cc5-af38-5fcb0834ba1f": {"__data__": {"id_": "a51764fd-9db6-4cc5-af38-5fcb0834ba1f", "embedding": null, "metadata": {"window": "We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n", "original_text": "Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03ddb6fa-b1e7-4d70-8b6c-983602e51c27", "node_type": "1", "metadata": {"window": "Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives. ", "original_text": "We operate from a position of financial strength. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "713a841149857d75672ccf282df2d0f6c5d4891594764f1f7e3be110cab3dbe5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8914b61-7de5-479e-81f4-23d08e42c5fe", "node_type": "1", "metadata": {"window": "I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n ", "original_text": "Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth. "}, "hash": "bac831b972d31d337b01894a55ae37d940a09e6ee8fa46d8694168a585aaa6be", "class_name": "RelatedNodeInfo"}}, "text": "Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n", "start_char_idx": 776, "end_char_idx": 896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8914b61-7de5-479e-81f4-23d08e42c5fe": {"__data__": {"id_": "d8914b61-7de5-479e-81f4-23d08e42c5fe", "embedding": null, "metadata": {"window": "I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n ", "original_text": "Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a51764fd-9db6-4cc5-af38-5fcb0834ba1f", "node_type": "1", "metadata": {"window": "We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009.  I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n", "original_text": "Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4422a754ba6fd6d48ccc3828a964844fcd9d8d8970900f84eac23fb87836d720", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba574bf3-7a0b-435e-aef2-3f33da8f3bd6", "node_type": "1", "metadata": {"window": "We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives. "}, "hash": "e64d91f6e0278a51df6a930d7277ce55f6bc79e9373d98efafa171205d7a07e3", "class_name": "RelatedNodeInfo"}}, "text": "Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth. ", "start_char_idx": 896, "end_char_idx": 1166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba574bf3-7a0b-435e-aef2-3f33da8f3bd6": {"__data__": {"id_": "ba574bf3-7a0b-435e-aef2-3f33da8f3bd6", "embedding": null, "metadata": {"window": "We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8914b61-7de5-479e-81f4-23d08e42c5fe", "node_type": "1", "metadata": {"window": "I  think the lessons we've learned and the expertise we've gained continue to serve us \nwell.  We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n ", "original_text": "Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cb4d084e24c152edc5f23e0a86292b7fd7bda629b0886b2fb6dfda922899f00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48d77a27-edb1-41df-a109-c3cd1871d347", "node_type": "1", "metadata": {"window": "Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone. ", "original_text": "The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n"}, "hash": "d034808112683e400a4cf6c93f187fc7f4a191edf8e18ba3e7716317555858ee", "class_name": "RelatedNodeInfo"}}, "text": "Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives. ", "start_char_idx": 1166, "end_char_idx": 1307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48d77a27-edb1-41df-a109-c3cd1871d347": {"__data__": {"id_": "48d77a27-edb1-41df-a109-c3cd1871d347", "embedding": null, "metadata": {"window": "Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone. ", "original_text": "The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba574bf3-7a0b-435e-aef2-3f33da8f3bd6", "node_type": "1", "metadata": {"window": "We operate from a position of financial strength.  Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2acc816650bb51d497d2347b4675f8f11d72cb83074eb44dceaa62b2331f05b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f30e7ab-b265-45e2-9599-cac53f8d2c9d", "node_type": "1", "metadata": {"window": "Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call. ", "original_text": "I, again, thank you for your time, and let me now turn it over to Britt.  \n "}, "hash": "afea4731aa1f7cc7992a6110862561b4b016bf0801434b3151e951001c2a2d0c", "class_name": "RelatedNodeInfo"}}, "text": "The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n", "start_char_idx": 1307, "end_char_idx": 1444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f30e7ab-b265-45e2-9599-cac53f8d2c9d": {"__data__": {"id_": "7f30e7ab-b265-45e2-9599-cac53f8d2c9d", "embedding": null, "metadata": {"window": "Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call. ", "original_text": "I, again, thank you for your time, and let me now turn it over to Britt.  \n ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48d77a27-edb1-41df-a109-c3cd1871d347", "node_type": "1", "metadata": {"window": "Our strong balance sheet, access to capital markets, strong \ncredit ratings provide us great financial flexibility.  \n \n Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone. ", "original_text": "The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52a22ea608d7363a0097b4402e4270fb482239d3037f1b431b1b07f549c6000f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "866b83b2-7277-4b69-ac78-516cd6313309", "node_type": "1", "metadata": {"window": "Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n"}, "hash": "4056eb010fd604c7ced06e9474302f905a1bf24956a758b3803cac78127a6b93", "class_name": "RelatedNodeInfo"}}, "text": "I, again, thank you for your time, and let me now turn it over to Britt.  \n ", "start_char_idx": 1444, "end_char_idx": 1520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "866b83b2-7277-4b69-ac78-516cd6313309": {"__data__": {"id_": "866b83b2-7277-4b69-ac78-516cd6313309", "embedding": null, "metadata": {"window": "Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f30e7ab-b265-45e2-9599-cac53f8d2c9d", "node_type": "1", "metadata": {"window": "Our fiscal 2020 results reinforce the operational momentum we're generating in our business and we have \nrepeatedly demonstrated our willingness and commitment to make the right, not always easy, but right decisions \nto best position the business for long -term growth.  Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call. ", "original_text": "I, again, thank you for your time, and let me now turn it over to Britt.  \n ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9b77c949eff0b8b3579fbd5050be0653bd47daafd63a97ef4e54bbb90fcf07d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6242b55d-e7ae-45ec-ad71-236b86fab9af", "node_type": "1", "metadata": {"window": "The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded. ", "original_text": "Thank you, Brian, and good morning, everyone. "}, "hash": "94e4c66c468d7c314a6c2cc144292ffb7d65fced667dcee00466759743564630", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "start_char_idx": 1520, "end_char_idx": 1881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6242b55d-e7ae-45ec-ad71-236b86fab9af": {"__data__": {"id_": "6242b55d-e7ae-45ec-ad71-236b86fab9af", "embedding": null, "metadata": {"window": "The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded. ", "original_text": "Thank you, Brian, and good morning, everyone. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "866b83b2-7277-4b69-ac78-516cd6313309", "node_type": "1", "metadata": {"window": "Despite the near -term challenges, we remain focused on \nexecuting against our priorities and investing in our strategic growth initiatives.  The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c0d25a55341ec7b845c9937336758c32a57513da756ba1fc96e72793b6337a1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a180024-5c0b-42ee-bacd-3e58581d9fe2", "node_type": "1", "metadata": {"window": "I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n", "original_text": "Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call. "}, "hash": "005f81e8c2d6792edce815fa6b424a27ffabb259c6a86759441b482f04500f65", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Brian, and good morning, everyone. ", "start_char_idx": 1881, "end_char_idx": 1927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a180024-5c0b-42ee-bacd-3e58581d9fe2": {"__data__": {"id_": "6a180024-5c0b-42ee-bacd-3e58581d9fe2", "embedding": null, "metadata": {"window": "I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n", "original_text": "Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6242b55d-e7ae-45ec-ad71-236b86fab9af", "node_type": "1", "metadata": {"window": "The positive energy, dedication, \ncommitment and togetherness of team McKesson is unmatched, and I do beli eve our future is bright.  \n \n I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded. ", "original_text": "Thank you, Brian, and good morning, everyone. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11bfd82d70ab1685228ebaaec850b30fa54786efa1ca603699697c4ed8eb5037", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ace7233c-1f5d-4c74-892d-0f56fc7bf6b8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid. ", "original_text": "The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n"}, "hash": "38c76dd8575d84f29ea96afcc9765c174130ae2b6a70beb1fff346a553c6716d", "class_name": "RelatedNodeInfo"}}, "text": "Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call. ", "start_char_idx": 1927, "end_char_idx": 2066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ace7233c-1f5d-4c74-892d-0f56fc7bf6b8": {"__data__": {"id_": "ace7233c-1f5d-4c74-892d-0f56fc7bf6b8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid. ", "original_text": "The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a180024-5c0b-42ee-bacd-3e58581d9fe2", "node_type": "1", "metadata": {"window": "I, again, thank you for your time, and let me now turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n", "original_text": "Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ce91d7fef17a2d438137119b99412392422c38b0d052e7933b0419c822234b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efcb04de-312d-4028-ba03-7e2721924e4a", "node_type": "1", "metadata": {"window": "Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising. ", "original_text": "We could not be prouder of  how our teams across the world have responded. "}, "hash": "dd33a1ba4824097cfc82c0d40debcf8a0434c676656a6d523a8f691d5f9e2582", "class_name": "RelatedNodeInfo"}}, "text": "The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n", "start_char_idx": 2066, "end_char_idx": 2186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efcb04de-312d-4028-ba03-7e2721924e4a": {"__data__": {"id_": "efcb04de-312d-4028-ba03-7e2721924e4a", "embedding": null, "metadata": {"window": "Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising. ", "original_text": "We could not be prouder of  how our teams across the world have responded. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ace7233c-1f5d-4c74-892d-0f56fc7bf6b8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid. ", "original_text": "The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b97c7b7d3434fde00666fd5750e5d2b7af02950737f22f9c04f18efaeda369f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74b5514b-f115-4460-8a41-876631f4fc42", "node_type": "1", "metadata": {"window": "Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain. ", "original_text": "In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n"}, "hash": "9449bc68a1d825a54729e9586cd789a688b8303ab9319320d91373f6c00f35c1", "class_name": "RelatedNodeInfo"}}, "text": "We could not be prouder of  how our teams across the world have responded. ", "start_char_idx": 2186, "end_char_idx": 2261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74b5514b-f115-4460-8a41-876631f4fc42": {"__data__": {"id_": "74b5514b-f115-4460-8a41-876631f4fc42", "embedding": null, "metadata": {"window": "Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain. ", "original_text": "In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efcb04de-312d-4028-ba03-7e2721924e4a", "node_type": "1", "metadata": {"window": "Thank you, Brian, and good morning, everyone.  Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising. ", "original_text": "We could not be prouder of  how our teams across the world have responded. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "576795cfe5c2c14bed2a4e7a517775eb2fc2f0eaa9452eecf11054f1c4393885", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24269b3b-2e65-48f3-816d-dda28b137f49", "node_type": "1", "metadata": {"window": "The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n", "original_text": "Let me start by reaffirming that the fundamentals of McKesson's business are solid. "}, "hash": "cdb637aa50889e18daf3047e71bfe01943b5915333e394459333e643a82925a3", "class_name": "RelatedNodeInfo"}}, "text": "In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n", "start_char_idx": 2261, "end_char_idx": 2490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24269b3b-2e65-48f3-816d-dda28b137f49": {"__data__": {"id_": "24269b3b-2e65-48f3-816d-dda28b137f49", "embedding": null, "metadata": {"window": "The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n", "original_text": "Let me start by reaffirming that the fundamentals of McKesson's business are solid. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74b5514b-f115-4460-8a41-876631f4fc42", "node_type": "1", "metadata": {"window": "Our fiscal fourth quar ter was certainly very different than we were \nexpecting when we last spoke during our third quarter earnings call.  The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain. ", "original_text": "In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c7fab281695021862b829ef7a7bb4cb0a6237a51542b072d11e9360d5bda6f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e94c4b7b-be3a-40e2-b270-10089b2200d8", "node_type": "1", "metadata": {"window": "We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment. ", "original_text": "Our strategy is clear, and the \nprospects for the business remain unchanged and promising. "}, "hash": "fd9a9004c33b7f147354b74cb28c7f31e29931dec54304015b66a4ba56827249", "class_name": "RelatedNodeInfo"}}, "text": "Let me start by reaffirming that the fundamentals of McKesson's business are solid. ", "start_char_idx": 2490, "end_char_idx": 2574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e94c4b7b-be3a-40e2-b270-10089b2200d8": {"__data__": {"id_": "e94c4b7b-be3a-40e2-b270-10089b2200d8", "embedding": null, "metadata": {"window": "We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment. ", "original_text": "Our strategy is clear, and the \nprospects for the business remain unchanged and promising. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24269b3b-2e65-48f3-816d-dda28b137f49", "node_type": "1", "metadata": {"window": "The COVID -19 health crisis has impacted the \nway our employees, customers, partners and communities live and work.  \n \n We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n", "original_text": "Let me start by reaffirming that the fundamentals of McKesson's business are solid. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "434f76ce14259807d6f7df175f7c81591544d6c48ad58706a1623795b0a4778f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4111a34f-7778-4528-9fb3-024fa46b2cf3", "node_type": "1", "metadata": {"window": "In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n", "original_text": "Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain. "}, "hash": "adf24dbb590f3dd3773a8ad73ea932c3c25152104546778f50ca9586e9486228", "class_name": "RelatedNodeInfo"}}, "text": "Our strategy is clear, and the \nprospects for the business remain unchanged and promising. ", "start_char_idx": 2574, "end_char_idx": 2665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4111a34f-7778-4528-9fb3-024fa46b2cf3": {"__data__": {"id_": "4111a34f-7778-4528-9fb3-024fa46b2cf3", "embedding": null, "metadata": {"window": "In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n", "original_text": "Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e94c4b7b-be3a-40e2-b270-10089b2200d8", "node_type": "1", "metadata": {"window": "We could not be prouder of  how our teams across the world have responded.  In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment. ", "original_text": "Our strategy is clear, and the \nprospects for the business remain unchanged and promising. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c04f5216c0d003aec96156fed9a51e6082f435e62d70498ee6d4a9cd6ee40e52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebaa484b-304f-4dd0-93e9-a1d764933c34", "node_type": "1", "metadata": {"window": "Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance. ", "original_text": "Our focus, \nexecution and financial discipline remain intact.  \n \n"}, "hash": "2fefa9c4a02df5c491d4a72aa381edd260619bfebac2409177a8d4c9239f04f9", "class_name": "RelatedNodeInfo"}}, "text": "Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain. ", "start_char_idx": 2665, "end_char_idx": 2815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebaa484b-304f-4dd0-93e9-a1d764933c34": {"__data__": {"id_": "ebaa484b-304f-4dd0-93e9-a1d764933c34", "embedding": null, "metadata": {"window": "Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance. ", "original_text": "Our focus, \nexecution and financial discipline remain intact.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4111a34f-7778-4528-9fb3-024fa46b2cf3", "node_type": "1", "metadata": {"window": "In this new environment, our team \nsupported our employees, customers, patients and communities, and demonstrated the resiliency and strength of \nour business with solid financial performance during these chall enging times.  \n \n Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n", "original_text": "Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbd20a05ef46cd34b6f15a8feb7b5697548af102a1414335ffcda8ac16113ee7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c39aa7d-20df-4ce7-83a1-b00cdd67e158", "node_type": "1", "metadata": {"window": "Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year. ", "original_text": "Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment. "}, "hash": "55384fa570b0640e4a457efecd8dee3aeecd9485bbb17731f5466e3fc018d022", "class_name": "RelatedNodeInfo"}}, "text": "Our focus, \nexecution and financial discipline remain intact.  \n \n", "start_char_idx": 2815, "end_char_idx": 2881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c39aa7d-20df-4ce7-83a1-b00cdd67e158": {"__data__": {"id_": "9c39aa7d-20df-4ce7-83a1-b00cdd67e158", "embedding": null, "metadata": {"window": "Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year. ", "original_text": "Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebaa484b-304f-4dd0-93e9-a1d764933c34", "node_type": "1", "metadata": {"window": "Let me start by reaffirming that the fundamentals of McKesson's business are solid.  Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance. ", "original_text": "Our focus, \nexecution and financial discipline remain intact.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80971cc276e66d9010f537ef81bc4c7495afca2a985f769d0b480b946a4a5b60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9780a963-0a2e-44cb-a7fe-1bcfe9953f07", "node_type": "1", "metadata": {"window": "Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks. ", "original_text": "I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n"}, "hash": "b72cbd32b54eaed38b6fc9b6dccfec1ad6c5735705998556de807e271c0d679c", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment. ", "start_char_idx": 2881, "end_char_idx": 3085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9780a963-0a2e-44cb-a7fe-1bcfe9953f07": {"__data__": {"id_": "9780a963-0a2e-44cb-a7fe-1bcfe9953f07", "embedding": null, "metadata": {"window": "Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks. ", "original_text": "I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c39aa7d-20df-4ce7-83a1-b00cdd67e158", "node_type": "1", "metadata": {"window": "Our strategy is clear, and the \nprospects for the business remain unchanged and promising.  Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year. ", "original_text": "Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cdb8dab67c49ae3db9ebe84ff35cdb9dd0a88b63120fd0916cea638ec646d8e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "828a863b-67ba-4771-8502-fb2e9f5a78cc", "node_type": "1", "metadata": {"window": "Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n", "original_text": "Many companies have withdrawn or not provided guidance. "}, "hash": "3af510e503b2d3570554bca757639ee60d92ea3790836422370941ea6c6f9361", "class_name": "RelatedNodeInfo"}}, "text": "I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n", "start_char_idx": 3085, "end_char_idx": 3381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "828a863b-67ba-4771-8502-fb2e9f5a78cc": {"__data__": {"id_": "828a863b-67ba-4771-8502-fb2e9f5a78cc", "embedding": null, "metadata": {"window": "Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n", "original_text": "Many companies have withdrawn or not provided guidance. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9780a963-0a2e-44cb-a7fe-1bcfe9953f07", "node_type": "1", "metadata": {"window": "Despite the challenges and uncertainties of the \ncurrent environment , our businesses continue to play a leading role in the healthcare supply chain.  Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks. ", "original_text": "I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d5cf6813c93e7284f7354f164e6de31fc835ae98d2f78cc452a478f411c211a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24183efe-5b45-4362-a9e7-821e650ccb06", "node_type": "1", "metadata": {"window": "Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30. ", "original_text": "However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year. "}, "hash": "59b254bfaa483551efb1ebf3c2ed2fd72994c8b36246df9c7d1c0fb142ae919a", "class_name": "RelatedNodeInfo"}}, "text": "Many companies have withdrawn or not provided guidance. ", "start_char_idx": 3381, "end_char_idx": 3437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24183efe-5b45-4362-a9e7-821e650ccb06": {"__data__": {"id_": "24183efe-5b45-4362-a9e7-821e650ccb06", "embedding": null, "metadata": {"window": "Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30. ", "original_text": "However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "828a863b-67ba-4771-8502-fb2e9f5a78cc", "node_type": "1", "metadata": {"window": "Our focus, \nexecution and financial discipline remain intact.  \n \n Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n", "original_text": "Many companies have withdrawn or not provided guidance. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27788b76b6e61021a39a768ccdd35deb55df7cc3b9cba6d2866094cd469b6473", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10596699-8392-46aa-88a7-17b1db1268ef", "node_type": "1", "metadata": {"window": "I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30.  We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n ", "original_text": "I will address our guidance in more detail later in my prepared remarks. "}, "hash": "13f5a15c4bb3214fce2b0285c1441dde85ca391469241771aa6acd9c3f0d1db5", "class_name": "RelatedNodeInfo"}}, "text": "However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year. ", "start_char_idx": 3437, "end_char_idx": 3629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10596699-8392-46aa-88a7-17b1db1268ef": {"__data__": {"id_": "10596699-8392-46aa-88a7-17b1db1268ef", "embedding": null, "metadata": {"window": "I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30.  We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n ", "original_text": "I will address our guidance in more detail later in my prepared remarks. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24183efe-5b45-4362-a9e7-821e650ccb06", "node_type": "1", "metadata": {"window": "Today, I'll provide you with more granularity than I typically do to help you understand our view on recent trend s \nand how our business is performing in this uncertain and rapidly evolving environment.  I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30. ", "original_text": "However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b00409fd4648960e63fd59d87ecbd49d4ea5275e15c3bf8ba86e3e7209decfaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3513aaaf-c37e-4bd6-ade6-14f1a57edbe8", "node_type": "1", "metadata": {"window": "Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30.  We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n ", "original_text": "However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n"}, "hash": "1c02880138f25ddaa4e375985fbe6cc7d62741830d7e5c02d65624fd84c4557e", "class_name": "RelatedNodeInfo"}}, "text": "I will address our guidance in more detail later in my prepared remarks. ", "start_char_idx": 3629, "end_char_idx": 3702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3513aaaf-c37e-4bd6-ade6-14f1a57edbe8": {"__data__": {"id_": "3513aaaf-c37e-4bd6-ade6-14f1a57edbe8", "embedding": null, "metadata": {"window": "Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30.  We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n ", "original_text": "However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10596699-8392-46aa-88a7-17b1db1268ef", "node_type": "1", "metadata": {"window": "I have three primary goals \nfor today's call: first, to provide an update on our fourth quarter and fiscal 2020 results, including the estimated \nimpacts from COVID -19; second, to provide an overview of the recent trends we are seeing; and third, to provide \na detailed fiscal 2021 outlook.  \n \n Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30.  We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n ", "original_text": "I will address our guidance in more detail later in my prepared remarks. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7048e7159ca7945b1fe3420f25387ebad0f1eabedb3bdff6a45e0c9b4344e28b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bbe7586-2618-4b8d-a11c-7cc3faaa25d7", "node_type": "1", "metadata": {"window": "However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30.  We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n ", "original_text": "The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30. "}, "hash": "7da55e658ff38aec2f46734abef6f2d66709ddd5375194c59c57e597999ebf82", "class_name": "RelatedNodeInfo"}}, "text": "However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n", "start_char_idx": 3702, "end_char_idx": 3783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bbe7586-2618-4b8d-a11c-7cc3faaa25d7": {"__data__": {"id_": "7bbe7586-2618-4b8d-a11c-7cc3faaa25d7", "embedding": null, "metadata": {"window": "However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30.  We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n ", "original_text": "The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3513aaaf-c37e-4bd6-ade6-14f1a57edbe8", "node_type": "1", "metadata": {"window": "Many companies have withdrawn or not provided guidance.  However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30.  We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n ", "original_text": "However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e99c582896b15b1906dbebd0a1e202ffbe4f37a5c87f38aa53cea064a50be619", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acb0a9cd-7baa-429a-8af7-ec1e1191ccc7", "node_type": "1", "metadata": {"window": "I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30.  We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n ", "original_text": "We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n "}, "hash": "26a750d82500e888569d62b8c07528eded2c08856c0ab40f419d812d56417f0b", "class_name": "RelatedNodeInfo"}}, "text": "The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30. ", "start_char_idx": 3783, "end_char_idx": 3985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acb0a9cd-7baa-429a-8af7-ec1e1191ccc7": {"__data__": {"id_": "acb0a9cd-7baa-429a-8af7-ec1e1191ccc7", "embedding": null, "metadata": {"window": "I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30.  We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n ", "original_text": "We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "356c67d2008305012ce98d361698233ce434006f1f78ad724479631afec7bf8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bbe7586-2618-4b8d-a11c-7cc3faaa25d7", "node_type": "1", "metadata": {"window": "However, given the uncertainties in the environment \nand the wide disparity acr oss analyst models, we felt it was important to provide our assumptions and views on \nthe upcoming fiscal year.  I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30.  We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n ", "original_text": "The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30. ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba1153e4edb98414307546702ad67796fc23a50a9de66a1f22d87961436c05af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84a71180-722b-4731-a2dc-e0704d6000cb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95. ", "original_text": "McKesson Corp.  "}, "hash": "a30e0a49684330055dbf9d51309f377041b72abeb6203ba3dd675b2b40e22bd9", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n ", "start_char_idx": 3985, "end_char_idx": 4178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84a71180-722b-4731-a2dc-e0704d6000cb": {"__data__": {"id_": "84a71180-722b-4731-a2dc-e0704d6000cb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acb0a9cd-7baa-429a-8af7-ec1e1191ccc7", "node_type": "1", "metadata": {"window": "I will address our guidance in more detail later in my prepared remarks.  However, I'd like \nto provide a bit of framing as it relates to fiscal 20 21. \n \n The guidance we are providing today assumes that the first half of fiscal 2021 will be challenging with the most \nsevere impacts from COVID -19 occurring during our fiscal first quarter ending June 30.  We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n ", "original_text": "We anticipate that we \nbegin to see gradual improvement in our fiscal second quarter ending September 30, with continued improvement \nin our results over the second half of our fiscal year.  \n ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "156647c2f0f0553d7a5acd0486060d4b9e4c37aab1b7649af0127c2f6621df79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24a9032c-f97e-446f-bc1c-13b330227f5e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n"}, "hash": "c0c6f8a3cbf6b5f62c1e668628d7daa4f2ba930b7bd1a2e99ab3988e5fd6aa1a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24a9032c-f97e-446f-bc1c-13b330227f5e": {"__data__": {"id_": "24a9032c-f97e-446f-bc1c-13b330227f5e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84a71180-722b-4731-a2dc-e0704d6000cb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7132f33ed2bc42b32ff52cc71cf5ee88546f75a180a94f839654790540564e11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d55efcb8-954c-4417-b433-198093413dee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction. ", "original_text": "Let's turn now to review of our fiscal 2020 res ults. "}, "hash": "4f64eed05ed0de0188865fa74f3fd80cfcb2d25e2fca990302f0aec3247c3839", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n", "start_char_idx": 16, "end_char_idx": 505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d55efcb8-954c-4417-b433-198093413dee": {"__data__": {"id_": "d55efcb8-954c-4417-b433-198093413dee", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction. ", "original_text": "Let's turn now to review of our fiscal 2020 res ults. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24a9032c-f97e-446f-bc1c-13b330227f5e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0adea614e3dfada445f27b70eb02ce34a8685eae77b6063d5e58a0e253b1ed0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fd95920-3e06-4b66-a7a4-8c4d252fa2ec", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n", "original_text": "McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95. "}, "hash": "b2f8cc00954ef826745e730a57d49e457731f6a841315018d7d2f96c22f8b0e9", "class_name": "RelatedNodeInfo"}}, "text": "Let's turn now to review of our fiscal 2020 res ults. ", "start_char_idx": 505, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fd95920-3e06-4b66-a7a4-8c4d252fa2ec": {"__data__": {"id_": "8fd95920-3e06-4b66-a7a4-8c4d252fa2ec", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n", "original_text": "McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d55efcb8-954c-4417-b433-198093413dee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction. ", "original_text": "Let's turn now to review of our fiscal 2020 res ults. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "756bb5ad2d688caa61e3a01100bf4e2557aacca568787c110f25b853d8dca918", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40aedd49-44d6-4544-a2ab-8bc4030d0feb", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives. ", "original_text": "This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n"}, "hash": "c2b7d5fdcaa6b57a8152e4370e676c1af18e83a0ec13ab0574d8a8c3d890037a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95. ", "start_char_idx": 559, "end_char_idx": 667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40aedd49-44d6-4544-a2ab-8bc4030d0feb": {"__data__": {"id_": "40aedd49-44d6-4544-a2ab-8bc4030d0feb", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives. ", "original_text": "This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fd95920-3e06-4b66-a7a4-8c4d252fa2ec", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n", "original_text": "McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c85f99757188ab2bcaa5f8a083d72a3c3f0268331e52db484a0dafb655604e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64af0dce-d020-4ae8-a5a2-e446080b252d", "node_type": "1", "metadata": {"window": "Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating. ", "original_text": "Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction. "}, "hash": "93d006cba84762ec236b0d9958a699b618590e18e2471e5423b0c8d9816a71d8", "class_name": "RelatedNodeInfo"}}, "text": "This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n", "start_char_idx": 667, "end_char_idx": 794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64af0dce-d020-4ae8-a5a2-e446080b252d": {"__data__": {"id_": "64af0dce-d020-4ae8-a5a2-e446080b252d", "embedding": null, "metadata": {"window": "Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating. ", "original_text": "Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40aedd49-44d6-4544-a2ab-8bc4030d0feb", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives. ", "original_text": "This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f76adee2bdf2cb4a60aafef846f7b658fcb6a9f09832bf354d5ae55758a5056", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc2f5ea9-16b9-4195-8a4f-a4ab5df205a9", "node_type": "1", "metadata": {"window": "McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n", "original_text": "Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n"}, "hash": "cb0778e62ca354cb5a1fe05c5aa85da1a94fa411d0a28ac90a4fbbd55722ce49", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction. ", "start_char_idx": 794, "end_char_idx": 968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc2f5ea9-16b9-4195-8a4f-a4ab5df205a9": {"__data__": {"id_": "fc2f5ea9-16b9-4195-8a4f-a4ab5df205a9", "embedding": null, "metadata": {"window": "McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n", "original_text": "Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64af0dce-d020-4ae8-a5a2-e446080b252d", "node_type": "1", "metadata": {"window": "Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating. ", "original_text": "Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a7015b915ed71cb2685d4bf90c1a5b5a2a250c737ec268aab019584e71201cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aed7fb18-dc88-4102-890e-0645de59e386", "node_type": "1", "metadata": {"window": "This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business. ", "original_text": "With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives. "}, "hash": "0de3a1ecc5c99bbae639554d14f4740ade0db0a3fa294c84cb83271e27c9f74a", "class_name": "RelatedNodeInfo"}}, "text": "Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n", "start_char_idx": 968, "end_char_idx": 1091, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aed7fb18-dc88-4102-890e-0645de59e386": {"__data__": {"id_": "aed7fb18-dc88-4102-890e-0645de59e386", "embedding": null, "metadata": {"window": "This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business. ", "original_text": "With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc2f5ea9-16b9-4195-8a4f-a4ab5df205a9", "node_type": "1", "metadata": {"window": "McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95.  This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n", "original_text": "Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1fc366b14d13122ba99c0fe369d7dbfb082bc6c8fd92cd763a5e81228f4da7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a359667-ed2a-4445-8f70-7c0b7f0098b2", "node_type": "1", "metadata": {"window": "Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March. ", "original_text": "Our balance sheet remains solid, which underpins our investment grade credit rating. "}, "hash": "fa56400a63f7640eeb8b1add19220609a1dde8377cddb936c1dc2111887bebb9", "class_name": "RelatedNodeInfo"}}, "text": "With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives. ", "start_char_idx": 1091, "end_char_idx": 1224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a359667-ed2a-4445-8f70-7c0b7f0098b2": {"__data__": {"id_": "4a359667-ed2a-4445-8f70-7c0b7f0098b2", "embedding": null, "metadata": {"window": "Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March. ", "original_text": "Our balance sheet remains solid, which underpins our investment grade credit rating. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aed7fb18-dc88-4102-890e-0645de59e386", "node_type": "1", "metadata": {"window": "This result was 10% above fiscal 2019 and included return to \nadjusted operating profit growth in all reportable segments.  \n \n Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business. ", "original_text": "With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5a95491725e42d634331d7359b723b4f21d77a9aba4a93f14acbf3a7203d661", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53270696-5b2d-45ba-9e08-67e34bd7edce", "node_type": "1", "metadata": {"window": "Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic. ", "original_text": "Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n"}, "hash": "1f5f609dd24dc1a941d02e9271a3697c7d170fc7ab77480410e5da7129e834bd", "class_name": "RelatedNodeInfo"}}, "text": "Our balance sheet remains solid, which underpins our investment grade credit rating. ", "start_char_idx": 1224, "end_char_idx": 1309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53270696-5b2d-45ba-9e08-67e34bd7edce": {"__data__": {"id_": "53270696-5b2d-45ba-9e08-67e34bd7edce", "embedding": null, "metadata": {"window": "Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic. ", "original_text": "Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a359667-ed2a-4445-8f70-7c0b7f0098b2", "node_type": "1", "metadata": {"window": "Additionally, we're pleased to have completed the successful exit of our investment in Change Healthcare during \nthe quarter through a tax -efficient split -off transaction.  Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March. ", "original_text": "Our balance sheet remains solid, which underpins our investment grade credit rating. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "025686745d2d2e0b7d74e71ce7c2ad08336ce607688e22f5420b76a6c7a2f673", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "454dd243-6e81-4969-8029-34c283ebc31c", "node_type": "1", "metadata": {"window": "With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n", "original_text": "On our February 4 third quarter earnings call, I discussed momentum building across the business. "}, "hash": "e919962a5f19dec06c14354af0eb32cedb8c4327dccef752c5f417e991f2a993", "class_name": "RelatedNodeInfo"}}, "text": "Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n", "start_char_idx": 1309, "end_char_idx": 1449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "454dd243-6e81-4969-8029-34c283ebc31c": {"__data__": {"id_": "454dd243-6e81-4969-8029-34c283ebc31c", "embedding": null, "metadata": {"window": "With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n", "original_text": "On our February 4 third quarter earnings call, I discussed momentum building across the business. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53270696-5b2d-45ba-9e08-67e34bd7edce", "node_type": "1", "metadata": {"window": "Our exit resulted in a pre and post -tax gain of $414 million, \nwhich impacted our GAAP -only results in the  quarter.  \n \n With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic. ", "original_text": "Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7dcf2c831547fcb00bc2bc3c1312d86249e5bfcc09a73ecc140e90b9d9fe29d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3367c7c0-2581-4933-89d9-aa85a212767e", "node_type": "1", "metadata": {"window": "Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment. ", "original_text": "This \nmomentum continued to build through mid -March. "}, "hash": "d2e9cf06d7a94d9abbe27b5038579016a1db469950bdb663be54315658262dd7", "class_name": "RelatedNodeInfo"}}, "text": "On our February 4 third quarter earnings call, I discussed momentum building across the business. ", "start_char_idx": 1449, "end_char_idx": 1547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3367c7c0-2581-4933-89d9-aa85a212767e": {"__data__": {"id_": "3367c7c0-2581-4933-89d9-aa85a212767e", "embedding": null, "metadata": {"window": "Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment. ", "original_text": "This \nmomentum continued to build through mid -March. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "454dd243-6e81-4969-8029-34c283ebc31c", "node_type": "1", "metadata": {"window": "With the split -off complete, we are well positioned to move forward with increased focus against our strategic \ngrowth initiatives.  Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n", "original_text": "On our February 4 third quarter earnings call, I discussed momentum building across the business. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9548fd0eca50bb5d8e97e4d127ba7994105735a51ed4039c8d29679b4e2e0b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7517c4d2-1ec6-4cbd-b66c-b2f03ef09e46", "node_type": "1", "metadata": {"window": "Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n", "original_text": "O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic. "}, "hash": "da17b6243d6e5b5d90eabf8333778075bc0738d0470d44909de7cae6ce7f7ce6", "class_name": "RelatedNodeInfo"}}, "text": "This \nmomentum continued to build through mid -March. ", "start_char_idx": 1547, "end_char_idx": 1601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7517c4d2-1ec6-4cbd-b66c-b2f03ef09e46": {"__data__": {"id_": "7517c4d2-1ec6-4cbd-b66c-b2f03ef09e46", "embedding": null, "metadata": {"window": "Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n", "original_text": "O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3367c7c0-2581-4933-89d9-aa85a212767e", "node_type": "1", "metadata": {"window": "Our balance sheet remains solid, which underpins our investment grade credit rating.  Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment. ", "original_text": "This \nmomentum continued to build through mid -March. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c40390368eddbf3f6566fc2ed34e4fbb5b6c7687cb6e7f0504c7a8c126ae2217", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c6cfe42-b566-4ce7-9a6e-0b0302404ebe", "node_type": "1", "metadata": {"window": "On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults. ", "original_text": "Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n"}, "hash": "198cf2e52b6f8397882f7321aa06b8851450db8c491b5e016d5c453c6c7250ad", "class_name": "RelatedNodeInfo"}}, "text": "O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic. ", "start_char_idx": 1601, "end_char_idx": 1690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c6cfe42-b566-4ce7-9a6e-0b0302404ebe": {"__data__": {"id_": "9c6cfe42-b566-4ce7-9a6e-0b0302404ebe", "embedding": null, "metadata": {"window": "On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults. ", "original_text": "Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7517c4d2-1ec6-4cbd-b66c-b2f03ef09e46", "node_type": "1", "metadata": {"window": "Our \nfinancial position provid es us the flexibility necessary to navigate current market uncertainty and future growth \nopportunities.  \n \n On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n", "original_text": "O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3076cf49188362a711a32ba9395e62aca7b1d7274567eaa29e0db8b6f563e749", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f432ea9c-2cf1-45c4-b2f8-61d21dcfdf28", "node_type": "1", "metadata": {"window": "This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals. ", "original_text": "Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment. "}, "hash": "5f225c16f0bf1d5d6b1c688edd0c59cbea0af115c838dc6a60f9a021c5c1cc3c", "class_name": "RelatedNodeInfo"}}, "text": "Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n", "start_char_idx": 1690, "end_char_idx": 1835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f432ea9c-2cf1-45c4-b2f8-61d21dcfdf28": {"__data__": {"id_": "f432ea9c-2cf1-45c4-b2f8-61d21dcfdf28", "embedding": null, "metadata": {"window": "This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals. ", "original_text": "Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c6cfe42-b566-4ce7-9a6e-0b0302404ebe", "node_type": "1", "metadata": {"window": "On our February 4 third quarter earnings call, I discussed momentum building across the business.  This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults. ", "original_text": "Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74b6bf3e46d965426e1399b7409117d06bde3519c46b764d10caf5f0b321ae6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d88250dd-ae0a-4c71-a11c-14ff840916fb", "node_type": "1", "metadata": {"window": "O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n", "original_text": "This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n"}, "hash": "996f390619f361044355a479d047caeabce4a5326baec4aca4cb7227e40d49ba", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment. ", "start_char_idx": 1835, "end_char_idx": 1984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d88250dd-ae0a-4c71-a11c-14ff840916fb": {"__data__": {"id_": "d88250dd-ae0a-4c71-a11c-14ff840916fb", "embedding": null, "metadata": {"window": "O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n", "original_text": "This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f432ea9c-2cf1-45c4-b2f8-61d21dcfdf28", "node_type": "1", "metadata": {"window": "This \nmomentum continued to build through mid -March.  O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals. ", "original_text": "Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59e39750ee05fdfede78d9e64594dde1a77b92f0fc5589e4f2ccfb156f2d40d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d763cf7-b575-4d19-8c33-0514706be632", "node_type": "1", "metadata": {"window": "Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes. ", "original_text": "I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults. "}, "hash": "d143c6ff385da4232122ce51435c66494ee573dfb7d3b9399a72851826e3e9e7", "class_name": "RelatedNodeInfo"}}, "text": "This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n", "start_char_idx": 1984, "end_char_idx": 2076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d763cf7-b575-4d19-8c33-0514706be632": {"__data__": {"id_": "8d763cf7-b575-4d19-8c33-0514706be632", "embedding": null, "metadata": {"window": "Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes. ", "original_text": "I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d88250dd-ae0a-4c71-a11c-14ff840916fb", "node_type": "1", "metadata": {"window": "O n March 11, the World Health Organization declared the \nCOVID -19 outbreak a pandemic.  Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n", "original_text": "This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf63af8f0d495f65c336659f4ce427573ed62549e8c7b9fba9ed4c0ac0f25e89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb3c88ff-ddaf-4b93-9908-25029b7a8f5a", "node_type": "1", "metadata": {"window": "Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities. ", "original_text": "There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals. "}, "hash": "3ae0dca1e9547bab62199eab8a4a1b79a230d09c04154293dbf755afeaf35576", "class_name": "RelatedNodeInfo"}}, "text": "I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults. ", "start_char_idx": 2076, "end_char_idx": 2199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb3c88ff-ddaf-4b93-9908-25029b7a8f5a": {"__data__": {"id_": "eb3c88ff-ddaf-4b93-9908-25029b7a8f5a", "embedding": null, "metadata": {"window": "Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities. ", "original_text": "There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d763cf7-b575-4d19-8c33-0514706be632", "node_type": "1", "metadata": {"window": "Shortly after, our businesses experienced increased demand and consumer \nbehavior patterns began to change as the virus continued to spread.  \n \n Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes. ", "original_text": "I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1952aead0ba432557f70652e59c7957b642feb485cf58b37c6cdeaf9097382b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5902bef1-65e2-403f-a277-45fb43fa1682", "node_type": "1", "metadata": {"window": "This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n", "original_text": "We expect this to reverse in the first quarter of fiscal 2021 . \n \n"}, "hash": "67d383d1d9baa0c8664b3c7336509b61e959242c8c376f8f7e2b69f7e119798a", "class_name": "RelatedNodeInfo"}}, "text": "There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals. ", "start_char_idx": 2199, "end_char_idx": 2326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5902bef1-65e2-403f-a277-45fb43fa1682": {"__data__": {"id_": "5902bef1-65e2-403f-a277-45fb43fa1682", "embedding": null, "metadata": {"window": "This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n", "original_text": "We expect this to reverse in the first quarter of fiscal 2021 . \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb3c88ff-ddaf-4b93-9908-25029b7a8f5a", "node_type": "1", "metadata": {"window": "Pharmaceutical distribution vo lumes in the US, Europe and Canada increased, as people stocked up on \nmedications and personal protective equipment.  This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities. ", "original_text": "There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41c58528ce80ca0e89542fff8fc34bbec558e9e516514e32c4f60909828874f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2751e32a-a0bd-4f65-99e1-900ebac181d1", "node_type": "1", "metadata": {"window": "I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter. ", "original_text": "Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes. "}, "hash": "4ee1214780f0e89029779926ec628af2c0bdd21ab19391b1d957bd6070bcfacf", "class_name": "RelatedNodeInfo"}}, "text": "We expect this to reverse in the first quarter of fiscal 2021 . \n \n", "start_char_idx": 2326, "end_char_idx": 2393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2751e32a-a0bd-4f65-99e1-900ebac181d1": {"__data__": {"id_": "2751e32a-a0bd-4f65-99e1-900ebac181d1", "embedding": null, "metadata": {"window": "I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter. ", "original_text": "Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5902bef1-65e2-403f-a277-45fb43fa1682", "node_type": "1", "metadata": {"window": "This incremental demand provided a net tailwind to our fourth \nquarter revenue results.  \n \n I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n", "original_text": "We expect this to reverse in the first quarter of fiscal 2021 . \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30137dd59966117e0f8a3cb59711e3c92db046e8d25ec9f740549955a766f6b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba0a9ae0-0b72-453f-864c-0018f796aa83", "node_type": "1", "metadata": {"window": "There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S. ", "original_text": "We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities. "}, "hash": "01afbfe6f713de97a3636c1cb83f799d420cdc9afd94f651da3c846ae7a143d2", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes. ", "start_char_idx": 2393, "end_char_idx": 2594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba0a9ae0-0b72-453f-864c-0018f796aa83": {"__data__": {"id_": "ba0a9ae0-0b72-453f-864c-0018f796aa83", "embedding": null, "metadata": {"window": "There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S. ", "original_text": "We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2751e32a-a0bd-4f65-99e1-900ebac181d1", "node_type": "1", "metadata": {"window": "I want to take a moment and provide the estimated i mpact of COVID -19 on our fiscal fourth quarter consolidated \nresults.  There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter. ", "original_text": "Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3044f364fbce45638a946cf0bbae1bf5afdd044e138dc189d7f41fe11013c997", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6a74a3e-413b-4473-9b17-126edfdad713", "node_type": "1", "metadata": {"window": "We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n", "original_text": "In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n"}, "hash": "8030980c8526ff0c9ad89a0267f4462a5c0a38868a980af85d041410e093ff4d", "class_name": "RelatedNodeInfo"}}, "text": "We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities. ", "start_char_idx": 2594, "end_char_idx": 2846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6a74a3e-413b-4473-9b17-126edfdad713": {"__data__": {"id_": "a6a74a3e-413b-4473-9b17-126edfdad713", "embedding": null, "metadata": {"window": "We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n", "original_text": "In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba0a9ae0-0b72-453f-864c-0018f796aa83", "node_type": "1", "metadata": {"window": "There's approximately $2 billion of incremental revenue, resulting primarily from higher customer demand \nfor pharmaceuticals.  We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S. ", "original_text": "We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fb5729876371765d9ccf97aef01dc6b7a8fb5290e0ca962de9d59c4e73915b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0171365-b4e4-4f79-84ed-4b31cdd2b75f", "node_type": "1", "metadata": {"window": "Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S. ", "original_text": "Let's transition now to a discussion of our adjusted earnings results for the fourth quarter. "}, "hash": "5e9f91eda65d03b54b34ea43f3cbd01344510a968dc1b71779ef06726bca0726", "class_name": "RelatedNodeInfo"}}, "text": "In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n", "start_char_idx": 2846, "end_char_idx": 3010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0171365-b4e4-4f79-84ed-4b31cdd2b75f": {"__data__": {"id_": "e0171365-b4e4-4f79-84ed-4b31cdd2b75f", "embedding": null, "metadata": {"window": "Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S. ", "original_text": "Let's transition now to a discussion of our adjusted earnings results for the fourth quarter. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6a74a3e-413b-4473-9b17-126edfdad713", "node_type": "1", "metadata": {"window": "We expect this to reverse in the first quarter of fiscal 2021 . \n \n Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n", "original_text": "In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71cca94c2d9fda91527b5b99e8d1324de52dd42aa619a6fea5c065a4670b61c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4032980-8916-4bec-ba63-fbb0697c56dc", "node_type": "1", "metadata": {"window": "We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment. ", "original_text": "Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S. "}, "hash": "d5032a2746278e911c1624e5f7d0dd8209105be229188000036646e5fc178716", "class_name": "RelatedNodeInfo"}}, "text": "Let's transition now to a discussion of our adjusted earnings results for the fourth quarter. ", "start_char_idx": 3010, "end_char_idx": 3104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4032980-8916-4bec-ba63-fbb0697c56dc": {"__data__": {"id_": "e4032980-8916-4bec-ba63-fbb0697c56dc", "embedding": null, "metadata": {"window": "We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment. ", "original_text": "Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0171365-b4e4-4f79-84ed-4b31cdd2b75f", "node_type": "1", "metadata": {"window": "Adjusted gross profit in the quarter was favorably impacted by approximately $65 million, offset by approximately \n$15 million in variable operating expenses, as a result of these incremental volumes.  We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S. ", "original_text": "Let's transition now to a discussion of our adjusted earnings results for the fourth quarter. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd8568a278272158d6a5b8f5d174ccb84ef915a9e365e1d9d3d91b468ad4688", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81129022-b37a-4cb7-99fc-68a91c9dcd0f", "node_type": "1", "metadata": {"window": "In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment.  As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter. ", "original_text": "Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n"}, "hash": "14bde5cb3cb303727cf60c589aca38fe49600af69e4b6c68a8cafa968fff2e8f", "class_name": "RelatedNodeInfo"}}, "text": "Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S. ", "start_char_idx": 3104, "end_char_idx": 3310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81129022-b37a-4cb7-99fc-68a91c9dcd0f": {"__data__": {"id_": "81129022-b37a-4cb7-99fc-68a91c9dcd0f", "embedding": null, "metadata": {"window": "In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment.  As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter. ", "original_text": "Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4032980-8916-4bec-ba63-fbb0697c56dc", "node_type": "1", "metadata": {"window": "We also had approximately \n$45 million of one -time adj usted operating expenses in the quarter, including investments in our frontline \nemployees, higher expenses to support a remote workforce and charitable contributions to support our \ncommunities.  In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment. ", "original_text": "Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ca82f2dfaa6c5f354e833a28fa46f6603aaeb9529180ad93e47a4557b6d7c49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8237e4f5-b5af-47f0-baf7-42e2fdf19b9c", "node_type": "1", "metadata": {"window": "Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment.  As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter.  Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n ", "original_text": "Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S. "}, "hash": "4646611547e0bd92937502f3f7abb150198bf38b1e3bbe20760d67c1a125fae6", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n", "start_char_idx": 3310, "end_char_idx": 3461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8237e4f5-b5af-47f0-baf7-42e2fdf19b9c": {"__data__": {"id_": "8237e4f5-b5af-47f0-baf7-42e2fdf19b9c", "embedding": null, "metadata": {"window": "Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment.  As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter.  Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n ", "original_text": "Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81129022-b37a-4cb7-99fc-68a91c9dcd0f", "node_type": "1", "metadata": {"window": "In summary, the impact of COVID -19 had a nominal effect on our  fourth quarter adjusted earnings \nresults, as the previously mentioned impacts largely offset.  \n \n Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment.  As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter. ", "original_text": "Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de631289bfbbb822a77ed6db4b7109349cc4bdbf8b9dd1e51c2e6795ca499450", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "159faf0c-e2e5-4e24-a1ec-edbf82db6a0b", "node_type": "1", "metadata": {"window": "Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment.  As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter.  Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n ", "original_text": "Pharmaceutical and \nSpec ialty Solutions segment. "}, "hash": "889fc476924eed034015da827c0b90af2653d305f092b988828d844a1559041d", "class_name": "RelatedNodeInfo"}}, "text": "Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S. ", "start_char_idx": 3461, "end_char_idx": 3669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "159faf0c-e2e5-4e24-a1ec-edbf82db6a0b": {"__data__": {"id_": "159faf0c-e2e5-4e24-a1ec-edbf82db6a0b", "embedding": null, "metadata": {"window": "Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment.  As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter.  Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n ", "original_text": "Pharmaceutical and \nSpec ialty Solutions segment. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8237e4f5-b5af-47f0-baf7-42e2fdf19b9c", "node_type": "1", "metadata": {"window": "Let's transition now to a discussion of our adjusted earnings results for the fourth quarter.  Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment.  As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter.  Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n ", "original_text": "Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9929fae70652f7ec2352fbff8df3438d3f0df888aed6f902ace7bf40776f6e44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4444c764-47fe-46b1-b16c-503dee7bb431", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment.  As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter.  Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n ", "original_text": "As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter. "}, "hash": "6d7bd5d60f3eaf359e85383fb86d2de3805eefa8d80840ff38d89a34c64f5e82", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and \nSpec ialty Solutions segment. ", "start_char_idx": 3669, "end_char_idx": 3719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4444c764-47fe-46b1-b16c-503dee7bb431": {"__data__": {"id_": "4444c764-47fe-46b1-b16c-503dee7bb431", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment.  As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter.  Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n ", "original_text": "As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "159faf0c-e2e5-4e24-a1ec-edbf82db6a0b", "node_type": "1", "metadata": {"window": "Fourth quarter adjusted \nearnings per diluted share was $4.27, up 1 6% in the quarter compared to the prior year, primarily driven by a \nlower share count and growth in the European Pharmaceutical and U.S.  Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment.  As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter.  Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n ", "original_text": "Pharmaceutical and \nSpec ialty Solutions segment. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "957a56da5d3a3f9be946b57c79d76ef6bb144700855848bfdba846fd9ee3ba7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19623459-80de-4eb4-b9a5-51afedfbb7ed", "node_type": "1", "metadata": {"window": "Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment.  As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter.  Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n ", "original_text": "Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n "}, "hash": "00c8e6bb9c5ed5abe55e2379cbc40d46d68544e8ea1ea2aad4a5d084f69b2e9d", "class_name": "RelatedNodeInfo"}}, "text": "As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter. ", "start_char_idx": 3719, "end_char_idx": 3847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19623459-80de-4eb4-b9a5-51afedfbb7ed": {"__data__": {"id_": "19623459-80de-4eb4-b9a5-51afedfbb7ed", "embedding": null, "metadata": {"window": "Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment.  As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter.  Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n ", "original_text": "Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8352efd400b46207f92c8934a79f0f30bfcf902854de805ff0f379e9a8a5d305", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4444c764-47fe-46b1-b16c-503dee7bb431", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions \nbusinesses, offset by higher corporate expenses, which includes the one -time cos ts I referenced earlier.  \n \n Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment.  As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter.  Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n ", "original_text": "As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter. ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0986b6797adc2b5cc65be54ff965cf1e175f407e28d94b5b0e139758642afd2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe18e34a-5259-4f42-b64f-6e4933c9f77d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter. ", "original_text": "McKesson Corp.  "}, "hash": "b9f5aea2d1997c1a150ebe519bc14470c72b1080ee4c01e69496911d462c0c27", "class_name": "RelatedNodeInfo"}}, "text": "Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n ", "start_char_idx": 3847, "end_char_idx": 3952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe18e34a-5259-4f42-b64f-6e4933c9f77d": {"__data__": {"id_": "fe18e34a-5259-4f42-b64f-6e4933c9f77d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19623459-80de-4eb4-b9a5-51afedfbb7ed", "node_type": "1", "metadata": {"window": "Moving to the details of our consolidated results, which can be found on slide 4, consolidated revenues for the \nfourth quarter increased 12% versus the prior period, principally driven by growth in our U.S.  Pharmaceutical and \nSpec ialty Solutions segment.  As previously mentioned, the estimated impact of COVID -19 was approximately $2 \nbillion of incremental revenue in the quarter.  Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n ", "original_text": "Excluding these incremental sales, consolidated revenues increased \napproximately 8% year -over-year.  \n ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c75748bd8c9c63825d288c44c8e4cec69faa059220d2165a24625ca8c7d3669", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6facb89-9895-42df-b558-2919db2033c9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n"}, "hash": "d90d5599e49906725465307719b2403f6809b20dfc0513d4bb0db4fa89f00abe", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6facb89-9895-42df-b558-2919db2033c9": {"__data__": {"id_": "d6facb89-9895-42df-b558-2919db2033c9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe18e34a-5259-4f42-b64f-6e4933c9f77d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68ac62081c18cf09d50f9e43ce693b946f9665b4ca41b3debb470b97aa6aca2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e034c0d-ff09-403c-ad40-ed06f3528f71", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n", "original_text": "Pharmaceutical and Specialty Solutions segments. "}, "hash": "633d0d2553c7f61a91906553078f4acb319ff334bcc10a03f836936d7349f70e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n", "start_char_idx": 16, "end_char_idx": 292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e034c0d-ff09-403c-ad40-ed06f3528f71": {"__data__": {"id_": "2e034c0d-ff09-403c-ad40-ed06f3528f71", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n", "original_text": "Pharmaceutical and Specialty Solutions segments. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6facb89-9895-42df-b558-2919db2033c9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5092005fa872794b0a54c6da3118520a49cf36cf0edc1cc62394316d36b4ccbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0120357-8781-49ea-8c83-84e4fac644f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances. ", "original_text": "Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter. "}, "hash": "6f1ef612a84220e95cef669c3da0868f42a3dc6c0c351e2894ccf95001cea827", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions segments. ", "start_char_idx": 292, "end_char_idx": 341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0120357-8781-49ea-8c83-84e4fac644f1": {"__data__": {"id_": "b0120357-8781-49ea-8c83-84e4fac644f1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances. ", "original_text": "Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e034c0d-ff09-403c-ad40-ed06f3528f71", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n", "original_text": "Pharmaceutical and Specialty Solutions segments. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "108e1595b6c3e560f618a403ce369f7c728842b9ca508470246757beaedc50fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c40d299-5ccc-40fb-b3e5-591eee596b65", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n", "original_text": "These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n"}, "hash": "c0c8dc1e10cad2def6249b3fc613a018a745bb014f5a14ada22a098ab0c235e1", "class_name": "RelatedNodeInfo"}}, "text": "Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter. ", "start_char_idx": 341, "end_char_idx": 609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c40d299-5ccc-40fb-b3e5-591eee596b65": {"__data__": {"id_": "6c40d299-5ccc-40fb-b3e5-591eee596b65", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n", "original_text": "These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0120357-8781-49ea-8c83-84e4fac644f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances. ", "original_text": "Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0966ce2a778a93741a496d21a7bb65da80a0e17529f690d1237c36867019755c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fb805a9-54b9-45b8-9ac0-661820f522ef", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year. ", "original_text": "Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n"}, "hash": "102a560725e3a11d3c60e29b5bc25da30b31042ee947e919b8d85d49f67d0370", "class_name": "RelatedNodeInfo"}}, "text": "These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n", "start_char_idx": 609, "end_char_idx": 734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fb805a9-54b9-45b8-9ac0-661820f522ef": {"__data__": {"id_": "9fb805a9-54b9-45b8-9ac0-661820f522ef", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year. ", "original_text": "Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c40d299-5ccc-40fb-b3e5-591eee596b65", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n", "original_text": "These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c14b51ad370a795b642ed330ab49a457f466299a0712a8569d9697b7badb1d3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14716f82-b1ba-4d9e-9d6e-9ee1813c860c", "node_type": "1", "metadata": {"window": "Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n", "original_text": "Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances. "}, "hash": "2aa8cd2f547620a56721f8b579e9b881e638f139c0ee5eda4ddf62eefbd8bcdd", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n", "start_char_idx": 734, "end_char_idx": 848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14716f82-b1ba-4d9e-9d6e-9ee1813c860c": {"__data__": {"id_": "14716f82-b1ba-4d9e-9d6e-9ee1813c860c", "embedding": null, "metadata": {"window": "Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n", "original_text": "Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fb805a9-54b9-45b8-9ac0-661820f522ef", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year. ", "original_text": "Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "742e7070b70429efc464eba49871803ff3e2f7123e23fa15ce84d876132ecd5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17d1a355-d23e-4d81-9d76-c392eca52b2b", "node_type": "1", "metadata": {"window": "These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S. ", "original_text": "Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n"}, "hash": "92b17845f86fbb10ebe0f4a1fa473f5d5606bcff00e3bc2784a7f0b275ed99e8", "class_name": "RelatedNodeInfo"}}, "text": "Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances. ", "start_char_idx": 848, "end_char_idx": 983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17d1a355-d23e-4d81-9d76-c392eca52b2b": {"__data__": {"id_": "17d1a355-d23e-4d81-9d76-c392eca52b2b", "embedding": null, "metadata": {"window": "These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S. ", "original_text": "Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14716f82-b1ba-4d9e-9d6e-9ee1813c860c", "node_type": "1", "metadata": {"window": "Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter.  These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n", "original_text": "Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f459601e4c00ee08817c950f77c83d67fc4d178ff5a1579a0dedbc5ab2129f88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80a7ddbd-b8e4-4e31-b575-7169c2f7b2fb", "node_type": "1", "metadata": {"window": "Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment. ", "original_text": "Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year. "}, "hash": "3ec0a24e4c5cd89ef03b3369d117acd6fc40f7c13e0a7665b1ae7c33cf983004", "class_name": "RelatedNodeInfo"}}, "text": "Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n", "start_char_idx": 983, "end_char_idx": 1101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80a7ddbd-b8e4-4e31-b575-7169c2f7b2fb": {"__data__": {"id_": "80a7ddbd-b8e4-4e31-b575-7169c2f7b2fb", "embedding": null, "metadata": {"window": "Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment. ", "original_text": "Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17d1a355-d23e-4d81-9d76-c392eca52b2b", "node_type": "1", "metadata": {"window": "These \nincremental one -time and COVID -driven expenses accounted for approximately 3% of the ye ar-over-year \nincrease.  \n \n Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S. ", "original_text": "Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2ea0543719b460b16fec86b51029c6e575166633b0ede2e42a15e71bc18c973", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "630bc1be-2c3c-4d95-bc0c-2834a0a175c5", "node_type": "1", "metadata": {"window": "Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19. ", "original_text": "Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n"}, "hash": "4a00e859d7932c857619071cf15a7b269c63d45a8f86c33a61f6d255b029d3b3", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year. ", "start_char_idx": 1101, "end_char_idx": 1243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "630bc1be-2c3c-4d95-bc0c-2834a0a175c5": {"__data__": {"id_": "630bc1be-2c3c-4d95-bc0c-2834a0a175c5", "embedding": null, "metadata": {"window": "Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19. ", "original_text": "Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80a7ddbd-b8e4-4e31-b575-7169c2f7b2fb", "node_type": "1", "metadata": {"window": "Adjusted income from operations was $1 billion for the quarter, an increase of 1% as compared to the prior year. \n Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment. ", "original_text": "Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50b9c675d9319b91092e72e86f6691bdffa519def5282aaebc07d75a907bf984", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4aa0dc88-8364-4b5c-9606-70a4659f90a5", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n", "original_text": "Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S. "}, "hash": "f51d14410fb1a647bab97e37e5044b5fd987b0d3d9b5342fceea1d8fa0a3adbc", "class_name": "RelatedNodeInfo"}}, "text": "Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n", "start_char_idx": 1243, "end_char_idx": 1420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4aa0dc88-8364-4b5c-9606-70a4659f90a5": {"__data__": {"id_": "4aa0dc88-8364-4b5c-9606-70a4659f90a5", "embedding": null, "metadata": {"window": "Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n", "original_text": "Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "630bc1be-2c3c-4d95-bc0c-2834a0a175c5", "node_type": "1", "metadata": {"window": "Interest expense was $65 million in the quarter, a decline of 7% compared to the prior year, due to lower \ncommercial pa per balances.  Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19. ", "original_text": "Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f1ec650c6dc636b0879e6c0eafe6b74ac56a9c2e5d9dc24ee682593a82b1b41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f98a661-9fc1-4522-87b2-5e9174cbb433", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n", "original_text": "Pharmaceutical and Specialty \nSolutions segment. "}, "hash": "8340b8526a7b82db1812736c36a7a9bd55b3170e590311a48793ad5894ebb73c", "class_name": "RelatedNodeInfo"}}, "text": "Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S. ", "start_char_idx": 1420, "end_char_idx": 1508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f98a661-9fc1-4522-87b2-5e9174cbb433": {"__data__": {"id_": "2f98a661-9fc1-4522-87b2-5e9174cbb433", "embedding": null, "metadata": {"window": "Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n", "original_text": "Pharmaceutical and Specialty \nSolutions segment. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4aa0dc88-8364-4b5c-9606-70a4659f90a5", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 17.3% for the quarter, mainly driven by our mix of \nbusiness and discrete tax benefits.  \n \n Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n", "original_text": "Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e4cbae937d7bfe56387b31730fc8cff94f967fe81788fdf94f6bc8bfda2b125", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0a8ccc3-de4d-42f0-8aa3-8e4b5c56ef70", "node_type": "1", "metadata": {"window": "Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n", "original_text": "Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19. "}, "hash": "2dcdd96a9db5c4152bf0e9e3d9c532a1ca70df6dc1ee3c3d52ebbf13bfb5b60f", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty \nSolutions segment. ", "start_char_idx": 1508, "end_char_idx": 1557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0a8ccc3-de4d-42f0-8aa3-8e4b5c56ef70": {"__data__": {"id_": "c0a8ccc3-de4d-42f0-8aa3-8e4b5c56ef70", "embedding": null, "metadata": {"window": "Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n", "original_text": "Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f98a661-9fc1-4522-87b2-5e9174cbb433", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated results, our fourth quarter diluted weighted average shares were 174 million, a \ndecrease of 9% year -over-year.  Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n", "original_text": "Pharmaceutical and Specialty \nSolutions segment. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8aaf0678f58213ed0bfa10dda42ad60c7efb50aab3062c3c8155a6a045f8d2ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9769874-1e19-4d22-9fde-c6b7aa661cdc", "node_type": "1", "metadata": {"window": "Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear. ", "original_text": "These were partially offset by branded to generic conversions.  \n \n"}, "hash": "535bfb18e70c0b3225d3c82297b00591108f7e286ecd6386d2b3774fb30f5c77", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19. ", "start_char_idx": 1557, "end_char_idx": 1778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9769874-1e19-4d22-9fde-c6b7aa661cdc": {"__data__": {"id_": "a9769874-1e19-4d22-9fde-c6b7aa661cdc", "embedding": null, "metadata": {"window": "Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear. ", "original_text": "These were partially offset by branded to generic conversions.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0a8ccc3-de4d-42f0-8aa3-8e4b5c56ef70", "node_type": "1", "metadata": {"window": "Our adjusted earnings results includes a $0.07 benefit from our previously \nmentioned split -off of Change Healthcare, which lowered our shares outstanding by 15.4 million.  \n \n Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n", "original_text": "Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5afbc13f8bf1065a48a390ab26990a2a98a7ce12d19076cb835a90a68f296819", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc0f5645-dc7f-4d82-86cd-d7d7d1950816", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n", "original_text": "Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n"}, "hash": "f55be95d74cf109026853386853969ef933b2b0ccfee383f01c5dfcc1e98ee2f", "class_name": "RelatedNodeInfo"}}, "text": "These were partially offset by branded to generic conversions.  \n \n", "start_char_idx": 1778, "end_char_idx": 1845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc0f5645-dc7f-4d82-86cd-d7d7d1950816": {"__data__": {"id_": "cc0f5645-dc7f-4d82-86cd-d7d7d1950816", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n", "original_text": "Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9769874-1e19-4d22-9fde-c6b7aa661cdc", "node_type": "1", "metadata": {"window": "Next, I'll review our results, which can be slides 5 through 8, starting  with the U.S.  Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear. ", "original_text": "These were partially offset by branded to generic conversions.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64dfbbd394c6c23a93dd498394700f9a53ed8333fe10c548ed6dfeb6e62ba58d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60e003bf-2d06-475a-be11-eb5e9a4f96e1", "node_type": "1", "metadata": {"window": "Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million. ", "original_text": "Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n"}, "hash": "fbc8c4aeeb1bf213361b3db7c97db5a443f67fa733a3c30b658e8b03c0488e10", "class_name": "RelatedNodeInfo"}}, "text": "Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n", "start_char_idx": 1845, "end_char_idx": 2067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60e003bf-2d06-475a-be11-eb5e9a4f96e1": {"__data__": {"id_": "60e003bf-2d06-475a-be11-eb5e9a4f96e1", "embedding": null, "metadata": {"window": "Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million. ", "original_text": "Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc0f5645-dc7f-4d82-86cd-d7d7d1950816", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty \nSolutions segment.  Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n", "original_text": "Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9cc0c9efbae468033425ca42f9b44c1b79228f05157e319cc0b7da257cbff261", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91f0d58a-6060-4e50-9729-4c9900aadbbb", "node_type": "1", "metadata": {"window": "These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n", "original_text": "Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear. "}, "hash": "b2c40caa07099ed3c92dcacf48c8d9efa72b194806cc3c5c6ea14225e747c65d", "class_name": "RelatedNodeInfo"}}, "text": "Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n", "start_char_idx": 2067, "end_char_idx": 2265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91f0d58a-6060-4e50-9729-4c9900aadbbb": {"__data__": {"id_": "91f0d58a-6060-4e50-9729-4c9900aadbbb", "embedding": null, "metadata": {"window": "These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n", "original_text": "Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60e003bf-2d06-475a-be11-eb5e9a4f96e1", "node_type": "1", "metadata": {"window": "Revenues were $46.3 billion for the quarter, up 13%, driven by branded pharmaceutical price \nincreases and growth from our large retail national account customers, including incremental volume r esulting \nfrom COVID -19.  These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million. ", "original_text": "Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6866af0f5864385124a317975598dec747c02cdeb547f3436e9c2e566cd1200b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "093b9008-0910-46ff-bcc2-3a2bd2c9500a", "node_type": "1", "metadata": {"window": "Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item. ", "original_text": "On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n"}, "hash": "5c9f2634ba73b4bcf019f6a4e557c884889c6d4bb8581c83de3a177c96a05f89", "class_name": "RelatedNodeInfo"}}, "text": "Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear. ", "start_char_idx": 2265, "end_char_idx": 2386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "093b9008-0910-46ff-bcc2-3a2bd2c9500a": {"__data__": {"id_": "093b9008-0910-46ff-bcc2-3a2bd2c9500a", "embedding": null, "metadata": {"window": "Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item. ", "original_text": "On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91f0d58a-6060-4e50-9729-4c9900aadbbb", "node_type": "1", "metadata": {"window": "These were partially offset by branded to generic conversions.  \n \n Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n", "original_text": "Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "316c74d6967a6e7e2784e1cd48228a6245358409840dc43dab0cb31e77ac4b81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ef81b63-419d-4143-bd71-0d5e1d3013ae", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n", "original_text": "Fourth quarter adjusted operating profit increased 226% to $75 million. "}, "hash": "2c6b45424de6dee5543adf2587bd35ea7374580bb62f0cd9a24ac876b258117c", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n", "start_char_idx": 2386, "end_char_idx": 2558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ef81b63-419d-4143-bd71-0d5e1d3013ae": {"__data__": {"id_": "7ef81b63-419d-4143-bd71-0d5e1d3013ae", "embedding": null, "metadata": {"window": "Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n", "original_text": "Fourth quarter adjusted operating profit increased 226% to $75 million. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "093b9008-0910-46ff-bcc2-3a2bd2c9500a", "node_type": "1", "metadata": {"window": "Fourth quarter adjusted operating profit increased 3% to $772 million, driven by continued growth in specialty \nbusinesses, partially offset by previously announced inve stments in the oncology and manufacturer services. \n Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item. ", "original_text": "On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b01371b94bf21e9adbb77d0d5850f986f62a0054a5590d2d628e0f4c2cd7d88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dda89814-4db8-4cfb-996f-258d6f81ee11", "node_type": "1", "metadata": {"window": "Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes. ", "original_text": "On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n"}, "hash": "b70eac6fcf6bcde3d9ca51768d2eea4c64e62563a76a0386553c026508fea166", "class_name": "RelatedNodeInfo"}}, "text": "Fourth quarter adjusted operating profit increased 226% to $75 million. ", "start_char_idx": 2558, "end_char_idx": 2630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dda89814-4db8-4cfb-996f-258d6f81ee11": {"__data__": {"id_": "dda89814-4db8-4cfb-996f-258d6f81ee11", "embedding": null, "metadata": {"window": "Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes. ", "original_text": "On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ef81b63-419d-4143-bd71-0d5e1d3013ae", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit for the full year increased 6% to $2.7 billion and the segment adjusted \noperating margin for the full year was 146 basis points, a decrease of 4 basis points.  \n \n Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n", "original_text": "Fourth quarter adjusted operating profit increased 226% to $75 million. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b26a43906ddb8fa20a7e85bedcf102384105b8ac57e01751454fc95483b1579", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81dd87e5-f9e2-4b47-b8bb-9fda74e8d6a5", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes.  Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n", "original_text": "Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item. "}, "hash": "da93d42aad9b2f61bf4f0b3dc0538f56760bd0bab06a9489361655ba0ad1a880", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n", "start_char_idx": 2630, "end_char_idx": 2941, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81dd87e5-f9e2-4b47-b8bb-9fda74e8d6a5": {"__data__": {"id_": "81dd87e5-f9e2-4b47-b8bb-9fda74e8d6a5", "embedding": null, "metadata": {"window": "On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes.  Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n", "original_text": "Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dda89814-4db8-4cfb-996f-258d6f81ee11", "node_type": "1", "metadata": {"window": "Next, Europ ean Pharmaceutical Solutions revenues were $7.2 billion for the quarter, an increase of 6% year -over-\nyear.  On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes. ", "original_text": "On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b3eb173f4d2609c71b83195a527ba0451459b33c44c5f858f2a0d2dadeaa4f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6039336-dd47-43f4-a05e-71ab7adfa8eb", "node_type": "1", "metadata": {"window": "Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes.  Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n ", "original_text": "Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n"}, "hash": "a8b43fafb943bdc9c398ca22ac67d2e5d12c4a1a5c9fa71dea432f615c4d55fa", "class_name": "RelatedNodeInfo"}}, "text": "Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item. ", "start_char_idx": 2941, "end_char_idx": 3115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6039336-dd47-43f4-a05e-71ab7adfa8eb": {"__data__": {"id_": "a6039336-dd47-43f4-a05e-71ab7adfa8eb", "embedding": null, "metadata": {"window": "Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes.  Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n ", "original_text": "Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81dd87e5-f9e2-4b47-b8bb-9fda74e8d6a5", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, revenues increased 9%, driven by growth in the pharmaceutical distribution \nbusiness, including incremental revenue as a resu lt of COVID -19. \n \n Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes.  Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n", "original_text": "Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3bf7ee0720e52abc2f383d978d0032eca352405627cbe3b484c059563edc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd5cd663-3d4c-4a2d-a282-a1a513aaf467", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes.  Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n ", "original_text": "Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes. "}, "hash": "d9652493d1e90fbd2c3286d049ad4ef0d7d8493d3ee9ac6f79e39e9c69084bd5", "class_name": "RelatedNodeInfo"}}, "text": "Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n", "start_char_idx": 3115, "end_char_idx": 3224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd5cd663-3d4c-4a2d-a282-a1a513aaf467": {"__data__": {"id_": "bd5cd663-3d4c-4a2d-a282-a1a513aaf467", "embedding": null, "metadata": {"window": "On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes.  Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n ", "original_text": "Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6039336-dd47-43f4-a05e-71ab7adfa8eb", "node_type": "1", "metadata": {"window": "Fourth quarter adjusted operating profit increased 226% to $75 million.  On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes.  Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n ", "original_text": "Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37d174ce369014aca9d109e12946c10c11076a094d65c30216f75f30b73f2b87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa94fcd8-1e33-48a1-82f4-88fce2a22969", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes.  Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n ", "original_text": "Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n"}, "hash": "7ecd1f4cef5678aa9354aa97a82ed014802a9292b67f88a7591956281103627f", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes. ", "start_char_idx": 3224, "end_char_idx": 3437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa94fcd8-1e33-48a1-82f4-88fce2a22969": {"__data__": {"id_": "fa94fcd8-1e33-48a1-82f4-88fce2a22969", "embedding": null, "metadata": {"window": "Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes.  Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n ", "original_text": "Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd5cd663-3d4c-4a2d-a282-a1a513aaf467", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, adjusted \noperating profit increased 239%, driven in part by lower operating expenses as a result of actions previously \ntaken to rationalize ou r store footprint and streamline back office functions, and the lapping of a prior year \ninventory charge of approximately $20 million.  \n \n Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes.  Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n ", "original_text": "Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes. ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c2ec29d0083ab43ab90325744ebe605b563a294190d9a921af3860a4d72469e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4be1f3a4-1135-407e-b1f5-b7fb566a4a83", "node_type": "1", "metadata": {"window": "Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes.  Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n ", "original_text": "Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n "}, "hash": "85d276b6fe46109becec5643475aa49f726d768d88205e310b333f9ecd9d38de", "class_name": "RelatedNodeInfo"}}, "text": "Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n", "start_char_idx": 3437, "end_char_idx": 3724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4be1f3a4-1135-407e-b1f5-b7fb566a4a83": {"__data__": {"id_": "4be1f3a4-1135-407e-b1f5-b7fb566a4a83", "embedding": null, "metadata": {"window": "Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes.  Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n ", "original_text": "Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de415c9efe7ea0feb319e32738ffab116bd1af5f6fc0ae7c125a19893c249b54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa94fcd8-1e33-48a1-82f4-88fce2a22969", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit for the full year increased 5% to $231 million, driven primarily by expense \nrationaliz ation and the previously mentioned prior year item.  Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes.  Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n ", "original_text": "Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "087c29a6e53c4a11a8a2cd4048b12f7cfc3dff683096018242dc76bd4c3a87d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a41ad611-721a-4b68-8f76-1aa42f1f4eee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "73feac782c771109b29f8b43855766f570dc0ca4886a08c8b91f18dcea41c1e5", "class_name": "RelatedNodeInfo"}}, "text": "Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n ", "start_char_idx": 3724, "end_char_idx": 3952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a41ad611-721a-4b68-8f76-1aa42f1f4eee": {"__data__": {"id_": "a41ad611-721a-4b68-8f76-1aa42f1f4eee", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4be1f3a4-1135-407e-b1f5-b7fb566a4a83", "node_type": "1", "metadata": {"window": "Segment adjusted operating margin for the full year \nwas 84 basis points, an increase of 4 basis points.  \n \n Moving now to Medical Surgical Solutions, revenues were $2.2 billion for the quarter, up 13%, drive n by organic \ngrowth led by our primary care business, including higher pharmaceutical and flu test kit volumes.  Segment \nadjusted operating profit for the quarter was down 1% to $170 million, driven primarily by higher expenses in the \nquarter, which include d a provision for bad debt in our primary care business, partially offset by organic growth, \nprincipally in our primary care business.  \n \n Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n ", "original_text": "Segment adjusted operating profit for the full year increased 12% to $679 million, driven by organic growth, and \nthe seg ment adjusted operating margin for the full year was 818 basis points, an increase of 24 basis points.  \n ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f2391973c8787c5c738e685f80479dc91cf8fd6024d88c675c57dfaeacf84d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9a4387c-6a12-4401-ba1c-3cb60dcb1505", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%. "}, "hash": "6c7bc088239c14b42eefddbe71cf88353b931f13594ef6fab43fdb8036099c8b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9a4387c-6a12-4401-ba1c-3cb60dcb1505": {"__data__": {"id_": "a9a4387c-6a12-4401-ba1c-3cb60dcb1505", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a41ad611-721a-4b68-8f76-1aa42f1f4eee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f9a9addef05b01f6f2e1e1d85e0d1ae1d66756b59815000f4c62cde8b56b1cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5b1e5d7-cf12-480d-a391-dec3f4b80a5b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year. ", "original_text": "On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n"}, "hash": "08620e849286ecfddda283512716e034e14579134d20bc7922c400393def2f7b", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%. ", "start_char_idx": 16, "end_char_idx": 274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5b1e5d7-cf12-480d-a391-dec3f4b80a5b": {"__data__": {"id_": "b5b1e5d7-cf12-480d-a391-dec3f4b80a5b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year. ", "original_text": "On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9a4387c-6a12-4401-ba1c-3cb60dcb1505", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d4b6b750a1ce13b194099ff100c4da092f1a181352516e89c34cf3887c008b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8784bdff-c5db-4937-aba1-8c5f6e7b92bf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n", "original_text": "Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n"}, "hash": "d6c18eca81b06ca58042080b5365e8e103a58f1592b0d1834850432dcc5e638f", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n", "start_char_idx": 274, "end_char_idx": 392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8784bdff-c5db-4937-aba1-8c5f6e7b92bf": {"__data__": {"id_": "8784bdff-c5db-4937-aba1-8c5f6e7b92bf", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n", "original_text": "Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5b1e5d7-cf12-480d-a391-dec3f4b80a5b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year. ", "original_text": "On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8012e7c71ffc99766a084300b24b7be40da47f9b3d0dfee9426a459d2bc8179", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f8c5862-3381-48b2-b997-a16ee39e2b2f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees. ", "original_text": "Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n"}, "hash": "2d91ba2576d03af6df3c279cf5187f51266a9883db5449f0d551d0ef9b9c3360", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n", "start_char_idx": 392, "end_char_idx": 670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f8c5862-3381-48b2-b997-a16ee39e2b2f": {"__data__": {"id_": "8f8c5862-3381-48b2-b997-a16ee39e2b2f", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees. ", "original_text": "Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8784bdff-c5db-4937-aba1-8c5f6e7b92bf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n", "original_text": "Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47b50899ca176d87fc87f8487cfc7c3cb53065d617b6efdd1d70c5306ba6bcb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ada6c77-2474-45a5-b314-1d74c16e3945", "node_type": "1", "metadata": {"window": "On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n", "original_text": "Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year. "}, "hash": "cf58b399edd5bea3f88c41b666f2f2be1fb0282db5f59cc3637f4abff146a30c", "class_name": "RelatedNodeInfo"}}, "text": "Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n", "start_char_idx": 670, "end_char_idx": 952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ada6c77-2474-45a5-b314-1d74c16e3945": {"__data__": {"id_": "8ada6c77-2474-45a5-b314-1d74c16e3945", "embedding": null, "metadata": {"window": "On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n", "original_text": "Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f8c5862-3381-48b2-b997-a16ee39e2b2f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees. ", "original_text": "Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5990c6a44b192dc0714d9f77e04a54875561fdef9be35be0b8d0d9db54bc6236", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e36bcd9e-78ed-42f9-a8f0-2d717d62ebd3", "node_type": "1", "metadata": {"window": "Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n", "original_text": "As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n"}, "hash": "5957a45fbf7b42a9d1a2a539173c26f33a2967f8233da3af13725b7c0dd88b3d", "class_name": "RelatedNodeInfo"}}, "text": "Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year. ", "start_char_idx": 952, "end_char_idx": 1053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e36bcd9e-78ed-42f9-a8f0-2d717d62ebd3": {"__data__": {"id_": "e36bcd9e-78ed-42f9-a8f0-2d717d62ebd3", "embedding": null, "metadata": {"window": "Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n", "original_text": "As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ada6c77-2474-45a5-b314-1d74c16e3945", "node_type": "1", "metadata": {"window": "On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n", "original_text": "Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce58895dc32dd7672f48044caaedc25249d01de1b1863cbad0851b9599a3f892", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e0d9e10-4284-477d-a373-b479f8b8052c", "node_type": "1", "metadata": {"window": "Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n", "original_text": "Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees. "}, "hash": "af59f2022243afb00c281cce703aa31c12d9408e26c88a4f0895d6f78c6848fd", "class_name": "RelatedNodeInfo"}}, "text": "As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n", "start_char_idx": 1053, "end_char_idx": 1206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e0d9e10-4284-477d-a373-b479f8b8052c": {"__data__": {"id_": "8e0d9e10-4284-477d-a373-b479f8b8052c", "embedding": null, "metadata": {"window": "Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n", "original_text": "Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e36bcd9e-78ed-42f9-a8f0-2d717d62ebd3", "node_type": "1", "metadata": {"window": "Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n", "original_text": "As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "324d7e8c5da3d91edd4b69c82fbf161e4fcd73c3e2a5efff564d7c8784b86610", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7b74bf8-e21e-435e-8a87-a0c1ef8cc9b7", "node_type": "1", "metadata": {"window": "Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures. ", "original_text": "These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n"}, "hash": "22561259d0897e5c652a2656c668bb296dfdea652c26a655c09657d2e5114e51", "class_name": "RelatedNodeInfo"}}, "text": "Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees. ", "start_char_idx": 1206, "end_char_idx": 1447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7b74bf8-e21e-435e-8a87-a0c1ef8cc9b7": {"__data__": {"id_": "a7b74bf8-e21e-435e-8a87-a0c1ef8cc9b7", "embedding": null, "metadata": {"window": "Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures. ", "original_text": "These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e0d9e10-4284-477d-a373-b479f8b8052c", "node_type": "1", "metadata": {"window": "Other adjusted operating profit for the full year was down 4% to $953 million, driven by the lapping of a $90 million \ncontractual liability reversal related to our investment in Change Hea lthcare in the prior year, partially offset by \nhigher volumes in our MRxTS businesses.  \n \n Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n", "original_text": "Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3af77971c83f8b01fd6178470f9affb89f4f500d34a01e99487b08313a72704c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e5665e1-82f0-428c-a97c-9d43196cd612", "node_type": "1", "metadata": {"window": "As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19. ", "original_text": "For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n"}, "hash": "43ab22389a69efe70d88d6d5917c7b9f4c91d395c7b964710c52cdb44cfb466b", "class_name": "RelatedNodeInfo"}}, "text": "These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n", "start_char_idx": 1447, "end_char_idx": 1540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e5665e1-82f0-428c-a97c-9d43196cd612": {"__data__": {"id_": "7e5665e1-82f0-428c-a97c-9d43196cd612", "embedding": null, "metadata": {"window": "As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19. ", "original_text": "For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7b74bf8-e21e-435e-8a87-a0c1ef8cc9b7", "node_type": "1", "metadata": {"window": "Included in Other, adjusted equity income from Change Healthcare was $253 million for the full year.  As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures. ", "original_text": "These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a9d694b6a1b0ab093c38b0aa4010a6cc83b2663f03b97932476ada97a0c6610", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0918980c-32a2-4c07-8c3f-0944eb562ad9", "node_type": "1", "metadata": {"window": "Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n", "original_text": "The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n"}, "hash": "923349c23d7391dcb3455bfb9857129547ba53d21384f23e6971a78061594e57", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n", "start_char_idx": 1540, "end_char_idx": 1655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0918980c-32a2-4c07-8c3f-0944eb562ad9": {"__data__": {"id_": "0918980c-32a2-4c07-8c3f-0944eb562ad9", "embedding": null, "metadata": {"window": "Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n", "original_text": "The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e5665e1-82f0-428c-a97c-9d43196cd612", "node_type": "1", "metadata": {"window": "As a \nreminder, McKesson will no longer record adjusted equity incom e for Change Healthcare beginning in fiscal 2021 \nas a result of the split -off. \n \n Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19. ", "original_text": "For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbda45a3809437aa395807b5a2543d6319dbe99986f40551949859e5c9068f2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dee559c-7bcb-4eda-b67a-8303a1a220d4", "node_type": "1", "metadata": {"window": "These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year. ", "original_text": "Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures. "}, "hash": "055c71677c85e9ff882ced9f63284f07f77eb5f0884530c98089a27f5ed6ef0e", "class_name": "RelatedNodeInfo"}}, "text": "The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n", "start_char_idx": 1655, "end_char_idx": 1858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dee559c-7bcb-4eda-b67a-8303a1a220d4": {"__data__": {"id_": "9dee559c-7bcb-4eda-b67a-8303a1a220d4", "embedding": null, "metadata": {"window": "These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year. ", "original_text": "Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0918980c-32a2-4c07-8c3f-0944eb562ad9", "node_type": "1", "metadata": {"window": "Moving to Corporate, McKesson reported $224 million in adjusted corporate expenses in the quarter, an increase \nof 25% year -over-year, driven primarily by the previously mention ed one -time expenses and higher opioid -related \nlegal fees.  These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n", "original_text": "The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3263f9c50c5371f0df49788d190653d8a5f763e07934433894ea475573147cac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a6fb73a-b4e5-4613-b40f-76b9c3459135", "node_type": "1", "metadata": {"window": "For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021. ", "original_text": "Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19. "}, "hash": "5496dd148dd008581b82ee6818b51a1a316c451fe03d7cec2f6c8e82845079db", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures. ", "start_char_idx": 1858, "end_char_idx": 2038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a6fb73a-b4e5-4613-b40f-76b9c3459135": {"__data__": {"id_": "4a6fb73a-b4e5-4613-b40f-76b9c3459135", "embedding": null, "metadata": {"window": "For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021. ", "original_text": "Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dee559c-7bcb-4eda-b67a-8303a1a220d4", "node_type": "1", "metadata": {"window": "These one -time expenses accounted for approximately 8% of the year -over-year increase.  \n \n For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year. ", "original_text": "Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a80c5791087e21ae4c4eb51e50876f3adc099a663765276dd9684ab61bbdb80d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98914559-8af2-4c0e-9b0a-59c2a00c974f", "node_type": "1", "metadata": {"window": "The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper. ", "original_text": "Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n"}, "hash": "813f090b1ce8099f94c36e39ccdae14a32aa3ba1ea0848cb76755c7ebf3c7ee3", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19. ", "start_char_idx": 2038, "end_char_idx": 2213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98914559-8af2-4c0e-9b0a-59c2a00c974f": {"__data__": {"id_": "98914559-8af2-4c0e-9b0a-59c2a00c974f", "embedding": null, "metadata": {"window": "The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper. ", "original_text": "Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a6fb73a-b4e5-4613-b40f-76b9c3459135", "node_type": "1", "metadata": {"window": "For the full year, adjusted corporate expenses were $685 million, an increase of 23% compared to the prior ye ar. \n The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021. ", "original_text": "Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf93d617aa3fe22151b7f74fdfd1a7eecd1b17ba00ff94e8e87969b3fd651916", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "288ad1a4-608c-4779-b4f5-91d84f4cb9e0", "node_type": "1", "metadata": {"window": "Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n", "original_text": "We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year. "}, "hash": "cb3420c06abc5306f5c402c6a39a074f67aad14a13f899517c1d89187e8cbc4f", "class_name": "RelatedNodeInfo"}}, "text": "Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n", "start_char_idx": 2213, "end_char_idx": 2354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "288ad1a4-608c-4779-b4f5-91d84f4cb9e0": {"__data__": {"id_": "288ad1a4-608c-4779-b4f5-91d84f4cb9e0", "embedding": null, "metadata": {"window": "Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n", "original_text": "We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98914559-8af2-4c0e-9b0a-59c2a00c974f", "node_type": "1", "metadata": {"window": "The year -over-year increase was a result of planned increases in technology -related investments and an increase \nof $36 million in opioid -related litigation costs to $150 million for fiscal 2020.  \n \n Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper. ", "original_text": "Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8be434def4fe3b74ccbd78a0adadf83071a0dc1c84a5cb9d42f4ed366b6e963f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb933ca9-2565-46f1-aeb3-b3dd15fb8f4e", "node_type": "1", "metadata": {"window": "Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position. ", "original_text": "We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021. "}, "hash": "94d0530f2418d42d517e0dafef1d5e9459982a593967553deebe00994e7f5277", "class_name": "RelatedNodeInfo"}}, "text": "We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year. ", "start_char_idx": 2354, "end_char_idx": 2513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb933ca9-2565-46f1-aeb3-b3dd15fb8f4e": {"__data__": {"id_": "bb933ca9-2565-46f1-aeb3-b3dd15fb8f4e", "embedding": null, "metadata": {"window": "Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position. ", "original_text": "We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "288ad1a4-608c-4779-b4f5-91d84f4cb9e0", "node_type": "1", "metadata": {"window": "Turning now to cash, which can be found on slide 10, for  the fiscal year, we generated $3.9 billion in free cash \nflow, which includes $506 million spent on capital expenditures.  Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n", "original_text": "We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34ac2c5c8849677c819df732d3fffb6a9c70c83ed44b5d6fac4c2b97d287339a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b838e76-55d6-47b1-866a-d8812ec7389b", "node_type": "1", "metadata": {"window": "Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution. ", "original_text": "We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper. "}, "hash": "42b1b1e62a830e3f67dc4d4af7a8413da70a927ce05ea91e8008890753a92f86", "class_name": "RelatedNodeInfo"}}, "text": "We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021. ", "start_char_idx": 2513, "end_char_idx": 2651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b838e76-55d6-47b1-866a-d8812ec7389b": {"__data__": {"id_": "8b838e76-55d6-47b1-866a-d8812ec7389b", "embedding": null, "metadata": {"window": "Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution. ", "original_text": "We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb933ca9-2565-46f1-aeb3-b3dd15fb8f4e", "node_type": "1", "metadata": {"window": "Fiscal 2020 represented another solid year of \ncash flow generation, resulting from our continued focus on working capital efficiency, positive timing impacts and \nCOVID -19.  Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position. ", "original_text": "We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ccd5293a14aaa7b25d4ccb047376e888a0a31a6b6cd77e1f6b025ee5864eeef4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "132da3f8-e279-4c2c-ac1f-c10c5cef8e56", "node_type": "1", "metadata": {"window": "We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n", "original_text": "And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n"}, "hash": "0bcc5d94d0adcf3ed5b37de7f10975424eb54472d3c0b35be89fe2753d78362e", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper. ", "start_char_idx": 2651, "end_char_idx": 2879, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "132da3f8-e279-4c2c-ac1f-c10c5cef8e56": {"__data__": {"id_": "132da3f8-e279-4c2c-ac1f-c10c5cef8e56", "embedding": null, "metadata": {"window": "We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n", "original_text": "And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b838e76-55d6-47b1-866a-d8812ec7389b", "node_type": "1", "metadata": {"window": "Similar to fiscal 2019, a portion of the fiscal 2020 result was due to favorable timing in our US \ndistribution and European businesses.  \n \n We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution. ", "original_text": "We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76d8c72b70dd87b234b99eb9b5b195566f09bad355104949887ccfd3e6d2f09e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64c51b1f-4de4-4a17-a597-595c70d6b62e", "node_type": "1", "metadata": {"window": "We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook. ", "original_text": "Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position. "}, "hash": "e0bb23b0a193da88bec05396671cd84eb72766a401b1f7a357de0b3e3d8e1707", "class_name": "RelatedNodeInfo"}}, "text": "And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n", "start_char_idx": 2879, "end_char_idx": 2987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64c51b1f-4de4-4a17-a597-595c70d6b62e": {"__data__": {"id_": "64c51b1f-4de4-4a17-a597-595c70d6b62e", "embedding": null, "metadata": {"window": "We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook. ", "original_text": "Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "132da3f8-e279-4c2c-ac1f-c10c5cef8e56", "node_type": "1", "metadata": {"window": "We also benefited from the previously mentioned demand pull -forward in response t o the COVID -19 pandemic, \nwhich coincided with the end of our fiscal year.  We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n", "original_text": "And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f04a24adfc68348d5c3721f531dcdcd4248ff5a0911e3eff99061cb38dfa92c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4a34552-24d9-4712-bd3e-9eb8d0e32db9", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook.  As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021. ", "original_text": "Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution. "}, "hash": "0dcfbe1bc2d4e3f3c4e7c22793c0da1f054ff5bcede7a8ac546ba7ed977fcc7a", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position. ", "start_char_idx": 2987, "end_char_idx": 3151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4a34552-24d9-4712-bd3e-9eb8d0e32db9": {"__data__": {"id_": "d4a34552-24d9-4712-bd3e-9eb8d0e32db9", "embedding": null, "metadata": {"window": "We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook.  As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021. ", "original_text": "Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64c51b1f-4de4-4a17-a597-595c70d6b62e", "node_type": "1", "metadata": {"window": "We estimate a COVID -19-related benefit of approximately $550 \nmillion, which is expected to reverse in the first quarter of fiscal 2021.  We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook. ", "original_text": "Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d297377c7599a60675e61bc22617eb5be7331d5526d9cd30387a51df6a8e4769", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b41ea45-e8eb-4dc9-83c2-7fe6ba05b2ac", "node_type": "1", "metadata": {"window": "And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook.  As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021.  We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n ", "original_text": "Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n"}, "hash": "3bc9482a1add90b7b123744f7ee347d848afbd07d0b923b4d886d97bb9953048", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution. ", "start_char_idx": 3151, "end_char_idx": 3293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b41ea45-e8eb-4dc9-83c2-7fe6ba05b2ac": {"__data__": {"id_": "9b41ea45-e8eb-4dc9-83c2-7fe6ba05b2ac", "embedding": null, "metadata": {"window": "And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook.  As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021.  We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n ", "original_text": "Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4a34552-24d9-4712-bd3e-9eb8d0e32db9", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance \nof $4  billion, after paying down approximately $2.4 billion of debt in the fourth quarter, net of issuances, which \ninclude a repayment of $2.1 billion of outstanding commercial paper.  And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook.  As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021. ", "original_text": "Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "415b0ba74a939be7bdd82dce05a6735713a6f4f652a32ebb85ea7e76ccb94809", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7be277d7-959c-452e-bb8d-6bebb744ed05", "node_type": "1", "metadata": {"window": "Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook.  As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021.  We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n ", "original_text": "With that, let me turn to our fiscal 2021 outlook. "}, "hash": "bff9bf58063c2173b1489aff514a58abd7b6ed1476a116772ad433d26a829291", "class_name": "RelatedNodeInfo"}}, "text": "Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n", "start_char_idx": 3293, "end_char_idx": 3395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7be277d7-959c-452e-bb8d-6bebb744ed05": {"__data__": {"id_": "7be277d7-959c-452e-bb8d-6bebb744ed05", "embedding": null, "metadata": {"window": "Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook.  As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021.  We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n ", "original_text": "With that, let me turn to our fiscal 2021 outlook. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b41ea45-e8eb-4dc9-83c2-7fe6ba05b2ac", "node_type": "1", "metadata": {"window": "And in fiscal 2020, we returned $2.2 billion \nto our shareholders via share re purchases and dividends.  \n \n Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook.  As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021.  We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n ", "original_text": "Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c896e820b99e056bc5f5c78f12a6d37bc41ba8598fbc5b02f39403e81e70db8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40aa555f-f376-4c43-a19c-9dbf30fe5ce6", "node_type": "1", "metadata": {"window": "Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook.  As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021.  We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n ", "original_text": "As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021. "}, "hash": "cbb6edfb4af83528db1829c0513a64f3381f67f8d0bf4f314888adb4582466bf", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn to our fiscal 2021 outlook. ", "start_char_idx": 3395, "end_char_idx": 3446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40aa555f-f376-4c43-a19c-9dbf30fe5ce6": {"__data__": {"id_": "40aa555f-f376-4c43-a19c-9dbf30fe5ce6", "embedding": null, "metadata": {"window": "Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook.  As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021.  We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n ", "original_text": "As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7be277d7-959c-452e-bb8d-6bebb744ed05", "node_type": "1", "metadata": {"window": "Wrapping up fiscal 2020 results, our performance in the fourth quarter highlights the resiliency of our business \nmodel and the strength of our financial position.  Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook.  As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021.  We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n ", "original_text": "With that, let me turn to our fiscal 2021 outlook. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30af866920190b1bb422e2497aa49da5c527eb575ad7e330cc8944c0b687154d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a55a092-0aa5-4ce8-9e1a-97384d10cbfa", "node_type": "1", "metadata": {"window": "Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook.  As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021.  We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n ", "original_text": "We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n "}, "hash": "86cc6ae6ebe172e27e40754a64e71491e8ace1cc85661c5bd3e5d5df0e4375f6", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021. ", "start_char_idx": 3446, "end_char_idx": 3658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a55a092-0aa5-4ce8-9e1a-97384d10cbfa": {"__data__": {"id_": "8a55a092-0aa5-4ce8-9e1a-97384d10cbfa", "embedding": null, "metadata": {"window": "Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook.  As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021.  We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n ", "original_text": "We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "04caef37-b299-40a1-88af-be38492b51c2", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4124f07376d56f039e591c15f612fa273aff110dc07134f39a3d193a971c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40aa555f-f376-4c43-a19c-9dbf30fe5ce6", "node_type": "1", "metadata": {"window": "Fiscal 2020 marked a return to adjusted operating profit growth \nacross every business, reflecting improved fundamentals and solid execution.  Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook.  As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021.  We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n ", "original_text": "As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021. ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4232c642a7b53746148ba04b956b81269ac6b2d40a608e5af18cf3faf279cf0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f486db4f-ff5a-4517-abd7-f4a144987b94", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "292c6cf859109bcff160da05f23f2d24143c0f3ba45ff4bd1a98be3cb3755341", "class_name": "RelatedNodeInfo"}}, "text": "We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n ", "start_char_idx": 3658, "end_char_idx": 3867, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f486db4f-ff5a-4517-abd7-f4a144987b94": {"__data__": {"id_": "f486db4f-ff5a-4517-abd7-f4a144987b94", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a55a092-0aa5-4ce8-9e1a-97384d10cbfa", "node_type": "1", "metadata": {"window": "Despite recent macroeconomic \nheadwinds, the company is in a solid and stable financial position.  \n \n With that, let me turn to our fiscal 2021 outlook.  As I mentioned in my opening r emarks, we believe it is important \nto provide our views of the environment, insight into the trends we are seeing across our businesses and to \nprovide an outlook for fiscal 2021.  We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n ", "original_text": "We believe it's constructive to provide you with our view of the business, \nincluding our perspective on the economic uncertainties surrounding the potential impact and duration of the \nCOVID -19 pandemic.  \n ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35fde11876c05c30d6924337226d747db3e0bae1123cf038f4bba7d7e45ee785", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36fcf97a-aa4d-4dab-a0e8-aceb9ca94bae", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses. "}, "hash": "1468918ccd42f776b11d589994faa6fb386c97f8b2c37b48b85427ca10e4e3a1", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36fcf97a-aa4d-4dab-a0e8-aceb9ca94bae": {"__data__": {"id_": "36fcf97a-aa4d-4dab-a0e8-aceb9ca94bae", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f486db4f-ff5a-4517-abd7-f4a144987b94", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f29bb712e383840d01e337270e6d7832cd172d5a53ec2b9a1403099af29e3ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78f19231-88c6-4c1e-a5b9-1bbaf4442c46", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses. ", "original_text": "And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary. "}, "hash": "fd00def5b1ec710f0a217de97377f5bdae3d23f8173f3798a3054ed779e862aa", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses. ", "start_char_idx": 16, "end_char_idx": 230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78f19231-88c6-4c1e-a5b9-1bbaf4442c46": {"__data__": {"id_": "78f19231-88c6-4c1e-a5b9-1bbaf4442c46", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses. ", "original_text": "And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36fcf97a-aa4d-4dab-a0e8-aceb9ca94bae", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3402e8196e8a3481922d10ae7264c70d987b7c8d2dbb4598f4e56e531d2d0453", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30c33ad0-1328-438e-9b82-41a8bccafd24", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n", "original_text": "The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n"}, "hash": "262ea5f56a12da00741de5fe2c1d1ce16bdd0952329f25423951d89ff0a84730", "class_name": "RelatedNodeInfo"}}, "text": "And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary. ", "start_char_idx": 230, "end_char_idx": 333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30c33ad0-1328-438e-9b82-41a8bccafd24": {"__data__": {"id_": "30c33ad0-1328-438e-9b82-41a8bccafd24", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n", "original_text": "The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78f19231-88c6-4c1e-a5b9-1bbaf4442c46", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses. ", "original_text": "And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "526ba19b6958c3790de3c185dbb401c01cb39c2ce6dee59ae10741a13e81d417", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80c4152b-2556-46b9-b4df-5fdb4afd9a5a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures. ", "original_text": "I'll start by providing a brief overview of the environment we are operating within. "}, "hash": "e6524acb6e2719ae6f8e7b947edc5fc066c6930d28fc15d439c267faa85676ae", "class_name": "RelatedNodeInfo"}}, "text": "The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n", "start_char_idx": 333, "end_char_idx": 480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80c4152b-2556-46b9-b4df-5fdb4afd9a5a": {"__data__": {"id_": "80c4152b-2556-46b9-b4df-5fdb4afd9a5a", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures. ", "original_text": "I'll start by providing a brief overview of the environment we are operating within. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30c33ad0-1328-438e-9b82-41a8bccafd24", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n", "original_text": "The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d26274635897db4664e3837c63a8fe14ce27db2b3222a2ad23da74a4de9cf219", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "165d1f1a-1ed1-49aa-9a63-2a3610b2ea7d", "node_type": "1", "metadata": {"window": "And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels. ", "original_text": "After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses. "}, "hash": "4d7932ea42255bf93bad47f9f6a9e7d9fe6b5d6e86f8ad30feaefd31ee09b669", "class_name": "RelatedNodeInfo"}}, "text": "I'll start by providing a brief overview of the environment we are operating within. ", "start_char_idx": 480, "end_char_idx": 565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "165d1f1a-1ed1-49aa-9a63-2a3610b2ea7d": {"__data__": {"id_": "165d1f1a-1ed1-49aa-9a63-2a3610b2ea7d", "embedding": null, "metadata": {"window": "And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels. ", "original_text": "After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80c4152b-2556-46b9-b4df-5fdb4afd9a5a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures. ", "original_text": "I'll start by providing a brief overview of the environment we are operating within. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "608e1741f13048583e70260b854d63939c54fee37fd955f9190cc486abb77a62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3a5b55d-b6bb-4349-a4a7-c7528cdbdb4c", "node_type": "1", "metadata": {"window": "The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n", "original_text": "In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n"}, "hash": "b9adf84492feff11c34664ad4b6decc356f9958de7299bfe6765ed1abde36a7e", "class_name": "RelatedNodeInfo"}}, "text": "After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses. ", "start_char_idx": 565, "end_char_idx": 713, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3a5b55d-b6bb-4349-a4a7-c7528cdbdb4c": {"__data__": {"id_": "e3a5b55d-b6bb-4349-a4a7-c7528cdbdb4c", "embedding": null, "metadata": {"window": "The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n", "original_text": "In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "165d1f1a-1ed1-49aa-9a63-2a3610b2ea7d", "node_type": "1", "metadata": {"window": "And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels. ", "original_text": "After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d67c559aecce5f3cace2165e37911aad90d93595d2d157cc958034f3343d2ad5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "449f8d6a-5021-4ad1-bebd-8d7cca57174f", "node_type": "1", "metadata": {"window": "I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019. ", "original_text": "As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures. "}, "hash": "531ec0367eed4aafcc813c03b7e906613229e8572ed38f807dde3a8b87687cc5", "class_name": "RelatedNodeInfo"}}, "text": "In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n", "start_char_idx": 713, "end_char_idx": 847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "449f8d6a-5021-4ad1-bebd-8d7cca57174f": {"__data__": {"id_": "449f8d6a-5021-4ad1-bebd-8d7cca57174f", "embedding": null, "metadata": {"window": "I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019. ", "original_text": "As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3a5b55d-b6bb-4349-a4a7-c7528cdbdb4c", "node_type": "1", "metadata": {"window": "The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n", "original_text": "In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe2d02514f0cd9c7b5017b6b39f8eb8c0477d6733e3821ac34393fd7e6a6fcc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d58cb710-f8d9-405b-9863-d6ebcf32863f", "node_type": "1", "metadata": {"window": "After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n", "original_text": "Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels. "}, "hash": "950b28c406a732029ae436f00e8d05f9fb4ce778305c4e4fb7863c3da2b3d8ea", "class_name": "RelatedNodeInfo"}}, "text": "As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures. ", "start_char_idx": 847, "end_char_idx": 1017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d58cb710-f8d9-405b-9863-d6ebcf32863f": {"__data__": {"id_": "d58cb710-f8d9-405b-9863-d6ebcf32863f", "embedding": null, "metadata": {"window": "After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n", "original_text": "Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "449f8d6a-5021-4ad1-bebd-8d7cca57174f", "node_type": "1", "metadata": {"window": "I'll start by providing a brief overview of the environment we are operating within.  After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019. ", "original_text": "As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bac184641ce5066395e9a59462eda2451c40ecd7ae9b41afeb81b387c0266348", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cd29a46-575d-43fc-b647-bfcc3a43ebee", "node_type": "1", "metadata": {"window": "In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels. ", "original_text": "Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n"}, "hash": "1c1083a59ccc26db147b703ff486be50e07f388cb54e5fdb53dd4ffff71e3d3b", "class_name": "RelatedNodeInfo"}}, "text": "Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels. ", "start_char_idx": 1017, "end_char_idx": 1155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cd29a46-575d-43fc-b647-bfcc3a43ebee": {"__data__": {"id_": "0cd29a46-575d-43fc-b647-bfcc3a43ebee", "embedding": null, "metadata": {"window": "In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels. ", "original_text": "Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d58cb710-f8d9-405b-9863-d6ebcf32863f", "node_type": "1", "metadata": {"window": "After the initial volume spikes \nfollowing the March 11 World Health Organization declaration, volumes began to trend lower across our \nbusinesses.  In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n", "original_text": "Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed18d580a152da6dfc46a2a31c3022619d674a2bbbee27a0d0c3789a9576446f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d10edaa-921c-4271-802a-c95d51052d04", "node_type": "1", "metadata": {"window": "As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n", "original_text": "From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019. "}, "hash": "b9da9f3fffe0a707bb901876bbc1316f4747a7c1b48b471b14aebd5b5bef37dc", "class_name": "RelatedNodeInfo"}}, "text": "Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n", "start_char_idx": 1155, "end_char_idx": 1384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d10edaa-921c-4271-802a-c95d51052d04": {"__data__": {"id_": "3d10edaa-921c-4271-802a-c95d51052d04", "embedding": null, "metadata": {"window": "As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n", "original_text": "From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cd29a46-575d-43fc-b647-bfcc3a43ebee", "node_type": "1", "metadata": {"window": "In April, the landscape continued to evolve quickly and state, provincial and local governments issued \nshelter -in-place orders.  \n \n As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels. ", "original_text": "Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "589102dd3a758f577c6d91fc9d367be8204226abe9c5948e5522f40c2caa6ce8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6733e202-61c0-4f52-9009-afb747bbcc74", "node_type": "1", "metadata": {"window": "Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n", "original_text": "In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n"}, "hash": "11adc1bd6547983a69d006740a79a29e8b9673be6f4325e9e2dbf07a5befa8bd", "class_name": "RelatedNodeInfo"}}, "text": "From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019. ", "start_char_idx": 1384, "end_char_idx": 1570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6733e202-61c0-4f52-9009-afb747bbcc74": {"__data__": {"id_": "6733e202-61c0-4f52-9009-afb747bbcc74", "embedding": null, "metadata": {"window": "Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n", "original_text": "In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d10edaa-921c-4271-802a-c95d51052d04", "node_type": "1", "metadata": {"window": "As a result, physician offices and surgery center sites began to close temporarily, meaning fewer patients going to \nsee their doctors and delays in elective procedures.  Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n", "original_text": "From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5a6653e094fc34117bcd44694806515dd9596b54eb019b17a2b5be410201d24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbff924c-69ee-4ff4-89ee-3d30028b416d", "node_type": "1", "metadata": {"window": "Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions. ", "original_text": "Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels. "}, "hash": "9ac1bd39be73eec1b6a68559de66a7a8e96eadd6fef329b05b1722e7bdb2ce4c", "class_name": "RelatedNodeInfo"}}, "text": "In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n", "start_char_idx": 1570, "end_char_idx": 1716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbff924c-69ee-4ff4-89ee-3d30028b416d": {"__data__": {"id_": "fbff924c-69ee-4ff4-89ee-3d30028b416d", "embedding": null, "metadata": {"window": "Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions. ", "original_text": "Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6733e202-61c0-4f52-9009-afb747bbcc74", "node_type": "1", "metadata": {"window": "Throughout April, average weekly volumes in our medical \nand specialty provider  business trailed off up to 50% of pre -COVID -19 levels.  Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n", "original_text": "In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b15f2e9cc8458e3aea0d03f198d3271610af3507893db5daea260192317ad86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c6719c0-fd95-4153-bb54-ecf2b2f92636", "node_type": "1", "metadata": {"window": "From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products. ", "original_text": "To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n"}, "hash": "862c91d96dde95fdea9fdce71b9879b0d750b6fa10af3fdf499d1729c234d1ca", "class_name": "RelatedNodeInfo"}}, "text": "Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels. ", "start_char_idx": 1716, "end_char_idx": 1843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c6719c0-fd95-4153-bb54-ecf2b2f92636": {"__data__": {"id_": "3c6719c0-fd95-4153-bb54-ecf2b2f92636", "embedding": null, "metadata": {"window": "From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products. ", "original_text": "To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbff924c-69ee-4ff4-89ee-3d30028b416d", "node_type": "1", "metadata": {"window": "Oncology visits declined, while \nvolumes in our pharmaceutical distribution and retail businesses experienced greater levels of volatility as \ncustomers adjusted to the environment and government orders  and recommendations.  \n \n From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions. ", "original_text": "Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8a1baac1bd7705b2f6d7d1d166636851d2d43ec150dcbeccffad909e7a74f34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f21f40f2-3fcb-4d43-a8b2-de01ee63c8f7", "node_type": "1", "metadata": {"window": "In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n", "original_text": "I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n"}, "hash": "15486a08eb7aac577707e6e79b6d8efbdfa040d6bff0d1f75cd4d7e3c6717f42", "class_name": "RelatedNodeInfo"}}, "text": "To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n", "start_char_idx": 1843, "end_char_idx": 2013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f21f40f2-3fcb-4d43-a8b2-de01ee63c8f7": {"__data__": {"id_": "f21f40f2-3fcb-4d43-a8b2-de01ee63c8f7", "embedding": null, "metadata": {"window": "In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n", "original_text": "I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c6719c0-fd95-4153-bb54-ecf2b2f92636", "node_type": "1", "metadata": {"window": "From the onset of the pandemic in the US, elective therapies showed a sharp decline through April, especially \nwithin ophthalmology, where declines were nearly 30% versus calendar 2019.  In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products. ", "original_text": "To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c59e098f5e56960cc32f610ddbb09eb31249c9ec238e580613eaea87b917da19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16bb928a-83d4-4afd-bba5-e62701195b44", "node_type": "1", "metadata": {"window": "Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year. ", "original_text": "Next, I'll provide some framing on a couple of key macro level economic assumptions. "}, "hash": "dc84f4c121db359a7dbb1a5db24602ca3680d59cdc47dc6e03389910c29b21d7", "class_name": "RelatedNodeInfo"}}, "text": "I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n", "start_char_idx": 2013, "end_char_idx": 2307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16bb928a-83d4-4afd-bba5-e62701195b44": {"__data__": {"id_": "16bb928a-83d4-4afd-bba5-e62701195b44", "embedding": null, "metadata": {"window": "Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year. ", "original_text": "Next, I'll provide some framing on a couple of key macro level economic assumptions. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f21f40f2-3fcb-4d43-a8b2-de01ee63c8f7", "node_type": "1", "metadata": {"window": "In the first couple of weeks of May, \nwe've seen volumes begin to stabilize and modestly improve in our pharmaceutical and retail businesses.  \n \n Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n", "original_text": "I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7e496ab68d4e9dab3bcde7fe7b4dbc0f991c41a9e25fb88eb15f0eaa23f4d1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd029429-c7e2-4e3c-9906-409f4ac577a4", "node_type": "1", "metadata": {"window": "To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n", "original_text": "We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products. "}, "hash": "c0fff427051e15f6b40e26c102a8cb2241502e003e790efa4cdbb15d418c94e0", "class_name": "RelatedNodeInfo"}}, "text": "Next, I'll provide some framing on a couple of key macro level economic assumptions. ", "start_char_idx": 2307, "end_char_idx": 2392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd029429-c7e2-4e3c-9906-409f4ac577a4": {"__data__": {"id_": "cd029429-c7e2-4e3c-9906-409f4ac577a4", "embedding": null, "metadata": {"window": "To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n", "original_text": "We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16bb928a-83d4-4afd-bba5-e62701195b44", "node_type": "1", "metadata": {"window": "Volumes in our medical and specialty provider businesses have also begun to stabilize, although well below pre -\nCOVID levels.  To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year. ", "original_text": "Next, I'll provide some framing on a couple of key macro level economic assumptions. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ec81415e64f190b69db9486276f87cceaaa27393c28ac902e37c7d6c785194a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "054f1e4d-fb63-48df-bb8a-ccfbf23c21fe", "node_type": "1", "metadata": {"window": "I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter. ", "original_text": "We are not assuming any systemic customer \ninsolvency events.  \n \n"}, "hash": "24a26c7130825eb41f1c244e5086da2aa536b503cb565398bb94f18e675fb536", "class_name": "RelatedNodeInfo"}}, "text": "We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products. ", "start_char_idx": 2392, "end_char_idx": 2587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "054f1e4d-fb63-48df-bb8a-ccfbf23c21fe": {"__data__": {"id_": "054f1e4d-fb63-48df-bb8a-ccfbf23c21fe", "embedding": null, "metadata": {"window": "I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter. ", "original_text": "We are not assuming any systemic customer \ninsolvency events.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd029429-c7e2-4e3c-9906-409f4ac577a4", "node_type": "1", "metadata": {"window": "To this point, the relative shape of the curve is in line with our expectations and confirms our view \non the progression of recovery over the course of fiscal 2021.  \n \n I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n", "original_text": "We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0c3dbacaa3b6f6ccf2023ccbbf275cfa63b7483a4a38910f7ec795584b8e5fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3033c553-d58d-4425-b23b-fea32c2c9d26", "node_type": "1", "metadata": {"window": "Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n", "original_text": "We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year. "}, "hash": "adfc90ce6bf421c4942efc3840f962898a03ceda007c981564fe388efcaca040", "class_name": "RelatedNodeInfo"}}, "text": "We are not assuming any systemic customer \ninsolvency events.  \n \n", "start_char_idx": 2587, "end_char_idx": 2653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3033c553-d58d-4425-b23b-fea32c2c9d26": {"__data__": {"id_": "3033c553-d58d-4425-b23b-fea32c2c9d26", "embedding": null, "metadata": {"window": "Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n", "original_text": "We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "054f1e4d-fb63-48df-bb8a-ccfbf23c21fe", "node_type": "1", "metadata": {"window": "I will note that the guidance we are providing today is based on what we know at this time, and I want to be clear \nthat one cer tainty is that events will occur in the coming days, weeks and months that will cause these underlying \nassumptions to change from what we present to you today.  \n \n Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter. ", "original_text": "We are not assuming any systemic customer \ninsolvency events.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "423a129603de3df19080d2122983c6dd88c58dac9fa950f32f912492521fa2f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81bb7834-9a58-42ae-bb62-e4ec12e5c5fd", "node_type": "1", "metadata": {"window": "We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions. ", "original_text": "We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n"}, "hash": "95dae0b7d6ab6322a5eef8a9cff4b1a3cf677cb7ded49aca47ada3960d0fb89c", "class_name": "RelatedNodeInfo"}}, "text": "We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year. ", "start_char_idx": 2653, "end_char_idx": 2802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81bb7834-9a58-42ae-bb62-e4ec12e5c5fd": {"__data__": {"id_": "81bb7834-9a58-42ae-bb62-e4ec12e5c5fd", "embedding": null, "metadata": {"window": "We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions. ", "original_text": "We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3033c553-d58d-4425-b23b-fea32c2c9d26", "node_type": "1", "metadata": {"window": "Next, I'll provide some framing on a couple of key macro level economic assumptions.  We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n", "original_text": "We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04636abd9d4eef5a770232b179fdd5c864715a5c0e6ee1f197db75538a7147f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c0dca00-0d14-41f0-a71e-9ed3d60ac95d", "node_type": "1", "metadata": {"window": "We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions.  As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n", "original_text": "Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter. "}, "hash": "fa2a9d388a3b210a91712d0beed46050e304ccf9a3bf89d8a2f4cee55fa46a41", "class_name": "RelatedNodeInfo"}}, "text": "We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n", "start_char_idx": 2802, "end_char_idx": 3011, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c0dca00-0d14-41f0-a71e-9ed3d60ac95d": {"__data__": {"id_": "7c0dca00-0d14-41f0-a71e-9ed3d60ac95d", "embedding": null, "metadata": {"window": "We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions.  As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n", "original_text": "Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81bb7834-9a58-42ae-bb62-e4ec12e5c5fd", "node_type": "1", "metadata": {"window": "We are not  assuming that \na second wave of the virus returns, leading to shelter -at-home scenarios precluding patient consumption of \nhealthcare services, supplies and pharmaceutical products.  We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions. ", "original_text": "We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf3324848b67dce1e5d300387fffe9d8bb29d8f92f9e037719c24c3384ccebb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcfdbbcf-6691-462e-89fa-ac59c04570a6", "node_type": "1", "metadata": {"window": "We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions.  As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n ", "original_text": "With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n"}, "hash": "e53a3ccce3cc1eefd4aea2e4835562cf3a6c9c5bfb49bfd0747de62c90c183bf", "class_name": "RelatedNodeInfo"}}, "text": "Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter. ", "start_char_idx": 3011, "end_char_idx": 3371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcfdbbcf-6691-462e-89fa-ac59c04570a6": {"__data__": {"id_": "bcfdbbcf-6691-462e-89fa-ac59c04570a6", "embedding": null, "metadata": {"window": "We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions.  As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n ", "original_text": "With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c0dca00-0d14-41f0-a71e-9ed3d60ac95d", "node_type": "1", "metadata": {"window": "We are not assuming any systemic customer \ninsolvency events.  \n \n We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions.  As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n", "original_text": "Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b11353f48fbd99bdd3a39bf5f5f31af0452455905b2b19ca577f46d19263ee3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5ba8673-4013-4964-8277-3cae99ff2465", "node_type": "1", "metadata": {"window": "We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions.  As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n ", "original_text": "We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions. "}, "hash": "c919f331f938e24a084e7dfec2d96df51bddf069fc3a90f14185c931f6030d7a", "class_name": "RelatedNodeInfo"}}, "text": "With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n", "start_char_idx": 3371, "end_char_idx": 3460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5ba8673-4013-4964-8277-3cae99ff2465": {"__data__": {"id_": "a5ba8673-4013-4964-8277-3cae99ff2465", "embedding": null, "metadata": {"window": "We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions.  As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n ", "original_text": "We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcfdbbcf-6691-462e-89fa-ac59c04570a6", "node_type": "1", "metadata": {"window": "We do assume that unemployment peaks in our fiscal first quarter, and gradually begins to improve across the \nremaining quarters of our fiscal year.  We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions.  As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n ", "original_text": "With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09079a0bc8f232d58badc1bd1bfa4e48a8aca6c625b1969878fbc0df46599901", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ec7c61f-6c07-44c6-ae59-0e42d9089096", "node_type": "1", "metadata": {"window": "Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions.  As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n ", "original_text": "As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n"}, "hash": "097cb6f9c39cd4e0ccdacff6b7affa7cd5e2f4d2a2d8b0bbe1016c4d94aa7cd5", "class_name": "RelatedNodeInfo"}}, "text": "We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions. ", "start_char_idx": 3460, "end_char_idx": 3678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ec7c61f-6c07-44c6-ae59-0e42d9089096": {"__data__": {"id_": "3ec7c61f-6c07-44c6-ae59-0e42d9089096", "embedding": null, "metadata": {"window": "Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions.  As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n ", "original_text": "As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5ba8673-4013-4964-8277-3cae99ff2465", "node_type": "1", "metadata": {"window": "We do assume that physician and oncology office visits and pharmacy \ninteractions will begin to gradually resume in our fi scal second quarter and continue to improve in the back half of \nour fiscal year.  \n \n Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions.  As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n ", "original_text": "We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions. ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db5592adea7b1622ad2e7bda5f66ee35990158874195d4034cb180c720baa6d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "439e3cff-b9fb-4251-8508-7b1ea09aabc2", "node_type": "1", "metadata": {"window": "With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions.  As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n ", "original_text": "We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n "}, "hash": "75a0889600301d3d72bbb6437c2c09030ff7b99b07d9be857c69c6eb5cda6a59", "class_name": "RelatedNodeInfo"}}, "text": "As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n", "start_char_idx": 3678, "end_char_idx": 3797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "439e3cff-b9fb-4251-8508-7b1ea09aabc2": {"__data__": {"id_": "439e3cff-b9fb-4251-8508-7b1ea09aabc2", "embedding": null, "metadata": {"window": "With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions.  As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n ", "original_text": "We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c299a84c-c422-4443-85c7-4a8b016785fc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28736fd929248ca83f65d38fb7ff48c197015b10219af596cd9ea00b84f4ba33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ec7c61f-6c07-44c6-ae59-0e42d9089096", "node_type": "1", "metadata": {"window": "Our view of the environment, in particular, our largest market, the US, assumes that the impact, in particular, to \nour medical, specialty provider and oncology businesses is more significant and severe in the first quarter and \nthat the shape of the recovery gradually improves each quarter with a return to more normal volumes in our fiscal \nfourth quarter.  With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions.  As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n ", "original_text": "As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef68c10669f2082acd7d7ddb81cbfd5ee962e2ccd8c576a2911cc01e89cb5c7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee1fbfc5-a9dc-4ac4-939c-6eb33f1c88a2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments. ", "original_text": "McKesson Corp.  "}, "hash": "6cec761efa48b793148d62bd06367d27516c93347bcbadf0a667e734cd20a273", "class_name": "RelatedNodeInfo"}}, "text": "We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n ", "start_char_idx": 3797, "end_char_idx": 3875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee1fbfc5-a9dc-4ac4-939c-6eb33f1c88a2": {"__data__": {"id_": "ee1fbfc5-a9dc-4ac4-939c-6eb33f1c88a2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "439e3cff-b9fb-4251-8508-7b1ea09aabc2", "node_type": "1", "metadata": {"window": "With those underlying assumptions in mind, let me turn to our fiscal 2021  guidance.  \n \n We expect adjusted earnings per diluted share to be in the range of $13.95 to $14.75, which is notably wider than \npast guidance ranges, given the economic uncertainty inherent in our previously mentioned assumptions.  As I \ndiscussed in my openin g remarks, we anticipate a positive progression of earnings over the course fiscal 2021. \n We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n ", "original_text": "We expect Q1 to be sharply down on a year -over-year and sequential basis.  \n ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "045975838e742669ef2109bab6fda118d264ecff80b7717f493c9c00f2b2fe67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81f1b4fd-049f-456b-ae93-81aad0996f1f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year. "}, "hash": "fe81580fb2783e315d779883dc55d7709dd2b7a31f89f9969e92ea9cea3d2495", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81f1b4fd-049f-456b-ae93-81aad0996f1f": {"__data__": {"id_": "81f1b4fd-049f-456b-ae93-81aad0996f1f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee1fbfc5-a9dc-4ac4-939c-6eb33f1c88a2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "583ef2880835bbd03324756f9ddd3a6548c58fc3dae9d5482c56fbe299ad4d22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31a1ec8c-8cc7-4053-b362-f0336331441f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n", "original_text": "For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n"}, "hash": "18b54518738164baecb05bd2c9c92d8de7faf3baa6443ffebfcc1e86f65e286d", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year. ", "start_char_idx": 16, "end_char_idx": 468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31a1ec8c-8cc7-4053-b362-f0336331441f": {"__data__": {"id_": "31a1ec8c-8cc7-4053-b362-f0336331441f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n", "original_text": "For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81f1b4fd-049f-456b-ae93-81aad0996f1f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0cf01d02e08a33e123ed60d917d421479950fca021b713488268a7576db52f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "513681dc-6454-49b8-844a-d6b1d4d2dded", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses. ", "original_text": "Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments. "}, "hash": "4cd8aa6b6389e8ee5c8412f56186c3e4559f9b1ed8d2e0afecba10e2216b1200", "class_name": "RelatedNodeInfo"}}, "text": "For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n", "start_char_idx": 468, "end_char_idx": 594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "513681dc-6454-49b8-844a-d6b1d4d2dded": {"__data__": {"id_": "513681dc-6454-49b8-844a-d6b1d4d2dded", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses. ", "original_text": "Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31a1ec8c-8cc7-4053-b362-f0336331441f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n", "original_text": "For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f0df94fdb3747060766a3d2f48566b1767835b7b292668512507e101ddbeba8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e86f018-fab3-4201-90bd-0f7eba5f93b8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n", "original_text": "In \nthe U.S. "}, "hash": "3f3410ae3488ab59cdfd6d09b63fd88b63ca2c028e8f3cdbecf56796b0cf35fa", "class_name": "RelatedNodeInfo"}}, "text": "Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments. ", "start_char_idx": 594, "end_char_idx": 706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e86f018-fab3-4201-90bd-0f7eba5f93b8": {"__data__": {"id_": "1e86f018-fab3-4201-90bd-0f7eba5f93b8", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n", "original_text": "In \nthe U.S. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "513681dc-6454-49b8-844a-d6b1d4d2dded", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses. ", "original_text": "Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87c9e06df9ea6b7e4d21ac5c317d22ea676b71f2b53a3387734b76f64b7c67fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b97047f-ef3d-444c-bee0-332f5745e0d7", "node_type": "1", "metadata": {"window": "For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020. ", "original_text": "Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n"}, "hash": "1c92bac41db63c69897e14d35c669bf2fc813c48b9d6bc55840a5a406ba20043", "class_name": "RelatedNodeInfo"}}, "text": "In \nthe U.S. ", "start_char_idx": 706, "end_char_idx": 719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b97047f-ef3d-444c-bee0-332f5745e0d7": {"__data__": {"id_": "3b97047f-ef3d-444c-bee0-332f5745e0d7", "embedding": null, "metadata": {"window": "For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020. ", "original_text": "Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e86f018-fab3-4201-90bd-0f7eba5f93b8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n", "original_text": "In \nthe U.S. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2731a533a9fee6525b96979d001e47891377341c87ffed17b8c987fafe2c93f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bcb6550-d84f-4d04-8973-41e0579f2e41", "node_type": "1", "metadata": {"window": "Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n", "original_text": "Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses. "}, "hash": "a4e6e4f488929fd0becf7d93ef8219eabacc9fa9305964ba2fc25493370ae232", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n", "start_char_idx": 719, "end_char_idx": 970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bcb6550-d84f-4d04-8973-41e0579f2e41": {"__data__": {"id_": "1bcb6550-d84f-4d04-8973-41e0579f2e41", "embedding": null, "metadata": {"window": "Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n", "original_text": "Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b97047f-ef3d-444c-bee0-332f5745e0d7", "node_type": "1", "metadata": {"window": "For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020. ", "original_text": "Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6f4f02188b67a605205dec5c5cd352d0020cb0c101eb13c73c4efa577857ff0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f340c165-778e-46e9-bcae-8618e25db32d", "node_type": "1", "metadata": {"window": "In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year. ", "original_text": "We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n"}, "hash": "a9fcf5916e5c2c236c02d050016465185af61b59fc4ba898ba9d316e5afeacc9", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses. ", "start_char_idx": 970, "end_char_idx": 1141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f340c165-778e-46e9-bcae-8618e25db32d": {"__data__": {"id_": "f340c165-778e-46e9-bcae-8618e25db32d", "embedding": null, "metadata": {"window": "In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year. ", "original_text": "We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bcb6550-d84f-4d04-8973-41e0579f2e41", "node_type": "1", "metadata": {"window": "Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments.  In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n", "original_text": "Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65406032c43a9ef4543723b8019be1be68dbdee274aa8aa4be595be36e3792d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "058d286e-5ed2-4a35-917d-66b2e795600d", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year. ", "original_text": "In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020. "}, "hash": "65ae9404f6e8f4e6798b3541cac8e582255fe5c5a6a69d96b207a512a2149e38", "class_name": "RelatedNodeInfo"}}, "text": "We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n", "start_char_idx": 1141, "end_char_idx": 1301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "058d286e-5ed2-4a35-917d-66b2e795600d": {"__data__": {"id_": "058d286e-5ed2-4a35-917d-66b2e795600d", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year. ", "original_text": "In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f340c165-778e-46e9-bcae-8618e25db32d", "node_type": "1", "metadata": {"window": "In \nthe U.S.  Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year. ", "original_text": "We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6eb70a4f9645603274bfc5bb626134d4147d32a6a24c4c478edc31e783a48c05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bebc3b2b-e825-4077-b284-3a116b6e4b6f", "node_type": "1", "metadata": {"window": "Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n", "original_text": "As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n"}, "hash": "80fb4ffd2f7c355abbb22f9149db827471199c13a1c0dd66e5a572a42ae7a1e5", "class_name": "RelatedNodeInfo"}}, "text": "In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020. ", "start_char_idx": 1301, "end_char_idx": 1449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bebc3b2b-e825-4077-b284-3a116b6e4b6f": {"__data__": {"id_": "bebc3b2b-e825-4077-b284-3a116b6e4b6f", "embedding": null, "metadata": {"window": "Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n", "original_text": "As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "058d286e-5ed2-4a35-917d-66b2e795600d", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions segment, we expect 3% to 6% revenue  growth, which considers \ncurrent headwinds in our practice management and provider solutions businesses as a result of office closures \nand delays in elective procedures.  \n \n Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year. ", "original_text": "In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20c74d7299285ca6178e4fbcc05a0ed3855b4180ce93f6a53f298114dfdafc05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2bbd195-a774-44d0-a45a-2dd4a51283d3", "node_type": "1", "metadata": {"window": "We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical. ", "original_text": "Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year. "}, "hash": "1df626b5800e1e3c4dcdde676c6a859421d2674d07f032b1c0619c171bb9d480", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n", "start_char_idx": 1449, "end_char_idx": 1571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2bbd195-a774-44d0-a45a-2dd4a51283d3": {"__data__": {"id_": "e2bbd195-a774-44d0-a45a-2dd4a51283d3", "embedding": null, "metadata": {"window": "We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical. ", "original_text": "Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bebc3b2b-e825-4077-b284-3a116b6e4b6f", "node_type": "1", "metadata": {"window": "Adjusted operating profit is expected to be flat to 4% down as compared to the prior year, as a result of the \npreviously mentioned headwinds in our specialty businesses.  We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n", "original_text": "As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a0520ff86d4d8556b8f5d6e87b9e51263b253390f3f6711b7dcfa2512f9a767", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0d90c94-c30d-4437-9a62-a15bc78087f0", "node_type": "1", "metadata": {"window": "In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations. ", "original_text": "Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year. "}, "hash": "bfddec6cc389d148ff92436d11e4264e713c2db8560c74f12fc13433b8c37059", "class_name": "RelatedNodeInfo"}}, "text": "Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year. ", "start_char_idx": 1571, "end_char_idx": 1744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0d90c94-c30d-4437-9a62-a15bc78087f0": {"__data__": {"id_": "d0d90c94-c30d-4437-9a62-a15bc78087f0", "embedding": null, "metadata": {"window": "In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations. ", "original_text": "Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2bbd195-a774-44d0-a45a-2dd4a51283d3", "node_type": "1", "metadata": {"window": "We expect that the second half adjusted operating \nprofit result will reflect flat to 3% growth, in line with our previously outlined recovery assumptions.  \n \n In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical. ", "original_text": "Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87778461558e15060ad64b1c614d6fe82028185b5defee46f0da1392f4dd6c7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2f7aa14-6dc8-43ce-8352-4150a8b59fc9", "node_type": "1", "metadata": {"window": "As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n", "original_text": "We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n"}, "hash": "a69746b8026abe9038142976fae6fe2ad5eb2a1dbcf61a4185d3867096e04287", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year. ", "start_char_idx": 1744, "end_char_idx": 1961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2f7aa14-6dc8-43ce-8352-4150a8b59fc9": {"__data__": {"id_": "e2f7aa14-6dc8-43ce-8352-4150a8b59fc9", "embedding": null, "metadata": {"window": "As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n", "original_text": "We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0d90c94-c30d-4437-9a62-a15bc78087f0", "node_type": "1", "metadata": {"window": "In the US marke t, we anticipate mid -single -digit branded pharmaceutical price increases, largely consistent with \nour experience in fiscal 2020.  As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations. ", "original_text": "Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06aa4de2ac144243d2da21cde47d7c0efd097d82c894de8617a99c5b094cc35c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88b1f3d6-61f4-48f3-a783-62f2537bb9d4", "node_type": "1", "metadata": {"window": "Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates. ", "original_text": "Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical. "}, "hash": "2919986b2078d15cc1a6181bba8b59b5b876274903656e9f7238b81dc9c15883", "class_name": "RelatedNodeInfo"}}, "text": "We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n", "start_char_idx": 1961, "end_char_idx": 2171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88b1f3d6-61f4-48f3-a783-62f2537bb9d4": {"__data__": {"id_": "88b1f3d6-61f4-48f3-a783-62f2537bb9d4", "embedding": null, "metadata": {"window": "Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates. ", "original_text": "Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2f7aa14-6dc8-43ce-8352-4150a8b59fc9", "node_type": "1", "metadata": {"window": "As a reminder, approximately 95% of our contracted branded manufacturers are on \na fixed fee -for-service rate basis.  \n \n Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n", "original_text": "We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88dfa2f137141a31ab4cb43599060fcf1caa9f90efe87de137c9864493f0fa9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1749adc-4f4d-4dac-95bc-f4606f10388b", "node_type": "1", "metadata": {"window": "Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n", "original_text": "Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations. "}, "hash": "51053de0812cc681bdff93d2c6a625649a10e0efafdf95114d2cd67c920921e3", "class_name": "RelatedNodeInfo"}}, "text": "Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical. ", "start_char_idx": 2171, "end_char_idx": 2301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1749adc-4f4d-4dac-95bc-f4606f10388b": {"__data__": {"id_": "c1749adc-4f4d-4dac-95bc-f4606f10388b", "embedding": null, "metadata": {"window": "Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n", "original_text": "Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88b1f3d6-61f4-48f3-a783-62f2537bb9d4", "node_type": "1", "metadata": {"window": "Moving to the European Solutions (sic) [European Pharmaceutical Solutions] (00:36:00) segment, we expect \nrevenues to be flat to a 5% decline as compared to the prior year.  Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates. ", "original_text": "Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60676314876e5d77c723610478a7393e4ca45cb59c04135d1aca0548f87e339c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad8f6c34-de72-439d-9444-537511ed460b", "node_type": "1", "metadata": {"window": "We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes. ", "original_text": "These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n"}, "hash": "8f26da35136a990f1f51b9871189f569bd95905f018ac3f1685dcc1aafbb916d", "class_name": "RelatedNodeInfo"}}, "text": "Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations. ", "start_char_idx": 2301, "end_char_idx": 2457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad8f6c34-de72-439d-9444-537511ed460b": {"__data__": {"id_": "ad8f6c34-de72-439d-9444-537511ed460b", "embedding": null, "metadata": {"window": "We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes. ", "original_text": "These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1749adc-4f4d-4dac-95bc-f4606f10388b", "node_type": "1", "metadata": {"window": "Adjusted operating profit is also expected to \ndecline between approximately 20% to 25%, driven  by anticipated impacts of the COVID -19 pandemic on \ncustomer behavior patterns over the first half of the fiscal year.  We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n", "original_text": "Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7769aaa5e32f88961f6bf04c876a119812e4202d1425cb0da446ca70981d66c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05e6f29e-adb6-40ed-9d3e-8b28b8a7ea6d", "node_type": "1", "metadata": {"window": "Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n", "original_text": "In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates. "}, "hash": "a1809b325dc03f1b819e8ed2383b60e9315c07efff2eade20880a92ed86efb49", "class_name": "RelatedNodeInfo"}}, "text": "These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n", "start_char_idx": 2457, "end_char_idx": 2593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05e6f29e-adb6-40ed-9d3e-8b28b8a7ea6d": {"__data__": {"id_": "05e6f29e-adb6-40ed-9d3e-8b28b8a7ea6d", "embedding": null, "metadata": {"window": "Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n", "original_text": "In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad8f6c34-de72-439d-9444-537511ed460b", "node_type": "1", "metadata": {"window": "We expect that the second half adjusted operating \nprofit results will be flat to 2% growth as compared to the prior year, with variabilit y by country as each market \nopens and begins to return to normal.  \n \n Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes. ", "original_text": "These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7bb7419936596c6ee7f2919e5d77e9a9264cffa3adc43f09dbe90c2b6c0d240e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "446d5929-8c3e-4a8f-90bf-803653e823ae", "node_type": "1", "metadata": {"window": "Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year. ", "original_text": "We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n"}, "hash": "574b2ccf24a4cf15ee495aa7f4950339e0a5435f257d61c36f09a10d90b4d650", "class_name": "RelatedNodeInfo"}}, "text": "In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates. ", "start_char_idx": 2593, "end_char_idx": 2768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "446d5929-8c3e-4a8f-90bf-803653e823ae": {"__data__": {"id_": "446d5929-8c3e-4a8f-90bf-803653e823ae", "embedding": null, "metadata": {"window": "Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year. ", "original_text": "We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05e6f29e-adb6-40ed-9d3e-8b28b8a7ea6d", "node_type": "1", "metadata": {"window": "Transitioning now to Medical Surgical, as we've discussed previously, we have a dynamic and broad portfolio in \nMedical Surgical.  Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n", "original_text": "In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a416f2aa8cf0920b2a12bf4ea1fbdf504b312703c992bab2fd9b7a8f1c9610ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e27297a-b36e-4e4c-b18e-94e2fca260d9", "node_type": "1", "metadata": {"window": "These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year. ", "original_text": "Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes. "}, "hash": "12f8e4b8b19eea21f9da7f70efc96e6402d860332c2191e97679efdd9757978d", "class_name": "RelatedNodeInfo"}}, "text": "We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n", "start_char_idx": 2768, "end_char_idx": 2971, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e27297a-b36e-4e4c-b18e-94e2fca260d9": {"__data__": {"id_": "9e27297a-b36e-4e4c-b18e-94e2fca260d9", "embedding": null, "metadata": {"window": "These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year. ", "original_text": "Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "446d5929-8c3e-4a8f-90bf-803653e823ae", "node_type": "1", "metadata": {"window": "Approximately 60% of our Medical Surgical business supports primary care sites, physician \noffices, ambulatory surgery centers and reference lab locations.  These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year. ", "original_text": "We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35acb50015251878e79061550c64c416f2a1b9ad372541cdd01040083c4ff972", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d8775dc-2947-410f-bd64-184e4c8861ac", "node_type": "1", "metadata": {"window": "In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year.  As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n", "original_text": "We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n"}, "hash": "b3dc1614a03720402de0e0a187c83f8d50dc29f070f9c6c5e76b6c72f1243259", "class_name": "RelatedNodeInfo"}}, "text": "Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes. ", "start_char_idx": 2971, "end_char_idx": 3101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d8775dc-2947-410f-bd64-184e4c8861ac": {"__data__": {"id_": "5d8775dc-2947-410f-bd64-184e4c8861ac", "embedding": null, "metadata": {"window": "In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year.  As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n", "original_text": "We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e27297a-b36e-4e4c-b18e-94e2fca260d9", "node_type": "1", "metadata": {"window": "These sites of care have been impacted more \nsignificantly as office visits and elective procedures have been canceled or deferred.  \n \n In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year. ", "original_text": "Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e618bb8885d1637d286fc28dc503ffcc341d4090ed01079056230304cd4c03af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36f171c5-0237-445f-8d00-c46448870a98", "node_type": "1", "metadata": {"window": "We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year.  As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n ", "original_text": "Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year. "}, "hash": "e62e265f976852a425bfd6925e46402949f21aa0312f59d8a775c8e7104ab2f0", "class_name": "RelatedNodeInfo"}}, "text": "We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n", "start_char_idx": 3101, "end_char_idx": 3252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36f171c5-0237-445f-8d00-c46448870a98": {"__data__": {"id_": "36f171c5-0237-445f-8d00-c46448870a98", "embedding": null, "metadata": {"window": "We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year.  As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n ", "original_text": "Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d8775dc-2947-410f-bd64-184e4c8861ac", "node_type": "1", "metadata": {"window": "In constructing our outlook f or the Medical Surgical segment, we developed several potential outcomes to inform \nthe range from the low end to the high end of our estimates.  We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year.  As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n", "original_text": "We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67c8090d3da10fb225d1cf064226e215e45792273b10a714f76059da1809bd6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a10c445-4b86-4116-8b12-71e60d59f9b1", "node_type": "1", "metadata": {"window": "Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year.  As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n ", "original_text": "As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year. "}, "hash": "9023b87aecac9ffd4c511ee2671f9d2bd5bb0841b27cedf015dda901e4b171be", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year. ", "start_char_idx": 3252, "end_char_idx": 3376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a10c445-4b86-4116-8b12-71e60d59f9b1": {"__data__": {"id_": "8a10c445-4b86-4116-8b12-71e60d59f9b1", "embedding": null, "metadata": {"window": "Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year.  As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n ", "original_text": "As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36f171c5-0237-445f-8d00-c46448870a98", "node_type": "1", "metadata": {"window": "We projected it could take a few quarters for patients \nto get comfortable returning to physician office sites an d with scheduling an elective procedure, but we do believe \nthis demand will return.  \n \n Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year.  As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n ", "original_text": "Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb57410e5de72f9cf5555dd4b0d234a2d7a6a4f5bea6911456df312818463011", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0a6d80c-2928-4d88-8b42-810c5bdd4035", "node_type": "1", "metadata": {"window": "We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year.  As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n ", "original_text": "As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n"}, "hash": "16f98d98b3a4918fbceb02ac0df45ae18fb286ebd86d57107deed1af21a273b3", "class_name": "RelatedNodeInfo"}}, "text": "As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year. ", "start_char_idx": 3376, "end_char_idx": 3503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0a6d80c-2928-4d88-8b42-810c5bdd4035": {"__data__": {"id_": "f0a6d80c-2928-4d88-8b42-810c5bdd4035", "embedding": null, "metadata": {"window": "We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year.  As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n ", "original_text": "As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a10c445-4b86-4116-8b12-71e60d59f9b1", "node_type": "1", "metadata": {"window": "Over the past few weeks, we've seen our Medical Surgical business begin to stabilize, and we see modest \nimprovements in volumes.  We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year.  As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n ", "original_text": "As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year. ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41534b75dd5f0a8e2227e812b733e6ba2d0778ba86701899a81f5fcc7ac5dd3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5cd1a9a-d5e0-4018-af76-7464c6c59bb5", "node_type": "1", "metadata": {"window": "Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year.  As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n ", "original_text": "For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n "}, "hash": "181d8c357e109ecb3b25f7ad864300723af5d4fcad816fd485212c4ac21542cd", "class_name": "RelatedNodeInfo"}}, "text": "As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n", "start_char_idx": 3503, "end_char_idx": 3656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5cd1a9a-d5e0-4018-af76-7464c6c59bb5": {"__data__": {"id_": "e5cd1a9a-d5e0-4018-af76-7464c6c59bb5", "embedding": null, "metadata": {"window": "Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year.  As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n ", "original_text": "For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e9000287b39b3e9c013a5c3153f914562dcfe5141b54411b872e4af5b04528", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0a6d80c-2928-4d88-8b42-810c5bdd4035", "node_type": "1", "metadata": {"window": "We expect the recovery in demand to contin ue through our fiscal second quarter, with \nfurther improvements in the second half of our fiscal year.  \n \n Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year.  As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n ", "original_text": "As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e3b274b831763d7be27bea9931e69b9e05a6171b50203e9e4a8ed435fd81259", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a42de16-e166-4114-8e89-b0293de60d48", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view. ", "original_text": "McKesson Corp.  "}, "hash": "9f35a1e6e744264ec437981775c979d56da2e78d7143800a553b8fd7a193523d", "class_name": "RelatedNodeInfo"}}, "text": "For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n ", "start_char_idx": 3656, "end_char_idx": 3893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a42de16-e166-4114-8e89-b0293de60d48": {"__data__": {"id_": "4a42de16-e166-4114-8e89-b0293de60d48", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5cd1a9a-d5e0-4018-af76-7464c6c59bb5", "node_type": "1", "metadata": {"window": "Therefore, we expect a 3% to 8% revenue decline, primarily driven by softened demand in the first half of the \nfiscal year.  As a result of these macro le vel headwinds, we also expect a 10% to 20% adjusted operating profit \ndecline for the full year.  As demand continues to improve, we expect that the second half adjusted operating profit \nresults will grow 5% to 15% as compared to the prior year.  \n \n For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n ", "original_text": "For the rem aining businesses included in Other, revenue is expected to decline approximately 7% to 12%, driven \nby expected lower foot traffic in retail stores across Canada in the short -term and lower prior authorization \nvolumes.  \n ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e24df0dc7347ecc02069e520e650d19289abc6dd2df275c147bc1f7259a425f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "846b67f4-3204-4c3c-9bdf-a900810929f6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020. "}, "hash": "32ec9fda799fcb98af513a7722de72c127079dd57765443d03d820d986597313", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "846b67f4-3204-4c3c-9bdf-a900810929f6": {"__data__": {"id_": "846b67f4-3204-4c3c-9bdf-a900810929f6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a42de16-e166-4114-8e89-b0293de60d48", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4848dea9ddd85c30e4cd8a419aed254539ea92bbe58fecb1c4d0ba41f8cb8b3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58959bb7-1eda-462b-b80b-3ecdeb3ff8d8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n", "original_text": "Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n"}, "hash": "55816ba77d92cdeb810255bc92a66d5d745320d89c359db4270702b5470c7d93", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020. ", "start_char_idx": 16, "end_char_idx": 333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58959bb7-1eda-462b-b80b-3ecdeb3ff8d8": {"__data__": {"id_": "58959bb7-1eda-462b-b80b-3ecdeb3ff8d8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n", "original_text": "Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "846b67f4-3204-4c3c-9bdf-a900810929f6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d7a51a00a72696c0a3f469a8687ae711eca33dbf4d82229d6683be10286b112", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f6ccce7-0ac8-4383-bb50-bdd01cd156b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year. ", "original_text": "Now, let me turn to the consolidated view. "}, "hash": "c294a22607539e7bd7c58ad1e2fb1a8a8a069032d2002ec18ab8f835bac106ce", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n", "start_char_idx": 333, "end_char_idx": 663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f6ccce7-0ac8-4383-bb50-bdd01cd156b1": {"__data__": {"id_": "1f6ccce7-0ac8-4383-bb50-bdd01cd156b1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year. ", "original_text": "Now, let me turn to the consolidated view. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58959bb7-1eda-462b-b80b-3ecdeb3ff8d8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n", "original_text": "Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "088d0b4d35d7920561645d36266fa74effd53846b361986a881dc5e76359c874", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f3f67b4-69b7-441c-a1d7-d0df2e52faed", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms. ", "original_text": "We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year. "}, "hash": "202bcccc621637f3cf768e6cfb4dd750e2d23628f32c24b952dd23265ce043ec", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me turn to the consolidated view. ", "start_char_idx": 663, "end_char_idx": 706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f3f67b4-69b7-441c-a1d7-d0df2e52faed": {"__data__": {"id_": "3f3f67b4-69b7-441c-a1d7-d0df2e52faed", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms. ", "original_text": "We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f6ccce7-0ac8-4383-bb50-bdd01cd156b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year. ", "original_text": "Now, let me turn to the consolidated view. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c74e0c13e53f6068a17d2835ec39bebaaf4456994f62d7d0ba092bf68ce63cd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "057f7d9f-2696-4123-a8a6-baeb8e5d8584", "node_type": "1", "metadata": {"window": "Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n", "original_text": "Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n"}, "hash": "039d9553546bb868c800788d7dd9c72d5a6768e18dc0ee35a10ce801c49dc5e0", "class_name": "RelatedNodeInfo"}}, "text": "We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year. ", "start_char_idx": 706, "end_char_idx": 851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "057f7d9f-2696-4123-a8a6-baeb8e5d8584": {"__data__": {"id_": "057f7d9f-2696-4123-a8a6-baeb8e5d8584", "embedding": null, "metadata": {"window": "Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n", "original_text": "Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f3f67b4-69b7-441c-a1d7-d0df2e52faed", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms. ", "original_text": "We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92f189f9ff5e0638b49e0e6e9b55255c39ddc00175f16aa21fca48c02f847b8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ab51ef8-94f7-4291-894c-38bb7078ad17", "node_type": "1", "metadata": {"window": "Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n", "original_text": "We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year. "}, "hash": "3f11ea042b181f1dc9614be54c2e42e8fa241c66300a3a991453b06179e0ead6", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n", "start_char_idx": 851, "end_char_idx": 1153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ab51ef8-94f7-4291-894c-38bb7078ad17": {"__data__": {"id_": "6ab51ef8-94f7-4291-894c-38bb7078ad17", "embedding": null, "metadata": {"window": "Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n", "original_text": "We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "057f7d9f-2696-4123-a8a6-baeb8e5d8584", "node_type": "1", "metadata": {"window": "Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n", "original_text": "Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df0014aaea574310ddb780e8bf7921325abcc6ca2bfde4f6c7604256db53acd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23fba246-fcdc-415c-a659-f225a589eaa0", "node_type": "1", "metadata": {"window": "We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million. ", "original_text": "We remain focused on our cost savings \nprograms. "}, "hash": "6d6f205350ea27bd37fdc65808229363dc1ba06be69e4cc63ea8968f56e20bc3", "class_name": "RelatedNodeInfo"}}, "text": "We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year. ", "start_char_idx": 1153, "end_char_idx": 1335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23fba246-fcdc-415c-a659-f225a589eaa0": {"__data__": {"id_": "23fba246-fcdc-415c-a659-f225a589eaa0", "embedding": null, "metadata": {"window": "We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million. ", "original_text": "We remain focused on our cost savings \nprograms. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ab51ef8-94f7-4291-894c-38bb7078ad17", "node_type": "1", "metadata": {"window": "Now, let me turn to the consolidated view.  We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n", "original_text": "We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d6a9fae6d4d8baad6187f0452b88d9ed82ac095cda8b9d639f1c3268135b961", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40e366f6-f73e-4faf-8e9d-77e7f01fbffe", "node_type": "1", "metadata": {"window": "Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million. ", "original_text": "Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n"}, "hash": "bddb3b9f94f6dc9f1cc2bb6807dfe3470fed2ea43da982cae7ce5742f6587048", "class_name": "RelatedNodeInfo"}}, "text": "We remain focused on our cost savings \nprograms. ", "start_char_idx": 1335, "end_char_idx": 1384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40e366f6-f73e-4faf-8e9d-77e7f01fbffe": {"__data__": {"id_": "40e366f6-f73e-4faf-8e9d-77e7f01fbffe", "embedding": null, "metadata": {"window": "Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million. ", "original_text": "Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23fba246-fcdc-415c-a659-f225a589eaa0", "node_type": "1", "metadata": {"window": "We expect 2% to 4% revenue grow th and adjusted income from \noperations is anticipated to be a 10% to 15% decline as compared to the prior year.  Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million. ", "original_text": "We remain focused on our cost savings \nprograms. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9178ede57e990794f8f257cb6baf1607dee7f8ff3e16dc20f886b65416bbbab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38a37ddf-057e-4291-94fb-47ddf6634ae0", "node_type": "1", "metadata": {"window": "We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n", "original_text": "Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n"}, "hash": "872f99cdfa106ad9ab8d989819d80c8d937f4f5dcbc643cda2fa739c5935c2bf", "class_name": "RelatedNodeInfo"}}, "text": "Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n", "start_char_idx": 1384, "end_char_idx": 1562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38a37ddf-057e-4291-94fb-47ddf6634ae0": {"__data__": {"id_": "38a37ddf-057e-4291-94fb-47ddf6634ae0", "embedding": null, "metadata": {"window": "We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n", "original_text": "Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40e366f6-f73e-4faf-8e9d-77e7f01fbffe", "node_type": "1", "metadata": {"window": "Excluding the results of \nChange Healthcare from fiscal 2020, we expect that adjusted income from operations will decline 5% to 8% for \nthe full y ear, but will grow 6% to 10% in the second half of the fiscal year on a year -over-year basis, in line with \nour stated economic recovery assumptions.  \n \n We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million. ", "original_text": "Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2d839ab118c5cd980079fddb414af2e1bb2d673496a58e070764a4731cad78f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "015ee6ed-7bd0-47b3-8a7d-d277c0d84b85", "node_type": "1", "metadata": {"window": "We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05. ", "original_text": "Moving below the line , we expect interest expense in the range of $230 million to $250 million. "}, "hash": "9f9fd9015c7aee2bf959ff1a2225848ba98b65cacdef630b7456655e56d3cb2c", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n", "start_char_idx": 1562, "end_char_idx": 1765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "015ee6ed-7bd0-47b3-8a7d-d277c0d84b85": {"__data__": {"id_": "015ee6ed-7bd0-47b3-8a7d-d277c0d84b85", "embedding": null, "metadata": {"window": "We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05. ", "original_text": "Moving below the line , we expect interest expense in the range of $230 million to $250 million. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38a37ddf-057e-4291-94fb-47ddf6634ae0", "node_type": "1", "metadata": {"window": "We expect corporate expenses to be approximately flat compared to prior year, and this assumption reflects  \nopioid -related litigation cost to also be roughly flat year -over-year.  We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n", "original_text": "Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5de9f92efd1ac776e8e4cbc5d6294da86afc6129abc2e13e6432dd942acd6b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a97dab4b-9a50-462e-b1dd-27ada54c7517", "node_type": "1", "metadata": {"window": "Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n", "original_text": "We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million. "}, "hash": "be00e0c17d4116507e888342916e96084fd175136794038bffdf47da4183642c", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line , we expect interest expense in the range of $230 million to $250 million. ", "start_char_idx": 1765, "end_char_idx": 1862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a97dab4b-9a50-462e-b1dd-27ada54c7517": {"__data__": {"id_": "a97dab4b-9a50-462e-b1dd-27ada54c7517", "embedding": null, "metadata": {"window": "Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n", "original_text": "We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "015ee6ed-7bd0-47b3-8a7d-d277c0d84b85", "node_type": "1", "metadata": {"window": "We remain focused on our cost savings \nprograms.  Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05. ", "original_text": "Moving below the line , we expect interest expense in the range of $230 million to $250 million. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a8c0657d0e6cb20354bf4ca9ab54d7c5934d1639ebeacdccd1259acdc6ed4c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2cdc94a-971a-4509-816f-5b0c053d30e3", "node_type": "1", "metadata": {"window": "Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment. ", "original_text": "We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n"}, "hash": "0906d1a490f881b8bf1cfb9cdbdc3b3fdb238719c37e9d7c23375c51ffe31cc0", "class_name": "RelatedNodeInfo"}}, "text": "We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million. ", "start_char_idx": 1862, "end_char_idx": 1968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2cdc94a-971a-4509-816f-5b0c053d30e3": {"__data__": {"id_": "b2cdc94a-971a-4509-816f-5b0c053d30e3", "embedding": null, "metadata": {"window": "Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment. ", "original_text": "We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a97dab4b-9a50-462e-b1dd-27ada54c7517", "node_type": "1", "metadata": {"window": "Our annual pre -tax gross cost savings target remains approximately $400 million to $500 million, which \nwe are on track to substantially realize for the end of fiscal 2021.  \n \n Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n", "original_text": "We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05e750e897e18584593b5c2a3775db9bd59d4dc2931016bfcabc316744e059af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a84dd63a-bfbd-4d40-8742-cdd2dacd4671", "node_type": "1", "metadata": {"window": "Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n", "original_text": "We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05. "}, "hash": "c59c1050185174650d86370ac2c7a09312a866341ec13058243135a0fbf4aa9b", "class_name": "RelatedNodeInfo"}}, "text": "We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n", "start_char_idx": 1968, "end_char_idx": 2185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a84dd63a-bfbd-4d40-8742-cdd2dacd4671": {"__data__": {"id_": "a84dd63a-bfbd-4d40-8742-cdd2dacd4671", "embedding": null, "metadata": {"window": "Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n", "original_text": "We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2cdc94a-971a-4509-816f-5b0c053d30e3", "node_type": "1", "metadata": {"window": "Additionally, we've implemented mitigation efforts in light of the headwinds presented by the COVID -19 pandemic, \nincluding an effort to continue to reduce controllable spend across all categories.  \n \n Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment. ", "original_text": "We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ddc39a6fd6be59282b0e1d6db33364b4b2293f395aa34d92d50f4252beb82996", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f700825c-cdaa-439e-be70-9d63cb62cc45", "node_type": "1", "metadata": {"window": "We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices. ", "original_text": "An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n"}, "hash": "e3e6a54a57560b1d2809fd15e11ce5b45e3efb08258aa39d1350788b530f9d8b", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05. ", "start_char_idx": 2185, "end_char_idx": 2307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f700825c-cdaa-439e-be70-9d63cb62cc45": {"__data__": {"id_": "f700825c-cdaa-439e-be70-9d63cb62cc45", "embedding": null, "metadata": {"window": "We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices. ", "original_text": "An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a84dd63a-bfbd-4d40-8742-cdd2dacd4671", "node_type": "1", "metadata": {"window": "Moving below the line , we expect interest expense in the range of $230 million to $250 million.  We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n", "original_text": "We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9e7f52a855e559ad10e70b0b0dfeb94f8a771475998ab1ada68d7ccb1dbb975", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0015d1fb-de9e-4c69-8053-8404e48cb132", "node_type": "1", "metadata": {"window": "We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n", "original_text": "Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment. "}, "hash": "72945f046af8cfbbeeaa7320fde4ccd3373fe702567022826a82e3a86e2d48fd", "class_name": "RelatedNodeInfo"}}, "text": "An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n", "start_char_idx": 2307, "end_char_idx": 2451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0015d1fb-de9e-4c69-8053-8404e48cb132": {"__data__": {"id_": "0015d1fb-de9e-4c69-8053-8404e48cb132", "embedding": null, "metadata": {"window": "We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n", "original_text": "Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f700825c-cdaa-439e-be70-9d63cb62cc45", "node_type": "1", "metadata": {"window": "We expect income \nattributable to non -controlling interest in the range of $200 million to $220 million.  We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices. ", "original_text": "An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f68d28d5482b6328e7cab3710f311f20290b9994704bbf74854f843ef476b490", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35325eae-0493-4a01-a2c3-bc6315cf53dd", "node_type": "1", "metadata": {"window": "We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow. ", "original_text": "We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n"}, "hash": "55cd3fc343017ee221adb829d62a507b282fd04548e247860b13584fee00b37a", "class_name": "RelatedNodeInfo"}}, "text": "Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment. ", "start_char_idx": 2451, "end_char_idx": 2547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35325eae-0493-4a01-a2c3-bc6315cf53dd": {"__data__": {"id_": "35325eae-0493-4a01-a2c3-bc6315cf53dd", "embedding": null, "metadata": {"window": "We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow. ", "original_text": "We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0015d1fb-de9e-4c69-8053-8404e48cb132", "node_type": "1", "metadata": {"window": "We assume a full year adjusted \ntax rate of approximately 18% to 20%, which ma y vary from quarter -to-quarter and includes anticipated discrete \ntax items that we expect to realize during the course of the year.  \n \n We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n", "original_text": "Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc3b30d0d37a0f77a9f76727be199bc7395598575a7ee5a3846de0ec0624d5cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f451f7bf-7c1a-4500-9560-beab9c5eb9b1", "node_type": "1", "metadata": {"window": "An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment. ", "original_text": "We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices. "}, "hash": "41bf1d9f45c96c15b61bc668083a0f128ba61786b6475f7ff5526885d98138c0", "class_name": "RelatedNodeInfo"}}, "text": "We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n", "start_char_idx": 2547, "end_char_idx": 2772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f451f7bf-7c1a-4500-9560-beab9c5eb9b1": {"__data__": {"id_": "f451f7bf-7c1a-4500-9560-beab9c5eb9b1", "embedding": null, "metadata": {"window": "An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment. ", "original_text": "We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35325eae-0493-4a01-a2c3-bc6315cf53dd", "node_type": "1", "metadata": {"window": "We anticipate the impact of foreign currency exchange rate movements be a net unfavorable impact of \napproximately $0.05.  An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow. ", "original_text": "We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54b665b3994585c09fc6977814f27e78805a39e3a612a4574388d0d9f83d11c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3e4a87f-9b6c-4411-83a1-ed97a9690f86", "node_type": "1", "metadata": {"window": "Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n", "original_text": "We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n"}, "hash": "adfeb80fea1b557c32138219e5800b963c2e4af33671ce4bbc63f8bc90dd6238", "class_name": "RelatedNodeInfo"}}, "text": "We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices. ", "start_char_idx": 2772, "end_char_idx": 2899, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3e4a87f-9b6c-4411-83a1-ed97a9690f86": {"__data__": {"id_": "e3e4a87f-9b6c-4411-83a1-ed97a9690f86", "embedding": null, "metadata": {"window": "Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n", "original_text": "We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f451f7bf-7c1a-4500-9560-beab9c5eb9b1", "node_type": "1", "metadata": {"window": "An d we expect weighted average diluted shares outstanding for fiscal 2021 to be in the \nrange of approximately 161 million to 163 million.  \n \n Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment. ", "original_text": "We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f23a92898e4f7948bf02d9c3c53d9f2e6273d01eba1f72bbb66a05207e746484", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1dd014a0-f86f-4413-88ed-030edbebf15f", "node_type": "1", "metadata": {"window": "We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n", "original_text": "At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow. "}, "hash": "6582a01832d08a6883800b1ef63f43ae1f43b1d19c0104e17a97d3ff7aedb612", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n", "start_char_idx": 2899, "end_char_idx": 3026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1dd014a0-f86f-4413-88ed-030edbebf15f": {"__data__": {"id_": "1dd014a0-f86f-4413-88ed-030edbebf15f", "embedding": null, "metadata": {"window": "We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n", "original_text": "At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3e4a87f-9b6c-4411-83a1-ed97a9690f86", "node_type": "1", "metadata": {"window": "Let me wrap up our fiscal 2021 outlook with a few comments on cash flow and capital deployment.  We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n", "original_text": "We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e233bb87e05a5b6d620f372e27ba9827814e25abd9b29bcb7db4a875f6726700", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "079cea04-75c8-4e21-95f0-3cbe7b41daac", "node_type": "1", "metadata": {"window": "We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets. ", "original_text": "We will \ncontinue a disciplined and balanced approach to capital deployment. "}, "hash": "186121cdfa4bddc7987d8dea100834b7fd762894a928f774865da558bf7be781", "class_name": "RelatedNodeInfo"}}, "text": "At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow. ", "start_char_idx": 3026, "end_char_idx": 3133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "079cea04-75c8-4e21-95f0-3cbe7b41daac": {"__data__": {"id_": "079cea04-75c8-4e21-95f0-3cbe7b41daac", "embedding": null, "metadata": {"window": "We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets. ", "original_text": "We will \ncontinue a disciplined and balanced approach to capital deployment. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1dd014a0-f86f-4413-88ed-030edbebf15f", "node_type": "1", "metadata": {"window": "We expect \nfree cash flo w of approximately $2.3 billion to $2.7 billion, which is net of property acquisitions and capitalized \nsoftware expenses and includes the pull -forward impacts of COVID -19 previously discussed.  \n \n We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n", "original_text": "At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa69ba33cf244a332e2ba763931369f7c45819c79c66fd61bb6342540379f8eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef954b44-3ba5-4d6e-bb17-2669f7a4b6df", "node_type": "1", "metadata": {"window": "We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n", "original_text": "Our priorities remain clear and consistent. \n"}, "hash": "06c099be50aac0ac9c5ec748a0c9dcc7d8cad8f2ecf7853be5a68b53db2230cc", "class_name": "RelatedNodeInfo"}}, "text": "We will \ncontinue a disciplined and balanced approach to capital deployment. ", "start_char_idx": 3133, "end_char_idx": 3210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef954b44-3ba5-4d6e-bb17-2669f7a4b6df": {"__data__": {"id_": "ef954b44-3ba5-4d6e-bb17-2669f7a4b6df", "embedding": null, "metadata": {"window": "We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n", "original_text": "Our priorities remain clear and consistent. \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "079cea04-75c8-4e21-95f0-3cbe7b41daac", "node_type": "1", "metadata": {"window": "We will use our cash flow to continue to invest internally in our strategic priorities of oncology and manufacturer \nservices.  We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets. ", "original_text": "We will \ncontinue a disciplined and balanced approach to capital deployment. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f0bc08d174461725b81697bdbf687dcb1d3d1dea8b0fcde2a002113ef7f4a4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17a620ff-3244-4f9d-8d39-bcdfb5988fec", "node_type": "1", "metadata": {"window": "At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth. ", "original_text": "Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n"}, "hash": "6f8175d0bdeb2ff9b5a1cf0449f32b3abda4dd0381a3fa08c299e8f05a3af433", "class_name": "RelatedNodeInfo"}}, "text": "Our priorities remain clear and consistent. \n", "start_char_idx": 3210, "end_char_idx": 3255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17a620ff-3244-4f9d-8d39-bcdfb5988fec": {"__data__": {"id_": "17a620ff-3244-4f9d-8d39-bcdfb5988fec", "embedding": null, "metadata": {"window": "At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth. ", "original_text": "Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef954b44-3ba5-4d6e-bb17-2669f7a4b6df", "node_type": "1", "metadata": {"window": "We anticipate property acquisitions and capitalized software expenses to be in the range of $400 million \nto $550 million.  \n \n At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n", "original_text": "Our priorities remain clear and consistent. \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c15393edf8993ecc707a1c782e6748620372b7fd5e37edd8230c0b3c1eda76f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27f02176-3fe2-460f-9609-d69e869ad7b1", "node_type": "1", "metadata": {"window": "We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth.  The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  ", "original_text": "First, we prioritize growth investments in our strategic assets. "}, "hash": "40e41e0154b5a6048ed758c2f2f415bf7efbcb56480ef415016fc5e19da65b53", "class_name": "RelatedNodeInfo"}}, "text": "Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n", "start_char_idx": 3255, "end_char_idx": 3374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27f02176-3fe2-460f-9609-d69e869ad7b1": {"__data__": {"id_": "27f02176-3fe2-460f-9609-d69e869ad7b1", "embedding": null, "metadata": {"window": "We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth.  The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  ", "original_text": "First, we prioritize growth investments in our strategic assets. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17a620ff-3244-4f9d-8d39-bcdfb5988fec", "node_type": "1", "metadata": {"window": "At McKesson, capital deployment starts with our continued ability to generate healthy operating cash flow.  We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth. ", "original_text": "Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e50b23b8c1fa6011a7208c1d7ffe4f0c6054d43ad6b151a2566dba76006b04ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66e17b00-7c03-4b09-a41f-9642d62e0c15", "node_type": "1", "metadata": {"window": "Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth.  The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  ", "original_text": "As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n"}, "hash": "7f7bad6fbecfe83d364a47a6456c3c200321a443686cf65ba54c62a27483066c", "class_name": "RelatedNodeInfo"}}, "text": "First, we prioritize growth investments in our strategic assets. ", "start_char_idx": 3374, "end_char_idx": 3439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66e17b00-7c03-4b09-a41f-9642d62e0c15": {"__data__": {"id_": "66e17b00-7c03-4b09-a41f-9642d62e0c15", "embedding": null, "metadata": {"window": "Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth.  The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  ", "original_text": "As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27f02176-3fe2-460f-9609-d69e869ad7b1", "node_type": "1", "metadata": {"window": "We will \ncontinue a disciplined and balanced approach to capital deployment.  Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth.  The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  ", "original_text": "First, we prioritize growth investments in our strategic assets. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1d834843d5c6c44a926c8f155e36a6f6cf2d258f82ffbcb8d040cf516af0f49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b8649f8-501a-403e-889c-9368786063c9", "node_type": "1", "metadata": {"window": "Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth.  The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  ", "original_text": "In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth. "}, "hash": "0e09a061d504c7e5077a868daeaa31386e2d5c033767eaccaa432c63573cd84b", "class_name": "RelatedNodeInfo"}}, "text": "As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n", "start_char_idx": 3439, "end_char_idx": 3609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b8649f8-501a-403e-889c-9368786063c9": {"__data__": {"id_": "7b8649f8-501a-403e-889c-9368786063c9", "embedding": null, "metadata": {"window": "Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth.  The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  ", "original_text": "In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66e17b00-7c03-4b09-a41f-9642d62e0c15", "node_type": "1", "metadata": {"window": "Our priorities remain clear and consistent. \n Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth.  The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  ", "original_text": "As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b372ecc2b72a48604aefaaaea3b016feaf20baa519a7eb7b249e4e3c8eaa12c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a2cfc02-99e2-48b9-8346-fdbdac67bb68", "node_type": "1", "metadata": {"window": "First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth.  The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  ", "original_text": "The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  "}, "hash": "981ce7dc3aa51bc674bbafad27ef58d1536d6209a444fe021139791fc0161018", "class_name": "RelatedNodeInfo"}}, "text": "In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth. ", "start_char_idx": 3609, "end_char_idx": 3767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a2cfc02-99e2-48b9-8346-fdbdac67bb68": {"__data__": {"id_": "5a2cfc02-99e2-48b9-8346-fdbdac67bb68", "embedding": null, "metadata": {"window": "First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth.  The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  ", "original_text": "The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bca7ee9f17a49e9bb15856416d4bc7eda8b2505b71eefe56f1da014b2da25117", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b8649f8-501a-403e-889c-9368786063c9", "node_type": "1", "metadata": {"window": "Our demonstrated history of solid cash flow generation provides us flexibility in our capital allo cation program.  \n \n First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth.  The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  ", "original_text": "In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth. ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2aaefff0ca6957851a389bfc7b9fc8b9794bac2f7cd4a81349193f9d5e3eaab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2721e56b-3f49-4d7c-adb4-73bc0ec82b4a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets. ", "original_text": "McKesson Corp.  "}, "hash": "1ac1d40b56b551267075b7df35caf5e72d130de2c5e71da6bf5c92997d57d48e", "class_name": "RelatedNodeInfo"}}, "text": "The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  ", "start_char_idx": 3767, "end_char_idx": 3981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2721e56b-3f49-4d7c-adb4-73bc0ec82b4a": {"__data__": {"id_": "2721e56b-3f49-4d7c-adb4-73bc0ec82b4a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a2cfc02-99e2-48b9-8346-fdbdac67bb68", "node_type": "1", "metadata": {"window": "First, we prioritize growth investments in our strategic assets.  As an example, in Q4, we continued to invest into \nour oncology and manufacturer services assets and capabilities to extend our differentiated and leading positions.  \n \n In fisca l 2021, we will continue to invest in our strategic initiatives to drive further differentiation and position our \nbusinesses for long -term growth.  The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  ", "original_text": "The current environment does not impact our desire to invest in M&A \nopportunities that are on strategy at mul tiples that offer superior returns on capital and accelerate future growth \nand cash flow generation.  ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fe12cfc53afdd40f5ca21235aea1102b67586b4a8c413273ce2fe840a9bd953", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d169cbf1-2cfa-4ff4-8441-6ff32b1f6b3f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks. "}, "hash": "e8035ee071a6717fd54ed79c4982f40d6313fa9ceb8cbf4a80f4bb4dbd034691", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d169cbf1-2cfa-4ff4-8441-6ff32b1f6b3f": {"__data__": {"id_": "d169cbf1-2cfa-4ff4-8441-6ff32b1f6b3f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2721e56b-3f49-4d7c-adb4-73bc0ec82b4a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea186ebf0b5507b4845b0dfa531041b16e188b84f3534609abb880a9eb95a03d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6311aef-cbbf-474f-9dc5-f3efce9d56f5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n", "original_text": "And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n"}, "hash": "5073c6dc80218db198e9eebdb1e6f75691157b7639e1ee3d466f934c0f18a190", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks. ", "start_char_idx": 16, "end_char_idx": 308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6311aef-cbbf-474f-9dc5-f3efce9d56f5": {"__data__": {"id_": "b6311aef-cbbf-474f-9dc5-f3efce9d56f5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n", "original_text": "And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d169cbf1-2cfa-4ff4-8441-6ff32b1f6b3f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b9c2191644181f957424f4dde0c773e144fa8c868cb899138487824631a68df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b0724c1-a96d-4133-b3dd-737e585ee5e4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic. ", "original_text": "We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets. "}, "hash": "5f2235b5209b73a0cebb2dd328d1443f12bd4505c4c0463415cf2237e5a65f50", "class_name": "RelatedNodeInfo"}}, "text": "And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n", "start_char_idx": 308, "end_char_idx": 422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b0724c1-a96d-4133-b3dd-737e585ee5e4": {"__data__": {"id_": "3b0724c1-a96d-4133-b3dd-737e585ee5e4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic. ", "original_text": "We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6311aef-cbbf-474f-9dc5-f3efce9d56f5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n", "original_text": "And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4df9f864a84fe8c194c3f9543f88a8815be77388eab54b08f5ac5373c0c4f10b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c659796-8a54-47b7-8b5a-68b25f0fb4af", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities. ", "original_text": "We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon. "}, "hash": "96e43dc629d0808b39930722f404e777e0236420af4087ea53a2c63238543a63", "class_name": "RelatedNodeInfo"}}, "text": "We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets. ", "start_char_idx": 422, "end_char_idx": 594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c659796-8a54-47b7-8b5a-68b25f0fb4af": {"__data__": {"id_": "5c659796-8a54-47b7-8b5a-68b25f0fb4af", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities. ", "original_text": "We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b0724c1-a96d-4133-b3dd-737e585ee5e4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic. ", "original_text": "We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7475b88b82442c36a8baf49607f75d99a95f0cb9a62b16ec46625204639769ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38ba0d18-d177-4ff0-a59d-44d5a14470d3", "node_type": "1", "metadata": {"window": "And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n", "original_text": "At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n"}, "hash": "2248375ff90a4bd1b2c9b10af6239143b4928c8482b84fd72c7cf2ae147c8f78", "class_name": "RelatedNodeInfo"}}, "text": "We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon. ", "start_char_idx": 594, "end_char_idx": 700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38ba0d18-d177-4ff0-a59d-44d5a14470d3": {"__data__": {"id_": "38ba0d18-d177-4ff0-a59d-44d5a14470d3", "embedding": null, "metadata": {"window": "And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n", "original_text": "At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c659796-8a54-47b7-8b5a-68b25f0fb4af", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities. ", "original_text": "We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dabd2b7c45324b6f23fa850c03dc848597dd1e5547253c95f4dbde83d0981181", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2186c5c6-700a-4096-9888-f72978c10ab2", "node_type": "1", "metadata": {"window": "We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders. ", "original_text": "In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic. "}, "hash": "42e0330182bbbfa6db967aad48ffbeb378c940f38910d5d1a9341648bcbba268", "class_name": "RelatedNodeInfo"}}, "text": "At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n", "start_char_idx": 700, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2186c5c6-700a-4096-9888-f72978c10ab2": {"__data__": {"id_": "2186c5c6-700a-4096-9888-f72978c10ab2", "embedding": null, "metadata": {"window": "We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders. ", "original_text": "In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38ba0d18-d177-4ff0-a59d-44d5a14470d3", "node_type": "1", "metadata": {"window": "And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n", "original_text": "At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc202def4d0b0284ef6a4356d0304cec4f7278af9f2c9e03193323bccd7a98bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8231e4c9-c80c-46a3-8924-cc48086e0b35", "node_type": "1", "metadata": {"window": "We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n", "original_text": "We remain focused on our employees, customers, partners, \nand communities. "}, "hash": "2ff1162d44f1bf7b74ac665daeefc6689c23554cee74fa8cef99b3d148942d43", "class_name": "RelatedNodeInfo"}}, "text": "In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic. ", "start_char_idx": 845, "end_char_idx": 1007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8231e4c9-c80c-46a3-8924-cc48086e0b35": {"__data__": {"id_": "8231e4c9-c80c-46a3-8924-cc48086e0b35", "embedding": null, "metadata": {"window": "We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n", "original_text": "We remain focused on our employees, customers, partners, \nand communities. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2186c5c6-700a-4096-9888-f72978c10ab2", "node_type": "1", "metadata": {"window": "We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets.  We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders. ", "original_text": "In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ad28309d5ddcda96469a6b07f3cf1ebb2d5da9b8c3edff6092f80b6f036bfcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "677137f4-d321-42e3-b0b9-d240925954e9", "node_type": "1", "metadata": {"window": "At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions. ", "original_text": "While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n"}, "hash": "650932246dea200e8d5017d6198457ea5a34d9fb411caaef4465f35b6bfb29e9", "class_name": "RelatedNodeInfo"}}, "text": "We remain focused on our employees, customers, partners, \nand communities. ", "start_char_idx": 1007, "end_char_idx": 1082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "677137f4-d321-42e3-b0b9-d240925954e9": {"__data__": {"id_": "677137f4-d321-42e3-b0b9-d240925954e9", "embedding": null, "metadata": {"window": "At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions. ", "original_text": "While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8231e4c9-c80c-46a3-8924-cc48086e0b35", "node_type": "1", "metadata": {"window": "We also  have access to $4 billion through our \nrevolving credit facility, which has not been drawn upon.  At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n", "original_text": "We remain focused on our employees, customers, partners, \nand communities. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b5d5e3cb28fb0859840919bf30fed565dbe9cdecdf6561593c1666234349db7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebbbf499-0edc-4cca-91ae-5c05053a5313", "node_type": "1", "metadata": {"window": "In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n ", "original_text": "We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders. "}, "hash": "23677165a1bb5c6b552c17caf8a480ddaf285a8b16de9aa2ec5085a79a54bfd2", "class_name": "RelatedNodeInfo"}}, "text": "While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n", "start_char_idx": 1082, "end_char_idx": 1241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebbbf499-0edc-4cca-91ae-5c05053a5313": {"__data__": {"id_": "ebbbf499-0edc-4cca-91ae-5c05053a5313", "embedding": null, "metadata": {"window": "In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n ", "original_text": "We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "677137f4-d321-42e3-b0b9-d240925954e9", "node_type": "1", "metadata": {"window": "At this time, we have no immediate need to access the \nlong-term debt market, nor draw upon our revolver to meet near -term liquidity needs.  \n \n In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions. ", "original_text": "While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "576d6b0f120158f543e0f767368e854e5bf313fe933a468fb7ddc746b1ae509d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c26b7fae-c59c-43d3-acc0-9e2dfac47d66", "node_type": "1", "metadata": {"window": "We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n"}, "hash": "321f5efb70cc2c1dcbea69ef8623736b6e46908c96de1886c343182ae0613f95", "class_name": "RelatedNodeInfo"}}, "text": "We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders. ", "start_char_idx": 1241, "end_char_idx": 1510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c26b7fae-c59c-43d3-acc0-9e2dfac47d66": {"__data__": {"id_": "c26b7fae-c59c-43d3-acc0-9e2dfac47d66", "embedding": null, "metadata": {"window": "We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebbbf499-0edc-4cca-91ae-5c05053a5313", "node_type": "1", "metadata": {"window": "In closing, we are pleased with the results of our fiscal fourth quarter and proud of how we responded to the \nextraordinary demands brought on by this pandemic.  We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n ", "original_text": "We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "862fb77f6f905cebd03861879db6c9b1ee527307165280b4fe379ea735cb36d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce145d13-8247-4fb9-828d-4be326dcec3e", "node_type": "1", "metadata": {"window": "While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n ", "original_text": "And with that, I'll turn the call over to the operator for your questions. "}, "hash": "738a3b1378d306614efe473901c71c8d500f8d1634a81a789dc33793a8262fc5", "class_name": "RelatedNodeInfo"}}, "text": "Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n", "start_char_idx": 1510, "end_char_idx": 1723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce145d13-8247-4fb9-828d-4be326dcec3e": {"__data__": {"id_": "ce145d13-8247-4fb9-828d-4be326dcec3e", "embedding": null, "metadata": {"window": "While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n ", "original_text": "And with that, I'll turn the call over to the operator for your questions. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c26b7fae-c59c-43d3-acc0-9e2dfac47d66", "node_type": "1", "metadata": {"window": "We remain focused on our employees, customers, partners, \nand communities.  While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "334c9031e8613e25e530b28deb87eddde33008c3deaf13f2027b1d6a84873126", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9e95e3f-4979-490a-95d1-d8ba6c05a599", "node_type": "1", "metadata": {"window": "We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning. ", "original_text": "In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n "}, "hash": "1575cf2366c766423dafb6a2c24dba2cb4f0ad094f3ee7c9122a95a0c1020c46", "class_name": "RelatedNodeInfo"}}, "text": "And with that, I'll turn the call over to the operator for your questions. ", "start_char_idx": 1723, "end_char_idx": 1798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9e95e3f-4979-490a-95d1-d8ba6c05a599": {"__data__": {"id_": "f9e95e3f-4979-490a-95d1-d8ba6c05a599", "embedding": null, "metadata": {"window": "We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning. ", "original_text": "In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce145d13-8247-4fb9-828d-4be326dcec3e", "node_type": "1", "metadata": {"window": "While the external environment presents many unknowns, our businesses continue to show \nresilient and stable fundamentals along with consistent execution.  \n \n We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n ", "original_text": "And with that, I'll turn the call over to the operator for your questions. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ebc304a7635f574ee303b341e8a81a85bd1a125f9bc0ca8f0bb96612327584b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed42014f-e7bb-44b6-b2a3-d916e11485e7", "node_type": "1", "metadata": {"window": "Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. "}, "hash": "140185f2eb195e209e498c16625e7f2c3105ee0ab160a4ebd37168caf9159d51", "class_name": "RelatedNodeInfo"}}, "text": "In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n ", "start_char_idx": 1798, "end_char_idx": 1926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed42014f-e7bb-44b6-b2a3-d916e11485e7": {"__data__": {"id_": "ed42014f-e7bb-44b6-b2a3-d916e11485e7", "embedding": null, "metadata": {"window": "Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9e95e3f-4979-490a-95d1-d8ba6c05a599", "node_type": "1", "metadata": {"window": "We continue to have a solid balance sheet and healthy cash generation, which underpin our investment grade \ncredit rating, and we'll continue to deploy capital to invest in growth areas aligned to our strategy, aimed at \ncreating balanced returns for our shareholders.  Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning. ", "original_text": "In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d7e1e046661d3d65301e25f517f2533a968d2de22f8c5c007ffaf1dbf3d3f58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a260604d-844c-4aee-91f3-98732f92921e", "node_type": "1", "metadata": {"window": "And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis. ", "original_text": "[Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n "}, "hash": "c2f42cc0d2901df0b6e5a1417896dc9a4c3fd58cbdf07ca957c47c6c8c8bd1ee", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "start_char_idx": 1926, "end_char_idx": 2255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a260604d-844c-4aee-91f3-98732f92921e": {"__data__": {"id_": "a260604d-844c-4aee-91f3-98732f92921e", "embedding": null, "metadata": {"window": "And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis. ", "original_text": "[Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed42014f-e7bb-44b6-b2a3-d916e11485e7", "node_type": "1", "metadata": {"window": "Despite the current macroeconomic headwinds, we remain \nconfident in our business and in our ability to create stability in the sup ply chain through the strength of our \nsourcing and distribution operations.  \n \n And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "286ff0e930e66bfbbe155392c1dd4cf2edbd47fdcb49b69621bfedb8d22ec17a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "400fcf58-8ae6-4de1-bad1-2ddaf7b4292c", "node_type": "1", "metadata": {"window": "In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\" ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning. "}, "hash": "eaf84083482921d60ea65e856029ec244486fbd28bd55805d43b93621e0a543c", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n ", "start_char_idx": 2255, "end_char_idx": 2369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "400fcf58-8ae6-4de1-bad1-2ddaf7b4292c": {"__data__": {"id_": "400fcf58-8ae6-4de1-bad1-2ddaf7b4292c", "embedding": null, "metadata": {"window": "In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\" ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a260604d-844c-4aee-91f3-98732f92921e", "node_type": "1", "metadata": {"window": "And with that, I'll turn the call over to the operator for your questions.  In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis. ", "original_text": "[Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20d42da09894215cff6a398d43473cbba2bb398a9efa3b44e4e1e5563f021c47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69e19d4e-5da6-46a7-b1d6-63d805229e72", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n ", "original_text": "Thank you for all the details. "}, "hash": "8dad487681d5e7ae5a62940a45ee685eed3357380736523e7d46ae554dcdaff6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning. ", "start_char_idx": 2369, "end_char_idx": 2715, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69e19d4e-5da6-46a7-b1d6-63d805229e72": {"__data__": {"id_": "69e19d4e-5da6-46a7-b1d6-63d805229e72", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n ", "original_text": "Thank you for all the details. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "400fcf58-8ae6-4de1-bad1-2ddaf7b4292c", "node_type": "1", "metadata": {"window": "In the interest of time, I'd ask you to limit \nyourself to just one question to allow others an opportuni ty to participate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\" ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6eef9badda4d90abf6e6529ed085e87794457fb0defbdc5e6f63ff80bcf244ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e4f1a28-417d-4993-9274-0bafd04dacb6", "node_type": "1", "metadata": {"window": "[Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis. "}, "hash": "8e4fb2a2e32e7fc9d74f8f8a35a1770558523015b563a186af29e181bfb43eac", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for all the details. ", "start_char_idx": 2715, "end_char_idx": 2746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e4f1a28-417d-4993-9274-0bafd04dacb6": {"__data__": {"id_": "7e4f1a28-417d-4993-9274-0bafd04dacb6", "embedding": null, "metadata": {"window": "[Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69e19d4e-5da6-46a7-b1d6-63d805229e72", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n ", "original_text": "Thank you for all the details. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98d271a0fa96a02c26008db2a2f5743ea3b2cdb473593ecff56a8f6527e9f21e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "681ed4e4-49e2-4ffa-aac4-b69cbd0323c2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question. ", "original_text": "So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\" "}, "hash": "e6b0bf5554c3e5f08a75d2f64ee21fc27ae0a21b40d91ad597081c564f4a2e11", "class_name": "RelatedNodeInfo"}}, "text": "I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis. ", "start_char_idx": 2746, "end_char_idx": 2960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "681ed4e4-49e2-4ffa-aac4-b69cbd0323c2": {"__data__": {"id_": "681ed4e4-49e2-4ffa-aac4-b69cbd0323c2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question. ", "original_text": "So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\" ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e4f1a28-417d-4993-9274-0bafd04dacb6", "node_type": "1", "metadata": {"window": "[Operator Instructions] And your first question comes from Michael Cherny with Bank of \nAmerica Merrill Lynch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "438792acc5666732a2e84b697f65506730a1d8097e6247fdafb4539d2c6fdb2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "621fd28c-c351-4310-ad8c-af508dec22b9", "node_type": "1", "metadata": {"window": "Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that. ", "original_text": "And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n "}, "hash": "7a21f29c76403b42613d4cdda70257dfa0ca835a8b7c94942170beb555ea02be", "class_name": "RelatedNodeInfo"}}, "text": "So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\" ", "start_char_idx": 2960, "end_char_idx": 3078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "621fd28c-c351-4310-ad8c-af508dec22b9": {"__data__": {"id_": "621fd28c-c351-4310-ad8c-af508dec22b9", "embedding": null, "metadata": {"window": "Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that. ", "original_text": "And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "681ed4e4-49e2-4ffa-aac4-b69cbd0323c2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood morning.  Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question. ", "original_text": "So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\" ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77252be0aeb681e424d685c1b1be015c72ed08127b741b2a02c8274de6d72b42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10a07395-a181-496d-b6b6-737d2a4197a4", "node_type": "1", "metadata": {"window": "I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "b008d8d91b007ac0a606ac6a98b1eedcfb1309cceea37be75568fa44a5354181", "class_name": "RelatedNodeInfo"}}, "text": "And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n ", "start_char_idx": 3078, "end_char_idx": 3209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10a07395-a181-496d-b6b6-737d2a4197a4": {"__data__": {"id_": "10a07395-a181-496d-b6b6-737d2a4197a4", "embedding": null, "metadata": {"window": "I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "621fd28c-c351-4310-ad8c-af508dec22b9", "node_type": "1", "metadata": {"window": "Thank you for all the details.  I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that. ", "original_text": "And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c11ec95fb1acdafbc795bb0fe46bcc21e27cf6866845aeabc0fb333ec1b0ce04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ac1c582-ca6d-4e7e-b453-49b429bca17a", "node_type": "1", "metadata": {"window": "So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020. ", "original_text": "A \nHi, Mike, thanks for that question. "}, "hash": "7f01b1b7ec3cb1164200a76555a7e63a4e13d051b26f408bc15670f5e9223598", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3209, "end_char_idx": 3570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ac1c582-ca6d-4e7e-b453-49b429bca17a": {"__data__": {"id_": "2ac1c582-ca6d-4e7e-b453-49b429bca17a", "embedding": null, "metadata": {"window": "So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020. ", "original_text": "A \nHi, Mike, thanks for that question. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10a07395-a181-496d-b6b6-737d2a4197a4", "node_type": "1", "metadata": {"window": "I want to just ask a bit of a follow -up clarification, additional question \non the pharma EBIT guidance, in particular you talked about 0% to 3% growth in the second half of the year on an \nadjusted profit basis.  So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d4a3f7cff6bb352cf87c6e19d1034e5ac1b07470a6c5f7e2ef39de97e07cb4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e76963b3-2ca6-45dc-a86e-36cde6ce7793", "node_type": "1", "metadata": {"window": "And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%. ", "original_text": "I'll start and let Brian add on to that. "}, "hash": "57eb4165c20ad056c1b0b1e85cf2ea778f450e5a367163b2fa4ed7f3dfc851d5", "class_name": "RelatedNodeInfo"}}, "text": "A \nHi, Mike, thanks for that question. ", "start_char_idx": 3570, "end_char_idx": 3609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e76963b3-2ca6-45dc-a86e-36cde6ce7793": {"__data__": {"id_": "e76963b3-2ca6-45dc-a86e-36cde6ce7793", "embedding": null, "metadata": {"window": "And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%. ", "original_text": "I'll start and let Brian add on to that. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ac1c582-ca6d-4e7e-b453-49b429bca17a", "node_type": "1", "metadata": {"window": "So, as you thi nk about the ramping, should we assume that you'll be exiting fiscal 2021 at a \n\"normalized run rate?\"  And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020. ", "original_text": "A \nHi, Mike, thanks for that question. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27cb4d1841389daa123fe50482c0740bb5b7929809950faf10c890b6766023c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e2fec4a-a165-410b-9e4c-e3b8f7ae3b6c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%.  We had strong revenue growth throughout the year. ", "original_text": "We're very pleased with our performance in \nour U.S. "}, "hash": "fcb0c1c4f68e4685f146b85585c2bf1ec059da8930ef42ac67357ba6ab0b05c1", "class_name": "RelatedNodeInfo"}}, "text": "I'll start and let Brian add on to that. ", "start_char_idx": 3609, "end_char_idx": 3650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e2fec4a-a165-410b-9e4c-e3b8f7ae3b6c": {"__data__": {"id_": "9e2fec4a-a165-410b-9e4c-e3b8f7ae3b6c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%.  We had strong revenue growth throughout the year. ", "original_text": "We're very pleased with our performance in \nour U.S. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e76963b3-2ca6-45dc-a86e-36cde6ce7793", "node_type": "1", "metadata": {"window": "And jumping into fiscal 2022, on what should be the normalized run rate or profit growth for \nthe pharma segment in particular?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%. ", "original_text": "I'll start and let Brian add on to that. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "927c5bc95871d6da14b3746dd24907d6e2a290b9bfbc68ab97d75356c65862ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f2f81e0-5e7b-4279-b59b-bdf0daef745a", "node_type": "1", "metadata": {"window": "A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%.  We had strong revenue growth throughout the year.  And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n ", "original_text": "Pharma and Specialty Solutions segment in fiscal 2020. "}, "hash": "ccf4a387b39805264092febfb0d0c75641a53f8d4381abb679739a49fd3810c8", "class_name": "RelatedNodeInfo"}}, "text": "We're very pleased with our performance in \nour U.S. ", "start_char_idx": 3650, "end_char_idx": 3703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f2f81e0-5e7b-4279-b59b-bdf0daef745a": {"__data__": {"id_": "9f2f81e0-5e7b-4279-b59b-bdf0daef745a", "embedding": null, "metadata": {"window": "A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%.  We had strong revenue growth throughout the year.  And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n ", "original_text": "Pharma and Specialty Solutions segment in fiscal 2020. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e2fec4a-a165-410b-9e4c-e3b8f7ae3b6c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecuti ve Vice President & Chief Financial Officer, McKesson Corp.   A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%.  We had strong revenue growth throughout the year. ", "original_text": "We're very pleased with our performance in \nour U.S. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e26ffa4aa56d447be329e3d8267f914abf4114737ce65571fcfbe670ad801bf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67e45273-8e78-420a-9b5d-7ff28fe63d20", "node_type": "1", "metadata": {"window": "I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%.  We had strong revenue growth throughout the year.  And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n ", "original_text": "We finish ed the year with full year adjusted \noperating profit of 6%. "}, "hash": "993ffe15a50a861151fd89cadcaf32c72717a2be4848cd7d90f79512e79c18cd", "class_name": "RelatedNodeInfo"}}, "text": "Pharma and Specialty Solutions segment in fiscal 2020. ", "start_char_idx": 3703, "end_char_idx": 3758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67e45273-8e78-420a-9b5d-7ff28fe63d20": {"__data__": {"id_": "67e45273-8e78-420a-9b5d-7ff28fe63d20", "embedding": null, "metadata": {"window": "I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%.  We had strong revenue growth throughout the year.  And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n ", "original_text": "We finish ed the year with full year adjusted \noperating profit of 6%. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f2f81e0-5e7b-4279-b59b-bdf0daef745a", "node_type": "1", "metadata": {"window": "A \nHi, Mike, thanks for that question.  I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%.  We had strong revenue growth throughout the year.  And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n ", "original_text": "Pharma and Specialty Solutions segment in fiscal 2020. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9928a25537e5712b00a33de0e340b86c78340f4f4c2d925e9cedf396b2d2d1ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41e5bff8-bd01-49f5-a591-eb972de6e9db", "node_type": "1", "metadata": {"window": "We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%.  We had strong revenue growth throughout the year.  And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n ", "original_text": "We had strong revenue growth throughout the year. "}, "hash": "abc6e69f2d3b013b336a04020222004a96358dad31f2d13aba8180c5142ce0c4", "class_name": "RelatedNodeInfo"}}, "text": "We finish ed the year with full year adjusted \noperating profit of 6%. ", "start_char_idx": 3758, "end_char_idx": 3829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41e5bff8-bd01-49f5-a591-eb972de6e9db": {"__data__": {"id_": "41e5bff8-bd01-49f5-a591-eb972de6e9db", "embedding": null, "metadata": {"window": "We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%.  We had strong revenue growth throughout the year.  And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n ", "original_text": "We had strong revenue growth throughout the year. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67e45273-8e78-420a-9b5d-7ff28fe63d20", "node_type": "1", "metadata": {"window": "I'll start and let Brian add on to that.  We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%.  We had strong revenue growth throughout the year.  And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n ", "original_text": "We finish ed the year with full year adjusted \noperating profit of 6%. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f48e4e9d56ab5707c60c540606372260ad99b77279d38f5f4a32145b807e5cad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "649a368b-2b9b-4500-a204-1041b9dda045", "node_type": "1", "metadata": {"window": "Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%.  We had strong revenue growth throughout the year.  And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n ", "original_text": "And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n "}, "hash": "4243676960553200ef17bae3f8b6823e56727cc45d77b36eb31074efaac3599e", "class_name": "RelatedNodeInfo"}}, "text": "We had strong revenue growth throughout the year. ", "start_char_idx": 3829, "end_char_idx": 3879, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "649a368b-2b9b-4500-a204-1041b9dda045": {"__data__": {"id_": "649a368b-2b9b-4500-a204-1041b9dda045", "embedding": null, "metadata": {"window": "Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%.  We had strong revenue growth throughout the year.  And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n ", "original_text": "And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974276ed8b2308a1b8d0363c9d69be8768416e91ba083843113e5854a01f8c6e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41e5bff8-bd01-49f5-a591-eb972de6e9db", "node_type": "1", "metadata": {"window": "We're very pleased with our performance in \nour U.S.  Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%.  We had strong revenue growth throughout the year.  And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n ", "original_text": "We had strong revenue growth throughout the year. ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c8d2c8705f692c299b463b738215d5661e1b594e4faaa79ccf1cd0f5c2f8d4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31b48097-120a-416e-a6ab-2e7feeed7eb1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter. ", "original_text": "McKesson Corp.  "}, "hash": "166ecf1a386071f7fd0db9192d2d79821518e2bf6b06944f58d95efa9824034c", "class_name": "RelatedNodeInfo"}}, "text": "And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n ", "start_char_idx": 3879, "end_char_idx": 4097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31b48097-120a-416e-a6ab-2e7feeed7eb1": {"__data__": {"id_": "31b48097-120a-416e-a6ab-2e7feeed7eb1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "649a368b-2b9b-4500-a204-1041b9dda045", "node_type": "1", "metadata": {"window": "Pharma and Specialty Solutions segment in fiscal 2020.  We finish ed the year with full year adjusted \noperating profit of 6%.  We had strong revenue growth throughout the year.  And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n ", "original_text": "And as we talked about, we expect \nthat the first half of the year, we're going to have some more sharp impacts on our Specialty Solutions \nbusiness es, which will impact, obviously, the full year operating profit.  \n ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bb048a614fbbd4ec56474f77ca984b057c5553a966545b33c7c6c27af57439f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e69ef688-9dd5-456b-8bb0-bb3876ebc954", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year. "}, "hash": "c741d13d2e7a79a6e4b1abe43ffb2f68e6f8c6ae9482f7ed7f52e3973b83eae1", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e69ef688-9dd5-456b-8bb0-bb3876ebc954": {"__data__": {"id_": "e69ef688-9dd5-456b-8bb0-bb3876ebc954", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31b48097-120a-416e-a6ab-2e7feeed7eb1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "abe000ea0acee18b9756ff5ae76838bcd242592239052f992e1bfcebffba183c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32886407-b972-4930-a843-fa2f01c634b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n ", "original_text": "And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year. "}, "hash": "3209a0145ea1b437efd65d2c685f6d9dc4d571acba31bd60247c0aec993eae15", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year. ", "start_char_idx": 16, "end_char_idx": 260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32886407-b972-4930-a843-fa2f01c634b7": {"__data__": {"id_": "32886407-b972-4930-a843-fa2f01c634b7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n ", "original_text": "And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e69ef688-9dd5-456b-8bb0-bb3876ebc954", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45de1c67ed12903fad0dd45eb7c9f573e6878f2ac0cdba7000279bfe00fcdea3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c438c0c-5083-442c-9b0a-5310c6976406", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "And so I think that as you think about this, there's going to be gradual improvement across each \nquarter. "}, "hash": "8a693d541488126847abd1500ecb51319b1de24f6a72e81772fc90ff60904503", "class_name": "RelatedNodeInfo"}}, "text": "And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year. ", "start_char_idx": 260, "end_char_idx": 424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c438c0c-5083-442c-9b0a-5310c6976406": {"__data__": {"id_": "7c438c0c-5083-442c-9b0a-5310c6976406", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "And so I think that as you think about this, there's going to be gradual improvement across each \nquarter. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32886407-b972-4930-a843-fa2f01c634b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n ", "original_text": "And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "023f87dc5f1006536dca92b314ef9eca6265731210fb5536fa3e32b6b8694b2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "583d99f7-116d-4361-8ce3-af44d3d43b4f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n "}, "hash": "ecca2acb10d941b127e02c62475b2210b4795b9a226a1332a4f5b7a3c61e9ac9", "class_name": "RelatedNodeInfo"}}, "text": "And so I think that as you think about this, there's going to be gradual improvement across each \nquarter. ", "start_char_idx": 424, "end_char_idx": 531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "583d99f7-116d-4361-8ce3-af44d3d43b4f": {"__data__": {"id_": "583d99f7-116d-4361-8ce3-af44d3d43b4f", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c438c0c-5083-442c-9b0a-5310c6976406", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "And so I think that as you think about this, there's going to be gradual improvement across each \nquarter. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8304fc81145b289cf5a5243a034a75dc04978dc42cab06f304d9f97beff104b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "843a9229-dddf-401b-812e-40d6bf75fedb", "node_type": "1", "metadata": {"window": "And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n "}, "hash": "635de6f27b05458e32aa12a9338edee524b76b331047adadba27ce8e8e7e1643", "class_name": "RelatedNodeInfo"}}, "text": "As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n ", "start_char_idx": 531, "end_char_idx": 679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "843a9229-dddf-401b-812e-40d6bf75fedb": {"__data__": {"id_": "843a9229-dddf-401b-812e-40d6bf75fedb", "embedding": null, "metadata": {"window": "And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "583d99f7-116d-4361-8ce3-af44d3d43b4f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24be8ebe266e325debd83f46beb8657b9c8337f5dadb81e6865476c01f0da156", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d8272e9-9bb4-47df-8620-de052cfba731", "node_type": "1", "metadata": {"window": "And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "0e2223dfbf27e30d75484073657498a3d7dd3a4a4de2f4524fb3b91d97ff94dd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n ", "start_char_idx": 679, "end_char_idx": 1042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d8272e9-9bb4-47df-8620-de052cfba731": {"__data__": {"id_": "7d8272e9-9bb4-47df-8620-de052cfba731", "embedding": null, "metadata": {"window": "And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "843a9229-dddf-401b-812e-40d6bf75fedb", "node_type": "1", "metadata": {"window": "And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55e900f042f2e721346bb724f8baf870b5a565ddef319b2fe8f1995dda9ea187", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "025f9a1d-0a3a-4113-9d09-b9e5a8ad8c0c", "node_type": "1", "metadata": {"window": "As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S. ", "original_text": "LLC  Q \nGreat. "}, "hash": "3fe957d1906f90520314230555fabe70d09cac22736c549b892fd347202bafcb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 1042, "end_char_idx": 1361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "025f9a1d-0a3a-4113-9d09-b9e5a8ad8c0c": {"__data__": {"id_": "025f9a1d-0a3a-4113-9d09-b9e5a8ad8c0c", "embedding": null, "metadata": {"window": "As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S. ", "original_text": "LLC  Q \nGreat. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d8272e9-9bb4-47df-8620-de052cfba731", "node_type": "1", "metadata": {"window": "And so I think that as you think about this, there's going to be gradual improvement across each \nquarter.  As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "13b11870c5a699c6ccc8e0a31748303ebef6bc952e8bc7a8b298155171229f86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8399e1e4-8da5-4534-be61-aeebf3dda126", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%. ", "original_text": "Thanks for the questions. "}, "hash": "d97db886b09631252a5d0379890d72135b3043829f236182bbded28f7301ea19", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nGreat. ", "start_char_idx": 1361, "end_char_idx": 1376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8399e1e4-8da5-4534-be61-aeebf3dda126": {"__data__": {"id_": "8399e1e4-8da5-4534-be61-aeebf3dda126", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%. ", "original_text": "Thanks for the questions. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "025f9a1d-0a3a-4113-9d09-b9e5a8ad8c0c", "node_type": "1", "metadata": {"window": "As we get to the end of the year, we're going to be exiting on a growth basis again, and feel good about \nthe prospects from that point forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S. ", "original_text": "LLC  Q \nGreat. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75232b603f694e2904714acb50eafac52cfcbdbbd365a695b02e865f74fa54a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06c93e77-720f-4931-8fed-6a2eaff1c5e8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q. ", "original_text": "I guess, maybe, Britt, just a follow -up on that. "}, "hash": "24bc8a763daab2ccb4b8d048f1b56c0b468ef0e97fbf2ab955a33296644b4348", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the questions. ", "start_char_idx": 1376, "end_char_idx": 1402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06c93e77-720f-4931-8fed-6a2eaff1c5e8": {"__data__": {"id_": "06c93e77-720f-4931-8fed-6a2eaff1c5e8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q. ", "original_text": "I guess, maybe, Britt, just a follow -up on that. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8399e1e4-8da5-4534-be61-aeebf3dda126", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%. ", "original_text": "Thanks for the questions. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d548e7fd60c3afa5927c1d5e97194223f29e87c9491a54616e0a4a856efa0c57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5012c8b3-9818-4221-ba41-f60e91c47623", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n", "original_text": "I mean, coming into fiscal 2020, \nyou guys had thought the U.S. "}, "hash": "faa47e112ed957640847672f4c67f694d2fdf84a9e8b11f9cc735ab683aa822c", "class_name": "RelatedNodeInfo"}}, "text": "I guess, maybe, Britt, just a follow -up on that. ", "start_char_idx": 1402, "end_char_idx": 1452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5012c8b3-9818-4221-ba41-f60e91c47623": {"__data__": {"id_": "5012c8b3-9818-4221-ba41-f60e91c47623", "embedding": null, "metadata": {"window": "LLC  Q \nGreat.  Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n", "original_text": "I mean, coming into fiscal 2020, \nyou guys had thought the U.S. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06c93e77-720f-4931-8fed-6a2eaff1c5e8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q. ", "original_text": "I guess, maybe, Britt, just a follow -up on that. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e93566001910468c19e882555e113d5851fde49369807abadb95501b71df156", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6fb4bc9-4b10-4e08-8f36-34d1108a818d", "node_type": "1", "metadata": {"window": "Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q? ", "original_text": "Pharma and Specialty business could grow at 3% to 5%. "}, "hash": "e14bbffb7a442c209657aa08aa62180e78cef316be85dcac8f3dbf47ff1d07ee", "class_name": "RelatedNodeInfo"}}, "text": "I mean, coming into fiscal 2020, \nyou guys had thought the U.S. ", "start_char_idx": 1452, "end_char_idx": 1516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6fb4bc9-4b10-4e08-8f36-34d1108a818d": {"__data__": {"id_": "d6fb4bc9-4b10-4e08-8f36-34d1108a818d", "embedding": null, "metadata": {"window": "Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q? ", "original_text": "Pharma and Specialty business could grow at 3% to 5%. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5012c8b3-9818-4221-ba41-f60e91c47623", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n", "original_text": "I mean, coming into fiscal 2020, \nyou guys had thought the U.S. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1815e790f69d3a67f156dd2904d1c4a47e0169da567459c309a9c509901bad93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "850ff376-7cd1-43c5-a0d8-60984ad0ee46", "node_type": "1", "metadata": {"window": "I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping. ", "original_text": "I'm sure there was a little \nbit of pull -forward in the 4Q. "}, "hash": "710db34beaa691747069ac4951f93336bc9fd54996bc5039badf5cf838d32f84", "class_name": "RelatedNodeInfo"}}, "text": "Pharma and Specialty business could grow at 3% to 5%. ", "start_char_idx": 1516, "end_char_idx": 1570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "850ff376-7cd1-43c5-a0d8-60984ad0ee46": {"__data__": {"id_": "850ff376-7cd1-43c5-a0d8-60984ad0ee46", "embedding": null, "metadata": {"window": "I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping. ", "original_text": "I'm sure there was a little \nbit of pull -forward in the 4Q. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6fb4bc9-4b10-4e08-8f36-34d1108a818d", "node_type": "1", "metadata": {"window": "Thanks for the questions.  I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q? ", "original_text": "Pharma and Specialty business could grow at 3% to 5%. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "727afe593aaf3442d8ad3103425a0e671b8b76d6b42cf394ab21b63baf39c6b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4422178d-2827-4b0a-b60a-9067d0435f93", "node_type": "1", "metadata": {"window": "I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter. ", "original_text": "But generally, business performed in line to slightly better than that.  \n \n"}, "hash": "d84502cfb1e53e2c88755e288b016af4fd195c245164dac3ddd58b77a3f54bf8", "class_name": "RelatedNodeInfo"}}, "text": "I'm sure there was a little \nbit of pull -forward in the 4Q. ", "start_char_idx": 1570, "end_char_idx": 1631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4422178d-2827-4b0a-b60a-9067d0435f93": {"__data__": {"id_": "4422178d-2827-4b0a-b60a-9067d0435f93", "embedding": null, "metadata": {"window": "I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter. ", "original_text": "But generally, business performed in line to slightly better than that.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "850ff376-7cd1-43c5-a0d8-60984ad0ee46", "node_type": "1", "metadata": {"window": "I guess, maybe, Britt, just a follow -up on that.  I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping. ", "original_text": "I'm sure there was a little \nbit of pull -forward in the 4Q. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "194b05c226d318f31161d2fb444a1883a5ac92deef0df09b7237e6b4870a73a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ca07e66-b45b-408e-a353-77e2e42b0813", "node_type": "1", "metadata": {"window": "Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n", "original_text": "I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q? "}, "hash": "27cea7582c84217e1c6d8b9893c4e4a227b8a1721c60fb80d82060cb87dfa579", "class_name": "RelatedNodeInfo"}}, "text": "But generally, business performed in line to slightly better than that.  \n \n", "start_char_idx": 1631, "end_char_idx": 1707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ca07e66-b45b-408e-a353-77e2e42b0813": {"__data__": {"id_": "6ca07e66-b45b-408e-a353-77e2e42b0813", "embedding": null, "metadata": {"window": "Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n", "original_text": "I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q? ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4422178d-2827-4b0a-b60a-9067d0435f93", "node_type": "1", "metadata": {"window": "I mean, coming into fiscal 2020, \nyou guys had thought the U.S.  Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter. ", "original_text": "But generally, business performed in line to slightly better than that.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fd1dc40de0dc465036e5ff7c2515be2d211111eb8aff43411d1dd06005a07bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a99a648-2ab5-429d-bc51-14bd10317ab4", "node_type": "1", "metadata": {"window": "I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n ", "original_text": "And then just one housekeeping. "}, "hash": "ebcb2ce20548c23370f893561ac9b0e6862b592629e534d748fcc9ff14bb7fac", "class_name": "RelatedNodeInfo"}}, "text": "I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q? ", "start_char_idx": 1707, "end_char_idx": 1894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a99a648-2ab5-429d-bc51-14bd10317ab4": {"__data__": {"id_": "1a99a648-2ab5-429d-bc51-14bd10317ab4", "embedding": null, "metadata": {"window": "I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n ", "original_text": "And then just one housekeeping. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ca07e66-b45b-408e-a353-77e2e42b0813", "node_type": "1", "metadata": {"window": "Pharma and Specialty business could grow at 3% to 5%.  I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n", "original_text": "I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q? ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "152d628e8d5541b97d0ebf3287ca9ce0e138e517be9169e281a1bc344799e169", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e583ddf-0787-4cb3-9481-7f05460f2e9c", "node_type": "1", "metadata": {"window": "But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.  ", "original_text": "I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter. "}, "hash": "dcc2016820d5117d282f54d704fa4d51da4e9c925e6f35e867de46c299e9e6bf", "class_name": "RelatedNodeInfo"}}, "text": "And then just one housekeeping. ", "start_char_idx": 1894, "end_char_idx": 1926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e583ddf-0787-4cb3-9481-7f05460f2e9c": {"__data__": {"id_": "9e583ddf-0787-4cb3-9481-7f05460f2e9c", "embedding": null, "metadata": {"window": "But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.  ", "original_text": "I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a99a648-2ab5-429d-bc51-14bd10317ab4", "node_type": "1", "metadata": {"window": "I'm sure there was a little \nbit of pull -forward in the 4Q.  But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n ", "original_text": "And then just one housekeeping. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "027246747d59fa1e239842b9c1536a6f991674ccda6838d65c7b8ca154cbd65e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "707da978-0b5d-4a02-8ddb-b4dcc84a674f", "node_type": "1", "metadata": {"window": "I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n"}, "hash": "dd56d7ed545bcbe509dabad5af3f905915b3113e897cbfcb85d7f31819e14c93", "class_name": "RelatedNodeInfo"}}, "text": "I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter. ", "start_char_idx": 1926, "end_char_idx": 2029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "707da978-0b5d-4a02-8ddb-b4dcc84a674f": {"__data__": {"id_": "707da978-0b5d-4a02-8ddb-b4dcc84a674f", "embedding": null, "metadata": {"window": "I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e583ddf-0787-4cb3-9481-7f05460f2e9c", "node_type": "1", "metadata": {"window": "But generally, business performed in line to slightly better than that.  \n \n I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.  ", "original_text": "I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "619baaba9b26349686eb5aa515b8965a981d04585f07796c45cbc90484e65a81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b021ed42-6176-48a4-b30a-2a6cc6aab861", "node_type": "1", "metadata": {"window": "And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question. ", "original_text": "Thanks.  \n "}, "hash": "a491fd12d6ede1b11545c5cad5e444d048ad4f399adc4d0f44b1950ae8a24f0c", "class_name": "RelatedNodeInfo"}}, "text": "I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n", "start_char_idx": 2029, "end_char_idx": 2159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b021ed42-6176-48a4-b30a-2a6cc6aab861": {"__data__": {"id_": "b021ed42-6176-48a4-b30a-2a6cc6aab861", "embedding": null, "metadata": {"window": "And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question. ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "707da978-0b5d-4a02-8ddb-b4dcc84a674f", "node_type": "1", "metadata": {"window": "I mean, just to follow -up on your previous answer, I mean, is the assumption that the business kind of gets back \nto those levels as we get through the year and, in particular, into 4Q?  And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4212e3deb33d517f6c3332d91e6c0444bc347bb96080589389004750aa583078", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbba4852-72fc-4919-804e-052a7809be34", "node_type": "1", "metadata": {"window": "I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me just step back to your first question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.  "}, "hash": "f06ad1cdb11ea87daf6d8efc6e01e320971ca2d4dfba6d66aabf5a67e15095b5", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2159, "end_char_idx": 2170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbba4852-72fc-4919-804e-052a7809be34": {"__data__": {"id_": "fbba4852-72fc-4919-804e-052a7809be34", "embedding": null, "metadata": {"window": "I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me just step back to your first question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b021ed42-6176-48a4-b30a-2a6cc6aab861", "node_type": "1", "metadata": {"window": "And then just one housekeeping.  I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question. ", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a790946ff073f683585f038649cf7a15352fb15fc03d33ce637db132e4bc44cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2aebbc35-99e7-40a3-a94a-29f12901e924", "node_type": "1", "metadata": {"window": "I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me just step back to your first question.  Again, as we talked about, in our U.S. \n", "original_text": "A \nYeah. "}, "hash": "56084c6281442f00af10f06a9eb03bfa04c8688c7eea559e3aa854fd590df489", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.  ", "start_char_idx": 2170, "end_char_idx": 2531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2aebbc35-99e7-40a3-a94a-29f12901e924": {"__data__": {"id_": "2aebbc35-99e7-40a3-a94a-29f12901e924", "embedding": null, "metadata": {"window": "I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me just step back to your first question.  Again, as we talked about, in our U.S. \n", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbba4852-72fc-4919-804e-052a7809be34", "node_type": "1", "metadata": {"window": "I know \nyou mentioned the $4 5 million of one -time adjusted operating expenses in the fourth quarter.  I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me just step back to your first question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b32ab7dc1ddc375878c3586e29c34811851a10e7edf8447f062f4aeafa28407e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e12dbb4f-f69d-4dc8-a367-c9f03dfe297f", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me just step back to your first question.  Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n", "original_text": "Thanks for the question. "}, "hash": "bd7cc7ba59e4875888e80f873bb6f2daffaf5bf1aa768045626169fedf1df31a", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2531, "end_char_idx": 2540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e12dbb4f-f69d-4dc8-a367-c9f03dfe297f": {"__data__": {"id_": "e12dbb4f-f69d-4dc8-a367-c9f03dfe297f", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me just step back to your first question.  Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n", "original_text": "Thanks for the question. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2aebbc35-99e7-40a3-a94a-29f12901e924", "node_type": "1", "metadata": {"window": "I was curious if that \nwas included, excluded, and then what's the assumption for additional COVID -related costs in 2020 guide? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me just step back to your first question.  Again, as we talked about, in our U.S. \n", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "deafb7b81fec49df1a3c8ba260831f0c7f675693a631ad64df8ca66ed8d63416", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32fd3f07-26d6-4c5b-9baa-854cb40619ea", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me just step back to your first question.  Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses. ", "original_text": "Let me just step back to your first question. "}, "hash": "a085b4b616b0e3b9c53783e6e6af105f0e1719a8e4a2f4f2b23f66f63621961c", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 2540, "end_char_idx": 2565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32fd3f07-26d6-4c5b-9baa-854cb40619ea": {"__data__": {"id_": "32fd3f07-26d6-4c5b-9baa-854cb40619ea", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me just step back to your first question.  Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses. ", "original_text": "Let me just step back to your first question. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e12dbb4f-f69d-4dc8-a367-c9f03dfe297f", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me just step back to your first question.  Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n", "original_text": "Thanks for the question. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7b57430f909d3c4dd9ea30a38e5ecdd6e6dd12da967bc00703db885f051b2f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bcb2ec5-89cb-4a46-abe1-42f394ad5898", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for the question.  Let me just step back to your first question.  Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n", "original_text": "Again, as we talked about, in our U.S. \n"}, "hash": "24bac3c4a38b2d98c5e10e7bde0911e76a294920e6019930d80b307bce9afdb6", "class_name": "RelatedNodeInfo"}}, "text": "Let me just step back to your first question. ", "start_char_idx": 2565, "end_char_idx": 2611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bcb2ec5-89cb-4a46-abe1-42f394ad5898": {"__data__": {"id_": "3bcb2ec5-89cb-4a46-abe1-42f394ad5898", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks for the question.  Let me just step back to your first question.  Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n", "original_text": "Again, as we talked about, in our U.S. \n", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32fd3f07-26d6-4c5b-9baa-854cb40619ea", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & C hief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  Let me just step back to your first question.  Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses. ", "original_text": "Let me just step back to your first question. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdcd2543d8437088eb8fd04c35b0e7bb7c0828731cf277ae37277c069297e575", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47e10057-506c-43af-9783-4ba65e4b3d28", "node_type": "1", "metadata": {"window": "Thanks for the question.  Let me just step back to your first question.  Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year. ", "original_text": "Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n"}, "hash": "f7177290ca3b1fda440ca7880802d2d3e82d9a2120425c530f74130f41c2862e", "class_name": "RelatedNodeInfo"}}, "text": "Again, as we talked about, in our U.S. \n", "start_char_idx": 2611, "end_char_idx": 2651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47e10057-506c-43af-9783-4ba65e4b3d28": {"__data__": {"id_": "47e10057-506c-43af-9783-4ba65e4b3d28", "embedding": null, "metadata": {"window": "Thanks for the question.  Let me just step back to your first question.  Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year. ", "original_text": "Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bcb2ec5-89cb-4a46-abe1-42f394ad5898", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for the question.  Let me just step back to your first question.  Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n", "original_text": "Again, as we talked about, in our U.S. \n", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "507a3dfb8da5276d5c617ececfda1a9a07f68174a127c582489704c358ba0097", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e4da976-11a6-4279-a38c-931acd976f9c", "node_type": "1", "metadata": {"window": "Let me just step back to your first question.  Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year.  We'll recover gradually throughout the year. ", "original_text": "So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses. "}, "hash": "909da8436fdc33291aad306dd8aa77416764f71bacb8c5c84e38aa37fb42decc", "class_name": "RelatedNodeInfo"}}, "text": "Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n", "start_char_idx": 2651, "end_char_idx": 3071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e4da976-11a6-4279-a38c-931acd976f9c": {"__data__": {"id_": "6e4da976-11a6-4279-a38c-931acd976f9c", "embedding": null, "metadata": {"window": "Let me just step back to your first question.  Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year.  We'll recover gradually throughout the year. ", "original_text": "So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47e10057-506c-43af-9783-4ba65e4b3d28", "node_type": "1", "metadata": {"window": "Thanks for the question.  Let me just step back to your first question.  Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year. ", "original_text": "Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca8091ebf31fc3666e78966541e25c25a9713219f65180024209c66c60e07784", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68f79454-7cd4-43ab-a099-b10fdad9510e", "node_type": "1", "metadata": {"window": "Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year.  We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n", "original_text": "And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n"}, "hash": "9532fee2e810a91f441ae95d651ad3ef9039575837f4511977d3df11632a2525", "class_name": "RelatedNodeInfo"}}, "text": "So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses. ", "start_char_idx": 3071, "end_char_idx": 3246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68f79454-7cd4-43ab-a099-b10fdad9510e": {"__data__": {"id_": "68f79454-7cd4-43ab-a099-b10fdad9510e", "embedding": null, "metadata": {"window": "Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year.  We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n", "original_text": "And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e4da976-11a6-4279-a38c-931acd976f9c", "node_type": "1", "metadata": {"window": "Let me just step back to your first question.  Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year.  We'll recover gradually throughout the year. ", "original_text": "So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23e2edf1fae8c80fb4d9102f4a1b6ff480f8939f28f14effbb60ac07436a9c88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97e15171-e5a4-4380-b314-52ed3e73d9d3", "node_type": "1", "metadata": {"window": "Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year.  We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses. ", "original_text": "We won't recover all of the volumes this year. "}, "hash": "3b646e8d682164290dab5bc4f939e3f9bae30b262e4f917c5cff210d1b554a94", "class_name": "RelatedNodeInfo"}}, "text": "And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n", "start_char_idx": 3246, "end_char_idx": 3448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97e15171-e5a4-4380-b314-52ed3e73d9d3": {"__data__": {"id_": "97e15171-e5a4-4380-b314-52ed3e73d9d3", "embedding": null, "metadata": {"window": "Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year.  We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses. ", "original_text": "We won't recover all of the volumes this year. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68f79454-7cd4-43ab-a099-b10fdad9510e", "node_type": "1", "metadata": {"window": "Again, as we talked about, in our U.S. \n Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year.  We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n", "original_text": "And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac12c81da80c1e0af1a66e23f4cefa88db511e60d66df3f881613c421ce7b0f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00af09c8-306b-4a40-bc74-508d9d892850", "node_type": "1", "metadata": {"window": "So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year.  We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses. ", "original_text": "We'll recover gradually throughout the year. "}, "hash": "df49ab250957ec2a30117bf5b64b082a7d8b5f8f52682ec3cb850886b837facf", "class_name": "RelatedNodeInfo"}}, "text": "We won't recover all of the volumes this year. ", "start_char_idx": 3448, "end_char_idx": 3495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00af09c8-306b-4a40-bc74-508d9d892850": {"__data__": {"id_": "00af09c8-306b-4a40-bc74-508d9d892850", "embedding": null, "metadata": {"window": "So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year.  We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses. ", "original_text": "We'll recover gradually throughout the year. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97e15171-e5a4-4380-b314-52ed3e73d9d3", "node_type": "1", "metadata": {"window": "Pharma and Specialty Solutions business, it's a broad business, US pharma distribution, but also a  broad -based \nspecialty set of businesses, which includes our multi -specialty provider businesses, which as we talked about \nhave been more severely impacted in April and early May, and we expect to have a greater impact through the \nfirst quarter with just g radual improvement throughout the balance of the year.  \n \n So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year.  We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses. ", "original_text": "We won't recover all of the volumes this year. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0307dbe4a6e5d8df32ebfcb60895842261dd1dbfa734bb510698099781b23ca2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9037e3f0-e3b6-4435-9f31-0de67f4da045", "node_type": "1", "metadata": {"window": "And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year.  We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n ", "original_text": "But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n"}, "hash": "e40ddef9f3978b3f80fe0271a90ca770c623d6e74787c4f53febf1e261dccaa8", "class_name": "RelatedNodeInfo"}}, "text": "We'll recover gradually throughout the year. ", "start_char_idx": 3495, "end_char_idx": 3540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9037e3f0-e3b6-4435-9f31-0de67f4da045": {"__data__": {"id_": "9037e3f0-e3b6-4435-9f31-0de67f4da045", "embedding": null, "metadata": {"window": "And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year.  We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n ", "original_text": "But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00af09c8-306b-4a40-bc74-508d9d892850", "node_type": "1", "metadata": {"window": "So as we think about that second half of the year, it's really going to be that continued improvement of not only \nvolumes, but profitability across both of those businesses.  And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year.  We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses. ", "original_text": "We'll recover gradually throughout the year. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58393c3e4f09e2d68a68744cf725e409b96618b827ee31d64ee18f159bd38f7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98aa52b0-9440-4f73-8b70-c211d78b7dd7", "node_type": "1", "metadata": {"window": "We won't recover all of the volumes this year.  We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "The $45 million that I referenced earlier on, that was across all of our businesses. "}, "hash": "e648d3fc765b5430a86063dab00c795804ab3ea837819ea2966b3ce24a9b48fa", "class_name": "RelatedNodeInfo"}}, "text": "But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n", "start_char_idx": 3540, "end_char_idx": 3779, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98aa52b0-9440-4f73-8b70-c211d78b7dd7": {"__data__": {"id_": "98aa52b0-9440-4f73-8b70-c211d78b7dd7", "embedding": null, "metadata": {"window": "We won't recover all of the volumes this year.  We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "The $45 million that I referenced earlier on, that was across all of our businesses. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9037e3f0-e3b6-4435-9f31-0de67f4da045", "node_type": "1", "metadata": {"window": "And we feel comfortable th at getting to a 0% to 3% \ngrowth in the balance of the second half, again, with that gradual improvement, sets us up well to returning to that \n3% to 5% as we go forward.  \n \n We won't recover all of the volumes this year.  We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n ", "original_text": "But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7c4c9944cc0b014ae3ce7263b557f1f49a1deb69cb4b669dfcc00a7baf07bf1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ccfad84-6b86-4c21-9cac-443f62361898", "node_type": "1", "metadata": {"window": "We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes. ", "original_text": "It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses. "}, "hash": "437bc88e41d5c163102832ac7e6264e180a042823049410da1ebfeb793fddf80", "class_name": "RelatedNodeInfo"}}, "text": "The $45 million that I referenced earlier on, that was across all of our businesses. ", "start_char_idx": 3779, "end_char_idx": 3864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ccfad84-6b86-4c21-9cac-443f62361898": {"__data__": {"id_": "7ccfad84-6b86-4c21-9cac-443f62361898", "embedding": null, "metadata": {"window": "We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes. ", "original_text": "It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98aa52b0-9440-4f73-8b70-c211d78b7dd7", "node_type": "1", "metadata": {"window": "We won't recover all of the volumes this year.  We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "The $45 million that I referenced earlier on, that was across all of our businesses. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d21b23e95a599083d139ac1b2a1cd1fbf7de3774f883ff02605e5b461928cc7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed001328-46d0-42dd-962f-16b547d47620", "node_type": "1", "metadata": {"window": "But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities. ", "original_text": "That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n "}, "hash": "d54361aae19909154199c764769da01e01bbfb251201afc9d694c72e73ec0589", "class_name": "RelatedNodeInfo"}}, "text": "It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses. ", "start_char_idx": 3864, "end_char_idx": 4128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed001328-46d0-42dd-962f-16b547d47620": {"__data__": {"id_": "ed001328-46d0-42dd-962f-16b547d47620", "embedding": null, "metadata": {"window": "But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities. ", "original_text": "That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ccfad84-6b86-4c21-9cac-443f62361898", "node_type": "1", "metadata": {"window": "We'll recover gradually throughout the year.  But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes. ", "original_text": "It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710b637a2b9b5ae6e25d68ea49075873ebcb5053ba8fb278470d91be94a138fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f9b7154-f200-4d93-806f-bd92a6a4f8dd", "node_type": "1", "metadata": {"window": "The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities.  And we thought it was just importa nt part of who we are ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "0b02152e590c5552a12f8717efb5856589e748e748849590043a8f8ec4159544", "class_name": "RelatedNodeInfo"}}, "text": "That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n ", "start_char_idx": 4128, "end_char_idx": 4299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f9b7154-f200-4d93-806f-bd92a6a4f8dd": {"__data__": {"id_": "9f9b7154-f200-4d93-806f-bd92a6a4f8dd", "embedding": null, "metadata": {"window": "The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities.  And we thought it was just importa nt part of who we are ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed001328-46d0-42dd-962f-16b547d47620", "node_type": "1", "metadata": {"window": "But again, I just would \npoint out that our broad -based specialty business, which includes our provider business and our practice \nmanagement business are more impacted and are going to gradually improve over the balance of the year.  \n \n The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities. ", "original_text": "That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de2782083237d47cf15e5f0b48fb4ef63c9778c33f2ba0cc32baaca6f952e90e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ee42c6b-8f17-4f20-92eb-e9763cba6dfb", "node_type": "1", "metadata": {"window": "It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities.  And we thought it was just importa nt part of who we are ", "original_text": "A \nYes. "}, "hash": "c9e6617bfc495fc6a296cf5ca0068e64cb750d9639339e2c945d0220dc283c8a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 4299, "end_char_idx": 4640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ee42c6b-8f17-4f20-92eb-e9763cba6dfb": {"__data__": {"id_": "8ee42c6b-8f17-4f20-92eb-e9763cba6dfb", "embedding": null, "metadata": {"window": "It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities.  And we thought it was just importa nt part of who we are ", "original_text": "A \nYes. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f9b7154-f200-4d93-806f-bd92a6a4f8dd", "node_type": "1", "metadata": {"window": "The $45 million that I referenced earlier on, that was across all of our businesses.  It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities.  And we thought it was just importa nt part of who we are ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc39eb84d2f02f202fdc96fe8f7e55615570708cd7645863235e94a92cd85a35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c485b85e-248d-4dd0-9a20-e143cfcf455d", "node_type": "1", "metadata": {"window": "That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities.  And we thought it was just importa nt part of who we are ", "original_text": "Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities. "}, "hash": "85ccbf4d409c5b922329e7966b59f82369dae936ec7a61a07aba75c650a13343", "class_name": "RelatedNodeInfo"}}, "text": "A \nYes. ", "start_char_idx": 4640, "end_char_idx": 4648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c485b85e-248d-4dd0-9a20-e143cfcf455d": {"__data__": {"id_": "c485b85e-248d-4dd0-9a20-e143cfcf455d", "embedding": null, "metadata": {"window": "That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities.  And we thought it was just importa nt part of who we are ", "original_text": "Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ee42c6b-8f17-4f20-92eb-e9763cba6dfb", "node_type": "1", "metadata": {"window": "It was, as Brian mentioned, to \npay bonuses to frontline workers in each of our businesses as well as donations that we made across \ncommunities as well as cost to set up remote work enviro nments, again, in our corporate environment, but also in \nour businesses.  That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities.  And we thought it was just importa nt part of who we are ", "original_text": "A \nYes. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e3f3ed71b9e7e9b0cf1abe1cdafd3ae81c82abf62414c739a83a689fac6c04a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "426115cd-d5a6-45d6-8604-7c84efe165b0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities.  And we thought it was just importa nt part of who we are ", "original_text": "And we thought it was just importa nt part of who we are "}, "hash": "8ac986926cbe67d5fe64e98e9ca5822e33a200d4ebc2e6b1da5e8a9232b5156d", "class_name": "RelatedNodeInfo"}}, "text": "Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities. ", "start_char_idx": 4648, "end_char_idx": 4812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "426115cd-d5a6-45d6-8604-7c84efe165b0": {"__data__": {"id_": "426115cd-d5a6-45d6-8604-7c84efe165b0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities.  And we thought it was just importa nt part of who we are ", "original_text": "And we thought it was just importa nt part of who we are ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2be06b0cb513b9b3ae5272a16ef7b467b896603bb678d8c2da4f65105fc255fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c485b85e-248d-4dd0-9a20-e143cfcf455d", "node_type": "1", "metadata": {"window": "That's, obviously, part of the year -over-year comparison that is included in our FY 2020 Q4 \nresults, and that will be included in for comparison purposes in FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities.  And we thought it was just importa nt part of who we are ", "original_text": "Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities. ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "413dd90e233320f461989a5d1b1f8e053fd111dc52a8b7e55a8f175fe11d55af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b9a8655-230c-479f-a967-a32979c308b5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  "}, "hash": "6fe71d511e16a2ab550cd24cecc3d928515bc80e67189f201eaeeeaeda7d1819", "class_name": "RelatedNodeInfo"}}, "text": "And we thought it was just importa nt part of who we are ", "start_char_idx": 4812, "end_char_idx": 4869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b9a8655-230c-479f-a967-a32979c308b5": {"__data__": {"id_": "4b9a8655-230c-479f-a967-a32979c308b5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "426115cd-d5a6-45d6-8604-7c84efe165b0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Those are actions taken really early part of March as we assessed the impact this would have on our teams, \nand frankly, anticipated the impact on our communities.  And we thought it was just importa nt part of who we are ", "original_text": "And we thought it was just importa nt part of who we are ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5018394a2728550853228f8e4266cf29499b2cf64183e3be5a1cfb7f8d5a55ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8eace5e-4056-4088-af0d-28b6a3bf7d19", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions. "}, "hash": "532ddba1ee716da6ca820af7c9b5984ef3ef539238765d430e504959556a43ad", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8eace5e-4056-4088-af0d-28b6a3bf7d19": {"__data__": {"id_": "e8eace5e-4056-4088-af0d-28b6a3bf7d19", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b9a8655-230c-479f-a967-a32979c308b5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb3fc28695b64bddc8695001b305afef7ff8f8e3193b40d4c8aa8642f0f305fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df437714-f292-47c4-a473-e321da3c0194", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n ", "original_text": "Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n "}, "hash": "ac7e23167326177163480b961a7f7ba2456a2b29cca5be5c1f64d62ef96e5350", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions. ", "start_char_idx": 16, "end_char_idx": 217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df437714-f292-47c4-a473-e321da3c0194": {"__data__": {"id_": "df437714-f292-47c4-a473-e321da3c0194", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n ", "original_text": "Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8eace5e-4056-4088-af0d-28b6a3bf7d19", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76d37dbd047eb81f0ad02da9ba681c46f8f40ff41ae82222e19f0762825e94c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e170744-9b1c-4b0d-8853-9a096c18265d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "0e70d07f7fd87c80d49a82e837a3dbdff18bb2ddd646c3d62ddc1d9c29ef0442", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n ", "start_char_idx": 217, "end_char_idx": 502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e170744-9b1c-4b0d-8853-9a096c18265d": {"__data__": {"id_": "1e170744-9b1c-4b0d-8853-9a096c18265d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df437714-f292-47c4-a473-e321da3c0194", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n ", "original_text": "Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e767274b33f51d2fcea5489db64bca7238f2660c5152bb6e2e986c4dbc93b3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0eeffd25-67c8-43ed-b479-9061a94120fe", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much. ", "original_text": "A \nNext question?  \n "}, "hash": "3da215abd728d8af0a1734d8507e79bd06198f0cecff9739d11eb84f47ee9b8a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 502, "end_char_idx": 847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0eeffd25-67c8-43ed-b479-9061a94120fe": {"__data__": {"id_": "0eeffd25-67c8-43ed-b479-9061a94120fe", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much. ", "original_text": "A \nNext question?  \n ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e170744-9b1c-4b0d-8853-9a096c18265d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cd19527a7e23203391c6e4d835ffb8e8ee526ce6d5d54d19bed6a4dd43719c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8955d631-73e4-4f30-9c58-185cc3e5c6bc", "node_type": "1", "metadata": {"window": "Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n "}, "hash": "f11e74f4fdc3a4a6ec45d9ea9b367d4133edd4d530a4b273575d13fe028d7361", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question?  \n ", "start_char_idx": 847, "end_char_idx": 868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8955d631-73e4-4f30-9c58-185cc3e5c6bc": {"__data__": {"id_": "8955d631-73e4-4f30-9c58-185cc3e5c6bc", "embedding": null, "metadata": {"window": "Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0eeffd25-67c8-43ed-b479-9061a94120fe", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much. ", "original_text": "A \nNext question?  \n ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b337c5b66f4fe797cc206ebb08cb4ed64252290579de2a8b4941102c13585b07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23a3975e-d1a1-45a6-9a56-80941342e9e3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Good morning.  Thanks for all the details. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "24b14d169246f2ebdb64860515d9cc385c94c65c9b8bc089e44cdbbb138acc31", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n ", "start_char_idx": 868, "end_char_idx": 1226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23a3975e-d1a1-45a6-9a56-80941342e9e3": {"__data__": {"id_": "23a3975e-d1a1-45a6-9a56-80941342e9e3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Good morning.  Thanks for all the details. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8955d631-73e4-4f30-9c58-185cc3e5c6bc", "node_type": "1", "metadata": {"window": "Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc76c84e5b91ed1ffd06feb7c5c06f4c261217b75c03eaf908424a8ff3f4bed6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b75d76d5-6994-40dd-8bd5-6ce9fa4e9bc2", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Good morning.  Thanks for all the details.  A couple of just unrelated questions. ", "original_text": "Q \nThanks very much. "}, "hash": "67f7c7dceee3b2c48b25370a02e5085eef055357131ed9399fbc2b166e61d5f2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 1226, "end_char_idx": 1558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b75d76d5-6994-40dd-8bd5-6ce9fa4e9bc2": {"__data__": {"id_": "b75d76d5-6994-40dd-8bd5-6ce9fa4e9bc2", "embedding": null, "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Good morning.  Thanks for all the details.  A couple of just unrelated questions. ", "original_text": "Q \nThanks very much. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23a3975e-d1a1-45a6-9a56-80941342e9e3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Good morning.  Thanks for all the details. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "466eb634cb2a79d892706df267271860f6869fe2d4ef7eb0e377c186d96fec1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18586dfa-29ce-4226-9bd4-4b538be84659", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Good morning.  Thanks for all the details.  A couple of just unrelated questions.  First one, share \nrepurchase. ", "original_text": "Good morning. "}, "hash": "6b61f880ee679514c790781ab2a215f3fd97784fea652785fb758e20ee3d2870", "class_name": "RelatedNodeInfo"}}, "text": "Q \nThanks very much. ", "start_char_idx": 1558, "end_char_idx": 1579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18586dfa-29ce-4226-9bd4-4b538be84659": {"__data__": {"id_": "18586dfa-29ce-4226-9bd4-4b538be84659", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Good morning.  Thanks for all the details.  A couple of just unrelated questions.  First one, share \nrepurchase. ", "original_text": "Good morning. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b75d76d5-6994-40dd-8bd5-6ce9fa4e9bc2", "node_type": "1", "metadata": {"window": "A \nNext question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Good morning.  Thanks for all the details.  A couple of just unrelated questions. ", "original_text": "Q \nThanks very much. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08f4af30a83757dae1ceecb1d9fef9d642daa3b319bdebb516dbfaadd9f9327f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cb2f251-0d0e-4fb8-90e6-ab17ed25da85", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Good morning.  Thanks for all the details.  A couple of just unrelated questions.  First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now. ", "original_text": "Thanks for all the details. "}, "hash": "63384d20038fbd003c8c81744bd5b7a4fed85684507108b173fe54fa87b1ff28", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 1579, "end_char_idx": 1593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cb2f251-0d0e-4fb8-90e6-ab17ed25da85": {"__data__": {"id_": "7cb2f251-0d0e-4fb8-90e6-ab17ed25da85", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Good morning.  Thanks for all the details.  A couple of just unrelated questions.  First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now. ", "original_text": "Thanks for all the details. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18586dfa-29ce-4226-9bd4-4b538be84659", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Good morning.  Thanks for all the details.  A couple of just unrelated questions.  First one, share \nrepurchase. ", "original_text": "Good morning. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a03a623d78acc08d6f3e2e17b4a985d9b9b5edfb30ba2f2c33f8893be6603117", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11ba0ee9-69e0-43bd-a77e-f833089bcedd", "node_type": "1", "metadata": {"window": "Q \nThanks very much.  Good morning.  Thanks for all the details.  A couple of just unrelated questions.  First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n", "original_text": "A couple of just unrelated questions. "}, "hash": "3db3442f708930a3eacef83b370b3f15f774af174d171268ee364ca02461670b", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for all the details. ", "start_char_idx": 1593, "end_char_idx": 1621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11ba0ee9-69e0-43bd-a77e-f833089bcedd": {"__data__": {"id_": "11ba0ee9-69e0-43bd-a77e-f833089bcedd", "embedding": null, "metadata": {"window": "Q \nThanks very much.  Good morning.  Thanks for all the details.  A couple of just unrelated questions.  First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n", "original_text": "A couple of just unrelated questions. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cb2f251-0d0e-4fb8-90e6-ab17ed25da85", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much.  Good morning.  Thanks for all the details.  A couple of just unrelated questions.  First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now. ", "original_text": "Thanks for all the details. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5016770ef73b2246e45a9c66914dee2d3c4d036c8347b54cb6ec6f9b8bc9078", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f6f2139-2aaa-4ee9-bbe4-d2d71d780dd9", "node_type": "1", "metadata": {"window": "Good morning.  Thanks for all the details.  A couple of just unrelated questions.  First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID? ", "original_text": "First one, share \nrepurchase. "}, "hash": "380de516baf520827650eb1c7ce6e467e5994c60d69bda3fbbc267fda39d02d7", "class_name": "RelatedNodeInfo"}}, "text": "A couple of just unrelated questions. ", "start_char_idx": 1621, "end_char_idx": 1659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f6f2139-2aaa-4ee9-bbe4-d2d71d780dd9": {"__data__": {"id_": "9f6f2139-2aaa-4ee9-bbe4-d2d71d780dd9", "embedding": null, "metadata": {"window": "Good morning.  Thanks for all the details.  A couple of just unrelated questions.  First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID? ", "original_text": "First one, share \nrepurchase. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11ba0ee9-69e0-43bd-a77e-f833089bcedd", "node_type": "1", "metadata": {"window": "Q \nThanks very much.  Good morning.  Thanks for all the details.  A couple of just unrelated questions.  First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n", "original_text": "A couple of just unrelated questions. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d2623aa93d3cc9ca3b536c645e94b35775225fffde2896175baf74185311f4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9a589b2-c404-4c4f-aa6e-37e4c7101db4", "node_type": "1", "metadata": {"window": "Thanks for all the details.  A couple of just unrelated questions.  First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n ", "original_text": "You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now. "}, "hash": "a2394010de829d1c2faa2d1adb3f2015d3cef00cdd6b023991077f25c5b094f6", "class_name": "RelatedNodeInfo"}}, "text": "First one, share \nrepurchase. ", "start_char_idx": 1659, "end_char_idx": 1689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9a589b2-c404-4c4f-aa6e-37e4c7101db4": {"__data__": {"id_": "a9a589b2-c404-4c4f-aa6e-37e4c7101db4", "embedding": null, "metadata": {"window": "Thanks for all the details.  A couple of just unrelated questions.  First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n ", "original_text": "You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f6f2139-2aaa-4ee9-bbe4-d2d71d780dd9", "node_type": "1", "metadata": {"window": "Good morning.  Thanks for all the details.  A couple of just unrelated questions.  First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID? ", "original_text": "First one, share \nrepurchase. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c32d02d62ede56f50fdd735c0c3bf2cfcebd01c104ef86ec8dbe76999344071", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e38748d4-1513-49de-9c58-adb80253906a", "node_type": "1", "metadata": {"window": "A couple of just unrelated questions.  First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.  ", "original_text": "I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n"}, "hash": "3cbb45d604410124dab10cea3eec5738268410cd0bef0d9ca0158d58299e543e", "class_name": "RelatedNodeInfo"}}, "text": "You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now. ", "start_char_idx": 1689, "end_char_idx": 1886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e38748d4-1513-49de-9c58-adb80253906a": {"__data__": {"id_": "e38748d4-1513-49de-9c58-adb80253906a", "embedding": null, "metadata": {"window": "A couple of just unrelated questions.  First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.  ", "original_text": "I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9a589b2-c404-4c4f-aa6e-37e4c7101db4", "node_type": "1", "metadata": {"window": "Thanks for all the details.  A couple of just unrelated questions.  First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n ", "original_text": "You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "acc04c7efd5a0d6df8b450b2e797d042f67939dcff0e5e6d5f5de644a1ad7e2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac03ce8f-5daf-45e0-b3e2-df08d50b5584", "node_type": "1", "metadata": {"window": "First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric. ", "original_text": "Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID? "}, "hash": "81c3a66bbe1bfd1feadf78730f582fd5ca97045dc0522a26f4fbbc79d0a0dd05", "class_name": "RelatedNodeInfo"}}, "text": "I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n", "start_char_idx": 1886, "end_char_idx": 1986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac03ce8f-5daf-45e0-b3e2-df08d50b5584": {"__data__": {"id_": "ac03ce8f-5daf-45e0-b3e2-df08d50b5584", "embedding": null, "metadata": {"window": "First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric. ", "original_text": "Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID? ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e38748d4-1513-49de-9c58-adb80253906a", "node_type": "1", "metadata": {"window": "A couple of just unrelated questions.  First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.  ", "original_text": "I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c3c51435a70c3c657127576f7250aae21834a9ffceed7c68a7fae753932d485", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98860d03-4def-4f85-b26a-807ad786caa9", "node_type": "1", "metadata": {"window": "You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian. ", "original_text": "Thanks very much.  \n "}, "hash": "69f74d35f0896e3242cb96261f961eb0260ecdb8f580ceadbef54a0465c9c8f4", "class_name": "RelatedNodeInfo"}}, "text": "Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID? ", "start_char_idx": 1986, "end_char_idx": 2180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98860d03-4def-4f85-b26a-807ad786caa9": {"__data__": {"id_": "98860d03-4def-4f85-b26a-807ad786caa9", "embedding": null, "metadata": {"window": "You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian. ", "original_text": "Thanks very much.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac03ce8f-5daf-45e0-b3e2-df08d50b5584", "node_type": "1", "metadata": {"window": "First one, share \nrepurchase.  You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric. ", "original_text": "Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID? ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eac2610f6b46ed9e709439c1e50cd0c3fb30a660ff28992e383c5b9d7276f8c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4103e707-ab0f-4c8d-9c5a-767adc602a4b", "node_type": "1", "metadata": {"window": "I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.  "}, "hash": "8d9e84037ed9fbba7c37998d0938ca8043c65d9f5b6d5c20d22059a8fa770aae", "class_name": "RelatedNodeInfo"}}, "text": "Thanks very much.  \n ", "start_char_idx": 2180, "end_char_idx": 2201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4103e707-ab0f-4c8d-9c5a-767adc602a4b": {"__data__": {"id_": "4103e707-ab0f-4c8d-9c5a-767adc602a4b", "embedding": null, "metadata": {"window": "I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98860d03-4def-4f85-b26a-807ad786caa9", "node_type": "1", "metadata": {"window": "You expressed interest in continuing with that program, but weighted average shares outstanding \nguidance seems a little bit higher than we would have expected given the low share price right now.  I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian. ", "original_text": "Thanks very much.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9db39779530b3a8c16d6fa261c526f15d6519bbface7f50535b361eea25a8564", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "224c93ef-4fdc-4659-af8b-cedb6cc2b543", "node_type": "1", "metadata": {"window": "Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million. ", "original_text": "A \nThanks, Eric. "}, "hash": "3fde7a4d69bcea26dae5c6be5bb3bdecb0d2b8f2c226f856e03b29c1bbbd6df9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.  ", "start_char_idx": 2201, "end_char_idx": 2562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "224c93ef-4fdc-4659-af8b-cedb6cc2b543": {"__data__": {"id_": "224c93ef-4fdc-4659-af8b-cedb6cc2b543", "embedding": null, "metadata": {"window": "Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million. ", "original_text": "A \nThanks, Eric. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4103e707-ab0f-4c8d-9c5a-767adc602a4b", "node_type": "1", "metadata": {"window": "I'm just \ncurious if you can give us any specificity on what you're thinking about share repos?  \n \n Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b7ca422dbf91572a0bdbe265fc720b76094905b650347a76a513f1279c91fb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fd5f7ba-545c-461b-b040-2b0414e4d76f", "node_type": "1", "metadata": {"window": "Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases. ", "original_text": "Let me start and take the first one off the table and then turn it over to Brian. "}, "hash": "14bab7de2fa58eaf8cdbdf2dd2ae5b5840ab42b0257369f51d303cde0edad7f7", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks, Eric. ", "start_char_idx": 2562, "end_char_idx": 2579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fd5f7ba-545c-461b-b040-2b0414e4d76f": {"__data__": {"id_": "7fd5f7ba-545c-461b-b040-2b0414e4d76f", "embedding": null, "metadata": {"window": "Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases. ", "original_text": "Let me start and take the first one off the table and then turn it over to Brian. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "224c93ef-4fdc-4659-af8b-cedb6cc2b543", "node_type": "1", "metadata": {"window": "Second question, unrelated, US on cology, it would be great to get an update on what you're seeing real -time with \nyour practice management business and what impacts you're getting from COVID?  Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million. ", "original_text": "A \nThanks, Eric. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68b5dc6f480bc647ad00d569a11f39beb66c299ab3c13809da63ec34ab9ef151", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0f4f223-fcfa-4131-b5df-b5ea72b88651", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n ", "original_text": "As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares. "}, "hash": "ee22e9f64dab860e965a294458cbe5f42c1a066878fe9fbf3dc41720397280f0", "class_name": "RelatedNodeInfo"}}, "text": "Let me start and take the first one off the table and then turn it over to Brian. ", "start_char_idx": 2579, "end_char_idx": 2661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0f4f223-fcfa-4131-b5df-b5ea72b88651": {"__data__": {"id_": "e0f4f223-fcfa-4131-b5df-b5ea72b88651", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n ", "original_text": "As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fd5f7ba-545c-461b-b040-2b0414e4d76f", "node_type": "1", "metadata": {"window": "Thanks very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases. ", "original_text": "Let me start and take the first one off the table and then turn it over to Brian. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5afc972864d61f135bc094ca1123e43a389c1b2593851048924602c2b34c2139", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d736201-e4d0-415c-b3b6-6a92d8626c38", "node_type": "1", "metadata": {"window": "A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And we've given you a guide \nof 161 millio n to 163 million. "}, "hash": "5098268653ddb2aee7ee683e9faf326c539b59ead1f50d0eb88f5a9755159da6", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares. ", "start_char_idx": 2661, "end_char_idx": 2771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d736201-e4d0-415c-b3b6-6a92d8626c38": {"__data__": {"id_": "2d736201-e4d0-415c-b3b6-6a92d8626c38", "embedding": null, "metadata": {"window": "A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And we've given you a guide \nof 161 millio n to 163 million. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0f4f223-fcfa-4131-b5df-b5ea72b88651", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n ", "original_text": "As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8af6a1fc1aad50909c972862b331724514136513fdbedc4174234c574448a38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ef1749f-c68c-456e-b898-e437fdc3e37b", "node_type": "1", "metadata": {"window": "Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes. ", "original_text": "Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases. "}, "hash": "2e144590d258f2ede1c58fed27c996b7e39fd602283316e5b16c39d8157379d4", "class_name": "RelatedNodeInfo"}}, "text": "And we've given you a guide \nof 161 millio n to 163 million. ", "start_char_idx": 2771, "end_char_idx": 2832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ef1749f-c68c-456e-b898-e437fdc3e37b": {"__data__": {"id_": "6ef1749f-c68c-456e-b898-e437fdc3e37b", "embedding": null, "metadata": {"window": "Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes. ", "original_text": "Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d736201-e4d0-415c-b3b6-6a92d8626c38", "node_type": "1", "metadata": {"window": "A \nThanks, Eric.  Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And we've given you a guide \nof 161 millio n to 163 million. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0a884b9f0b58df997d156e4815bfed77f386a2ff6233b4c66b1f702cd875f4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfd28e99-529b-4695-bcff-e4de21215b1d", "node_type": "1", "metadata": {"window": "As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Let me maybe take up the US oncology question. ", "original_text": "And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n "}, "hash": "2f52927e773c92c3eb42213501378b9509246c8affe81628701e1ae6bf208761", "class_name": "RelatedNodeInfo"}}, "text": "Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases. ", "start_char_idx": 2832, "end_char_idx": 3117, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfd28e99-529b-4695-bcff-e4de21215b1d": {"__data__": {"id_": "dfd28e99-529b-4695-bcff-e4de21215b1d", "embedding": null, "metadata": {"window": "As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Let me maybe take up the US oncology question. ", "original_text": "And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ef1749f-c68c-456e-b898-e437fdc3e37b", "node_type": "1", "metadata": {"window": "Let me start and take the first one off the table and then turn it over to Brian.  As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes. ", "original_text": "Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73627cf63783f45a0490ddf1d469bc3eaf4d011cd4046629efae99ecc56f6756", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c6698b3-1895-40d5-b0be-652b95f9b61b", "node_type": "1", "metadata": {"window": "And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "d27d830efa5362639c4c0c561e1ee9c29af09455c1648151da95fecb8c9a9623", "class_name": "RelatedNodeInfo"}}, "text": "And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n ", "start_char_idx": 3117, "end_char_idx": 3251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c6698b3-1895-40d5-b0be-652b95f9b61b": {"__data__": {"id_": "2c6698b3-1895-40d5-b0be-652b95f9b61b", "embedding": null, "metadata": {"window": "And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfd28e99-529b-4695-bcff-e4de21215b1d", "node_type": "1", "metadata": {"window": "As I mentioned, in the \nfourth quarter through the exit of Change Healthcare, we retired 15.4 million shares.  And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Let me maybe take up the US oncology question. ", "original_text": "And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ac147c524cbf307efa744dc32203d4cd5d46ee6fd6d32a9c14c9075c8afed45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2ff70c8-14ab-4e4c-8995-dd53f995bbe3", "node_type": "1", "metadata": {"window": "Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n", "original_text": "A \nYes. "}, "hash": "599236256a2b818fda3337ef30eb1108610887f4f92af51fad393de36cfc3324", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3251, "end_char_idx": 3592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2ff70c8-14ab-4e4c-8995-dd53f995bbe3": {"__data__": {"id_": "b2ff70c8-14ab-4e4c-8995-dd53f995bbe3", "embedding": null, "metadata": {"window": "Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n", "original_text": "A \nYes. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c6698b3-1895-40d5-b0be-652b95f9b61b", "node_type": "1", "metadata": {"window": "And we've given you a guide \nof 161 millio n to 163 million.  Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59c1160925c4906bb69998a644b7bcba8a023e74e2d11eae8b157cfd784875f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aff7ef72-5a4e-485f-ab78-35cd71276ab0", "node_type": "1", "metadata": {"window": "And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much. ", "original_text": "Let me maybe take up the US oncology question. "}, "hash": "7b8219826736583a2281b998fb8ff14bf973e95c102b73951b33b2454239a3c4", "class_name": "RelatedNodeInfo"}}, "text": "A \nYes. ", "start_char_idx": 3592, "end_char_idx": 3600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aff7ef72-5a4e-485f-ab78-35cd71276ab0": {"__data__": {"id_": "aff7ef72-5a4e-485f-ab78-35cd71276ab0", "embedding": null, "metadata": {"window": "And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much. ", "original_text": "Let me maybe take up the US oncology question. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2ff70c8-14ab-4e4c-8995-dd53f995bbe3", "node_type": "1", "metadata": {"window": "Our capital deployment program will include broad -based balanced approaches we \nalways have, and that will include M&A as it presents itself on strategy and with good returns, but it also include \ncontinue to return capital to our sharehold ers which could include share repurchases.  And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n", "original_text": "A \nYes. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ad9b0d2a197623b80891d39cc94ae3c41276219374f15fb7bb970277176a4ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e87bc492-8c38-4be3-8985-ecef045adc83", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay. ", "original_text": "So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers. "}, "hash": "2a2ae4f58e8776914fb2fb53ce5a00dffe16832dee1b4b50f3031eada58d2821", "class_name": "RelatedNodeInfo"}}, "text": "Let me maybe take up the US oncology question. ", "start_char_idx": 3600, "end_char_idx": 3647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e87bc492-8c38-4be3-8985-ecef045adc83": {"__data__": {"id_": "e87bc492-8c38-4be3-8985-ecef045adc83", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay. ", "original_text": "So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aff7ef72-5a4e-485f-ab78-35cd71276ab0", "node_type": "1", "metadata": {"window": "And we do have $1.5 billion \nremaining on the authorization, and we'll continue to use that to return capital as it's appropriate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much. ", "original_text": "Let me maybe take up the US oncology question. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "439f2d6c7b4edb25273990ac0489a7b8813e1107e64fe8d1344cf561e4154661", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5821e655-1a69-4c49-b6c3-569123350724", "node_type": "1", "metadata": {"window": "A \nYes.  Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n", "original_text": "The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n"}, "hash": "698e6f6eed0f80c65e34006e76c781ce33815dc71c3387cc51f21499364e23d2", "class_name": "RelatedNodeInfo"}}, "text": "So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers. ", "start_char_idx": 3647, "end_char_idx": 3785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5821e655-1a69-4c49-b6c3-569123350724": {"__data__": {"id_": "5821e655-1a69-4c49-b6c3-569123350724", "embedding": null, "metadata": {"window": "A \nYes.  Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n", "original_text": "The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e87bc492-8c38-4be3-8985-ecef045adc83", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay. ", "original_text": "So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a589acf9faa268e24851b8f6748219a684323dd14bb23fb96b29638bf2b8adc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87f29cbb-ca92-43d9-b8ed-6e868195e0b4", "node_type": "1", "metadata": {"window": "Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months. ", "original_text": "I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much. "}, "hash": "e5125c06f8d1fb2f490de2993d4d35bdb2975816fed9090280b46ccca0da3f42", "class_name": "RelatedNodeInfo"}}, "text": "The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n", "start_char_idx": 3785, "end_char_idx": 4007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87f29cbb-ca92-43d9-b8ed-6e868195e0b4": {"__data__": {"id_": "87f29cbb-ca92-43d9-b8ed-6e868195e0b4", "embedding": null, "metadata": {"window": "Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months. ", "original_text": "I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5821e655-1a69-4c49-b6c3-569123350724", "node_type": "1", "metadata": {"window": "A \nYes.  Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n", "original_text": "The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "235a8be241633ea0ea7b7e681e6ce347a4482d246829dcfaa85ff82fde67878c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d586f839-6d88-456b-8f90-e475d576882e", "node_type": "1", "metadata": {"window": "So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected. ", "original_text": "In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay. "}, "hash": "f4e6fd20b8cf76af106856bdc6869a5c49843ac9986c780caa989d015e0cd6a4", "class_name": "RelatedNodeInfo"}}, "text": "I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much. ", "start_char_idx": 4007, "end_char_idx": 4111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d586f839-6d88-456b-8f90-e475d576882e": {"__data__": {"id_": "d586f839-6d88-456b-8f90-e475d576882e", "embedding": null, "metadata": {"window": "So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected. ", "original_text": "In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87f29cbb-ca92-43d9-b8ed-6e868195e0b4", "node_type": "1", "metadata": {"window": "Let me maybe take up the US oncology question.  So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months. ", "original_text": "I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87e54252c145f137b240836187eceb65134bd9d62f6e5f6dffd6e71ed2ebedb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b90322a8-08e1-4a42-891d-8007a8e4f638", "node_type": "1", "metadata": {"window": "The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected.  But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n ", "original_text": "So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n"}, "hash": "c7c9c6151af3058e033ae2a4370c908101fe5797ff37861278beecbe79903d34", "class_name": "RelatedNodeInfo"}}, "text": "In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay. ", "start_char_idx": 4111, "end_char_idx": 4282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b90322a8-08e1-4a42-891d-8007a8e4f638": {"__data__": {"id_": "b90322a8-08e1-4a42-891d-8007a8e4f638", "embedding": null, "metadata": {"window": "The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected.  But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n ", "original_text": "So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d586f839-6d88-456b-8f90-e475d576882e", "node_type": "1", "metadata": {"window": "So we worked very closely with our partners in the \npractices to respond to this unprecedented time and it's impacted all care providers.  The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected. ", "original_text": "In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e421cc9e1b588cc4d93811c763f5a40188a6735750e1b3563b2f85af47e6150", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14e768ac-d2ac-4bbd-9125-4d29d1cbf325", "node_type": "1", "metadata": {"window": "I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected.  But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months. "}, "hash": "9c8cacf337891e641b1000c12d9e47b9cd67de7e0af326bccb9be9a37db2e37d", "class_name": "RelatedNodeInfo"}}, "text": "So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n", "start_char_idx": 4282, "end_char_idx": 4418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14e768ac-d2ac-4bbd-9125-4d29d1cbf325": {"__data__": {"id_": "14e768ac-d2ac-4bbd-9125-4d29d1cbf325", "embedding": null, "metadata": {"window": "I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected.  But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b90322a8-08e1-4a42-891d-8007a8e4f638", "node_type": "1", "metadata": {"window": "The US oncology patient \nvisits have certainly declined as social distancing gui delines were implemented, and that impact is really varied \ndepending on what kind of oncology, what kind of cancer you're experiencing.  \n \n I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected.  But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n ", "original_text": "So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9226c54c718ab28faec25cb5243c3749e72d2508517b35ffab9a0afefc07aeeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bdeafe5-a558-4974-bff1-692c238f10ce", "node_type": "1", "metadata": {"window": "In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected.  But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected. "}, "hash": "dfdb280b6ddca634ef79af58ef1a75c1dfca81310a24c7b0ec76bb5028b32a79", "class_name": "RelatedNodeInfo"}}, "text": "We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months. ", "start_char_idx": 4418, "end_char_idx": 4586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bdeafe5-a558-4974-bff1-692c238f10ce": {"__data__": {"id_": "3bdeafe5-a558-4974-bff1-692c238f10ce", "embedding": null, "metadata": {"window": "In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected.  But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14e768ac-d2ac-4bbd-9125-4d29d1cbf325", "node_type": "1", "metadata": {"window": "I mean, you see in the very fast -moving aggressive cancers, patient volume has not fallen off so much.  In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected.  But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cb48963af4ab59a853f31e4779eba609e03c063a09e26fd5dd40f1bc7ce8a83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d80a3b49-6546-4de7-beaa-69408a48de34", "node_type": "1", "metadata": {"window": "So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected.  But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n "}, "hash": "e52c4cb228b6986c59a894d2954f0edf38fbdcb9745c6a0223be1d55edd93f89", "class_name": "RelatedNodeInfo"}}, "text": "So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected. ", "start_char_idx": 4586, "end_char_idx": 4801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d80a3b49-6546-4de7-beaa-69408a48de34": {"__data__": {"id_": "d80a3b49-6546-4de7-beaa-69408a48de34", "embedding": null, "metadata": {"window": "So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected.  But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bdeafe5-a558-4974-bff1-692c238f10ce", "node_type": "1", "metadata": {"window": "In some of \nthe s olid tumor cancers where progression is slower, people are more hesitant to go in and get testing, get \ndiagnosis, may feel they had some time to delay.  So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected.  But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected. ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "801c49c1117adc15df6330b99d1d57a0b481ee5d789790e4f77c0861269d05d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65926d6e-e8c7-449a-95f3-fca012f67efe", "node_type": "1", "metadata": {"window": "We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected.  But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "10187ef791a8c394ac791056c1176db49a9135fb43b3b8f7e8c9db9dd87bba92", "class_name": "RelatedNodeInfo"}}, "text": "But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n ", "start_char_idx": 4801, "end_char_idx": 4968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65926d6e-e8c7-449a-95f3-fca012f67efe": {"__data__": {"id_": "65926d6e-e8c7-449a-95f3-fca012f67efe", "embedding": null, "metadata": {"window": "We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected.  But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "92c62c48-d292-4190-87e0-026a2232d32c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63bff1e5ffa16574b801d12bcf744370e148446ea25e48bcb5de48093eea0032", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d80a3b49-6546-4de7-beaa-69408a48de34", "node_type": "1", "metadata": {"window": "So we have seen a bit of visit decline, but the revenue decline \nhas been less than the visit decline, wh ich is encouraging to us.  \n \n We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected.  But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21d186cd5d117af0bc44e66e00dc919c6b2abfec741c231aff591ec0cc17091e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "610dad96-61cf-4603-9698-e0a9e12b7efc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful. ", "original_text": "McKesson Corp.  "}, "hash": "e3f457297f87167c7cac8e6697bc61e9f4af850e727351a543d53f0ecccde2ce", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 502, "end_char_idx": 773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "610dad96-61cf-4603-9698-e0a9e12b7efc": {"__data__": {"id_": "610dad96-61cf-4603-9698-e0a9e12b7efc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65926d6e-e8c7-449a-95f3-fca012f67efe", "node_type": "1", "metadata": {"window": "We've also taken actions to implement things like telepresence or virtual consultation services, and we've ramped \nup that pretty significantly in the last few months.  So, overall, I think, I'd say, we feel good about our position ing, \noncology of all the ologies or specialties has probably been a little more insulated as you think about diseases \nthat's probably not unexpected.  But we continue to work closely with our practices to think about all the ways we \ncan help feel \u2013 make pat ients feel more comfortable to returning to their care.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c536ae3979ca2d8029f8034eec0b36d1d35c59670ad2b4be855d2d968721a5bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3571846f-ffc3-49e7-95b3-9de314528912", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n "}, "hash": "b0d2ba2ac4de50e33c94be5c31b3e277a6e4100bf6559a385d0e25984fb62aa8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3571846f-ffc3-49e7-95b3-9de314528912": {"__data__": {"id_": "3571846f-ffc3-49e7-95b3-9de314528912", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "610dad96-61cf-4603-9698-e0a9e12b7efc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39fcc60fb6f1349274db2db7c0070af7446afed604a49474c9bf9ba27b6890a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ac13c6f-1aa2-43cf-9928-39f1060129e5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts. "}, "hash": "a64c568929f628a9790c4576edc75b26580539e2c1363525819176f0ff46370f", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n ", "start_char_idx": 16, "end_char_idx": 279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ac13c6f-1aa2-43cf-9928-39f1060129e5": {"__data__": {"id_": "3ac13c6f-1aa2-43cf-9928-39f1060129e5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3571846f-ffc3-49e7-95b3-9de314528912", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67beb659c81302a8ba0b8f71dcf066302c64b3aee5c1a8d6782ce8e00a31f2ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cffc15b8-435e-4af7-b781-7c7043d5937a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there. ", "original_text": "A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful. "}, "hash": "3a0eee7bd35cc6d95e8919aa1f98757e1c3bb675cb6715de65bebe48d7bfb5c8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts. ", "start_char_idx": 279, "end_char_idx": 648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cffc15b8-435e-4af7-b781-7c7043d5937a": {"__data__": {"id_": "cffc15b8-435e-4af7-b781-7c7043d5937a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there. ", "original_text": "A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ac13c6f-1aa2-43cf-9928-39f1060129e5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d1ddce67d65a2d3c57fc2d5eb31030b4d7ccc96b368518c25856255823a7cd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65a7fb24-46e2-4130-804f-923f005aba4a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements? ", "original_text": "I imagine there's some very different dynamics in the ASC versus the physician office. "}, "hash": "cb14895ab126d7d4d6e85f2cc35d7a1a5fb95d2fb4237ab7dadc3a29ebcaa753", "class_name": "RelatedNodeInfo"}}, "text": "A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful. ", "start_char_idx": 648, "end_char_idx": 735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65a7fb24-46e2-4130-804f-923f005aba4a": {"__data__": {"id_": "65a7fb24-46e2-4130-804f-923f005aba4a", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements? ", "original_text": "I imagine there's some very different dynamics in the ASC versus the physician office. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cffc15b8-435e-4af7-b781-7c7043d5937a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there. ", "original_text": "A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5aac473b834a06d9d6a9749fb6f5042e665abbde28020c7aa52ae73ffeb8a6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6648bad6-d685-4807-9eab-51b7038b12ec", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)? ", "original_text": "Could \nyou help us with an understanding of what your distribution business here focuses on? "}, "hash": "e6fc675930d6dd62438ba82a77985e49982c60171c9ac169904569cde5cddc53", "class_name": "RelatedNodeInfo"}}, "text": "I imagine there's some very different dynamics in the ASC versus the physician office. ", "start_char_idx": 735, "end_char_idx": 822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6648bad6-d685-4807-9eab-51b7038b12ec": {"__data__": {"id_": "6648bad6-d685-4807-9eab-51b7038b12ec", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)? ", "original_text": "Could \nyou help us with an understanding of what your distribution business here focuses on? ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65a7fb24-46e2-4130-804f-923f005aba4a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements? ", "original_text": "I imagine there's some very different dynamics in the ASC versus the physician office. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e8fad4d6b3345c78d266170da0476ee39b19c0899929542b840529fd406d660", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf4b7305-cbdf-470b-8264-755b0903c4e7", "node_type": "1", "metadata": {"window": "A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n", "original_text": "I 'm thinking less on PP&E \nand potential benefits there. "}, "hash": "3065ed941f6c5fa967e4d9cd48776241e585d5f74c687666f1fdd891bfb71617", "class_name": "RelatedNodeInfo"}}, "text": "Could \nyou help us with an understanding of what your distribution business here focuses on? ", "start_char_idx": 822, "end_char_idx": 915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf4b7305-cbdf-470b-8264-755b0903c4e7": {"__data__": {"id_": "cf4b7305-cbdf-470b-8264-755b0903c4e7", "embedding": null, "metadata": {"window": "A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n", "original_text": "I 'm thinking less on PP&E \nand potential benefits there. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6648bad6-d685-4807-9eab-51b7038b12ec", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)? ", "original_text": "Could \nyou help us with an understanding of what your distribution business here focuses on? ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "badf255d0b62dc701b5c91daa4d4a902f4e904a6cf8da0ba69a82a35ca0151a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6367a389-b7dc-4223-8668-2a2815d2058a", "node_type": "1", "metadata": {"window": "I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n And how might you participate in vaccines in the future?  \n ", "original_text": "Are there significant pharmaceutical elements? "}, "hash": "cfd5ae9a5ff4996ea9fbc129098d97bc3b843a991ebd7d311c9e89348303dd94", "class_name": "RelatedNodeInfo"}}, "text": "I 'm thinking less on PP&E \nand potential benefits there. ", "start_char_idx": 915, "end_char_idx": 973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6367a389-b7dc-4223-8668-2a2815d2058a": {"__data__": {"id_": "6367a389-b7dc-4223-8668-2a2815d2058a", "embedding": null, "metadata": {"window": "I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n And how might you participate in vaccines in the future?  \n ", "original_text": "Are there significant pharmaceutical elements? ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf4b7305-cbdf-470b-8264-755b0903c4e7", "node_type": "1", "metadata": {"window": "A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful.  I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n", "original_text": "I 'm thinking less on PP&E \nand potential benefits there. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f47affd40e48250fa4b36ecd703cc762efe7ff8f14a500da2403d6b6f027011f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1c58d75-9730-4f88-9a63-6526a1a24e3c", "node_type": "1", "metadata": {"window": "Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)? "}, "hash": "0b093643b2712363caa8df238e26667285782a742d025a10515d290e68504178", "class_name": "RelatedNodeInfo"}}, "text": "Are there significant pharmaceutical elements? ", "start_char_idx": 973, "end_char_idx": 1020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1c58d75-9730-4f88-9a63-6526a1a24e3c": {"__data__": {"id_": "f1c58d75-9730-4f88-9a63-6526a1a24e3c", "embedding": null, "metadata": {"window": "Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)? ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6367a389-b7dc-4223-8668-2a2815d2058a", "node_type": "1", "metadata": {"window": "I imagine there's some very different dynamics in the ASC versus the physician office.  Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n And how might you participate in vaccines in the future?  \n ", "original_text": "Are there significant pharmaceutical elements? ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "313e769d6a59cee9e36086a14a8b9344bfc7f4328dd66e2bfa886021b7bc72c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4aa4417-cac3-41af-9615-659dd98e8eb7", "node_type": "1", "metadata": {"window": "I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat. ", "original_text": "How is that running? \n"}, "hash": "504020ff74194cbdb4b66f5948ae29ae03b793239bdcef65773962e923b955d0", "class_name": "RelatedNodeInfo"}}, "text": "Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)? ", "start_char_idx": 1020, "end_char_idx": 1254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4aa4417-cac3-41af-9615-659dd98e8eb7": {"__data__": {"id_": "d4aa4417-cac3-41af-9615-659dd98e8eb7", "embedding": null, "metadata": {"window": "I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat. ", "original_text": "How is that running? \n", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1c58d75-9730-4f88-9a63-6526a1a24e3c", "node_type": "1", "metadata": {"window": "Could \nyou help us with an understanding of what your distribution business here focuses on?  I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)? ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4612a156e8ebf11cfc1da0c4cec3137653e599db4b8a6dec5787ebc3f1c2961", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "831a7db9-5d8c-4e24-8f51-d4d92562844b", "node_type": "1", "metadata": {"window": "Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  Thanks, Eric. ", "original_text": "And how might you participate in vaccines in the future?  \n "}, "hash": "3a3b2309f1f1247852094292149bb9e5e854d33f4f78432f2b30db735452859b", "class_name": "RelatedNodeInfo"}}, "text": "How is that running? \n", "start_char_idx": 1254, "end_char_idx": 1276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "831a7db9-5d8c-4e24-8f51-d4d92562844b": {"__data__": {"id_": "831a7db9-5d8c-4e24-8f51-d4d92562844b", "embedding": null, "metadata": {"window": "Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  Thanks, Eric. ", "original_text": "And how might you participate in vaccines in the future?  \n ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4aa4417-cac3-41af-9615-659dd98e8eb7", "node_type": "1", "metadata": {"window": "I 'm thinking less on PP&E \nand potential benefits there.  Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat. ", "original_text": "How is that running? \n", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "942212a705667fa0bd35e13527756cceacab1b6336ece2c2d50e26b5ed02913b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b8f3b23-bfde-40a1-9f8a-f94e49c2383f", "node_type": "1", "metadata": {"window": "Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  Thanks, Eric.  Appreciate that question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "5f2d4af7cef52367723d3f1bde2d0662382f3af27ffc22701802308058755589", "class_name": "RelatedNodeInfo"}}, "text": "And how might you participate in vaccines in the future?  \n ", "start_char_idx": 1276, "end_char_idx": 1336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b8f3b23-bfde-40a1-9f8a-f94e49c2383f": {"__data__": {"id_": "3b8f3b23-bfde-40a1-9f8a-f94e49c2383f", "embedding": null, "metadata": {"window": "Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  Thanks, Eric.  Appreciate that question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "831a7db9-5d8c-4e24-8f51-d4d92562844b", "node_type": "1", "metadata": {"window": "Are there significant pharmaceutical elements?  Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  Thanks, Eric. ", "original_text": "And how might you participate in vaccines in the future?  \n ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd2d6a4a84fa0b59397353b5656027938b3bd6535e963e67be51dfca57c8263a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28285f8c-92bd-44da-90f5-dfcf0bcb8a28", "node_type": "1", "metadata": {"window": "How is that running? \n And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  Thanks, Eric.  Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there. ", "original_text": "A \nGreat. "}, "hash": "3ecf0f5385bc6df87a6a685d3b2d1755e73a4092b65495f6e87e2cfec40906fa", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1336, "end_char_idx": 1677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28285f8c-92bd-44da-90f5-dfcf0bcb8a28": {"__data__": {"id_": "28285f8c-92bd-44da-90f5-dfcf0bcb8a28", "embedding": null, "metadata": {"window": "How is that running? \n And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  Thanks, Eric.  Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there. ", "original_text": "A \nGreat. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b8f3b23-bfde-40a1-9f8a-f94e49c2383f", "node_type": "1", "metadata": {"window": "Is there a number that you can \nprovide us relative to the pharmaceutical component of medical and any expectation for vaccines or experience \nwith the Vacc ines for Childrens Program (sic) [Vaccines for Children Program] (00:53:41)?  How is that running? \n And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  Thanks, Eric.  Appreciate that question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29942cc8638f1310cc283c67f9f92da5e54d7fbb6e790b655e8db1adb0da301e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "582f6482-9d36-40ba-bc11-ce76bdfb5a4b", "node_type": "1", "metadata": {"window": "And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  Thanks, Eric.  Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products. ", "original_text": "Thanks, Eric. "}, "hash": "1d0d753eadbf2e244c9c8ae9aa6af1d6552a3304e6f681e79bdf5ba128bdb314", "class_name": "RelatedNodeInfo"}}, "text": "A \nGreat. ", "start_char_idx": 1677, "end_char_idx": 1687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "582f6482-9d36-40ba-bc11-ce76bdfb5a4b": {"__data__": {"id_": "582f6482-9d36-40ba-bc11-ce76bdfb5a4b", "embedding": null, "metadata": {"window": "And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  Thanks, Eric.  Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products. ", "original_text": "Thanks, Eric. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28285f8c-92bd-44da-90f5-dfcf0bcb8a28", "node_type": "1", "metadata": {"window": "How is that running? \n And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  Thanks, Eric.  Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there. ", "original_text": "A \nGreat. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f55d38a3b0097b2c2b56bd29599453da23208357b4217ba8c7bf603620996e45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22773ebd-6561-481f-b4f8-5a20ae230cdb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  Thanks, Eric.  Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded. ", "original_text": "Appreciate that question. "}, "hash": "f049fc0f21c1c79800e8ce4fe67200ccfd35cbf5b1c98aa48f86b9bfb6bfd20c", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Eric. ", "start_char_idx": 1687, "end_char_idx": 1701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22773ebd-6561-481f-b4f8-5a20ae230cdb": {"__data__": {"id_": "22773ebd-6561-481f-b4f8-5a20ae230cdb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  Thanks, Eric.  Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded. ", "original_text": "Appreciate that question. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "582f6482-9d36-40ba-bc11-ce76bdfb5a4b", "node_type": "1", "metadata": {"window": "And how might you participate in vaccines in the future?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  Thanks, Eric.  Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products. ", "original_text": "Thanks, Eric. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95d1691a74cc042f56fb4c20ba658f75d1cd504f16cad9f03759db7c442deb4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa413a45-5990-4aeb-9e6b-225696c5262e", "node_type": "1", "metadata": {"window": "A \nGreat.  Thanks, Eric.  Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n", "original_text": "Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there. "}, "hash": "36e74b0072059cfb54b6ba72f3f51086e82aac7dec93e5da1b4188d733765cf4", "class_name": "RelatedNodeInfo"}}, "text": "Appreciate that question. ", "start_char_idx": 1701, "end_char_idx": 1727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa413a45-5990-4aeb-9e6b-225696c5262e": {"__data__": {"id_": "fa413a45-5990-4aeb-9e6b-225696c5262e", "embedding": null, "metadata": {"window": "A \nGreat.  Thanks, Eric.  Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n", "original_text": "Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22773ebd-6561-481f-b4f8-5a20ae230cdb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat.  Thanks, Eric.  Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded. ", "original_text": "Appreciate that question. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99bd92db2d682d148388af5b7326b8c8c09554d882adf708ee6ca48c82f40a4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0284d63f-f408-4abf-b224-4b26cc183608", "node_type": "1", "metadata": {"window": "Thanks, Eric.  Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices. ", "original_text": "And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products. "}, "hash": "53eb4505f6fc72373a93cc1cb798759c6cc1be905500945bd446dcdd2c0dd558", "class_name": "RelatedNodeInfo"}}, "text": "Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there. ", "start_char_idx": 1727, "end_char_idx": 1857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0284d63f-f408-4abf-b224-4b26cc183608": {"__data__": {"id_": "0284d63f-f408-4abf-b224-4b26cc183608", "embedding": null, "metadata": {"window": "Thanks, Eric.  Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices. ", "original_text": "And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa413a45-5990-4aeb-9e6b-225696c5262e", "node_type": "1", "metadata": {"window": "A \nGreat.  Thanks, Eric.  Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n", "original_text": "Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "930a28eefdf2cddd9af0532916f6d6a249eb8e8aeb8d2f05baec73ecc453e119", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb858e80-24e9-4ae2-9f2c-1bde9b6ba979", "node_type": "1", "metadata": {"window": "Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly. ", "original_text": "And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded. "}, "hash": "cdd1cce881e6c33d63b09da089700f3a58eb1b36c5a20d69c8e2de3eac301cfd", "class_name": "RelatedNodeInfo"}}, "text": "And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products. ", "start_char_idx": 1857, "end_char_idx": 2062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb858e80-24e9-4ae2-9f2c-1bde9b6ba979": {"__data__": {"id_": "bb858e80-24e9-4ae2-9f2c-1bde9b6ba979", "embedding": null, "metadata": {"window": "Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly. ", "original_text": "And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0284d63f-f408-4abf-b224-4b26cc183608", "node_type": "1", "metadata": {"window": "Thanks, Eric.  Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices. ", "original_text": "And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40871cd76ca999c2f692bc7cabea06a28ea8d404a35b54e376654ce74f19c7e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3081133a-e798-44f3-b915-f785dc833c63", "node_type": "1", "metadata": {"window": "Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents. ", "original_text": "And as you're well aware, we have a very broad \noffering to these practices.  \n \n"}, "hash": "a10cb03624910d5317e2d7cbc5add1fa2f2cc58266b52ba0b46dba36644084f0", "class_name": "RelatedNodeInfo"}}, "text": "And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded. ", "start_char_idx": 2062, "end_char_idx": 2190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3081133a-e798-44f3-b915-f785dc833c63": {"__data__": {"id_": "3081133a-e798-44f3-b915-f785dc833c63", "embedding": null, "metadata": {"window": "Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents. ", "original_text": "And as you're well aware, we have a very broad \noffering to these practices.  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb858e80-24e9-4ae2-9f2c-1bde9b6ba979", "node_type": "1", "metadata": {"window": "Appreciate that question.  Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly. ", "original_text": "And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "469b1f49ad65bd54c2a041a79c51adfbfdba693e29f67a76e050d6fd81629110", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16bb211f-e884-46ed-a35f-cbebdbdc9b3c", "node_type": "1", "metadata": {"window": "And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n", "original_text": "It is PP&E, which it tends to be a pretty small, historically a very small part of these practices. "}, "hash": "b08213e2c1e31df06d0d74a42a54db4cc0da9aa19e7e47df3cde4317b02d770b", "class_name": "RelatedNodeInfo"}}, "text": "And as you're well aware, we have a very broad \noffering to these practices.  \n \n", "start_char_idx": 2190, "end_char_idx": 2271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16bb211f-e884-46ed-a35f-cbebdbdc9b3c": {"__data__": {"id_": "16bb211f-e884-46ed-a35f-cbebdbdc9b3c", "embedding": null, "metadata": {"window": "And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n", "original_text": "It is PP&E, which it tends to be a pretty small, historically a very small part of these practices. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3081133a-e798-44f3-b915-f785dc833c63", "node_type": "1", "metadata": {"window": "Our medical business does have a significant footprint in primary \ncare, which we include the ambulatory surgery center in there.  And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents. ", "original_text": "And as you're well aware, we have a very broad \noffering to these practices.  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c4673c3d0ffc5352fad836382dfd0835fe8f0afffedbe16d23bcfa81cff7390", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3bfb2f2-547c-45dc-bcdd-3dc37241e05b", "node_type": "1", "metadata": {"window": "And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted. ", "original_text": "Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly. "}, "hash": "d071607d3c7fbd2bad25f174e1286f7fae888a710ff5c12e7a1192e2590f75ca", "class_name": "RelatedNodeInfo"}}, "text": "It is PP&E, which it tends to be a pretty small, historically a very small part of these practices. ", "start_char_idx": 2271, "end_char_idx": 2371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3bfb2f2-547c-45dc-bcdd-3dc37241e05b": {"__data__": {"id_": "a3bfb2f2-547c-45dc-bcdd-3dc37241e05b", "embedding": null, "metadata": {"window": "And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted. ", "original_text": "Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16bb211f-e884-46ed-a35f-cbebdbdc9b3c", "node_type": "1", "metadata": {"window": "And within the kinds of practices, we serve \nbasically all different kinds of practices from general p ractitioners, OB/GYN, even up to special \u2013 more specialty -\noriented practices with medical products.  And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n", "original_text": "It is PP&E, which it tends to be a pretty small, historically a very small part of these practices. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2757e3aead98ae1c2b223d5278b25e12f94ed7653d0087d0d8ebb6c9d2863fc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "003b3241-53f2-446a-98aa-f34f5457a837", "node_type": "1", "metadata": {"window": "And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year. ", "original_text": "But we're also in specialty Rx, Rx, lab, equipment, reagents. "}, "hash": "0a6c89f59601f035616fb74dc0be52ec88d90460fb20e5f5f255a99f81855eb2", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly. ", "start_char_idx": 2371, "end_char_idx": 2508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "003b3241-53f2-446a-98aa-f34f5457a837": {"__data__": {"id_": "003b3241-53f2-446a-98aa-f34f5457a837", "embedding": null, "metadata": {"window": "And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year. ", "original_text": "But we're also in specialty Rx, Rx, lab, equipment, reagents. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3bfb2f2-547c-45dc-bcdd-3dc37241e05b", "node_type": "1", "metadata": {"window": "And so there's been a pretty wide variation in the way specific \nspecialties or focuses of those practice would have responded.  And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted. ", "original_text": "Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac6370bff90936365fd521ed660473ea7c0684861149218288f19989ea105a9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ee09084-09f1-4f24-bce8-7c23811c8943", "node_type": "1", "metadata": {"window": "It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early. ", "original_text": "I mean, we've a very, very broad \nbusiness.  \n \n"}, "hash": "9d34b221018c55e029c0f742724df0c526827c4b3f7193fc7898057928865d86", "class_name": "RelatedNodeInfo"}}, "text": "But we're also in specialty Rx, Rx, lab, equipment, reagents. ", "start_char_idx": 2508, "end_char_idx": 2570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ee09084-09f1-4f24-bce8-7c23811c8943": {"__data__": {"id_": "1ee09084-09f1-4f24-bce8-7c23811c8943", "embedding": null, "metadata": {"window": "It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early. ", "original_text": "I mean, we've a very, very broad \nbusiness.  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "003b3241-53f2-446a-98aa-f34f5457a837", "node_type": "1", "metadata": {"window": "And as you're well aware, we have a very broad \noffering to these practices.  \n \n It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year. ", "original_text": "But we're also in specialty Rx, Rx, lab, equipment, reagents. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c72d3b73569999c4a1bebb4fb89a2e2adcec03a08fe94756b1f90a0589f94c33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b915f4b6-2ea9-489a-94c4-912fba0b188b", "node_type": "1", "metadata": {"window": "Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market. ", "original_text": "And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted. "}, "hash": "347dfd11755123cb6e2d9e5b31adffb9b6a6a26c0833c72db6163b9e9632bce3", "class_name": "RelatedNodeInfo"}}, "text": "I mean, we've a very, very broad \nbusiness.  \n \n", "start_char_idx": 2570, "end_char_idx": 2618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b915f4b6-2ea9-489a-94c4-912fba0b188b": {"__data__": {"id_": "b915f4b6-2ea9-489a-94c4-912fba0b188b", "embedding": null, "metadata": {"window": "Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market. ", "original_text": "And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ee09084-09f1-4f24-bce8-7c23811c8943", "node_type": "1", "metadata": {"window": "It is PP&E, which it tends to be a pretty small, historically a very small part of these practices.  Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early. ", "original_text": "I mean, we've a very, very broad \nbusiness.  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d994cbe7d375271703d1f7fba9ea66a3d7081fd7a7efdbd6f0922126030f81a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d132cf31-1c1f-4ccd-9b05-f2a1c91b5037", "node_type": "1", "metadata": {"window": "But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today. ", "original_text": "And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year. "}, "hash": "7e791b7e5fb90bc620d827b724d703631060d12694bd7e6e193f1bf7d51eeb2c", "class_name": "RelatedNodeInfo"}}, "text": "And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted. ", "start_char_idx": 2618, "end_char_idx": 2811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d132cf31-1c1f-4ccd-9b05-f2a1c91b5037": {"__data__": {"id_": "d132cf31-1c1f-4ccd-9b05-f2a1c91b5037", "embedding": null, "metadata": {"window": "But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today. ", "original_text": "And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b915f4b6-2ea9-489a-94c4-912fba0b188b", "node_type": "1", "metadata": {"window": "Obviously, in the \nlast months, with social distancing and all the changes we've all experienced, the PP&E de mand is up \nsignificantly.  But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market. ", "original_text": "And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ad990630dfa71d86d052f4168ee330cb1c58813352e3c87102eee499a736f94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e0f8bba-bff0-4cf6-8db5-c1a04ee98e30", "node_type": "1", "metadata": {"window": "I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n", "original_text": "It's \u2013 \nobviously, from a vaccine perspective, it' s a little early. "}, "hash": "745b17de6c49a7b6807a5fcf2d181698c6eca674c43cdf0a491f8cb91c47b9f8", "class_name": "RelatedNodeInfo"}}, "text": "And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year. ", "start_char_idx": 2811, "end_char_idx": 2952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e0f8bba-bff0-4cf6-8db5-c1a04ee98e30": {"__data__": {"id_": "9e0f8bba-bff0-4cf6-8db5-c1a04ee98e30", "embedding": null, "metadata": {"window": "I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n", "original_text": "It's \u2013 \nobviously, from a vaccine perspective, it' s a little early. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d132cf31-1c1f-4ccd-9b05-f2a1c91b5037", "node_type": "1", "metadata": {"window": "But we're also in specialty Rx, Rx, lab, equipment, reagents.  I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today. ", "original_text": "And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e67745c96161aaa9d41abf8ab514f53acc80b54c4d80d9050d3a5a5d4073c5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d0d4c17-d2b1-42c0-afaf-eea3c9ad1b42", "node_type": "1", "metadata": {"window": "And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines. ", "original_text": "Vaccines are not on market. "}, "hash": "eac3a6a3ac522f6154274a1b4a178aeb7028cf48f96eea4f3885d22ec2ae71b1", "class_name": "RelatedNodeInfo"}}, "text": "It's \u2013 \nobviously, from a vaccine perspective, it' s a little early. ", "start_char_idx": 2952, "end_char_idx": 3021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d0d4c17-d2b1-42c0-afaf-eea3c9ad1b42": {"__data__": {"id_": "1d0d4c17-d2b1-42c0-afaf-eea3c9ad1b42", "embedding": null, "metadata": {"window": "And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines. ", "original_text": "Vaccines are not on market. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e0f8bba-bff0-4cf6-8db5-c1a04ee98e30", "node_type": "1", "metadata": {"window": "I mean, we've a very, very broad \nbusiness.  \n \n And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n", "original_text": "It's \u2013 \nobviously, from a vaccine perspective, it' s a little early. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d01d06ddc33d9fbc4e2d43b382c25aaac853350896592787e3d2ce84068f2d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fea055e6-8234-45b4-93bb-9be9153db4ad", "node_type": "1", "metadata": {"window": "And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine. ", "original_text": "But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today. "}, "hash": "236f35664bb653c26165e3f591cb2295b29b713f19a64325723432345e88e9cc", "class_name": "RelatedNodeInfo"}}, "text": "Vaccines are not on market. ", "start_char_idx": 3021, "end_char_idx": 3049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fea055e6-8234-45b4-93bb-9be9153db4ad": {"__data__": {"id_": "fea055e6-8234-45b4-93bb-9be9153db4ad", "embedding": null, "metadata": {"window": "And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine. ", "original_text": "But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d0d4c17-d2b1-42c0-afaf-eea3c9ad1b42", "node_type": "1", "metadata": {"window": "And what I would say to you is that, we see patient volumes decline, and as Britt reviewed the metrics that we've \nseen there , I mean, really all of those various elements have been impacted.  And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines. ", "original_text": "Vaccines are not on market. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91d8c324a2baae75991b6244c9e4e59fec803cd01ba6837ef61e892831f53152", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f16dcb49-8a9e-4e57-ad0d-89c2677f6d18", "node_type": "1", "metadata": {"window": "It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability. ", "original_text": "We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n"}, "hash": "c653f06da659e54c491f9cfc7989ccd3354a8cd856b77b10b0cbf827c62b8667", "class_name": "RelatedNodeInfo"}}, "text": "But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today. ", "start_char_idx": 3049, "end_char_idx": 3156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f16dcb49-8a9e-4e57-ad0d-89c2677f6d18": {"__data__": {"id_": "f16dcb49-8a9e-4e57-ad0d-89c2677f6d18", "embedding": null, "metadata": {"window": "It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability. ", "original_text": "We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fea055e6-8234-45b4-93bb-9be9153db4ad", "node_type": "1", "metadata": {"window": "And as patients begin to return to \nthe practices, we think we'll begin to see those volumes all rebuild over the course of the coming year.  It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine. ", "original_text": "But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c378cc108e2ada8b90de92c574cf159145fdd6c0b19f7a52d6d20dbd297da376", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19a7fa9f-c2b0-471c-a078-a0546fb0c9bd", "node_type": "1", "metadata": {"window": "Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast? ", "original_text": "We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines. "}, "hash": "6d3ffd705987ae89d9d3354c9ceb5d19e93b9eec34de087437fcd7d20021afac", "class_name": "RelatedNodeInfo"}}, "text": "We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n", "start_char_idx": 3156, "end_char_idx": 3246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19a7fa9f-c2b0-471c-a078-a0546fb0c9bd": {"__data__": {"id_": "19a7fa9f-c2b0-471c-a078-a0546fb0c9bd", "embedding": null, "metadata": {"window": "Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast? ", "original_text": "We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f16dcb49-8a9e-4e57-ad0d-89c2677f6d18", "node_type": "1", "metadata": {"window": "It's \u2013 \nobviously, from a vaccine perspective, it' s a little early.  Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability. ", "original_text": "We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cdd86eba0ee8f66ba5cc64cc8749be585323e03bac6521d623cc8d33c7d354d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18900f5a-e98c-4d65-ab4c-7ba413123f2f", "node_type": "1", "metadata": {"window": "But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n ", "original_text": "Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine. "}, "hash": "d576772a3f14b39d40f66f50459ecea132eada0379a2f414fdfaf5ed83f39a9d", "class_name": "RelatedNodeInfo"}}, "text": "We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines. ", "start_char_idx": 3246, "end_char_idx": 3404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18900f5a-e98c-4d65-ab4c-7ba413123f2f": {"__data__": {"id_": "18900f5a-e98c-4d65-ab4c-7ba413123f2f", "embedding": null, "metadata": {"window": "But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n ", "original_text": "Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19a7fa9f-c2b0-471c-a078-a0546fb0c9bd", "node_type": "1", "metadata": {"window": "Vaccines are not on market.  But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast? ", "original_text": "We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef7381fc50131b60045663597288635b47f781c85ecf21b65605dbb1b9591d8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d2d6add-2bef-4939-ae87-1c3dc8ffd9b4", "node_type": "1", "metadata": {"window": "We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n ", "original_text": "So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability. "}, "hash": "0435004f01cc5aa2787ef710b85d7dcbcb29396a7f48ac2a10d7b36f903d65d0", "class_name": "RelatedNodeInfo"}}, "text": "Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine. ", "start_char_idx": 3404, "end_char_idx": 3518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d2d6add-2bef-4939-ae87-1c3dc8ffd9b4": {"__data__": {"id_": "5d2d6add-2bef-4939-ae87-1c3dc8ffd9b4", "embedding": null, "metadata": {"window": "We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n ", "original_text": "So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18900f5a-e98c-4d65-ab4c-7ba413123f2f", "node_type": "1", "metadata": {"window": "But I would remind \neverybody, we have quite an extensive footprint in the distribution of vaccines today.  We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n ", "original_text": "Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ee1772ccc8d8c9ba6ab05dda72de84109dfc8e7a1151795fa4885765f93fa89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "215a2806-4ed5-4e32-a8f2-4da624d3ec4b", "node_type": "1", "metadata": {"window": "We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q ", "original_text": "And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast? "}, "hash": "617f3ce7e8bbb9533da84c5d52e4cbb8c61610b81b26a2ee4cefc5720430fda4", "class_name": "RelatedNodeInfo"}}, "text": "So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability. ", "start_char_idx": 3518, "end_char_idx": 3716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "215a2806-4ed5-4e32-a8f2-4da624d3ec4b": {"__data__": {"id_": "215a2806-4ed5-4e32-a8f2-4da624d3ec4b", "embedding": null, "metadata": {"window": "We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q ", "original_text": "And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast? ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d2d6add-2bef-4939-ae87-1c3dc8ffd9b4", "node_type": "1", "metadata": {"window": "We do distribute vaccines \nthrough the medical business to all of our practice areas.  \n \n We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n ", "original_text": "So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability. ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d7d9ff6e90db47cbfc96d7753b4bf2c214b0567abe93e208fbb9bb278b4df43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe5bc88e-dc46-41f7-8ce7-3321999f80eb", "node_type": "1", "metadata": {"window": "Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q ", "original_text": "But we would expect to be very \nengaged in those discussions.  \n "}, "hash": "855f3c9e407b0800ee250735019851b47eb28478f7975aa6168c94cfb597cc54", "class_name": "RelatedNodeInfo"}}, "text": "And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast? ", "start_char_idx": 3716, "end_char_idx": 3880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe5bc88e-dc46-41f7-8ce7-3321999f80eb": {"__data__": {"id_": "fe5bc88e-dc46-41f7-8ce7-3321999f80eb", "embedding": null, "metadata": {"window": "Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q ", "original_text": "But we would expect to be very \nengaged in those discussions.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "215a2806-4ed5-4e32-a8f2-4da624d3ec4b", "node_type": "1", "metadata": {"window": "We are \u2013 we work w ith CDC and their Vaccine for Childrens Program (sic) [Vaccines for Children Program] \n(00:55:40) program as a supplier of those vaccines.  Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q ", "original_text": "And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast? ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a8993a0a790796b195a695de334a7a20e65bd93070e1746eb96ceab0f32bfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3719a21c-fa7d-4b32-b646-b83a2a14b5c9", "node_type": "1", "metadata": {"window": "So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n "}, "hash": "219950e6ac7f58332dd66d4bbcdfba578d31b453abc2beb1884f4f103d4e7914", "class_name": "RelatedNodeInfo"}}, "text": "But we would expect to be very \nengaged in those discussions.  \n ", "start_char_idx": 3880, "end_char_idx": 3945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3719a21c-fa7d-4b32-b646-b83a2a14b5c9": {"__data__": {"id_": "3719a21c-fa7d-4b32-b646-b83a2a14b5c9", "embedding": null, "metadata": {"window": "So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe5bc88e-dc46-41f7-8ce7-3321999f80eb", "node_type": "1", "metadata": {"window": "Many years ago, when H1N1 hit us, we worked with public \npartners to facilitate a program to manage that vaccine.  So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q ", "original_text": "But we would expect to be very \nengaged in those discussions.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "756f9382741ecb084c03e533638d198c778daeab5fc673aaec9df51045362bb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1c7471e-425b-4503-99a2-08bdd622bca7", "node_type": "1", "metadata": {"window": "And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q "}, "hash": "5e7f88915c3a3961e14019ff1b1c3e6c1c348019d18b26c56847ba599f0527f1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n ", "start_char_idx": 3945, "end_char_idx": 4300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1c7471e-425b-4503-99a2-08bdd622bca7": {"__data__": {"id_": "a1c7471e-425b-4503-99a2-08bdd622bca7", "embedding": null, "metadata": {"window": "And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74def47fd1fbde08bb27ff41c88f433a3fea7a3ce70e89724e877b87b9899e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3719a21c-fa7d-4b32-b646-b83a2a14b5c9", "node_type": "1", "metadata": {"window": "So we 're very engaged with all the various agencies that \nwill have interest in this, with our manufacturer partners to make sure we're availing our insights and our \nknowledge and our capability.  And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5667895b71db25f4df9a5571a03d479b73f44d1f401dec9c560c7b9b797cfe2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f51d9b03-2b57-4e1b-b00f-8a39e554ad3d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago. ", "original_text": "McKesson Corp.  "}, "hash": "c3f0eb96b796ea110f43c17d754cd558f7714225acc40f20e9d789e49fa57a64", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q ", "start_char_idx": 4300, "end_char_idx": 4624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f51d9b03-2b57-4e1b-b00f-8a39e554ad3d": {"__data__": {"id_": "f51d9b03-2b57-4e1b-b00f-8a39e554ad3d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1c7471e-425b-4503-99a2-08bdd622bca7", "node_type": "1", "metadata": {"window": "And I suspect that as vaccines come to market, acceptance ramps up , we'll have to \nlook at what is the production, how does that production scale up and how fast?  But we would expect to be very \nengaged in those discussions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnal yst, JPMorgan Securities LLC  Q ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91b4403844f1edeba19ddd199e0117d9c63e12eb800f0716af69997d942c6ed2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "033b8f3f-4590-469a-85f5-3f060bd6f8c3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning. "}, "hash": "868c6bd2bebfd437033aab033cdd65d74728814595c3e37c04619f50507aaf87", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "033b8f3f-4590-469a-85f5-3f060bd6f8c3": {"__data__": {"id_": "033b8f3f-4590-469a-85f5-3f060bd6f8c3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f51d9b03-2b57-4e1b-b00f-8a39e554ad3d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18dd26d1c432663429602189a667d9db3aa0add5252c60d362cea964683da3dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a4747ed-aaa5-4c96-8ccd-a9971a508d00", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n ", "original_text": "Brian, can you give us an update on where you are as far as an opioid \npotential settlement? "}, "hash": "795c24d87ea17ecf46e7e514d76ffb778d8ec643c80730c3ef1261b0324bc2e3", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning. ", "start_char_idx": 16, "end_char_idx": 216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a4747ed-aaa5-4c96-8ccd-a9971a508d00": {"__data__": {"id_": "3a4747ed-aaa5-4c96-8ccd-a9971a508d00", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n ", "original_text": "Brian, can you give us an update on where you are as far as an opioid \npotential settlement? ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "033b8f3f-4590-469a-85f5-3f060bd6f8c3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "419ab4f23a4a54a9c875cc79a706ada51998a975902c23d581ddd924784a30b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcd58db8-11e0-4e95-85c8-c1e3070d0cec", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I know we talked about the framework, which was several months ago. "}, "hash": "f8135f0a956242f03c058cff764575c4ec162575ec3ac5a5520afc0f62401839", "class_name": "RelatedNodeInfo"}}, "text": "Brian, can you give us an update on where you are as far as an opioid \npotential settlement? ", "start_char_idx": 216, "end_char_idx": 309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcd58db8-11e0-4e95-85c8-c1e3070d0cec": {"__data__": {"id_": "fcd58db8-11e0-4e95-85c8-c1e3070d0cec", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I know we talked about the framework, which was several months ago. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a4747ed-aaa5-4c96-8ccd-a9971a508d00", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n ", "original_text": "Brian, can you give us an update on where you are as far as an opioid \npotential settlement? ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1043bc5bfc7252853a46d1065b7efcaf5c80727fefdf9b7a7eb6725127054eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c61e642-e9ee-4736-8233-d9bd75035b70", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa. ", "original_text": "Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward. "}, "hash": "d8dc28d887236f10ca3917e492112b4263bb9d21922076b97e53ce3a5324f72f", "class_name": "RelatedNodeInfo"}}, "text": "I know we talked about the framework, which was several months ago. ", "start_char_idx": 309, "end_char_idx": 377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c61e642-e9ee-4736-8233-d9bd75035b70": {"__data__": {"id_": "6c61e642-e9ee-4736-8233-d9bd75035b70", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa. ", "original_text": "Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcd58db8-11e0-4e95-85c8-c1e3070d0cec", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I know we talked about the framework, which was several months ago. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15bfaf613273f6ea2567bee782774586261fe9cc088cecdf8df0f1e9a167798a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "789c5b58-f635-46e0-817a-322d68bbcf5c", "node_type": "1", "metadata": {"window": "Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa.  I'd be happy to. ", "original_text": "So if \nyou could just give us any update there, that'd be really helpful.  \n "}, "hash": "d3e5cd10bbf7e5ae2b86a80252996f063afcccfcc7f7c33b072c2ca00966a461", "class_name": "RelatedNodeInfo"}}, "text": "Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward. ", "start_char_idx": 377, "end_char_idx": 513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "789c5b58-f635-46e0-817a-322d68bbcf5c": {"__data__": {"id_": "789c5b58-f635-46e0-817a-322d68bbcf5c", "embedding": null, "metadata": {"window": "Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa.  I'd be happy to. ", "original_text": "So if \nyou could just give us any update there, that'd be really helpful.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c61e642-e9ee-4736-8233-d9bd75035b70", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa. ", "original_text": "Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a42b846dd08ad9806d63fe6d12346542d566fe86c4ba3a9a0b3ac988f0fca10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69cf8baf-4b20-4c6c-bfaa-feca59b2c0f5", "node_type": "1", "metadata": {"window": "I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa.  I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "7d0095be237cb7755eb88a58be7cf43976aa50460ddedfaea44b0f9ba71a369b", "class_name": "RelatedNodeInfo"}}, "text": "So if \nyou could just give us any update there, that'd be really helpful.  \n ", "start_char_idx": 513, "end_char_idx": 590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69cf8baf-4b20-4c6c-bfaa-feca59b2c0f5": {"__data__": {"id_": "69cf8baf-4b20-4c6c-bfaa-feca59b2c0f5", "embedding": null, "metadata": {"window": "I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa.  I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "789c5b58-f635-46e0-817a-322d68bbcf5c", "node_type": "1", "metadata": {"window": "Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa.  I'd be happy to. ", "original_text": "So if \nyou could just give us any update there, that'd be really helpful.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a26908c723a17962705ebc36f659ea5100bf6ff03723d6cca901fe1a2e9a50b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62498967-743d-47f5-b4ae-bb2560ae3edb", "node_type": "1", "metadata": {"window": "Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa.  I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n", "original_text": "A \nSure,  Lisa. "}, "hash": "a35ea48a7fbe21439c7c2b1ee9911cef58c1157d6849efa37acef557a48565ab", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 590, "end_char_idx": 931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62498967-743d-47f5-b4ae-bb2560ae3edb": {"__data__": {"id_": "62498967-743d-47f5-b4ae-bb2560ae3edb", "embedding": null, "metadata": {"window": "Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa.  I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n", "original_text": "A \nSure,  Lisa. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69cf8baf-4b20-4c6c-bfaa-feca59b2c0f5", "node_type": "1", "metadata": {"window": "I know we talked about the framework, which was several months ago.  Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa.  I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fefd51396304702dee890c31567539e487b5c26e92014d5dcfae254342bc5310", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1eb63626-8990-41fb-87fe-40b974ac99ef", "node_type": "1", "metadata": {"window": "So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa.  I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions. ", "original_text": "I'd be happy to. "}, "hash": "09a44a1e8ac36fd87a2219a86f0041ae6698c3e1c4c4b3253b32d01f986fe609", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure,  Lisa. ", "start_char_idx": 931, "end_char_idx": 947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1eb63626-8990-41fb-87fe-40b974ac99ef": {"__data__": {"id_": "1eb63626-8990-41fb-87fe-40b974ac99ef", "embedding": null, "metadata": {"window": "So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa.  I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions. ", "original_text": "I'd be happy to. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62498967-743d-47f5-b4ae-bb2560ae3edb", "node_type": "1", "metadata": {"window": "Sitting here today, I \nwould anticipate that states being in a difficult financial position may be more likely to want to move forward.  So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa.  I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n", "original_text": "A \nSure,  Lisa. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "309db46b098725db8cab43a40f651dbfb204835b61b157ae90818e8524b3537b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9645b362-9ba1-4858-ba56-fd503d500b06", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa.  I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged. ", "original_text": "I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n"}, "hash": "d6f664667e39e1d4bd5e42e87f868bcfd0a18cda45016628cd999298d3e234df", "class_name": "RelatedNodeInfo"}}, "text": "I'd be happy to. ", "start_char_idx": 947, "end_char_idx": 964, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9645b362-9ba1-4858-ba56-fd503d500b06": {"__data__": {"id_": "9645b362-9ba1-4858-ba56-fd503d500b06", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa.  I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged. ", "original_text": "I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1eb63626-8990-41fb-87fe-40b974ac99ef", "node_type": "1", "metadata": {"window": "So if \nyou could just give us any update there, that'd be really helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa.  I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions. ", "original_text": "I'd be happy to. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a292f2b591773cd27448ab3f5ca222d9e7695476b10814a2a805faf5ffe7a71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3efc9ba8-5399-4fa7-8da0-d2b4dfacb1ec", "node_type": "1", "metadata": {"window": "A \nSure,  Lisa.  I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved. ", "original_text": "And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n"}, "hash": "ad72ccc655b89190d81ea9fcddd9b5eaf6a94087c30e0e5691b00aab55ef8da0", "class_name": "RelatedNodeInfo"}}, "text": "I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n", "start_char_idx": 964, "end_char_idx": 1152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3efc9ba8-5399-4fa7-8da0-d2b4dfacb1ec": {"__data__": {"id_": "3efc9ba8-5399-4fa7-8da0-d2b4dfacb1ec", "embedding": null, "metadata": {"window": "A \nSure,  Lisa.  I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved. ", "original_text": "And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9645b362-9ba1-4858-ba56-fd503d500b06", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure,  Lisa.  I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged. ", "original_text": "I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1af1e1d391b8b333d26856ea9c532ed22cbd2a1bb2ab91862e99471ab1b669d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b49cbecf-666c-45fe-b469-80a4e6f83370", "node_type": "1", "metadata": {"window": "I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n ", "original_text": "I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions. "}, "hash": "a06a6b574b36698b8d65e3ea8b0052256c35e9adace488a576cebde11adae9df", "class_name": "RelatedNodeInfo"}}, "text": "And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n", "start_char_idx": 1152, "end_char_idx": 1302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b49cbecf-666c-45fe-b469-80a4e6f83370": {"__data__": {"id_": "b49cbecf-666c-45fe-b469-80a4e6f83370", "embedding": null, "metadata": {"window": "I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n ", "original_text": "I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3efc9ba8-5399-4fa7-8da0-d2b4dfacb1ec", "node_type": "1", "metadata": {"window": "A \nSure,  Lisa.  I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved. ", "original_text": "And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4cb2af5f6e883c8738a45d52b2104b67a67eb027dc53ba0476114cd3762e598e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5baddf33-75ee-47c1-92c2-42f41ed53b1f", "node_type": "1", "metadata": {"window": "I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n ", "original_text": "I mean, we continue  to be engaged. "}, "hash": "a53b4082d141f1e2db3906fa05c8367ea0f2037f6e6e8ca3e7d57f62116807c9", "class_name": "RelatedNodeInfo"}}, "text": "I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions. ", "start_char_idx": 1302, "end_char_idx": 1442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5baddf33-75ee-47c1-92c2-42f41ed53b1f": {"__data__": {"id_": "5baddf33-75ee-47c1-92c2-42f41ed53b1f", "embedding": null, "metadata": {"window": "I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n ", "original_text": "I mean, we continue  to be engaged. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b49cbecf-666c-45fe-b469-80a4e6f83370", "node_type": "1", "metadata": {"window": "I'd be happy to.  I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n ", "original_text": "I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "509f7d5de5d72e3e91c9ce6bef62f30b71c64106df129579dfc11002705ebe09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44652fcc-b33e-43a0-a88e-a3237c2fa4fe", "node_type": "1", "metadata": {"window": "And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys. ", "original_text": "We continue to be hopeful that a broad resolution \ncan be achieved. "}, "hash": "e7661ad357666a9373d8b96759f21a0575e0dd9f57dcf9e9c31b9b83e2e92295", "class_name": "RelatedNodeInfo"}}, "text": "I mean, we continue  to be engaged. ", "start_char_idx": 1442, "end_char_idx": 1478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44652fcc-b33e-43a0-a88e-a3237c2fa4fe": {"__data__": {"id_": "44652fcc-b33e-43a0-a88e-a3237c2fa4fe", "embedding": null, "metadata": {"window": "And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys. ", "original_text": "We continue to be hopeful that a broad resolution \ncan be achieved. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5baddf33-75ee-47c1-92c2-42f41ed53b1f", "node_type": "1", "metadata": {"window": "I mean, probably goes without saying that our primary focus the last weeks and \nmonths has been on responding to COVID -19, supporting our communities and our customers in that response. \n And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n ", "original_text": "I mean, we continue  to be engaged. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b787e8c21c049663a84e8bba9759d13d6333f2e43746ef30fb7b35b7a8a39193", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c1da8b8-a169-4263-b8bb-e5b4c0b4bf75", "node_type": "1", "metadata": {"window": "I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions. ", "original_text": "We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n "}, "hash": "e78b06891bbce1658f5ecd61a7ae3863a7c0267f1f5b967a6144e5970424ee76", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be hopeful that a broad resolution \ncan be achieved. ", "start_char_idx": 1478, "end_char_idx": 1546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c1da8b8-a169-4263-b8bb-e5b4c0b4bf75": {"__data__": {"id_": "1c1da8b8-a169-4263-b8bb-e5b4c0b4bf75", "embedding": null, "metadata": {"window": "I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions. ", "original_text": "We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44652fcc-b33e-43a0-a88e-a3237c2fa4fe", "node_type": "1", "metadata": {"window": "And I'm sure the same has been true for a lot o f the public officials that have been involved, I guess, on the other \nside of this opioid issue.  \n \n I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys. ", "original_text": "We continue to be hopeful that a broad resolution \ncan be achieved. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae3c6ab2617161dbfcc8ab75d52de24ef5327fb56c18a38643f4d5e5064d7de6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50c941ff-d4b4-4e16-9261-5a1371ec3ab4", "node_type": "1", "metadata": {"window": "I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n "}, "hash": "377cdf120fd7abc8efe1bbc9b997341220db7704d69fa23f31f291f0b5a7bc2f", "class_name": "RelatedNodeInfo"}}, "text": "We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n ", "start_char_idx": 1546, "end_char_idx": 1772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50c941ff-d4b4-4e16-9261-5a1371ec3ab4": {"__data__": {"id_": "50c941ff-d4b4-4e16-9261-5a1371ec3ab4", "embedding": null, "metadata": {"window": "I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c1da8b8-a169-4263-b8bb-e5b4c0b4bf75", "node_type": "1", "metadata": {"window": "I really don't think there's a lot to add to the commentary we provided last time in terms of the specifics of the \nsettlement discussions.  I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions. ", "original_text": "We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a39c9a0f37472da9de1fa40b3ddf29b6c555d21112bc8a5d72a3e786d692554", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49846bee-dc58-451a-a947-5d3a966a22e9", "node_type": "1", "metadata": {"window": "We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys. "}, "hash": "b17c1ec25fc99ae07b84407eba5c5f906e926fafedb73abe5ced002cb3aac617", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n ", "start_char_idx": 1772, "end_char_idx": 2134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49846bee-dc58-451a-a947-5d3a966a22e9": {"__data__": {"id_": "49846bee-dc58-451a-a947-5d3a966a22e9", "embedding": null, "metadata": {"window": "We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50c941ff-d4b4-4e16-9261-5a1371ec3ab4", "node_type": "1", "metadata": {"window": "I mean, we continue  to be engaged.  We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "009bafe1ef7b64bf563fd69d48ee19dab165bc6c13aeb44d0aada17bb1533447", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c585781c-7e5f-4b3d-a3a1-622f46be57cf", "node_type": "1", "metadata": {"window": "We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question. ", "original_text": "Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions. "}, "hash": "0d22bed3f40f7434cf4d3dcb07da9e0e57e1cf22dc5d21d240708567e0d8fb2d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys. ", "start_char_idx": 2134, "end_char_idx": 2480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c585781c-7e5f-4b3d-a3a1-622f46be57cf": {"__data__": {"id_": "c585781c-7e5f-4b3d-a3a1-622f46be57cf", "embedding": null, "metadata": {"window": "We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question. ", "original_text": "Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49846bee-dc58-451a-a947-5d3a966a22e9", "node_type": "1", "metadata": {"window": "We continue to be hopeful that a broad resolution \ncan be achieved.  We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e205c7a90d801bc22e10cb8377b3d925a0bb89737d524749cab84aab0a5e4c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a11814f5-a257-4269-928b-6303049c608d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry. ", "original_text": "But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n "}, "hash": "6929f2d3f83b2bc112c10d535ecd24ae84ade39eec14c8d5b40eb79b1d455e72", "class_name": "RelatedNodeInfo"}}, "text": "Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions. ", "start_char_idx": 2480, "end_char_idx": 2613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a11814f5-a257-4269-928b-6303049c608d": {"__data__": {"id_": "a11814f5-a257-4269-928b-6303049c608d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry. ", "original_text": "But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c585781c-7e5f-4b3d-a3a1-622f46be57cf", "node_type": "1", "metadata": {"window": "We do think that one of the drivers has always been for us the recognition that people and \ncommunities have needs, and it would be great to get the resolution for them and t hose needs are probably \ngreater now than ever.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question. ", "original_text": "Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c915832450e4bd2101d61fbeaafb577a33b94031cf4d4efbf3ec0d2cec7e36dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe384570-c2a2-456e-a936-31d9c7c26150", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "b602d297d759c2f7b8257e36b71173fa2785c440e03bdfd90ea83670bbf6a069", "class_name": "RelatedNodeInfo"}}, "text": "But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n ", "start_char_idx": 2613, "end_char_idx": 2885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe384570-c2a2-456e-a936-31d9c7c26150": {"__data__": {"id_": "fe384570-c2a2-456e-a936-31d9c7c26150", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a11814f5-a257-4269-928b-6303049c608d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry. ", "original_text": "But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8910fce72ed9a7622bad86ff24f5e0e26bdb2a18f40f82845c65edf6ae932f66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f69109e-a7e0-4337-8b70-600e28cfe5c4", "node_type": "1", "metadata": {"window": "Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession. ", "original_text": "A \nGreat question. "}, "hash": "72d1b226017f55f4895a3c48dc1398f21807dca548d756a8e114a0253698cf24", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 590, "end_char_idx": 931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f69109e-a7e0-4337-8b70-600e28cfe5c4": {"__data__": {"id_": "9f69109e-a7e0-4337-8b70-600e28cfe5c4", "embedding": null, "metadata": {"window": "Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession. ", "original_text": "A \nGreat question. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe384570-c2a2-456e-a936-31d9c7c26150", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good morning, guys.  Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cf69a1de4d83493f62a26c8b86f87eabf5f8d4cab4e8a25ab47f1b4faedd4c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39eb0e46-6b32-4070-b9d2-6f66ff7b8796", "node_type": "1", "metadata": {"window": "But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n", "original_text": "We've \u2013 our business has been through many economic cycles over its histo ry. "}, "hash": "70c8976f9b1b7b1d683d10794606a22f8c9c7f4981b579f6ee881245bd2ee169", "class_name": "RelatedNodeInfo"}}, "text": "A \nGreat question. ", "start_char_idx": 3226, "end_char_idx": 3245, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39eb0e46-6b32-4070-b9d2-6f66ff7b8796": {"__data__": {"id_": "39eb0e46-6b32-4070-b9d2-6f66ff7b8796", "embedding": null, "metadata": {"window": "But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n", "original_text": "We've \u2013 our business has been through many economic cycles over its histo ry. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f69109e-a7e0-4337-8b70-600e28cfe5c4", "node_type": "1", "metadata": {"window": "Brian or Britt, as I think about the guidance, and obviously, I appreciate all the color \nyou've given in terms of your assumptions.  But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession. ", "original_text": "A \nGreat question. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "951ef1d26121d47b887ec37574110d50f0c775ef858f53db1f1db2635c95a128", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1266136b-0f7f-4a4a-844c-1b6fb37f3e60", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic. ", "original_text": "Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one. "}, "hash": "d81a537fb9527f5f82b4aa10142e573917e1eb1b0ac64555249a96143174974f", "class_name": "RelatedNodeInfo"}}, "text": "We've \u2013 our business has been through many economic cycles over its histo ry. ", "start_char_idx": 3245, "end_char_idx": 3323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1266136b-0f7f-4a4a-844c-1b6fb37f3e60": {"__data__": {"id_": "1266136b-0f7f-4a4a-844c-1b6fb37f3e60", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic. ", "original_text": "Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39eb0e46-6b32-4070-b9d2-6f66ff7b8796", "node_type": "1", "metadata": {"window": "But as we stare down a recession heading into 2021, I mean, based \non your experience being with the company during the last recession, how are you thinking about just the likely \ndecline in physician office visits and how your business will be resilient through that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n", "original_text": "We've \u2013 our business has been through many economic cycles over its histo ry. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7b351707006f79e251e8bc4e1103096f45101b69db2fe7c3ed967a31b63d649", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f533a8c9-64f7-46a5-a110-fdfe2272f57d", "node_type": "1", "metadata": {"window": "A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\" ", "original_text": "And what I would say in general is I \nthink our business model is pretty resilient to an economic recession. "}, "hash": "d2fe7fbda1465e1cc9534bf54544f0dc74ce3df8a091c6dffd3885924a034831", "class_name": "RelatedNodeInfo"}}, "text": "Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one. ", "start_char_idx": 3323, "end_char_idx": 3420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f533a8c9-64f7-46a5-a110-fdfe2272f57d": {"__data__": {"id_": "f533a8c9-64f7-46a5-a110-fdfe2272f57d", "embedding": null, "metadata": {"window": "A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\" ", "original_text": "And what I would say in general is I \nthink our business model is pretty resilient to an economic recession. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1266136b-0f7f-4a4a-844c-1b6fb37f3e60", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic. ", "original_text": "Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09594bc8edb08de9213ca9d662c25ac7441b2b6882d4a707890dbfb2975f5241", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acb017b6-da4c-4de2-89ff-7c8b35fe10c0", "node_type": "1", "metadata": {"window": "We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n", "original_text": "And I think if you look back over history, you \nwould see that to be the case.  \n \n"}, "hash": "310a6f2e38c6182c30239aff981f1dd196d4596abfaf5dca0f94643615e39dd9", "class_name": "RelatedNodeInfo"}}, "text": "And what I would say in general is I \nthink our business model is pretty resilient to an economic recession. ", "start_char_idx": 3420, "end_char_idx": 3529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acb017b6-da4c-4de2-89ff-7c8b35fe10c0": {"__data__": {"id_": "acb017b6-da4c-4de2-89ff-7c8b35fe10c0", "embedding": null, "metadata": {"window": "We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n", "original_text": "And I think if you look back over history, you \nwould see that to be the case.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f533a8c9-64f7-46a5-a110-fdfe2272f57d", "node_type": "1", "metadata": {"window": "A \nGreat question.  We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\" ", "original_text": "And what I would say in general is I \nthink our business model is pretty resilient to an economic recession. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c71a186fd77b622e942f417be99f08df6d8a07a76011889f5564c25b2dfb4526", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5bda0c0-726f-4992-93b6-583dad8a6d89", "node_type": "1", "metadata": {"window": "Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate. ", "original_text": "I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic. "}, "hash": "aac56c36047652c9826d971150d98d7aa230561724e9cd8c3c5d2516a689a032", "class_name": "RelatedNodeInfo"}}, "text": "And I think if you look back over history, you \nwould see that to be the case.  \n \n", "start_char_idx": 3529, "end_char_idx": 3612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5bda0c0-726f-4992-93b6-583dad8a6d89": {"__data__": {"id_": "b5bda0c0-726f-4992-93b6-583dad8a6d89", "embedding": null, "metadata": {"window": "Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate. ", "original_text": "I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acb017b6-da4c-4de2-89ff-7c8b35fe10c0", "node_type": "1", "metadata": {"window": "We've \u2013 our business has been through many economic cycles over its histo ry.  Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n", "original_text": "And I think if you look back over history, you \nwould see that to be the case.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3765cba579767f9b83a9253e9422669dc9870dc9f66e7d7e80e152a68eb10a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ab69f38-a06f-4cda-a0c5-fbae798e140c", "node_type": "1", "metadata": {"window": "And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage? ", "original_text": "And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\" "}, "hash": "16ac82543fbb4ab5c79eb86b0aaf8f4fd934a8c07f64917fd9b393ab8d5e482f", "class_name": "RelatedNodeInfo"}}, "text": "I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic. ", "start_char_idx": 3612, "end_char_idx": 3767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ab69f38-a06f-4cda-a0c5-fbae798e140c": {"__data__": {"id_": "1ab69f38-a06f-4cda-a0c5-fbae798e140c", "embedding": null, "metadata": {"window": "And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage? ", "original_text": "And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\" ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5bda0c0-726f-4992-93b6-583dad8a6d89", "node_type": "1", "metadata": {"window": "Fortunately, Britt \nand I weren't here for all of them, but we were here for the 2008, 2009 one.  And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate. ", "original_text": "I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8be61fee3e8271266324b45b4a676d39dead4d18883fc8adb9a74f9dd4a411", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e85725be-dfa1-451a-b144-d057e512d4b6", "node_type": "1", "metadata": {"window": "And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid? ", "original_text": "The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n"}, "hash": "924a609e418fdd74829a3ce046200d699645f5c90630eef92e8d5e8625cd90e9", "class_name": "RelatedNodeInfo"}}, "text": "And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\" ", "start_char_idx": 3767, "end_char_idx": 3908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e85725be-dfa1-451a-b144-d057e512d4b6": {"__data__": {"id_": "e85725be-dfa1-451a-b144-d057e512d4b6", "embedding": null, "metadata": {"window": "And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid? ", "original_text": "The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ab69f38-a06f-4cda-a0c5-fbae798e140c", "node_type": "1", "metadata": {"window": "And what I would say in general is I \nthink our business model is pretty resilient to an economic recession.  And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage? ", "original_text": "And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\" ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d276d9741eac6ad22b32187bdf3216e4d83702701a5bb8172968fda708f310fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20d2c88c-247c-403d-b558-c2e03b1598a4", "node_type": "1", "metadata": {"window": "I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that. ", "original_text": "And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate. "}, "hash": "af104f2ce6e0f77ba83f75ba57b378ca705f759f2e5adbb386bf010a06f6a67a", "class_name": "RelatedNodeInfo"}}, "text": "The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n", "start_char_idx": 3908, "end_char_idx": 4280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20d2c88c-247c-403d-b558-c2e03b1598a4": {"__data__": {"id_": "20d2c88c-247c-403d-b558-c2e03b1598a4", "embedding": null, "metadata": {"window": "I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that. ", "original_text": "And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e85725be-dfa1-451a-b144-d057e512d4b6", "node_type": "1", "metadata": {"window": "And I think if you look back over history, you \nwould see that to be the case.  \n \n I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid? ", "original_text": "The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b3ab3ad30575759a8aa5ddf220670cb26b9cb6b6ad7688ae81e47624d9058e40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1b85b3c-fb5f-4fbf-8c00-5bfd22fe7764", "node_type": "1", "metadata": {"window": "And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that.  So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n ", "original_text": "I \nmean, there's always puts and takes with are you uninsured with no coverage? "}, "hash": "a89ade98635c7bf083d0be96dfe6866b121f528031eb9e27dd7e8d5219f52a67", "class_name": "RelatedNodeInfo"}}, "text": "And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate. ", "start_char_idx": 4280, "end_char_idx": 4385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1b85b3c-fb5f-4fbf-8c00-5bfd22fe7764": {"__data__": {"id_": "b1b85b3c-fb5f-4fbf-8c00-5bfd22fe7764", "embedding": null, "metadata": {"window": "And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that.  So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n ", "original_text": "I \nmean, there's always puts and takes with are you uninsured with no coverage? ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20d2c88c-247c-403d-b558-c2e03b1598a4", "node_type": "1", "metadata": {"window": "I will say this situation is a little bit different, though, because it's an economic recession, but it's really driven by \nan underlying health pandemic.  And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that. ", "original_text": "And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6d40c75d8e1d0dbd5aa5320a77d1ec192545d14b752db087149597b101b3dde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1611e406-ec9c-47cf-b741-8e382e203143", "node_type": "1", "metadata": {"window": "The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that.  So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Do you go to Medicaid? "}, "hash": "bcd5db898369511caed6b1005a8f88cc9f24eddaf5f1ff02f2c9ed7447d4ef5a", "class_name": "RelatedNodeInfo"}}, "text": "I \nmean, there's always puts and takes with are you uninsured with no coverage? ", "start_char_idx": 4385, "end_char_idx": 4465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1611e406-ec9c-47cf-b741-8e382e203143": {"__data__": {"id_": "1611e406-ec9c-47cf-b741-8e382e203143", "embedding": null, "metadata": {"window": "The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that.  So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Do you go to Medicaid? ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1b85b3c-fb5f-4fbf-8c00-5bfd22fe7764", "node_type": "1", "metadata": {"window": "And so, in my mind, the way the business will respond is a little bit m ore about \nhow we respond to the health pandemic than a \"recession.\"  The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that.  So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n ", "original_text": "I \nmean, there's always puts and takes with are you uninsured with no coverage? ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "454328de3d3c20f70352cab945840727b4a681792df23eecd8317f33c5f8960d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae4fd2be-a534-4492-be30-7be7555ad972", "node_type": "1", "metadata": {"window": "And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that.  So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "But those \nare \u2013 we tend to be a little more insulated from that. "}, "hash": "63905f963a9bd886fda063fc71ac21afa54797497a3ae20a3d78a820f5db5ddc", "class_name": "RelatedNodeInfo"}}, "text": "Do you go to Medicaid? ", "start_char_idx": 4465, "end_char_idx": 4488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae4fd2be-a534-4492-be30-7be7555ad972": {"__data__": {"id_": "ae4fd2be-a534-4492-be30-7be7555ad972", "embedding": null, "metadata": {"window": "And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that.  So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "But those \nare \u2013 we tend to be a little more insulated from that. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1611e406-ec9c-47cf-b741-8e382e203143", "node_type": "1", "metadata": {"window": "The faster patients get comfortable being out of their \nhomes, the faster they get comfortable going into healthcare settings, the faster social policy, testing, tracing, all \nthese things w e're talking about in the business and the public community, and as these comes to place and our \nconfidence resumes, I think that's really what's going to tilt the trajectory.  \n \n And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that.  So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Do you go to Medicaid? ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66b855b1dac0dd5f547d3a0cacac1139fd601c75e274ce5aaba35b68a14c17cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47d28449-0aca-46fa-941c-61e340e6a3da", "node_type": "1", "metadata": {"window": "I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that.  So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n "}, "hash": "f38d19662f2dd09f25d2e7e63785c8c1a99c0de72dd6804c67f18af0ab2b907a", "class_name": "RelatedNodeInfo"}}, "text": "But those \nare \u2013 we tend to be a little more insulated from that. ", "start_char_idx": 4488, "end_char_idx": 4554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47d28449-0aca-46fa-941c-61e340e6a3da": {"__data__": {"id_": "47d28449-0aca-46fa-941c-61e340e6a3da", "embedding": null, "metadata": {"window": "I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that.  So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae4fd2be-a534-4492-be30-7be7555ad972", "node_type": "1", "metadata": {"window": "And so for me, it's much more about how healthcare demand comes back than the g eneral economic climate.  I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that.  So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "But those \nare \u2013 we tend to be a little more insulated from that. ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08826e7ff17ceb642be8e313dfc0aca0c66c4251b96b6ff3bafa32f4e6dadb7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01a4be31-e26a-427e-a3ee-4de52c626579", "node_type": "1", "metadata": {"window": "Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that.  So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "2470b98c7fe43f2ca86a0e7654780cc0a5940a0a9cda13a4a1e2c4b4e46929f4", "class_name": "RelatedNodeInfo"}}, "text": "So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n ", "start_char_idx": 4554, "end_char_idx": 4668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01a4be31-e26a-427e-a3ee-4de52c626579": {"__data__": {"id_": "01a4be31-e26a-427e-a3ee-4de52c626579", "embedding": null, "metadata": {"window": "Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that.  So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef610940-3921-4423-8958-6c921bf25ccd", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5b49297a131d758b5080bf9b7315d5447df7cef3d1626cec9a2d1fcf2faa938", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47d28449-0aca-46fa-941c-61e340e6a3da", "node_type": "1", "metadata": {"window": "I \nmean, there's always puts and takes with are you uninsured with no coverage?  Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that.  So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb7c4d8b49c4d69d2268e4c422079b4893846bf041cbab2688bfd77d680c76c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "493041bd-83d3-4648-87ef-627f6bd0a4e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return. ", "original_text": "McKesson Corp.  "}, "hash": "b7e131943d709ef2e20fb0fb9e83427ad6270dd18656f44b52249b85b2c5a291", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 590, "end_char_idx": 861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "493041bd-83d3-4648-87ef-627f6bd0a4e2": {"__data__": {"id_": "493041bd-83d3-4648-87ef-627f6bd0a4e2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01a4be31-e26a-427e-a3ee-4de52c626579", "node_type": "1", "metadata": {"window": "Do you go to Medicaid?  But those \nare \u2013 we tend to be a little more insulated from that.  So I think it's really all about how quickly confidence comes \nback in patients consuming healthcare services.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58495b3e09fdbc2712b3dc9ed252974cd7259f392e1f33dc2e0bf21ac7f09a2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa68b644-7bdf-486f-8aed-160665ceccb2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "651783f376446b97c935d873f06f97c3c004475bc0c448786590795ca703af50", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa68b644-7bdf-486f-8aed-160665ceccb2": {"__data__": {"id_": "fa68b644-7bdf-486f-8aed-160665ceccb2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "493041bd-83d3-4648-87ef-627f6bd0a4e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67ee94ffdde177ae351dde53cf10dd4bdbcce7d699dbd4fabb5c1e4008785b8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30468a99-f51d-4d87-b9b6-ba37db693cf3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n", "original_text": "A \nYeah. "}, "hash": "4b2b437ad9e5a938e4a63e94c6276545715b51a377cfbe3aebb5b3b0aaf5b003", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30468a99-f51d-4d87-b9b6-ba37db693cf3": {"__data__": {"id_": "30468a99-f51d-4d87-b9b6-ba37db693cf3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa68b644-7bdf-486f-8aed-160665ceccb2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c504c8d476470c3ccfc62b1e906794fd5ee6fac52534c06dc0f8df9642b527c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "243bf40f-5cbc-4fba-931b-ede6c0b9aa27", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n ", "original_text": "I might just add that our guidance really assumes that healthcare demand will return. "}, "hash": "c8a858e757decd2fe668967c39059029c88770a7f88a817ec2a86b43ddb2164d", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 269, "end_char_idx": 278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "243bf40f-5cbc-4fba-931b-ede6c0b9aa27": {"__data__": {"id_": "243bf40f-5cbc-4fba-931b-ede6c0b9aa27", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n ", "original_text": "I might just add that our guidance really assumes that healthcare demand will return. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30468a99-f51d-4d87-b9b6-ba37db693cf3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61db4fef8355f3957b49bff30f5fee8843a56bf87817271dbebdb5c0a9f4822c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4544173-7b65-4692-ba57-8771c95b85da", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n ", "original_text": "We've seen that in \nprior recessions like this. "}, "hash": "76e3415b17f90e0d4107dbb2c081cf4ee7c10063153ea028f9d25a6537b92a29", "class_name": "RelatedNodeInfo"}}, "text": "I might just add that our guidance really assumes that healthcare demand will return. ", "start_char_idx": 278, "end_char_idx": 364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4544173-7b65-4692-ba57-8771c95b85da": {"__data__": {"id_": "b4544173-7b65-4692-ba57-8771c95b85da", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n ", "original_text": "We've seen that in \nprior recessions like this. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "243bf40f-5cbc-4fba-931b-ede6c0b9aa27", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n ", "original_text": "I might just add that our guidance really assumes that healthcare demand will return. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab16d5679154e0a82efc623ff454820e1c73093bdfa8dc0b507810fd162df094", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20ebc75d-c6a3-45b9-8eff-d623e4e67d2b", "node_type": "1", "metadata": {"window": "A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question. ", "original_text": "And our guidance really assumes that it's a gradual build over the course of the year. \n"}, "hash": "e23a6378dfbb88f812f4ee3f4f1032188320366883f60722b85c520e33f745fb", "class_name": "RelatedNodeInfo"}}, "text": "We've seen that in \nprior recessions like this. ", "start_char_idx": 364, "end_char_idx": 412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20ebc75d-c6a3-45b9-8eff-d623e4e67d2b": {"__data__": {"id_": "20ebc75d-c6a3-45b9-8eff-d623e4e67d2b", "embedding": null, "metadata": {"window": "A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question. ", "original_text": "And our guidance really assumes that it's a gradual build over the course of the year. \n", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4544173-7b65-4692-ba57-8771c95b85da", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n ", "original_text": "We've seen that in \nprior recessions like this. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3d48f3329d89305a69aa143f43f973e58ad61f27e00e866f3a9c7660ea436f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad832d3f-5c43-46c4-9991-5220c34ee0d1", "node_type": "1", "metadata": {"window": "I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well. ", "original_text": "We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n "}, "hash": "5f2eb061fce07f1bcfdabb1633a927c210008faa399e0215e18268b47b9e2e0a", "class_name": "RelatedNodeInfo"}}, "text": "And our guidance really assumes that it's a gradual build over the course of the year. \n", "start_char_idx": 412, "end_char_idx": 500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad832d3f-5c43-46c4-9991-5220c34ee0d1": {"__data__": {"id_": "ad832d3f-5c43-46c4-9991-5220c34ee0d1", "embedding": null, "metadata": {"window": "I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well. ", "original_text": "We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20ebc75d-c6a3-45b9-8eff-d623e4e67d2b", "node_type": "1", "metadata": {"window": "A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question. ", "original_text": "And our guidance really assumes that it's a gradual build over the course of the year. \n", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23ad744163a5b57cae75f5dde8ccbf46f84de9ecd691c21f2e2268adaa2aaa49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "931a14a4-e65d-4027-8cc4-d5337a010d74", "node_type": "1", "metadata": {"window": "We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n "}, "hash": "c20af25cfc7f0638eb434744db0c2f5f03f1ff69a177872b1835f1a40404ff33", "class_name": "RelatedNodeInfo"}}, "text": "We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n ", "start_char_idx": 500, "end_char_idx": 802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "931a14a4-e65d-4027-8cc4-d5337a010d74": {"__data__": {"id_": "931a14a4-e65d-4027-8cc4-d5337a010d74", "embedding": null, "metadata": {"window": "We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad832d3f-5c43-46c4-9991-5220c34ee0d1", "node_type": "1", "metadata": {"window": "I might just add that our guidance really assumes that healthcare demand will return.  We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well. ", "original_text": "We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1c0635114c7f69b6a946f1f51d66c4244c0329caa6a65f2107794185b93bc71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b82e00d-5d29-4534-9d8e-619c2bbb2c71", "node_type": "1", "metadata": {"window": "And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question. "}, "hash": "614869c75aa5bb05c744275189751f08535e20349728e882fec2712dd9632098", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n ", "start_char_idx": 802, "end_char_idx": 1168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b82e00d-5d29-4534-9d8e-619c2bbb2c71": {"__data__": {"id_": "3b82e00d-5d29-4534-9d8e-619c2bbb2c71", "embedding": null, "metadata": {"window": "And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "931a14a4-e65d-4027-8cc4-d5337a010d74", "node_type": "1", "metadata": {"window": "We've seen that in \nprior recessions like this.  And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "485390b0e7e917a591dceb61cefa14c01defa00bd3b90e94a0a01f67d4b272de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b348c3c-9713-4c7b-9f81-b4a6084dca34", "node_type": "1", "metadata": {"window": "We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords. ", "original_text": "I hope you all are doing well. "}, "hash": "a87eabe10384359e33e848bfd0aa0a90c899410491cbd26de8f0f54a1863c3bc", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question. ", "start_char_idx": 1168, "end_char_idx": 1519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b348c3c-9713-4c7b-9f81-b4a6084dca34": {"__data__": {"id_": "3b348c3c-9713-4c7b-9f81-b4a6084dca34", "embedding": null, "metadata": {"window": "We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords. ", "original_text": "I hope you all are doing well. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b82e00d-5d29-4534-9d8e-619c2bbb2c71", "node_type": "1", "metadata": {"window": "And our guidance really assumes that it's a gradual build over the course of the year. \n We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "769d0fbb9a8a8d49745418b35d35e4f9d300e2f2fcba2a048c30c2aaa9edf576", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7279c13-7fc9-43b4-a700-06b375b01aaf", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage? ", "original_text": "This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession. "}, "hash": "9bc879669f4c172f1e8c68ad7b9ffc6637f2465bc4acff6052e90f9762760c6c", "class_name": "RelatedNodeInfo"}}, "text": "I hope you all are doing well. ", "start_char_idx": 1519, "end_char_idx": 1550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7279c13-7fc9-43b4-a700-06b375b01aaf": {"__data__": {"id_": "a7279c13-7fc9-43b4-a700-06b375b01aaf", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage? ", "original_text": "This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b348c3c-9713-4c7b-9f81-b4a6084dca34", "node_type": "1", "metadata": {"window": "We're already seeing some \u2013 as I mentioned, we're seeing some evidence of modest increases in May, that's \nearly obviously, but we do expect that he althcare demand will return, and we do expect that we'll be well \npositioned for that in really in all the different settings that we participate in.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords. ", "original_text": "I hope you all are doing well. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a11a3e279f62cbddb5d5764aca0e440f4c3c54d68ffb04632b8ec6cc2ebb4c1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15fa5889-10b2-47a2-9560-09d3e2ac3aa2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful? ", "original_text": "I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years. "}, "hash": "74afdc137f7da3e9ec093bd91a279764a63bd7129915856e03ca7e9f8af7c7d6", "class_name": "RelatedNodeInfo"}}, "text": "This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession. ", "start_char_idx": 1550, "end_char_idx": 1653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15fa5889-10b2-47a2-9560-09d3e2ac3aa2": {"__data__": {"id_": "15fa5889-10b2-47a2-9560-09d3e2ac3aa2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful? ", "original_text": "I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7279c13-7fc9-43b4-a700-06b375b01aaf", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage? ", "original_text": "This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21f56739138a7839b870895d1b5176705bdacc75a7c76e4416f21ef251d904f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a880dea-7944-49a6-a382-448b02f90c43", "node_type": "1", "metadata": {"window": "I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful?  Thanks.  \n ", "original_text": "For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords. "}, "hash": "4c02ce7915a27988348342a0319ac6d81731f40f7d3427716a57677fd87a29d5", "class_name": "RelatedNodeInfo"}}, "text": "I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years. ", "start_char_idx": 1653, "end_char_idx": 1863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a880dea-7944-49a6-a382-448b02f90c43": {"__data__": {"id_": "4a880dea-7944-49a6-a382-448b02f90c43", "embedding": null, "metadata": {"window": "I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful?  Thanks.  \n ", "original_text": "For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15fa5889-10b2-47a2-9560-09d3e2ac3aa2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHey, thanks for the question.  I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful? ", "original_text": "I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b24bace7b13d58317d8342eec1be52265dccc216d80e1f2619244ba33da719", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3af13569-be04-43b1-9796-a139f2b06f9b", "node_type": "1", "metadata": {"window": "This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So, I guess, what, if anything, are your customers asking of \nyou at this stage? "}, "hash": "ebe19988a939841ec6621c576c74be268a351617f90fbaef5247072797d7ac9a", "class_name": "RelatedNodeInfo"}}, "text": "For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords. ", "start_char_idx": 1863, "end_char_idx": 1996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3af13569-be04-43b1-9796-a139f2b06f9b": {"__data__": {"id_": "3af13569-be04-43b1-9796-a139f2b06f9b", "embedding": null, "metadata": {"window": "This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So, I guess, what, if anything, are your customers asking of \nyou at this stage? ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a880dea-7944-49a6-a382-448b02f90c43", "node_type": "1", "metadata": {"window": "I hope you all are doing well.  This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful?  Thanks.  \n ", "original_text": "For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d11fc2cace0cc4167cdb5d11c25ea06dc9bfbe504a786362a55ffccb4de867d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01746f08-a513-4429-85cc-df1798757c0f", "node_type": "1", "metadata": {"window": "I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question. ", "original_text": "Any insight into your conversations with your customers would be helpful? "}, "hash": "3fc36eefd6aaf9dfb42cc0a509827fcf34c2ebeea451f387d742bc2a1066e411", "class_name": "RelatedNodeInfo"}}, "text": "So, I guess, what, if anything, are your customers asking of \nyou at this stage? ", "start_char_idx": 1996, "end_char_idx": 2077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01746f08-a513-4429-85cc-df1798757c0f": {"__data__": {"id_": "01746f08-a513-4429-85cc-df1798757c0f", "embedding": null, "metadata": {"window": "I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question. ", "original_text": "Any insight into your conversations with your customers would be helpful? ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3af13569-be04-43b1-9796-a139f2b06f9b", "node_type": "1", "metadata": {"window": "This is a bit of a follow -up on the prior question about \nthe economy in a more normalized recession.  I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So, I guess, what, if anything, are your customers asking of \nyou at this stage? ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8900c5fa75e19d7f6b257acc9a2d6136e9eed001d911b89dfc99cf8ae4b415a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65bf2359-8e30-42b0-aca5-7dbda8bb18b9", "node_type": "1", "metadata": {"window": "For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n", "original_text": "Thanks.  \n "}, "hash": "8d8fd28af0146af24df45856069df1031957fc17c4a5d6a50cc5c59fd78de1f8", "class_name": "RelatedNodeInfo"}}, "text": "Any insight into your conversations with your customers would be helpful? ", "start_char_idx": 2077, "end_char_idx": 2151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65bf2359-8e30-42b0-aca5-7dbda8bb18b9": {"__data__": {"id_": "65bf2359-8e30-42b0-aca5-7dbda8bb18b9", "embedding": null, "metadata": {"window": "For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n", "original_text": "Thanks.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01746f08-a513-4429-85cc-df1798757c0f", "node_type": "1", "metadata": {"window": "I was hoping you could spend a little time talking about how w e \nshould think about the financial healthier customers and how you could see the business being impacted by that \nin the coming months and years.  For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question. ", "original_text": "Any insight into your conversations with your customers would be helpful? ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be5d7a43ed98657ce8356fe8dbe044d7374da26447c2fb8ea134c23cd48e5f23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f59689f-941e-4d03-8e90-59d2a9507181", "node_type": "1", "metadata": {"window": "So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "af47cde6dccb1880a696d2a36712d233e44037fe5499bfe7bed777ea5058a4c2", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2151, "end_char_idx": 2162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f59689f-941e-4d03-8e90-59d2a9507181": {"__data__": {"id_": "2f59689f-941e-4d03-8e90-59d2a9507181", "embedding": null, "metadata": {"window": "So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65bf2359-8e30-42b0-aca5-7dbda8bb18b9", "node_type": "1", "metadata": {"window": "For example, there are headlines in the news today where even large and well -\nfunded businesses are seeking reli ef from landlords.  So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n", "original_text": "Thanks.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18823b83bf8afad9d0582a31098febbd30db8fb64c8b4bf782792ad67f130e20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cce2bcb-cabc-4659-be8e-1974b7e29e71", "node_type": "1", "metadata": {"window": "Any insight into your conversations with your customers would be helpful?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n", "original_text": "A \nThan ks for that question, and it's a really good question. "}, "hash": "3efb5e7edbedfc5a6b88a0d3cd4c1275fc47f48c0cd9945ff0ea999c9930fb29", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2162, "end_char_idx": 2503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cce2bcb-cabc-4659-be8e-1974b7e29e71": {"__data__": {"id_": "4cce2bcb-cabc-4659-be8e-1974b7e29e71", "embedding": null, "metadata": {"window": "Any insight into your conversations with your customers would be helpful?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n", "original_text": "A \nThan ks for that question, and it's a really good question. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f59689f-941e-4d03-8e90-59d2a9507181", "node_type": "1", "metadata": {"window": "So, I guess, what, if anything, are your customers asking of \nyou at this stage?  Any insight into your conversations with your customers would be helpful?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22680faa6e1993152f2eab414b55b1aa70c604162d5e0d78ed5b25d1f556d2f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b3998d9-cdad-4443-b084-0e441a82a9c1", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses. ", "original_text": "And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n"}, "hash": "57828030cb84b15422de7aeb81cad8260e0b26f52d53e2ffbc3c8a1ecea5fc5a", "class_name": "RelatedNodeInfo"}}, "text": "A \nThan ks for that question, and it's a really good question. ", "start_char_idx": 2503, "end_char_idx": 2566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b3998d9-cdad-4443-b084-0e441a82a9c1": {"__data__": {"id_": "6b3998d9-cdad-4443-b084-0e441a82a9c1", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses. ", "original_text": "And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cce2bcb-cabc-4659-be8e-1974b7e29e71", "node_type": "1", "metadata": {"window": "Any insight into your conversations with your customers would be helpful?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n", "original_text": "A \nThan ks for that question, and it's a really good question. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b3bc16a047408f1f8a82589dc1d918f3a8621ba4609731060b1ca395988a60c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e90eb2f7-07e9-4d1f-8534-48040d44b2ba", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is. ", "original_text": "We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out. "}, "hash": "4559ce50ef886c9038c739b1a950a7769381651d7965094d12d1a897ff9ff77d", "class_name": "RelatedNodeInfo"}}, "text": "And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n", "start_char_idx": 2566, "end_char_idx": 2733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e90eb2f7-07e9-4d1f-8534-48040d44b2ba": {"__data__": {"id_": "e90eb2f7-07e9-4d1f-8534-48040d44b2ba", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is. ", "original_text": "We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b3998d9-cdad-4443-b084-0e441a82a9c1", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses. ", "original_text": "And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0a2d692c0a9bf5128882891c67e30d3b4aa3c8739ab80ecaeecf050d7165388", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e3125e5-bc70-4cbf-b928-2537f2df3e2e", "node_type": "1", "metadata": {"window": "A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point. ", "original_text": "It's \nreally more a mechanical adjustment.  \n \n"}, "hash": "00b4e49ba0b713f5c6ecd2decdf1c7be8204251d564881383d866584a9af1ede", "class_name": "RelatedNodeInfo"}}, "text": "We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out. ", "start_char_idx": 2733, "end_char_idx": 2846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e3125e5-bc70-4cbf-b928-2537f2df3e2e": {"__data__": {"id_": "9e3125e5-bc70-4cbf-b928-2537f2df3e2e", "embedding": null, "metadata": {"window": "A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point. ", "original_text": "It's \nreally more a mechanical adjustment.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e90eb2f7-07e9-4d1f-8534-48040d44b2ba", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is. ", "original_text": "We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1a41f02e443c8218fc4b477747b0b9561ffcfc142bc144ddcb872a84697505d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15f061a5-0898-4fc1-aa6b-55b20c1158a4", "node_type": "1", "metadata": {"window": "And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships. ", "original_text": "We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses. "}, "hash": "233f6afe63025bc4c17a3ee39ac66fa5bedb03c3037b3ad24db9a4a1c74531a3", "class_name": "RelatedNodeInfo"}}, "text": "It's \nreally more a mechanical adjustment.  \n \n", "start_char_idx": 2846, "end_char_idx": 2893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15f061a5-0898-4fc1-aa6b-55b20c1158a4": {"__data__": {"id_": "15f061a5-0898-4fc1-aa6b-55b20c1158a4", "embedding": null, "metadata": {"window": "And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships. ", "original_text": "We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e3125e5-bc70-4cbf-b928-2537f2df3e2e", "node_type": "1", "metadata": {"window": "A \nThan ks for that question, and it's a really good question.  And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point. ", "original_text": "It's \nreally more a mechanical adjustment.  \n \n", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6b9d594f62f940830c994b9bdb79464703cc0ba90eaefaa5ebc92a8b63d3865", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93718238-1705-4323-9303-f825cb564c96", "node_type": "1", "metadata": {"window": "We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n ", "original_text": "And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is. "}, "hash": "012bb867efff9c36bdb62219e40ebc2e873d9f0f8d6d98561c006a582d579e1d", "class_name": "RelatedNodeInfo"}}, "text": "We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses. ", "start_char_idx": 2893, "end_char_idx": 3030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93718238-1705-4323-9303-f825cb564c96": {"__data__": {"id_": "93718238-1705-4323-9303-f825cb564c96", "embedding": null, "metadata": {"window": "We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n ", "original_text": "And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15f061a5-0898-4fc1-aa6b-55b20c1158a4", "node_type": "1", "metadata": {"window": "And we've been working with our customers since the \npandemic really started, and particularly those customers who have had to shut their doors on a temporary basis. \n We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships. ", "original_text": "We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d700af073bd8015cd873e06d19933a79c8f56930cc80e315c847824f95f1afc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f311363c-f86e-48f0-965e-64a4839ed8f8", "node_type": "1", "metadata": {"window": "It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "So we've not really seen a degradation in credit quality to this point. "}, "hash": "073fff775bd91f43d22bb4136dc64a78f0ff2dc78facdb9cb6fcc9c3c1748bf0", "class_name": "RelatedNodeInfo"}}, "text": "And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is. ", "start_char_idx": 3030, "end_char_idx": 3261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f311363c-f86e-48f0-965e-64a4839ed8f8": {"__data__": {"id_": "f311363c-f86e-48f0-965e-64a4839ed8f8", "embedding": null, "metadata": {"window": "It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "So we've not really seen a degradation in credit quality to this point. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93718238-1705-4323-9303-f825cb564c96", "node_type": "1", "metadata": {"window": "We did record a small incremental re serve in our medical business in the fourth quarter, and I called that out.  It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n ", "original_text": "And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2721601d1517f4de879d4f86af6ec4b779366743763cffc5af82f386d7686efc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b91477d-7375-4a39-b0d8-e4172b29b1d6", "node_type": "1", "metadata": {"window": "We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "We'll continue to work \nvery closely with those relationships. "}, "hash": "612ee67060ca7a0c6e8e0bd6e57eec4e9fab026b23e20e9297905081a49f145d", "class_name": "RelatedNodeInfo"}}, "text": "So we've not really seen a degradation in credit quality to this point. ", "start_char_idx": 3261, "end_char_idx": 3333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b91477d-7375-4a39-b0d8-e4172b29b1d6": {"__data__": {"id_": "6b91477d-7375-4a39-b0d8-e4172b29b1d6", "embedding": null, "metadata": {"window": "We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "We'll continue to work \nvery closely with those relationships. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f311363c-f86e-48f0-965e-64a4839ed8f8", "node_type": "1", "metadata": {"window": "It's \nreally more a mechanical adjustment.  \n \n We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "So we've not really seen a degradation in credit quality to this point. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3284f6c188455c5b94dca0e170229c7fd3b63ddd2cafba947909890b59c24754", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea793e11-d4a1-4d0f-8bb5-d5f51d05e558", "node_type": "1", "metadata": {"window": "And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event. ", "original_text": "At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n "}, "hash": "fde81962e025a3cd6bd3da60c9d9922d2cec8dc209865bf18d6ee6090a08a282", "class_name": "RelatedNodeInfo"}}, "text": "We'll continue to work \nvery closely with those relationships. ", "start_char_idx": 3333, "end_char_idx": 3396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea793e11-d4a1-4d0f-8bb5-d5f51d05e558": {"__data__": {"id_": "ea793e11-d4a1-4d0f-8bb5-d5f51d05e558", "embedding": null, "metadata": {"window": "And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event. ", "original_text": "At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b91477d-7375-4a39-b0d8-e4172b29b1d6", "node_type": "1", "metadata": {"window": "We've been working very closely to try to understand when these customers would reopen, what the demand is in \neach of their businesses.  And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "We'll continue to work \nvery closely with those relationships. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02f1f43aac7cac60f1d71bf9782358c1d818c2b4d74f78c782014b25020b8b95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba588ef1-d2d0-4c98-9246-746f15815fa4", "node_type": "1", "metadata": {"window": "So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "4172437cf5791f19357a3fdc7c089ae0a876b6e6360c66461188b89950372562", "class_name": "RelatedNodeInfo"}}, "text": "At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n ", "start_char_idx": 3396, "end_char_idx": 3553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba588ef1-d2d0-4c98-9246-746f15815fa4": {"__data__": {"id_": "ba588ef1-d2d0-4c98-9246-746f15815fa4", "embedding": null, "metadata": {"window": "So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea793e11-d4a1-4d0f-8bb5-d5f51d05e558", "node_type": "1", "metadata": {"window": "And to this point, our customers have either been able to go out and get loans or access \npublic funds that are available, work very closely with us, and we've been able to help them and really understand \nwhat their situation is.  So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event. ", "original_text": "At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ca8e6a9a72a51927d9028fe0a5d6a29bb67ff00b4c927a43a8ed603c5130cea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f7aaf34-3b73-4936-9fe2-e5ace0e09f50", "node_type": "1", "metadata": {"window": "We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n ", "original_text": "A \nYeah. "}, "hash": "4222e9ffcab7aaca0b21d1cc86ac8db211031b428c1e06a1c6b0abe8ab36ddb2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3553, "end_char_idx": 3913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f7aaf34-3b73-4936-9fe2-e5ace0e09f50": {"__data__": {"id_": "1f7aaf34-3b73-4936-9fe2-e5ace0e09f50", "embedding": null, "metadata": {"window": "We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba588ef1-d2d0-4c98-9246-746f15815fa4", "node_type": "1", "metadata": {"window": "So we've not really seen a degradation in credit quality to this point.  We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9eb4691793f91049acb202708634d5f19b539c5c0fdcfc1fcaa6c4128b257bb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb6c3d80-3952-45c7-87d3-14c4c3f0eb4b", "node_type": "1", "metadata": {"window": "At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n ", "original_text": "And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event. "}, "hash": "862ccfaa7a7980efa03143119b7dc03baa8c7bcc3be2563954b4505db81cf422", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 269, "end_char_idx": 278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb6c3d80-3952-45c7-87d3-14c4c3f0eb4b": {"__data__": {"id_": "cb6c3d80-3952-45c7-87d3-14c4c3f0eb4b", "embedding": null, "metadata": {"window": "At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n ", "original_text": "And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f7aaf34-3b73-4936-9fe2-e5ace0e09f50", "node_type": "1", "metadata": {"window": "We'll continue to work \nvery closely with those relationships.  At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "214782f558c617cfac483525cb0ebdec4278e1023ee2d54a3e214a6daca603f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36d8701a-3ffa-4f9f-bdf9-2814e6705e74", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true. "}, "hash": "e1baf4c366d24ef04381ee284d5eb1e67b151e436c537287baba4c0b20d21574", "class_name": "RelatedNodeInfo"}}, "text": "And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event. ", "start_char_idx": 3922, "end_char_idx": 4166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36d8701a-3ffa-4f9f-bdf9-2814e6705e74": {"__data__": {"id_": "36d8701a-3ffa-4f9f-bdf9-2814e6705e74", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb6c3d80-3952-45c7-87d3-14c4c3f0eb4b", "node_type": "1", "metadata": {"window": "At this point, I think our customers are very resilient as well, and we're very \nclose in working with them to keep them as credit resilient as possib le. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n ", "original_text": "And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04bd580fd5b65aa2198fb7576038d56c27d46b98801e668f890edad301416901", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a773db0f-9f0c-4035-af54-f2b0ec50ea71", "node_type": "1", "metadata": {"window": "A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat. ", "original_text": "So, risk, we'll monitor very closely  over the course of the year.  \n "}, "hash": "826d89892f624f44fd0dc27cd305b9f3efc512a0d7ad917bd52cd95f7c75f06e", "class_name": "RelatedNodeInfo"}}, "text": "Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true. ", "start_char_idx": 4166, "end_char_idx": 4302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a773db0f-9f0c-4035-af54-f2b0ec50ea71": {"__data__": {"id_": "a773db0f-9f0c-4035-af54-f2b0ec50ea71", "embedding": null, "metadata": {"window": "A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat. ", "original_text": "So, risk, we'll monitor very closely  over the course of the year.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36d8701a-3ffa-4f9f-bdf9-2814e6705e74", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3a285860b1a8fe6be32f10611426ccbda02b04c504141a49d9513de2c0e30bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "710d771f-d5a0-4fd4-9ce6-abf6c7de77dd", "node_type": "1", "metadata": {"window": "And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n "}, "hash": "14f06945dccf071c7d3a36e43a76a8ea731c1620963f34d2a3d174a711ca6771", "class_name": "RelatedNodeInfo"}}, "text": "So, risk, we'll monitor very closely  over the course of the year.  \n ", "start_char_idx": 4302, "end_char_idx": 4372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "710d771f-d5a0-4fd4-9ce6-abf6c7de77dd": {"__data__": {"id_": "710d771f-d5a0-4fd4-9ce6-abf6c7de77dd", "embedding": null, "metadata": {"window": "And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a773db0f-9f0c-4035-af54-f2b0ec50ea71", "node_type": "1", "metadata": {"window": "A \nYeah.  And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat. ", "original_text": "So, risk, we'll monitor very closely  over the course of the year.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20eb93d3b2adefbfd93bb5a83cf051990fcd2d24aa547134ded0342735d0b48c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba28c47a-e011-4cfa-a52f-6e66887da0a0", "node_type": "1", "metadata": {"window": "Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, Brian and Britt. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  "}, "hash": "7a721037e527397447148da0494a8c71ac1de9faf7917cdadef7be4eec21f8fb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n ", "start_char_idx": 4372, "end_char_idx": 4735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba28c47a-e011-4cfa-a52f-6e66887da0a0": {"__data__": {"id_": "ba28c47a-e011-4cfa-a52f-6e66887da0a0", "embedding": null, "metadata": {"window": "Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, Brian and Britt. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "710d771f-d5a0-4fd4-9ce6-abf6c7de77dd", "node_type": "1", "metadata": {"window": "And based on the way we've described our expectation for volume to come back gradually over the course \nof the year and based on what we see now, you did cal l out that we built into our assumptions is that there is no \nmajor insolvency event.  Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c2adf7a99d7a5d5101e61e6bd0ad267d6139de65822ded1296fdbd320627698", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1b83846-c5d7-47ba-b15b-4e95e48f034f", "node_type": "1", "metadata": {"window": "So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, Brian and Britt.  I hope everyone is staying safe. ", "original_text": "Q \nGreat. "}, "hash": "c4c9e438a8c0d8b30bbe63a2165d7d122da73953e9767a3e177fbec2732f2974", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "start_char_idx": 4735, "end_char_idx": 5060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1b83846-c5d7-47ba-b15b-4e95e48f034f": {"__data__": {"id_": "b1b83846-c5d7-47ba-b15b-4e95e48f034f", "embedding": null, "metadata": {"window": "So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, Brian and Britt.  I hope everyone is staying safe. ", "original_text": "Q \nGreat. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba28c47a-e011-4cfa-a52f-6e66887da0a0", "node_type": "1", "metadata": {"window": "Now, if our assumptions play out correct, we believe based on our conversations and \nwhat we are seeing, that will continue to be true.  So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, Brian and Britt. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72aab764faf6c4db36af5605edb671c807234d9cd585e47d5a0de8a6cc866e0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2ca0c43-bfba-4ffb-8789-6a95ee5af26c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, Brian and Britt.  I hope everyone is staying safe.  So I  just have two interrelated \nquestions on the European business. ", "original_text": "Thanks. "}, "hash": "9cd5bee94dcb1445686cf0e659b1b3090e5237836484491a2920de54487931ec", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGreat. ", "start_char_idx": 5060, "end_char_idx": 5070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2ca0c43-bfba-4ffb-8789-6a95ee5af26c": {"__data__": {"id_": "b2ca0c43-bfba-4ffb-8789-6a95ee5af26c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, Brian and Britt.  I hope everyone is staying safe.  So I  just have two interrelated \nquestions on the European business. ", "original_text": "Thanks. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1b83846-c5d7-47ba-b15b-4e95e48f034f", "node_type": "1", "metadata": {"window": "So, risk, we'll monitor very closely  over the course of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, Brian and Britt.  I hope everyone is staying safe. ", "original_text": "Q \nGreat. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "457a0911f53d06ac5a401ad39f2863fa89a3ec19418b236e1cfc5832aa58216f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9af25d68-f9e4-4f71-8ef4-ae82019c2a39", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, Brian and Britt.  I hope everyone is staying safe.  So I  just have two interrelated \nquestions on the European business.  First, I guess, I'm curious how the German JV transaction with Walgreens ", "original_text": "Good morning, Brian and Britt. "}, "hash": "4f346a5c03dc8b358a41ab2265f35f8579d6d06d8ee29af670176a67e48665e5", "class_name": "RelatedNodeInfo"}}, "text": "Thanks. ", "start_char_idx": 2151, "end_char_idx": 2159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9af25d68-f9e4-4f71-8ef4-ae82019c2a39": {"__data__": {"id_": "9af25d68-f9e4-4f71-8ef4-ae82019c2a39", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, Brian and Britt.  I hope everyone is staying safe.  So I  just have two interrelated \nquestions on the European business.  First, I guess, I'm curious how the German JV transaction with Walgreens ", "original_text": "Good morning, Brian and Britt. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2ca0c43-bfba-4ffb-8789-6a95ee5af26c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, Brian and Britt.  I hope everyone is staying safe.  So I  just have two interrelated \nquestions on the European business. ", "original_text": "Thanks. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47c0bedfcca0a639b8008332eee84806eef9d31f4762f87a80ba25216fcbabde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4654289-7188-4ee8-804a-b8d29224e84f", "node_type": "1", "metadata": {"window": "Q \nGreat.  Thanks.  Good morning, Brian and Britt.  I hope everyone is staying safe.  So I  just have two interrelated \nquestions on the European business.  First, I guess, I'm curious how the German JV transaction with Walgreens ", "original_text": "I hope everyone is staying safe. "}, "hash": "2cb55fe178cb661943ba5ce35696028e8b56c4d82eb4f425bcd8735b7f7afab2", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, Brian and Britt. ", "start_char_idx": 5078, "end_char_idx": 5109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4654289-7188-4ee8-804a-b8d29224e84f": {"__data__": {"id_": "a4654289-7188-4ee8-804a-b8d29224e84f", "embedding": null, "metadata": {"window": "Q \nGreat.  Thanks.  Good morning, Brian and Britt.  I hope everyone is staying safe.  So I  just have two interrelated \nquestions on the European business.  First, I guess, I'm curious how the German JV transaction with Walgreens ", "original_text": "I hope everyone is staying safe. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9af25d68-f9e4-4f71-8ef4-ae82019c2a39", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good morning, Brian and Britt.  I hope everyone is staying safe.  So I  just have two interrelated \nquestions on the European business.  First, I guess, I'm curious how the German JV transaction with Walgreens ", "original_text": "Good morning, Brian and Britt. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa3d9eb7f036e8f9109e9a713a47127cbccd9216a1a8f37681007b6135d45e8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1736811d-3b89-479e-b1cd-93622c334845", "node_type": "1", "metadata": {"window": "Thanks.  Good morning, Brian and Britt.  I hope everyone is staying safe.  So I  just have two interrelated \nquestions on the European business.  First, I guess, I'm curious how the German JV transaction with Walgreens ", "original_text": "So I  just have two interrelated \nquestions on the European business. "}, "hash": "21c6ab09487a935638246a8db5ad61c7f3a4f4ab96f3554a97b168d397ca8102", "class_name": "RelatedNodeInfo"}}, "text": "I hope everyone is staying safe. ", "start_char_idx": 5109, "end_char_idx": 5142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1736811d-3b89-479e-b1cd-93622c334845": {"__data__": {"id_": "1736811d-3b89-479e-b1cd-93622c334845", "embedding": null, "metadata": {"window": "Thanks.  Good morning, Brian and Britt.  I hope everyone is staying safe.  So I  just have two interrelated \nquestions on the European business.  First, I guess, I'm curious how the German JV transaction with Walgreens ", "original_text": "So I  just have two interrelated \nquestions on the European business. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4654289-7188-4ee8-804a-b8d29224e84f", "node_type": "1", "metadata": {"window": "Q \nGreat.  Thanks.  Good morning, Brian and Britt.  I hope everyone is staying safe.  So I  just have two interrelated \nquestions on the European business.  First, I guess, I'm curious how the German JV transaction with Walgreens ", "original_text": "I hope everyone is staying safe. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c166acaab6edbc7be78ffe5e563179ffd815c288f3d6763727a7516cea6b1089", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75af7e69-1ba9-4e74-988c-e5858129cae5", "node_type": "1", "metadata": {"window": "Good morning, Brian and Britt.  I hope everyone is staying safe.  So I  just have two interrelated \nquestions on the European business.  First, I guess, I'm curious how the German JV transaction with Walgreens ", "original_text": "First, I guess, I'm curious how the German JV transaction with Walgreens "}, "hash": "b6a2693ba2ba6470b4eb9180e1eea52e11711e0d14af7fa3581f6faf6fd00693", "class_name": "RelatedNodeInfo"}}, "text": "So I  just have two interrelated \nquestions on the European business. ", "start_char_idx": 5142, "end_char_idx": 5212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75af7e69-1ba9-4e74-988c-e5858129cae5": {"__data__": {"id_": "75af7e69-1ba9-4e74-988c-e5858129cae5", "embedding": null, "metadata": {"window": "Good morning, Brian and Britt.  I hope everyone is staying safe.  So I  just have two interrelated \nquestions on the European business.  First, I guess, I'm curious how the German JV transaction with Walgreens ", "original_text": "First, I guess, I'm curious how the German JV transaction with Walgreens ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1924040d6538326883f4c875a6d0f76dd6a4383ddd18c7d0b4d10e24908250bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1736811d-3b89-479e-b1cd-93622c334845", "node_type": "1", "metadata": {"window": "Thanks.  Good morning, Brian and Britt.  I hope everyone is staying safe.  So I  just have two interrelated \nquestions on the European business.  First, I guess, I'm curious how the German JV transaction with Walgreens ", "original_text": "So I  just have two interrelated \nquestions on the European business. ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea1eb23d4fb4cfe2aa4ece442a9615c3e845a612b639b8e78abb8b266d43ead1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d990a539-b066-418a-9505-820ffd73f9de", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n ", "original_text": "McKesson Corp.  "}, "hash": "525aa4a05ea0a3e09c7ede064a830ba5508a48b570e726d5028878a328d14d7a", "class_name": "RelatedNodeInfo"}}, "text": "First, I guess, I'm curious how the German JV transaction with Walgreens ", "start_char_idx": 5212, "end_char_idx": 5285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d990a539-b066-418a-9505-820ffd73f9de": {"__data__": {"id_": "d990a539-b066-418a-9505-820ffd73f9de", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75af7e69-1ba9-4e74-988c-e5858129cae5", "node_type": "1", "metadata": {"window": "Good morning, Brian and Britt.  I hope everyone is staying safe.  So I  just have two interrelated \nquestions on the European business.  First, I guess, I'm curious how the German JV transaction with Walgreens ", "original_text": "First, I guess, I'm curious how the German JV transaction with Walgreens ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0987383f743cd779a103baac298f3cb655e6ed877d0ec9c0a673c2624afed471", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc757813-0fc8-4145-a320-6ba0c6a781c8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments. "}, "hash": "95b81322c79be9c31fc2d0dfea6553e7080b7cb7984dfe2c8ed317dc4c814d7f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc757813-0fc8-4145-a320-6ba0c6a781c8": {"__data__": {"id_": "cc757813-0fc8-4145-a320-6ba0c6a781c8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d990a539-b066-418a-9505-820ffd73f9de", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a122c1a32907a936947d93ac7052bbb385eecc38e7a927dbe2d8557bd0898abf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9075f32-c828-4eb5-869f-fd3eff235948", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021. ", "original_text": "Any color on the dynamics there would help as well. "}, "hash": "a3ee9c5c8ef4294a4475b0062229deccc6357071bd7da654d754ae4ef14ea2df", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments. ", "start_char_idx": 16, "end_char_idx": 676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9075f32-c828-4eb5-869f-fd3eff235948": {"__data__": {"id_": "d9075f32-c828-4eb5-869f-fd3eff235948", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021. ", "original_text": "Any color on the dynamics there would help as well. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc757813-0fc8-4145-a320-6ba0c6a781c8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7b17baf5599504c949a93db6371b56107a7c44b9535d337e508a90e84c31b29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfbac72d-2b84-4a3a-988c-e20bee728ecf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now. ", "original_text": "Thanks.  \n "}, "hash": "62aea515f8cc7965ab8a31dfe6f5f53a195916cc45801b6c152a00b7b460cff9", "class_name": "RelatedNodeInfo"}}, "text": "Any color on the dynamics there would help as well. ", "start_char_idx": 676, "end_char_idx": 728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfbac72d-2b84-4a3a-988c-e20bee728ecf": {"__data__": {"id_": "dfbac72d-2b84-4a3a-988c-e20bee728ecf", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now. ", "original_text": "Thanks.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9075f32-c828-4eb5-869f-fd3eff235948", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021. ", "original_text": "Any color on the dynamics there would help as well. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef2474bce857349e117980e50123a5055ac404a30354b4af8f14c7b760549df3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13eb746d-a7aa-46da-9453-d46441c138bb", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "b0063c60df02460652e82e5b6a93c19c207876e80e90a4940e4799b34da9b9f4", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 728, "end_char_idx": 739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13eb746d-a7aa-46da-9453-d46441c138bb": {"__data__": {"id_": "13eb746d-a7aa-46da-9453-d46441c138bb", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfbac72d-2b84-4a3a-988c-e20bee728ecf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now. ", "original_text": "Thanks.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7050da0b578e7983e2e913d85f5d6f3034dfcc58bce940d6e55b06ccdd63c8f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2f4593c-1dde-4f38-9f0f-d9dc0b06ea0d", "node_type": "1", "metadata": {"window": "Any color on the dynamics there would help as well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge. ", "original_text": "A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021. "}, "hash": "c94f2d581af6d1173f473eda2ce1d96b66bc5cbe0f7b6ced32bfcb1d20ada850", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 739, "end_char_idx": 1080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2f4593c-1dde-4f38-9f0f-d9dc0b06ea0d": {"__data__": {"id_": "f2f4593c-1dde-4f38-9f0f-d9dc0b06ea0d", "embedding": null, "metadata": {"window": "Any color on the dynamics there would help as well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge. ", "original_text": "A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13eb746d-a7aa-46da-9453-d46441c138bb", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e5df8be714b68690cdd4f80c3ed144bf2a07c7eb5cd95050cd44ef22dc14144", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "192ffac8-602b-4a1b-8277-42b85fdf7cd2", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be. ", "original_text": "It is in competition \nreview right now. "}, "hash": "7e3df5d4ece343e8815fd988234b732ba690d43884cb366578a27f65d29cd80d", "class_name": "RelatedNodeInfo"}}, "text": "A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021. ", "start_char_idx": 1080, "end_char_idx": 1180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "192ffac8-602b-4a1b-8277-42b85fdf7cd2": {"__data__": {"id_": "192ffac8-602b-4a1b-8277-42b85fdf7cd2", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be. ", "original_text": "It is in competition \nreview right now. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2f4593c-1dde-4f38-9f0f-d9dc0b06ea0d", "node_type": "1", "metadata": {"window": "Any color on the dynamics there would help as well.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge. ", "original_text": "A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7581891b3901fcacd77f620bf6037bc8dd3314a0f96a20373998855d5927d1cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29153c8c-3b4c-455b-9c1c-6e64f6c7d974", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n ", "original_text": "We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n"}, "hash": "11801dd511e71135ab94cd6da63c7299c2cf62053b607561c91b53acf69dcda7", "class_name": "RelatedNodeInfo"}}, "text": "It is in competition \nreview right now. ", "start_char_idx": 1180, "end_char_idx": 1220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29153c8c-3b4c-455b-9c1c-6e64f6c7d974": {"__data__": {"id_": "29153c8c-3b4c-455b-9c1c-6e64f6c7d974", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n ", "original_text": "We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "192ffac8-602b-4a1b-8277-42b85fdf7cd2", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be. ", "original_text": "It is in competition \nreview right now. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd4bc930631708879ccf0419134d06fe733aba3bcefcc7247b806d55ec52772e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0be952f3-1fc7-41a6-8767-279a3078d87b", "node_type": "1", "metadata": {"window": "A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge. "}, "hash": "ae4d7d5190f1c5e110e14d0173e6e7d6c18aa843349bb05a2f0cf3316d62a78b", "class_name": "RelatedNodeInfo"}}, "text": "We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n", "start_char_idx": 1220, "end_char_idx": 1330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0be952f3-1fc7-41a6-8767-279a3078d87b": {"__data__": {"id_": "0be952f3-1fc7-41a6-8767-279a3078d87b", "embedding": null, "metadata": {"window": "A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29153c8c-3b4c-455b-9c1c-6e64f6c7d974", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n ", "original_text": "We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1aab6969423bdd471c5b808a9e5e8e9d191f48ba2a0baff7ff08b7a87650176d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47ad31d5-32ed-45bf-91e4-44a4691a6ac9", "node_type": "1", "metadata": {"window": "It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results. ", "original_text": "And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be. "}, "hash": "be87c9309fc7d5b6cc861576689fcac9c016259e62a7a30184f854080319c36c", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge. ", "start_char_idx": 1330, "end_char_idx": 1573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47ad31d5-32ed-45bf-91e4-44a4691a6ac9": {"__data__": {"id_": "47ad31d5-32ed-45bf-91e4-44a4691a6ac9", "embedding": null, "metadata": {"window": "It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results. ", "original_text": "And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0be952f3-1fc7-41a6-8767-279a3078d87b", "node_type": "1", "metadata": {"window": "A \nGenerally,  so start with the German JV, I don't think this will be material to our fiscal 2021.  It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1010f9f442b82426b2b7e6fcaad0726c177abaec105097dd89606791c83f94b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d56d6d0a-91b8-4de4-8788-02dce0d3b647", "node_type": "1", "metadata": {"window": "We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan. ", "original_text": "I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n "}, "hash": "1cb48612e334290a8e1e6081c28e9469f157f0b14b8a826cb657f819ea323a48", "class_name": "RelatedNodeInfo"}}, "text": "And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be. ", "start_char_idx": 1573, "end_char_idx": 1716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d56d6d0a-91b8-4de4-8788-02dce0d3b647": {"__data__": {"id_": "d56d6d0a-91b8-4de4-8788-02dce0d3b647", "embedding": null, "metadata": {"window": "We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan. ", "original_text": "I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47ad31d5-32ed-45bf-91e4-44a4691a6ac9", "node_type": "1", "metadata": {"window": "It is in competition \nreview right now.  We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results. ", "original_text": "And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b69f8fd06d2574123d0778fca9882b114576c2a0e913091ae52c3e9aab0826f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d029efc-a78f-42d0-9305-1daca853392a", "node_type": "1", "metadata": {"window": "As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "01604f74defda0a79e3e0d5a9f966b707935fd684e376f84ccddfde95ce4b7a5", "class_name": "RelatedNodeInfo"}}, "text": "I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n ", "start_char_idx": 1716, "end_char_idx": 1966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d029efc-a78f-42d0-9305-1daca853392a": {"__data__": {"id_": "6d029efc-a78f-42d0-9305-1daca853392a", "embedding": null, "metadata": {"window": "As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d56d6d0a-91b8-4de4-8788-02dce0d3b647", "node_type": "1", "metadata": {"window": "We think it's continuing to progress on the timelines we expected to, so not really a lot to add to \nthat. \n \n As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan. ", "original_text": "I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ecd6131c99adf0ddbf7b3c3d9952b9f710c7230a2b6a5b693a83d4a4658217fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e6da954-4a8f-4cc7-8c92-d630eacd196c", "node_type": "1", "metadata": {"window": "And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance. ", "original_text": "A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results. "}, "hash": "2531909a9da0b23485e2a0f721cfda8aa83a74102adc9f6c914dc70079372f2e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 1966, "end_char_idx": 2326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e6da954-4a8f-4cc7-8c92-d630eacd196c": {"__data__": {"id_": "8e6da954-4a8f-4cc7-8c92-d630eacd196c", "embedding": null, "metadata": {"window": "And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance. ", "original_text": "A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d029efc-a78f-42d0-9305-1daca853392a", "node_type": "1", "metadata": {"window": "As it relates to the fis cal 2021 impact on Europe, I mean, obviously, we're dealing with 13 countries that are going \nto have \u2013 have had 13 different kind of degrees of challenge and reaction with associated social policy to that \nchallenge.  And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f5ec5a067d89d5b8795b2a695a2a1369e939b4ef62da5e8eb8b4b8b66c7b3de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29f48664-5c0c-4b51-bffb-3e7ba5b09e4e", "node_type": "1", "metadata": {"window": "I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n", "original_text": "It is included \u2013 we did include Germany in our FY 2021 plan. "}, "hash": "891cd160cf31a4b0bc312636ddeabbbff87d6199844a2b8fc6915afa099c39ec", "class_name": "RelatedNodeInfo"}}, "text": "A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results. ", "start_char_idx": 2326, "end_char_idx": 2471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29f48664-5c0c-4b51-bffb-3e7ba5b09e4e": {"__data__": {"id_": "29f48664-5c0c-4b51-bffb-3e7ba5b09e4e", "embedding": null, "metadata": {"window": "I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n", "original_text": "It is included \u2013 we did include Germany in our FY 2021 plan. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e6da954-4a8f-4cc7-8c92-d630eacd196c", "node_type": "1", "metadata": {"window": "And so, when we look at an aggregate lev el, it's going to depend a little bit on how these countries \nreopen and what their response will be.  I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance. ", "original_text": "A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3ec2087e371aca639a3eee868b52ead0c93190ab4c9d1b6bda7c9c574a0c8a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8940454-451c-46ba-977d-cfdc52754ea0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot. ", "original_text": "But again, it's relatively \nimmaterial.  \n \n"}, "hash": "a784018954206e083210252f21795fc77f2a003a951a7274e22c5958bd00b0bc", "class_name": "RelatedNodeInfo"}}, "text": "It is included \u2013 we did include Germany in our FY 2021 plan. ", "start_char_idx": 2471, "end_char_idx": 2532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8940454-451c-46ba-977d-cfdc52754ea0": {"__data__": {"id_": "c8940454-451c-46ba-977d-cfdc52754ea0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot. ", "original_text": "But again, it's relatively \nimmaterial.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29f48664-5c0c-4b51-bffb-3e7ba5b09e4e", "node_type": "1", "metadata": {"window": "I will say that in the UK, our largest country in Europe, I mean, they have \nbeen one of the more severely impacted and have had some of the more severe soc ial restrictions implied, and \nthat's what you're seeing really flow through our numbers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n", "original_text": "It is included \u2013 we did include Germany in our FY 2021 plan. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2585ee24bddc1f46568bf9314a344eac306c0ccfa51b8a91159da7242eead6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b28e6d6-58bb-48f1-ac17-187437f17e6f", "node_type": "1", "metadata": {"window": "A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n ", "original_text": "I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance. "}, "hash": "c312c19f1cb1382119115c8b88a7892328c710c556cbc69997d2199520b73306", "class_name": "RelatedNodeInfo"}}, "text": "But again, it's relatively \nimmaterial.  \n \n", "start_char_idx": 2532, "end_char_idx": 2576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b28e6d6-58bb-48f1-ac17-187437f17e6f": {"__data__": {"id_": "9b28e6d6-58bb-48f1-ac17-187437f17e6f", "embedding": null, "metadata": {"window": "A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n ", "original_text": "I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8940454-451c-46ba-977d-cfdc52754ea0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot. ", "original_text": "But again, it's relatively \nimmaterial.  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8b5d58c5d0efe4129f782f3ff03e576e5ebfa67faee6594f6efbc1e3fb427e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f479543-3b4b-42f2-b5e0-efa32d56b004", "node_type": "1", "metadata": {"window": "It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n"}, "hash": "0caea1f0e1339bdbb5c66207e1ff2d4f67a4db823c62882fd38f728e6272fe24", "class_name": "RelatedNodeInfo"}}, "text": "I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance. ", "start_char_idx": 2576, "end_char_idx": 2728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f479543-3b4b-42f2-b5e0-efa32d56b004": {"__data__": {"id_": "5f479543-3b4b-42f2-b5e0-efa32d56b004", "embedding": null, "metadata": {"window": "It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b28e6d6-58bb-48f1-ac17-187437f17e6f", "node_type": "1", "metadata": {"window": "A \nMaybe if I would just add on, our German business, as we talked about previou sly, is relatively immaterial to the \noverall European results.  It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n ", "original_text": "I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "958af0e6bc2ebb886f55f92c8ed4a327ff48d3a34cd80022ba7ba36ec37b76ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "139b4aca-d3b5-462c-ba28-91407d1c3a6d", "node_type": "1", "metadata": {"window": "But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "And as Brian mentioned, mix matters a lot. "}, "hash": "ea8ac48252f6af47120845ac83c3c39263e0d69da57ef18ec07c5a0ca2dc2c97", "class_name": "RelatedNodeInfo"}}, "text": "And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n", "start_char_idx": 2728, "end_char_idx": 2922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "139b4aca-d3b5-462c-ba28-91407d1c3a6d": {"__data__": {"id_": "139b4aca-d3b5-462c-ba28-91407d1c3a6d", "embedding": null, "metadata": {"window": "But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "And as Brian mentioned, mix matters a lot. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f479543-3b4b-42f2-b5e0-efa32d56b004", "node_type": "1", "metadata": {"window": "It is included \u2013 we did include Germany in our FY 2021 plan.  But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06efcf82cfa11b2426a88e0ec00893b44e08f43ecbaa4d965f492355b7e7cc80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47a397ca-ddcf-4ce1-8408-c7911b2eddf8", "node_type": "1", "metadata": {"window": "I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n "}, "hash": "669b388e0464c91b16b39c94970de670d2486ac76a12b463b4c54a535060c6d1", "class_name": "RelatedNodeInfo"}}, "text": "And as Brian mentioned, mix matters a lot. ", "start_char_idx": 2922, "end_char_idx": 2965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47a397ca-ddcf-4ce1-8408-c7911b2eddf8": {"__data__": {"id_": "47a397ca-ddcf-4ce1-8408-c7911b2eddf8", "embedding": null, "metadata": {"window": "I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "139b4aca-d3b5-462c-ba28-91407d1c3a6d", "node_type": "1", "metadata": {"window": "But again, it's relatively \nimmaterial.  \n \n I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "And as Brian mentioned, mix matters a lot. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29988aa7f8758e8a25d7ce141102309c7ecc4db8e14ac8d30a2ac8614e63afd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99423f8f-19c1-4f23-828b-edc5537a9d33", "node_type": "1", "metadata": {"window": "And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n "}, "hash": "ff9f35ed90fee9613c33bc98207fa973aff20561a714cf3b64f996237a8a1bff", "class_name": "RelatedNodeInfo"}}, "text": "How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n ", "start_char_idx": 2965, "end_char_idx": 3146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99423f8f-19c1-4f23-828b-edc5537a9d33": {"__data__": {"id_": "99423f8f-19c1-4f23-828b-edc5537a9d33", "embedding": null, "metadata": {"window": "And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47a397ca-ddcf-4ce1-8408-c7911b2eddf8", "node_type": "1", "metadata": {"window": "I would just point to the fact that our second half European results in FY 2020 were quite good and we exited the \nyear with pretty strong performance.  And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65c50d1dd0770e73d5c217e101a4589030bfb1eedd17567a431500e3ac99974e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7dfd16d-7414-41ce-9ec8-42a53e778330", "node_type": "1", "metadata": {"window": "And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "adcf1c5c566673edfb4c4300eda8ce1c17b12a9ad24ec8f1b7016d18b15c81e2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n ", "start_char_idx": 3146, "end_char_idx": 3515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7dfd16d-7414-41ce-9ec8-42a53e778330": {"__data__": {"id_": "a7dfd16d-7414-41ce-9ec8-42a53e778330", "embedding": null, "metadata": {"window": "And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99423f8f-19c1-4f23-828b-edc5537a9d33", "node_type": "1", "metadata": {"window": "And as we think about FY 2021, really gets back to what we've talked about \nwith many of our other businesses that there is a temporary shock that is more severe in the first half of the year. \n And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04607c294f89aa516dc31e805b5650cf3d26b5d165dd4229b8f3fc7217f27340", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a3c004b-e261-4dc6-a223-ca3fe57b6d36", "node_type": "1", "metadata": {"window": "How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  My question is focused on generic pricing. ", "original_text": "LLC  Q \nYeah. "}, "hash": "af2772c33ec56c5116860454b115fd7724309a0d465bf610771c9efa6a1245da", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 3515, "end_char_idx": 3839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a3c004b-e261-4dc6-a223-ca3fe57b6d36": {"__data__": {"id_": "4a3c004b-e261-4dc6-a223-ca3fe57b6d36", "embedding": null, "metadata": {"window": "How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  My question is focused on generic pricing. ", "original_text": "LLC  Q \nYeah. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7dfd16d-7414-41ce-9ec8-42a53e778330", "node_type": "1", "metadata": {"window": "And as Brian mentioned, mix matters a lot.  How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1622631a0a571de89989a03c91b8bd848d4e69ea03c9ccf377976717ccb735df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0706bfe6-07f8-48a4-b5c8-0858e6c7e633", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up. ", "original_text": "Hi. "}, "hash": "5c31a829101c7c43f79405b41cb0d7a11aeb393d9c34a5053a1222c71a62aef1", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah. ", "start_char_idx": 3839, "end_char_idx": 3853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0706bfe6-07f8-48a4-b5c8-0858e6c7e633": {"__data__": {"id_": "0706bfe6-07f8-48a4-b5c8-0858e6c7e633", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up. ", "original_text": "Hi. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a3c004b-e261-4dc6-a223-ca3fe57b6d36", "node_type": "1", "metadata": {"window": "How do countries open, one by one, they'll open at different rates in \ndifferent times, and that mix is really what you're seeing flow through our business and our 2021 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  My question is focused on generic pricing. ", "original_text": "LLC  Q \nYeah. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac232723f4434eacd1e28e48f9634622cafa70290a9b5d7de3d2c03b636abb82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb80a4d3-fc37-4203-a0a6-3143ebe65430", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment? ", "original_text": "Good morning. "}, "hash": "7e346e57ce34fffedf3e06589db141942cec71fe84a21d0876ff8f1c911b9b1e", "class_name": "RelatedNodeInfo"}}, "text": "Hi. ", "start_char_idx": 3853, "end_char_idx": 3857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb80a4d3-fc37-4203-a0a6-3143ebe65430": {"__data__": {"id_": "bb80a4d3-fc37-4203-a0a6-3143ebe65430", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment? ", "original_text": "Good morning. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0706bfe6-07f8-48a4-b5c8-0858e6c7e633", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes fr om the line of Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up. ", "original_text": "Hi. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "228101b0d820f589d58529161eddd3e97861e74bbe6981532c9b06b65a5d416b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94634ae8-ef38-4127-bf77-77d1f6fde289", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good morning.  My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n", "original_text": "My question is focused on generic pricing. "}, "hash": "fe8b3ddd83e7778dda707dbfe0395665eca5a291ba090a5db92d59ea3a890158", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 3857, "end_char_idx": 3871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94634ae8-ef38-4127-bf77-77d1f6fde289": {"__data__": {"id_": "94634ae8-ef38-4127-bf77-77d1f6fde289", "embedding": null, "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good morning.  My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n", "original_text": "My question is focused on generic pricing. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb80a4d3-fc37-4203-a0a6-3143ebe65430", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment? ", "original_text": "Good morning. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73894ccfe8f6985ae4e1793e701caf55ca9e11ead463cfabc4c7fbb0ab2c8672", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea7a3bea-ce1c-4fd2-9b10-007db46d3dc9", "node_type": "1", "metadata": {"window": "Hi.  Good morning.  My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US. ", "original_text": "We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up. "}, "hash": "b3348f3b5a479cb1f5a2266daba969d65195b028d254d6fb79a0716003ae4b6d", "class_name": "RelatedNodeInfo"}}, "text": "My question is focused on generic pricing. ", "start_char_idx": 3871, "end_char_idx": 3914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea7a3bea-ce1c-4fd2-9b10-007db46d3dc9": {"__data__": {"id_": "ea7a3bea-ce1c-4fd2-9b10-007db46d3dc9", "embedding": null, "metadata": {"window": "Hi.  Good morning.  My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US. ", "original_text": "We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94634ae8-ef38-4127-bf77-77d1f6fde289", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good morning.  My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n", "original_text": "My question is focused on generic pricing. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc0ab55801c72a87e6620b66240d18d4daa345a439576898949b02965d27c959", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfc6ad7b-74d5-4c66-8499-9dd95dd0e037", "node_type": "1", "metadata": {"window": "Good morning.  My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n ", "original_text": "So what are you seeing on the buy \nside environment? "}, "hash": "8f26e833abccc088871ca168defb1b9fd572f5cb7fe6babc3832c254e3bcf2dc", "class_name": "RelatedNodeInfo"}}, "text": "We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up. ", "start_char_idx": 3914, "end_char_idx": 4040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfc6ad7b-74d5-4c66-8499-9dd95dd0e037": {"__data__": {"id_": "bfc6ad7b-74d5-4c66-8499-9dd95dd0e037", "embedding": null, "metadata": {"window": "Good morning.  My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n ", "original_text": "So what are you seeing on the buy \nside environment? ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea7a3bea-ce1c-4fd2-9b10-007db46d3dc9", "node_type": "1", "metadata": {"window": "Hi.  Good morning.  My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US. ", "original_text": "We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30c20d7ade94e67d73fa52c90a3c2d8d13fc673e9460bd1381fe2cb8b4c67edb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c99bc1f3-5116-4c26-bc86-15fd7ed7ee6e", "node_type": "1", "metadata": {"window": "My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.  ", "original_text": "How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n"}, "hash": "f64318e28848d3f1f957b69f1bf324d4f0ff591f757476ae38a071b698b5c847", "class_name": "RelatedNodeInfo"}}, "text": "So what are you seeing on the buy \nside environment? ", "start_char_idx": 4040, "end_char_idx": 4093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c99bc1f3-5116-4c26-bc86-15fd7ed7ee6e": {"__data__": {"id_": "c99bc1f3-5116-4c26-bc86-15fd7ed7ee6e", "embedding": null, "metadata": {"window": "My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.  ", "original_text": "How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfc6ad7b-74d5-4c66-8499-9dd95dd0e037", "node_type": "1", "metadata": {"window": "Good morning.  My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n ", "original_text": "So what are you seeing on the buy \nside environment? ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c399bcc7cb5381ad72cf7519f1f745d0fffb4005cf4783f54e170de59a1a8218", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffef22b0-4577-47a5-a312-9338bec52383", "node_type": "1", "metadata": {"window": "We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.   A ", "original_text": "And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US. "}, "hash": "75be2d10cc9464de54a9ffde26aeef157eb03a0b817a10efdb1f8e44aa5b74e7", "class_name": "RelatedNodeInfo"}}, "text": "How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n", "start_char_idx": 4093, "end_char_idx": 4178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffef22b0-4577-47a5-a312-9338bec52383": {"__data__": {"id_": "ffef22b0-4577-47a5-a312-9338bec52383", "embedding": null, "metadata": {"window": "We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.   A ", "original_text": "And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c99bc1f3-5116-4c26-bc86-15fd7ed7ee6e", "node_type": "1", "metadata": {"window": "My question is focused on generic pricing.  We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.  ", "original_text": "How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f31c45fe693c0182d7d7d179f378491b456de3aaf4ef126015be06af47065273", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8eb44234-40e6-4420-a36e-65a043726eea", "node_type": "1", "metadata": {"window": "So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.   A ", "original_text": "Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n "}, "hash": "70d1dd0827cb509ab82666e6c69a061b72319879d73b9506813f970de4b1d962", "class_name": "RelatedNodeInfo"}}, "text": "And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US. ", "start_char_idx": 4178, "end_char_idx": 4297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8eb44234-40e6-4420-a36e-65a043726eea": {"__data__": {"id_": "8eb44234-40e6-4420-a36e-65a043726eea", "embedding": null, "metadata": {"window": "So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.   A ", "original_text": "Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffef22b0-4577-47a5-a312-9338bec52383", "node_type": "1", "metadata": {"window": "We're hearing that manufacturing in India is \nbelow historical levels and, obv iously, freight costs are seeing some step up.  So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.   A ", "original_text": "And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US. ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d611504c519585fc78cd6b2fcdb479c00fefa1d9205ce63d48fa4c78dc5205a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16e9a285-b012-455d-b703-697983e30b39", "node_type": "1", "metadata": {"window": "How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.  "}, "hash": "50f56ef17a2116a5c724a05fa2d39d8459d26037f3fbb720baac4234f1c21e29", "class_name": "RelatedNodeInfo"}}, "text": "Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n ", "start_char_idx": 4297, "end_char_idx": 4438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16e9a285-b012-455d-b703-697983e30b39": {"__data__": {"id_": "16e9a285-b012-455d-b703-697983e30b39", "embedding": null, "metadata": {"window": "How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8eb44234-40e6-4420-a36e-65a043726eea", "node_type": "1", "metadata": {"window": "So what are you seeing on the buy \nside environment?  How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.   A ", "original_text": "Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e1d3e40cd5124c124dda28f18b2eab52f3c234cb41a7c8b9ea24134a4d23a8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4e7f027-be24-4932-b012-9277453c5c8b", "node_type": "1", "metadata": {"window": "And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.   A ", "original_text": "A "}, "hash": "21437cf7211dabf45770ac4478e0108fbdc4725c34ecd74f0925c2ee2eb99832", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.  ", "start_char_idx": 4438, "end_char_idx": 4799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4e7f027-be24-4932-b012-9277453c5c8b": {"__data__": {"id_": "a4e7f027-be24-4932-b012-9277453c5c8b", "embedding": null, "metadata": {"window": "And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.   A ", "original_text": "A ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0ad67568dcf5da808f801d94f6f98b9a5dccca6230bbbe2d665bea07a8bd64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16e9a285-b012-455d-b703-697983e30b39", "node_type": "1", "metadata": {"window": "How are you thinking about return to generic inflation in your fiscal year 2021?  \n \n And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5c7327b265c4ef23fc525b91fc6362b8555b9994498518a2bfb60fc9dc377af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b501238b-80f9-4537-8d96-30a7072b4419", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period. ", "original_text": "McKesson Corp.  "}, "hash": "d34fbbc0c59389fe4a9e4b79cf7959cdc6dbd06a4c0fc53e36eee639ae1b86c7", "class_name": "RelatedNodeInfo"}}, "text": "A ", "start_char_idx": 1080, "end_char_idx": 1082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b501238b-80f9-4537-8d96-30a7072b4419": {"__data__": {"id_": "b501238b-80f9-4537-8d96-30a7072b4419", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period. ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4e7f027-be24-4932-b012-9277453c5c8b", "node_type": "1", "metadata": {"window": "And then also along the line of manufacturing, yesterday, HHS gave some fun ding to manufacturing of drugs in \nthe US.  Any thoughts of whether we will see generic manufacturing coming back to the US and what role would \nyou play in that type of a scenario?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKes son Corp.   A ", "original_text": "A ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "791929a48cd17b3688742579d9e9441b92ee9a0128b1ff145cc53e002f81fc3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faa22aeb-f90f-4e06-84f5-976b5ecc1a81", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question. "}, "hash": "c00df8d2fe512eae6fdfd679188528af1702266ccf4b9c23800ad111cfafded9", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faa22aeb-f90f-4e06-84f5-976b5ecc1a81": {"__data__": {"id_": "faa22aeb-f90f-4e06-84f5-976b5ecc1a81", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b501238b-80f9-4537-8d96-30a7072b4419", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period. ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1c132c53f5ad012a983061f25936960f44dbd090510dd62f0cda178c8d6bc95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "057d371c-72ee-4495-8859-721ac4a47fb8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment. ", "original_text": "Let me start with your first question and then let Brian take it from there. "}, "hash": "9490c4ecc0ff69b700d245da420f420a884144ef86063eb4eb043ab7921529ef", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question. ", "start_char_idx": 16, "end_char_idx": 215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "057d371c-72ee-4495-8859-721ac4a47fb8": {"__data__": {"id_": "057d371c-72ee-4495-8859-721ac4a47fb8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment. ", "original_text": "Let me start with your first question and then let Brian take it from there. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faa22aeb-f90f-4e06-84f5-976b5ecc1a81", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c92a434fbd27841fd6f94d6c1c933f621709aad6746b4f4ce73de0daf53139a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "518b375f-4ea5-4820-ae5a-01dc936a79d5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive. ", "original_text": "From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period. "}, "hash": "26b0341d276a93c986cb220f4e6827652ff57f2b6023256ce239ae4bc8354695", "class_name": "RelatedNodeInfo"}}, "text": "Let me start with your first question and then let Brian take it from there. ", "start_char_idx": 215, "end_char_idx": 292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "518b375f-4ea5-4820-ae5a-01dc936a79d5": {"__data__": {"id_": "518b375f-4ea5-4820-ae5a-01dc936a79d5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive. ", "original_text": "From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "057d371c-72ee-4495-8859-721ac4a47fb8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment. ", "original_text": "Let me start with your first question and then let Brian take it from there. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a503f72f8bccf467719f1ec4d4a3bcc46927fe1b07c438b43b9d5fb115299646", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dfcfd60-d008-4fc2-92af-fb500ed71998", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts. ", "original_text": "The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n"}, "hash": "cc2d6469d90414bb130b44e929fbcc6f8c7bfbaf5001f2f39eff11bf716bb9e8", "class_name": "RelatedNodeInfo"}}, "text": "From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period. ", "start_char_idx": 292, "end_char_idx": 449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dfcfd60-d008-4fc2-92af-fb500ed71998": {"__data__": {"id_": "8dfcfd60-d008-4fc2-92af-fb500ed71998", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts. ", "original_text": "The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "518b375f-4ea5-4820-ae5a-01dc936a79d5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive. ", "original_text": "From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02b7fdcbedca9498606f3e14512ec1658d8a022c6e73623cb3361564be912975", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf9fc912-cd61-4e70-a4ff-8f272bd60f0f", "node_type": "1", "metadata": {"window": "Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n ", "original_text": "On the sell side, we continue to see a relatively stable environment. "}, "hash": "bc8be1d0ab0313cc2878180f20f93d97a909821c14d73dd79c4411d3b64e5edd", "class_name": "RelatedNodeInfo"}}, "text": "The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n", "start_char_idx": 449, "end_char_idx": 609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf9fc912-cd61-4e70-a4ff-8f272bd60f0f": {"__data__": {"id_": "cf9fc912-cd61-4e70-a4ff-8f272bd60f0f", "embedding": null, "metadata": {"window": "Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n ", "original_text": "On the sell side, we continue to see a relatively stable environment. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dfcfd60-d008-4fc2-92af-fb500ed71998", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts. ", "original_text": "The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c91461f2a7a5998a46e71b730d7e0060304801f576863c17cea3849e82d2f5cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68d1d7ea-2845-4468-98a6-dc3e2fe508a3", "node_type": "1", "metadata": {"window": "From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And so there's competition, but pricing has \ncontinued to be stable and competitive. "}, "hash": "0e1df2ac5f91e5d9ccee571639d6f7c7c013e6cd9d4f51fab42fa38c69cb564b", "class_name": "RelatedNodeInfo"}}, "text": "On the sell side, we continue to see a relatively stable environment. ", "start_char_idx": 609, "end_char_idx": 679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68d1d7ea-2845-4468-98a6-dc3e2fe508a3": {"__data__": {"id_": "68d1d7ea-2845-4468-98a6-dc3e2fe508a3", "embedding": null, "metadata": {"window": "From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And so there's competition, but pricing has \ncontinued to be stable and competitive. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf9fc912-cd61-4e70-a4ff-8f272bd60f0f", "node_type": "1", "metadata": {"window": "Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n ", "original_text": "On the sell side, we continue to see a relatively stable environment. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b93a4ee40f9b050a7b9eafa305deeef2eff5037d75b77b0d7212cb9cb05bfa38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "612e984e-e512-4900-a5ac-5a89dbde056d", "node_type": "1", "metadata": {"window": "The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "And so that's allowed us to continue to earn a spread on our generic \nproducts. "}, "hash": "dbfcef7e765d21b7b8baf27d126ba8c1d64926c2b2a2f1f255b3a7896539f489", "class_name": "RelatedNodeInfo"}}, "text": "And so there's competition, but pricing has \ncontinued to be stable and competitive. ", "start_char_idx": 679, "end_char_idx": 764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "612e984e-e512-4900-a5ac-5a89dbde056d": {"__data__": {"id_": "612e984e-e512-4900-a5ac-5a89dbde056d", "embedding": null, "metadata": {"window": "The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "And so that's allowed us to continue to earn a spread on our generic \nproducts. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68d1d7ea-2845-4468-98a6-dc3e2fe508a3", "node_type": "1", "metadata": {"window": "From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period.  The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And so there's competition, but pricing has \ncontinued to be stable and competitive. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4de6293d2e0c6339a2d8641d8e3c3f38c4c7d974bf91c62a298b7b97b0ced5d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f29f2aa-298d-44db-88f6-60bf47898fee", "node_type": "1", "metadata": {"window": "On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability. ", "original_text": "And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n "}, "hash": "6d591169f0e27f58d6414b09cba198883903d9af32ff18c29770e75fce097919", "class_name": "RelatedNodeInfo"}}, "text": "And so that's allowed us to continue to earn a spread on our generic \nproducts. ", "start_char_idx": 764, "end_char_idx": 844, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f29f2aa-298d-44db-88f6-60bf47898fee": {"__data__": {"id_": "3f29f2aa-298d-44db-88f6-60bf47898fee", "embedding": null, "metadata": {"window": "On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability. ", "original_text": "And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "612e984e-e512-4900-a5ac-5a89dbde056d", "node_type": "1", "metadata": {"window": "The relationships that we have with manufacturers, our ability to continue to \nsecure supply in a very stable and consistent manner has played well for us.  \n \n On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "And so that's allowed us to continue to earn a spread on our generic \nproducts. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fb54c04e65c1e76499eb6ff429336b7e75f12ca7c1a2d76205949be4f2d2e0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43361eb5-8071-45f8-8c3f-bba2e1ac794d", "node_type": "1", "metadata": {"window": "And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "62219c90b53e58be407e2673932301259be7ea6cb6b5a624f6e15a5db13d5f43", "class_name": "RelatedNodeInfo"}}, "text": "And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n ", "start_char_idx": 844, "end_char_idx": 1079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43361eb5-8071-45f8-8c3f-bba2e1ac794d": {"__data__": {"id_": "43361eb5-8071-45f8-8c3f-bba2e1ac794d", "embedding": null, "metadata": {"window": "And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f29f2aa-298d-44db-88f6-60bf47898fee", "node_type": "1", "metadata": {"window": "On the sell side, we continue to see a relatively stable environment.  And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability. ", "original_text": "And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd1c7a2e8323635ef55573cf239b6b4b90721f5fa92ef341385f62087c37f35c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f1b5b1f-a4a1-46d7-ac99-71b40733ff02", "node_type": "1", "metadata": {"window": "And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.  ", "original_text": "A \nYeah. "}, "hash": "6722273f982c589747963d2d271881a97846dbf38642b29fea576621df252b3d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1079, "end_char_idx": 1420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f1b5b1f-a4a1-46d7-ac99-71b40733ff02": {"__data__": {"id_": "1f1b5b1f-a4a1-46d7-ac99-71b40733ff02", "embedding": null, "metadata": {"window": "And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.  ", "original_text": "A \nYeah. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43361eb5-8071-45f8-8c3f-bba2e1ac794d", "node_type": "1", "metadata": {"window": "And so there's competition, but pricing has \ncontinued to be stable and competitive.  And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ed68314f6f830269747dcda9be5458ffc9b8ede1fcabe931c4180949782cce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15d1fa13-1b6c-47b5-b762-c84216fedb60", "node_type": "1", "metadata": {"window": "And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that. ", "original_text": "I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability. "}, "hash": "3ca8ed8d4256f3835aa7e376b29dfdbfb81ce8777cf1ff0fe54b1acfde458b0c", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1420, "end_char_idx": 1429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15d1fa13-1b6c-47b5-b762-c84216fedb60": {"__data__": {"id_": "15d1fa13-1b6c-47b5-b762-c84216fedb60", "embedding": null, "metadata": {"window": "And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that. ", "original_text": "I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f1b5b1f-a4a1-46d7-ac99-71b40733ff02", "node_type": "1", "metadata": {"window": "And so that's allowed us to continue to earn a spread on our generic \nproducts.  And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.  ", "original_text": "A \nYeah. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aea7ad24aa11749bc3545d8424c9c12293d7fcbb61304d600d5e7a4e3dcff38a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e81c257f-526f-4677-bf22-60907c0525fe", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay. ", "original_text": "And, obviously, we began monitoring this very closely. "}, "hash": "63c15c14cd3d52caf0abd50c5d1cb79111f03d9038e2644898a733a1524470c0", "class_name": "RelatedNodeInfo"}}, "text": "I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability. ", "start_char_idx": 1429, "end_char_idx": 1558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e81c257f-526f-4677-bf22-60907c0525fe": {"__data__": {"id_": "e81c257f-526f-4677-bf22-60907c0525fe", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay. ", "original_text": "And, obviously, we began monitoring this very closely. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15d1fa13-1b6c-47b5-b762-c84216fedb60", "node_type": "1", "metadata": {"window": "And I think it really \u2013 it starts with our ability to secure that supply in a consistent manner, and \nClarusONE has been able to do that very well over the last several years, honestly, and we expect that to \ncontinue into FY 2021.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that. ", "original_text": "I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d35bef0e0ccbc93b6a16168247527121f2ce1e5f64c4a628b338afc1cef7aa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57f95438-a01d-4234-a875-931f700b3082", "node_type": "1", "metadata": {"window": "A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n", "original_text": "I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.  "}, "hash": "333bbe900994497653fcc5bdb0b442e31474a6452ee19f3629ca640d92dbe069", "class_name": "RelatedNodeInfo"}}, "text": "And, obviously, we began monitoring this very closely. ", "start_char_idx": 1558, "end_char_idx": 1613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57f95438-a01d-4234-a875-931f700b3082": {"__data__": {"id_": "57f95438-a01d-4234-a875-931f700b3082", "embedding": null, "metadata": {"window": "A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n", "original_text": "I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.  ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e81c257f-526f-4677-bf22-60907c0525fe", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay. ", "original_text": "And, obviously, we began monitoring this very closely. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793ce362495f20eed8983e58fe2c80312e5451ce3d0c2a4fb08ade96f59290e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff96691e-ce10-4258-8046-8b79072e7fbf", "node_type": "1", "metadata": {"window": "I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this . ", "original_text": "Frankly, we get very detailed \nupdates every week on that. "}, "hash": "f4405a42b94b1faec60423204de0025a63835de6b71e9eab2f4f6a8ee60db96e", "class_name": "RelatedNodeInfo"}}, "text": "I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.  ", "start_char_idx": 1613, "end_char_idx": 1737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff96691e-ce10-4258-8046-8b79072e7fbf": {"__data__": {"id_": "ff96691e-ce10-4258-8046-8b79072e7fbf", "embedding": null, "metadata": {"window": "I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this . ", "original_text": "Frankly, we get very detailed \nupdates every week on that. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57f95438-a01d-4234-a875-931f700b3082", "node_type": "1", "metadata": {"window": "A \nYeah.  I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n", "original_text": "I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.  ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5371049b826d426468b366cae2d2dde427b75b82f970e93712514c09b93e3d9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bcec97a-9a9d-4164-8739-58c6f6c50b26", "node_type": "1", "metadata": {"window": "And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early. ", "original_text": "So I think, generally, we still feel okay. "}, "hash": "bf3c34f59474d8f61862352336afa0630876c294f651137245bb91167b5ba928", "class_name": "RelatedNodeInfo"}}, "text": "Frankly, we get very detailed \nupdates every week on that. ", "start_char_idx": 1737, "end_char_idx": 1796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bcec97a-9a9d-4164-8739-58c6f6c50b26": {"__data__": {"id_": "0bcec97a-9a9d-4164-8739-58c6f6c50b26", "embedding": null, "metadata": {"window": "And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early. ", "original_text": "So I think, generally, we still feel okay. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff96691e-ce10-4258-8046-8b79072e7fbf", "node_type": "1", "metadata": {"window": "I think from an overall perspective, I mean, i t's been pretty good performance industry -wide in terms of \nsupply availability.  And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this . ", "original_text": "Frankly, we get very detailed \nupdates every week on that. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "997937a61c1dcc148098e167f850af65e9159257016b59fe1abfb7761f4ac0e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8697e6e-412d-4069-a047-da82828ce262", "node_type": "1", "metadata": {"window": "I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done. ", "original_text": "I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n"}, "hash": "8514d05f7f3488cfcaf81d78ce14180d0c14a27364e618b898bca0b9b74374d1", "class_name": "RelatedNodeInfo"}}, "text": "So I think, generally, we still feel okay. ", "start_char_idx": 1796, "end_char_idx": 1839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8697e6e-412d-4069-a047-da82828ce262": {"__data__": {"id_": "e8697e6e-412d-4069-a047-da82828ce262", "embedding": null, "metadata": {"window": "I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done. ", "original_text": "I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bcec97a-9a9d-4164-8739-58c6f6c50b26", "node_type": "1", "metadata": {"window": "And, obviously, we began monitoring this very closely.  I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early. ", "original_text": "So I think, generally, we still feel okay. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04ba73e0f7b66f4932742b0303996a6ab510a932cb567e786e34a32a7fbe8c09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d909cc2a-ec42-4ef0-a960-bf477a4704e8", "node_type": "1", "metadata": {"window": "Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n", "original_text": "I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this . "}, "hash": "8e161211083e94f7d5227cc92e07ef2638e8410ad4c8b6a4ec9e3af04e893340", "class_name": "RelatedNodeInfo"}}, "text": "I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n", "start_char_idx": 1839, "end_char_idx": 1989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d909cc2a-ec42-4ef0-a960-bf477a4704e8": {"__data__": {"id_": "d909cc2a-ec42-4ef0-a960-bf477a4704e8", "embedding": null, "metadata": {"window": "Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n", "original_text": "I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this . ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8697e6e-412d-4069-a047-da82828ce262", "node_type": "1", "metadata": {"window": "I mentioned we set up our critical care \ntask force in really the very end of our fiscal 2020 to continue to monitor this.   Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done. ", "original_text": "I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d759c7c6be741ec9c1cf30f53f4cde4c20ff5c8a0590dbe968093a081278d5f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9da4b98e-4dfc-43c8-aabd-00b572aec9fb", "node_type": "1", "metadata": {"window": "So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that. ", "original_text": "And that \u2013 those are \u2013 it's very early. "}, "hash": "bc7c7ea34279c89d816f058cf11a80f568088d3434e90eb4dcc8511319bf11b3", "class_name": "RelatedNodeInfo"}}, "text": "I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this . ", "start_char_idx": 1989, "end_char_idx": 2258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9da4b98e-4dfc-43c8-aabd-00b572aec9fb": {"__data__": {"id_": "9da4b98e-4dfc-43c8-aabd-00b572aec9fb", "embedding": null, "metadata": {"window": "So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that. ", "original_text": "And that \u2013 those are \u2013 it's very early. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d909cc2a-ec42-4ef0-a960-bf477a4704e8", "node_type": "1", "metadata": {"window": "Frankly, we get very detailed \nupdates every week on that.  So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n", "original_text": "I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this . ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4edaec136182875e5242ac3ef8b1b060780cbe4130f65d3d1ed0df6d470c3d7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a172503e-3c3f-4005-bd61-7a57705031a6", "node_type": "1", "metadata": {"window": "I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that.  We also have to recognize there are trade -offs in that. ", "original_text": "I think there will be a lot of good questions \nasked, a lot of good work done. "}, "hash": "bc7fbc4ecfe3524109283b83c61a597dcbc6dc5d0d8ccafee9c31b99ed06cd49", "class_name": "RelatedNodeInfo"}}, "text": "And that \u2013 those are \u2013 it's very early. ", "start_char_idx": 2258, "end_char_idx": 2298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a172503e-3c3f-4005-bd61-7a57705031a6": {"__data__": {"id_": "a172503e-3c3f-4005-bd61-7a57705031a6", "embedding": null, "metadata": {"window": "I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that.  We also have to recognize there are trade -offs in that. ", "original_text": "I think there will be a lot of good questions \nasked, a lot of good work done. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9da4b98e-4dfc-43c8-aabd-00b572aec9fb", "node_type": "1", "metadata": {"window": "So I think, generally, we still feel okay.  I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that. ", "original_text": "And that \u2013 those are \u2013 it's very early. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4bf2dcc9a3f8bd29f74ac8bf3fa0654dc2aaf4313d7f7985480c645a8b99711", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e83ad6b6-e8b6-4aa5-83fc-dff9d4a838f6", "node_type": "1", "metadata": {"window": "I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that.  We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through. ", "original_text": "We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n"}, "hash": "c6705f3d346261111f0993b4f96feb55baf485afdb9afaf93a194ca69c1df984", "class_name": "RelatedNodeInfo"}}, "text": "I think there will be a lot of good questions \nasked, a lot of good work done. ", "start_char_idx": 2298, "end_char_idx": 2377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e83ad6b6-e8b6-4aa5-83fc-dff9d4a838f6": {"__data__": {"id_": "e83ad6b6-e8b6-4aa5-83fc-dff9d4a838f6", "embedding": null, "metadata": {"window": "I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that.  We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through. ", "original_text": "We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a172503e-3c3f-4005-bd61-7a57705031a6", "node_type": "1", "metadata": {"window": "I [ph] would say (01:08:12) we've seen \nanything I would describe as a material change in pricing or ability to supply and things of that nature.  \n \n I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that.  We also have to recognize there are trade -offs in that. ", "original_text": "I think there will be a lot of good questions \nasked, a lot of good work done. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9e3a77d88f09951b8f51c111efd63ec529947ff36bf55882a355bafeec4424e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9375c9e-19bd-40b9-adf5-35e77d6bb857", "node_type": "1", "metadata": {"window": "And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that.  We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n ", "original_text": "We are supportive of  that. "}, "hash": "02d18bf6761b110bd67a14a5c0f0da046087ce1facb7588cd3d061a9987dbb08", "class_name": "RelatedNodeInfo"}}, "text": "We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n", "start_char_idx": 2377, "end_char_idx": 2497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9375c9e-19bd-40b9-adf5-35e77d6bb857": {"__data__": {"id_": "c9375c9e-19bd-40b9-adf5-35e77d6bb857", "embedding": null, "metadata": {"window": "And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that.  We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n ", "original_text": "We are supportive of  that. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e83ad6b6-e8b6-4aa5-83fc-dff9d4a838f6", "node_type": "1", "metadata": {"window": "I mean, to your last question about will generic supply come back to the US or will \u2013 I think the broader question \nis, how will diversification and how will the supply community think about being a little bit more buffered for future \nevents that may look like this .  And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that.  We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through. ", "original_text": "We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5401cbf786485caf4dde385b09ef919ed2d040ed02ae1a14c1d7784fd11aa1ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee018f74-24a0-415c-b4b0-442ad586988b", "node_type": "1", "metadata": {"window": "I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that.  We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n ", "original_text": "We also have to recognize there are trade -offs in that. "}, "hash": "d0651aa193196a34e402f6a04593f6020359a12389c927301318d39ccb5a242d", "class_name": "RelatedNodeInfo"}}, "text": "We are supportive of  that. ", "start_char_idx": 2497, "end_char_idx": 2525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee018f74-24a0-415c-b4b0-442ad586988b": {"__data__": {"id_": "ee018f74-24a0-415c-b4b0-442ad586988b", "embedding": null, "metadata": {"window": "I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that.  We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n ", "original_text": "We also have to recognize there are trade -offs in that. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9375c9e-19bd-40b9-adf5-35e77d6bb857", "node_type": "1", "metadata": {"window": "And that \u2013 those are \u2013 it's very early.  I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that.  We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n ", "original_text": "We are supportive of  that. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41142c934e6bd8c985b39164f785e8803c8258bddc4f31c7ec72f5de5a258120", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99d3f8f9-fdc1-40df-aa5a-a133ae76cfab", "node_type": "1", "metadata": {"window": "We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that.  We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "original_text": "I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through. "}, "hash": "96954ce1bc32f6e96ca4aa8178ac37849ea9b72293d155ac27575d2a677f77b2", "class_name": "RelatedNodeInfo"}}, "text": "We also have to recognize there are trade -offs in that. ", "start_char_idx": 2525, "end_char_idx": 2582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99d3f8f9-fdc1-40df-aa5a-a133ae76cfab": {"__data__": {"id_": "99d3f8f9-fdc1-40df-aa5a-a133ae76cfab", "embedding": null, "metadata": {"window": "We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that.  We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "original_text": "I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee018f74-24a0-415c-b4b0-442ad586988b", "node_type": "1", "metadata": {"window": "I think there will be a lot of good questions \nasked, a lot of good work done.  We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that.  We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n ", "original_text": "We also have to recognize there are trade -offs in that. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "094bd998b4f57db36ecde4b81f90b3eb09aaddc19147a74b6fddd1f569d2a806", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84ff0bf7-6005-4f00-b1c8-9156931a3827", "node_type": "1", "metadata": {"window": "We are supportive of  that.  We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call. ", "original_text": "But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n "}, "hash": "c60a01eac8a5bd49caeee4cd465494a1cea09a615e6619e7774c5fd407567ac9", "class_name": "RelatedNodeInfo"}}, "text": "I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through. ", "start_char_idx": 2582, "end_char_idx": 2763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84ff0bf7-6005-4f00-b1c8-9156931a3827": {"__data__": {"id_": "84ff0bf7-6005-4f00-b1c8-9156931a3827", "embedding": null, "metadata": {"window": "We are supportive of  that.  We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call. ", "original_text": "But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99d3f8f9-fdc1-40df-aa5a-a133ae76cfab", "node_type": "1", "metadata": {"window": "We do think anything that diversifies availability of supplies creates kind of a \ninsurance mechanism, if you will.  \n \n We are supportive of  that.  We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "original_text": "I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aaa33e9e8b6b0de7a7a32f83d70db43f7997e072abcc8339d754eb852b911dfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfbb2a07-3da0-468f-90c6-4f5eef259362", "node_type": "1", "metadata": {"window": "We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n "}, "hash": "8aabd2a195f22063398dc20bb9ad5527df821bf56d370475b9b54815c6a7cdab", "class_name": "RelatedNodeInfo"}}, "text": "But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n ", "start_char_idx": 2763, "end_char_idx": 2880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfbb2a07-3da0-468f-90c6-4f5eef259362": {"__data__": {"id_": "dfbb2a07-3da0-468f-90c6-4f5eef259362", "embedding": null, "metadata": {"window": "We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84ff0bf7-6005-4f00-b1c8-9156931a3827", "node_type": "1", "metadata": {"window": "We are supportive of  that.  We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call. ", "original_text": "But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33ff9bdf8c9edb8b026aabcdb772eb0735bfdbf7158362159a12a8b5b90fd34c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4e7e264-9244-43d9-b29c-b5c2d04e33b4", "node_type": "1", "metadata": {"window": "I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. "}, "hash": "7acb578113540448ed43ca0c0926effc3b6554e4319d7869a23f144dcc79af21", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n ", "start_char_idx": 2880, "end_char_idx": 3235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4e7e264-9244-43d9-b29c-b5c2d04e33b4": {"__data__": {"id_": "a4e7e264-9244-43d9-b29c-b5c2d04e33b4", "embedding": null, "metadata": {"window": "I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfbb2a07-3da0-468f-90c6-4f5eef259362", "node_type": "1", "metadata": {"window": "We also have to recognize there are trade -offs in that.  I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "606d87c397640665c5ae4df664d38d18baa523db3670cd8c0dd0f7030730a1fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71448a78-2a33-4d0d-803b-7ea903d38070", "node_type": "1", "metadata": {"window": "But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Thanks for taking my call. "}, "hash": "8b4696211396ec05250e0f0b2dc7fa830a0d03221825b9d3e936a22bbdcf70f1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "start_char_idx": 3235, "end_char_idx": 3560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71448a78-2a33-4d0d-803b-7ea903d38070": {"__data__": {"id_": "71448a78-2a33-4d0d-803b-7ea903d38070", "embedding": null, "metadata": {"window": "But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Thanks for taking my call. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4e7e264-9244-43d9-b29c-b5c2d04e33b4", "node_type": "1", "metadata": {"window": "I mean, there are cost trade -offs \nand figuring out how that cost gets funded and whether that's working capital or cost of the product, we'll have to \nnavigate ourselves through.  But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67223ffa089c840cd446b006731ef6cf3a24fec0f3bab3cfac76207115c348f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9306b42-0062-4ee4-9b46-5ee23f48800f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan. "}, "hash": "748e7af74ba679b14c6aac3849f1d8e8fa6d7610b85da5821dcb60fed8d4051a", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my call. ", "start_char_idx": 3560, "end_char_idx": 3587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9306b42-0062-4ee4-9b46-5ee23f48800f": {"__data__": {"id_": "e9306b42-0062-4ee4-9b46-5ee23f48800f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71448a78-2a33-4d0d-803b-7ea903d38070", "node_type": "1", "metadata": {"window": "But we're invol ved in many of these conversations, but I'd characterize them all as \nvery early stage right now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Thanks for taking my call. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84a884579147ec757ee16f9016b44c798c046d3c8158663ca1beb826a798cd11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4946593-def1-44a8-94b4-71e15b7771f4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that questions. ", "original_text": "But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n "}, "hash": "bf2013e71e9d1c1c4d508a7e92f69747f08ef8eb60b5d124fbf1f940b9cb7c0d", "class_name": "RelatedNodeInfo"}}, "text": "I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan. ", "start_char_idx": 3587, "end_char_idx": 3710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4946593-def1-44a8-94b4-71e15b7771f4": {"__data__": {"id_": "d4946593-def1-44a8-94b4-71e15b7771f4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that questions. ", "original_text": "But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9306b42-0062-4ee4-9b46-5ee23f48800f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce1e7555b230a7d6d4c3450335a3dbe0a043a3ce6397bb3f728296204e31b5e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d6ea7bf-8048-43dc-8060-868c4b00c9ad", "node_type": "1", "metadata": {"window": "Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "6311068844b3e19186e73eb1b1a9dc94a46c2c673409ba04699553a48a15a5e5", "class_name": "RelatedNodeInfo"}}, "text": "But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n ", "start_char_idx": 3710, "end_char_idx": 4092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d6ea7bf-8048-43dc-8060-868c4b00c9ad": {"__data__": {"id_": "1d6ea7bf-8048-43dc-8060-868c4b00c9ad", "embedding": null, "metadata": {"window": "Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4946593-def1-44a8-94b4-71e15b7771f4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi.  Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that questions. ", "original_text": "But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82d26de2b6b35128c9670b845f2345dcd230ead59cfe9979c396ef7b870a2176", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f42dfac-7ac3-436b-9490-8b07b38479ec", "node_type": "1", "metadata": {"window": "I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost.  And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp. ", "original_text": "A \nYeah. "}, "hash": "249a80b37ee8ee11c4193cbdc94daf0942f89210ec74ee9ab857efe038cabf4d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 4092, "end_char_idx": 4433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f42dfac-7ac3-436b-9490-8b07b38479ec": {"__data__": {"id_": "9f42dfac-7ac3-436b-9490-8b07b38479ec", "embedding": null, "metadata": {"window": "I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost.  And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp. ", "original_text": "A \nYeah. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d6ea7bf-8048-43dc-8060-868c4b00c9ad", "node_type": "1", "metadata": {"window": "Thanks for taking my call.  I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec951b46e0a65db8fd0c03f9bcaad8f33c807a1cd8cd993cf2d03622fa8f5344", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4624e023-4f18-4260-bc16-1acbc0aff3e2", "node_type": "1", "metadata": {"window": "But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost.  And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp.  And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n ", "original_text": "Thanks for that questions. "}, "hash": "bac00a1a51b9db86d103ee32f0802f6c36c558d77e5e96c891567efed9359295", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1420, "end_char_idx": 1429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4624e023-4f18-4260-bc16-1acbc0aff3e2": {"__data__": {"id_": "4624e023-4f18-4260-bc16-1acbc0aff3e2", "embedding": null, "metadata": {"window": "But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost.  And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp.  And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n ", "original_text": "Thanks for that questions. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f42dfac-7ac3-436b-9490-8b07b38479ec", "node_type": "1", "metadata": {"window": "I really wanted to delve into the cost side a little bit, understanding that there's an \nongoing larger cost savings plan.  But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost.  And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp. ", "original_text": "A \nYeah. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cdfafd0c72c79f6937828f64557545e89e95b66eebe738a71c01e9d5f23e9dc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a335cac-afd1-45c4-8ed6-eee993a7fb04", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost.  And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp.  And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n ", "original_text": "Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost. "}, "hash": "a96592b112b188565377d08c581fa7427f2c7444fcde3cd6e52ac746b25f30ae", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for that questions. ", "start_char_idx": 4442, "end_char_idx": 4469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a335cac-afd1-45c4-8ed6-eee993a7fb04": {"__data__": {"id_": "0a335cac-afd1-45c4-8ed6-eee993a7fb04", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost.  And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp.  And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n ", "original_text": "Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4624e023-4f18-4260-bc16-1acbc0aff3e2", "node_type": "1", "metadata": {"window": "But going through the businesses, if you would, talk about how much variable \nspending you have in each and really what the plan is, ju st thinking in looking at the margins and backing into sort \nof what you're saying, the margins versus the revenues definitely look like, and I'm just trying to gauge how much \nvariable spending you might be taking out of the business or not?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost.  And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp.  And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n ", "original_text": "Thanks for that questions. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee1fdad004a96ab36335ca192c55acbd5ca9429c9abc2f3d6dfb0e1331298479", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97dfd7fa-32ac-40a8-821f-792cb7331e52", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost.  And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp.  And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n ", "original_text": "And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp. "}, "hash": "b26d2377105f2f4cce2a2d125d9991264447a0d775323fe775a8fecc7eff92b9", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost. ", "start_char_idx": 4469, "end_char_idx": 4583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97dfd7fa-32ac-40a8-821f-792cb7331e52": {"__data__": {"id_": "97dfd7fa-32ac-40a8-821f-792cb7331e52", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost.  And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp.  And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n ", "original_text": "And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a335cac-afd1-45c4-8ed6-eee993a7fb04", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyle r \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost.  And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp.  And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n ", "original_text": "Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a22f3243318d4699152d3c4eff7401e743858dd35848e7d809476b31038a2cc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d819206c-013c-4902-8fdc-d5b5ff7cef6c", "node_type": "1", "metadata": {"window": "Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost.  And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp.  And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n ", "original_text": "And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n "}, "hash": "7091af19407635c3f549555ba09504750db53f524505b800ee47d8d20238bae0", "class_name": "RelatedNodeInfo"}}, "text": "And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp. ", "start_char_idx": 4583, "end_char_idx": 4721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d819206c-013c-4902-8fdc-d5b5ff7cef6c": {"__data__": {"id_": "d819206c-013c-4902-8fdc-d5b5ff7cef6c", "embedding": null, "metadata": {"window": "Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost.  And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp.  And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n ", "original_text": "And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8a8101d3560da27b35d68c31a89f36cfd422a7f18a6083be88da0acdd9f122b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97dfd7fa-32ac-40a8-821f-792cb7331e52", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost.  And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp.  And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n ", "original_text": "And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp. ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee86dbc954a023f391946ada15e9c3c417e658b4434b44660bfd526a99452c64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "564157ba-55a8-42a5-8b58-24bd2f00816a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "f7e4de8d73b19afcaeef92f65e4e010ec33569dd8844ed09347669a2887633be", "class_name": "RelatedNodeInfo"}}, "text": "And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n ", "start_char_idx": 4721, "end_char_idx": 4818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "564157ba-55a8-42a5-8b58-24bd2f00816a": {"__data__": {"id_": "564157ba-55a8-42a5-8b58-24bd2f00816a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d819206c-013c-4902-8fdc-d5b5ff7cef6c", "node_type": "1", "metadata": {"window": "Thanks for that questions.  Certainly, each of our businesses is a little bit differently positioned in terms of \nfixed versus variable cost.  And I think the challenge that we're having in our fir st half of the year, in particular, is \nthat the revenue declines are quite sharp.  And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n ", "original_text": "And so that kind of revenue decline is really putting pressure on the \noverall cost position.  \n ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59e53320c5df000bd39b2e6cf81b043e07fe8e40e90d1036893da77b63a11f2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcd67d5b-b2c0-44f6-8a3c-bbca14e611a8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n"}, "hash": "d129146f9c157316b4b2ddb1c12093db5b4b55dad25f2a299658a7533db40da6", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcd67d5b-b2c0-44f6-8a3c-bbca14e611a8": {"__data__": {"id_": "fcd67d5b-b2c0-44f6-8a3c-bbca14e611a8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "564157ba-55a8-42a5-8b58-24bd2f00816a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a35a5355977ec03600e1c4a9bf1c0f02899ce255caee1eeb1f709628bd55ab82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ca0d899-117e-4604-9b5f-55e801fcbd51", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period. ", "original_text": "So we're certainly making great progress on that. "}, "hash": "c4c61389aaf1519da7e62a07aee08688cd12bb64a46d0445121751a19fb3a41e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n", "start_char_idx": 16, "end_char_idx": 416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ca0d899-117e-4604-9b5f-55e801fcbd51": {"__data__": {"id_": "8ca0d899-117e-4604-9b5f-55e801fcbd51", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period. ", "original_text": "So we're certainly making great progress on that. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcd67d5b-b2c0-44f6-8a3c-bbca14e611a8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "440351ba8cf9cd4c032778b446e1d8655695c185b4cad93705e04de1c7f1a17b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f3ee4fb-ca60-4376-8ae8-97ddf5ae497d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n ", "original_text": "We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n"}, "hash": "c616ca12a3ebda9e1e36e9aef97903d7c1c5e286819cec6cb1692b61b460769b", "class_name": "RelatedNodeInfo"}}, "text": "So we're certainly making great progress on that. ", "start_char_idx": 416, "end_char_idx": 466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f3ee4fb-ca60-4376-8ae8-97ddf5ae497d": {"__data__": {"id_": "5f3ee4fb-ca60-4376-8ae8-97ddf5ae497d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n ", "original_text": "We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ca0d899-117e-4604-9b5f-55e801fcbd51", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period. ", "original_text": "So we're certainly making great progress on that. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "704765d25702b553cd6d310daa2d7865b6ccb3a83de49cb5380bfbf45f380797", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da1b334a-39b9-45c7-a135-0608fd84c341", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n ", "original_text": "But generally speaking, our variable costs will adjust with the volumes that we're seeing. "}, "hash": "159d1438ef7352fc8d65dd04158619c16481c57d4797708977c8bfbda4bde5f4", "class_name": "RelatedNodeInfo"}}, "text": "We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n", "start_char_idx": 466, "end_char_idx": 664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da1b334a-39b9-45c7-a135-0608fd84c341": {"__data__": {"id_": "da1b334a-39b9-45c7-a135-0608fd84c341", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n ", "original_text": "But generally speaking, our variable costs will adjust with the volumes that we're seeing. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f3ee4fb-ca60-4376-8ae8-97ddf5ae497d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n ", "original_text": "We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "653081b4fc0e9b430a7199cd8f8ad956270958e09f96ea5e5f881d0577adb9b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f5ba30f-5e92-40ed-b986-3855eee5d5ac", "node_type": "1", "metadata": {"window": "So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call. ", "original_text": "But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period. "}, "hash": "24569c83fa0e9a6007cdce146e17c01db73fd15c0bebdf581301662aa9795f36", "class_name": "RelatedNodeInfo"}}, "text": "But generally speaking, our variable costs will adjust with the volumes that we're seeing. ", "start_char_idx": 664, "end_char_idx": 755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f5ba30f-5e92-40ed-b986-3855eee5d5ac": {"__data__": {"id_": "8f5ba30f-5e92-40ed-b986-3855eee5d5ac", "embedding": null, "metadata": {"window": "So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call. ", "original_text": "But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da1b334a-39b9-45c7-a135-0608fd84c341", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n ", "original_text": "But generally speaking, our variable costs will adjust with the volumes that we're seeing. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a141c7ebdd4c0e8a9a55e41c777a5697a3abe0251c2a366b2ce63988ab97f0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a32ed2d-df70-4cd7-9fe4-e143dc008bff", "node_type": "1", "metadata": {"window": "We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question. ", "original_text": "And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n "}, "hash": "bb3fb64a4fc55a95101e740a2c10ba93f55b00e9be87ea93d1d4cf2adb61779b", "class_name": "RelatedNodeInfo"}}, "text": "But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period. ", "start_char_idx": 755, "end_char_idx": 958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a32ed2d-df70-4cd7-9fe4-e143dc008bff": {"__data__": {"id_": "8a32ed2d-df70-4cd7-9fe4-e143dc008bff", "embedding": null, "metadata": {"window": "We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question. ", "original_text": "And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f5ba30f-5e92-40ed-b986-3855eee5d5ac", "node_type": "1", "metadata": {"window": "So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call. ", "original_text": "But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2451935bc4109db3d8007676c638b85396af21b6c7694901a0d65f27a0bc9b74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2785415-ff5f-4018-b1c4-77208b035e07", "node_type": "1", "metadata": {"window": "But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n "}, "hash": "4ba70fa038bec4b6b1089225be6a8846ef498e9bc0b24bb430bb4d827a599f8f", "class_name": "RelatedNodeInfo"}}, "text": "And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n ", "start_char_idx": 958, "end_char_idx": 1226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2785415-ff5f-4018-b1c4-77208b035e07": {"__data__": {"id_": "a2785415-ff5f-4018-b1c4-77208b035e07", "embedding": null, "metadata": {"window": "But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a32ed2d-df70-4cd7-9fe4-e143dc008bff", "node_type": "1", "metadata": {"window": "We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question. ", "original_text": "And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4655c6cdccdac9c5c593de0bbec610a469c966a1f3b236012dcc2e20e71a2199", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb6ce991-7fe4-44f8-ad8b-185d4953897d", "node_type": "1", "metadata": {"window": "But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call. "}, "hash": "c6b3d8813d5c6617cbb9bf2e09e942cfde94e040826a8f99914610dc5302a9f9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n ", "start_char_idx": 1226, "end_char_idx": 1589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb6ce991-7fe4-44f8-ad8b-185d4953897d": {"__data__": {"id_": "fb6ce991-7fe4-44f8-ad8b-185d4953897d", "embedding": null, "metadata": {"window": "But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2785415-ff5f-4018-b1c4-77208b035e07", "node_type": "1", "metadata": {"window": "But generally speaking, our variable costs will adjust with the volumes that we're seeing.  But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57e1257a63f6793eb403e428545aa02ee51f8c2bb87630386e2c05f7f1af3fe0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37ba9765-bef6-47c6-80d7-784e44961202", "node_type": "1", "metadata": {"window": "And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n ", "original_text": "I just want to follow -up on this negative operating profit leverage question. "}, "hash": "af2a21bc2b6083ad7b369da1eb4a4e3a84035658b0d6934c96ae7afe5e836736", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call. ", "start_char_idx": 1589, "end_char_idx": 1955, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37ba9765-bef6-47c6-80d7-784e44961202": {"__data__": {"id_": "37ba9765-bef6-47c6-80d7-784e44961202", "embedding": null, "metadata": {"window": "And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n ", "original_text": "I just want to follow -up on this negative operating profit leverage question. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb6ce991-7fe4-44f8-ad8b-185d4953897d", "node_type": "1", "metadata": {"window": "But because some of our \nbusinesses have more significant and severe declines in volumes over the first half of the year, there will be some \ndeleveraging that occurs in our businesses over that period.  And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca7568011caaee9577041e6b5a7b04dacba22c80594831c077df631ac18ae0fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fce5487-98dd-444e-b8c3-b0b3283164e1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I \nmean, I appreciate all the details. "}, "hash": "c93ef032ef98ec60f2e272aaaf92ca8f1e659bc34b1e831925f052874a21066e", "class_name": "RelatedNodeInfo"}}, "text": "I just want to follow -up on this negative operating profit leverage question. ", "start_char_idx": 1955, "end_char_idx": 2034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fce5487-98dd-444e-b8c3-b0b3283164e1": {"__data__": {"id_": "3fce5487-98dd-444e-b8c3-b0b3283164e1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I \nmean, I appreciate all the details. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37ba9765-bef6-47c6-80d7-784e44961202", "node_type": "1", "metadata": {"window": "And as the year goes on, cost savings initiatives that \nwe put in place, not only ou r cost savings program, but these mitigation activities will generally start to benefit our \nbusinesses and lead to that growth that we're seeing over the second half of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n ", "original_text": "I just want to follow -up on this negative operating profit leverage question. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "baa8b197198e38b56b5c0843a3b9181ae27601d4cfdea05ddd38074d1a945c02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96fcefc1-5b1c-4f7c-8ca4-08cea1414561", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n"}, "hash": "2bf4f950f00c54336564bd394000d2dee8e09403e4fc37ac2aeb8d1e2c694f81", "class_name": "RelatedNodeInfo"}}, "text": "I \nmean, I appreciate all the details. ", "start_char_idx": 2034, "end_char_idx": 2073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96fcefc1-5b1c-4f7c-8ca4-08cea1414561": {"__data__": {"id_": "96fcefc1-5b1c-4f7c-8ca4-08cea1414561", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fce5487-98dd-444e-b8c3-b0b3283164e1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Your next question comes from the line of Glen Santangelo with Guggenheim.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I \nmean, I appreciate all the details. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "174436d3f545e1c274b63b1c684d8ee4e5bd9f5deb2e3273d00a23b96ec50b27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f539f494-9e2a-456d-93c9-ff3e02b9ed27", "node_type": "1", "metadata": {"window": "I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question. ", "original_text": "Thanks.  \n "}, "hash": "bf428aad5d91ffcd1f757fa56df5d4d95da9b1c3f80ec46503d8a42846af5d82", "class_name": "RelatedNodeInfo"}}, "text": "But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n", "start_char_idx": 2073, "end_char_idx": 2605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f539f494-9e2a-456d-93c9-ff3e02b9ed27": {"__data__": {"id_": "f539f494-9e2a-456d-93c9-ff3e02b9ed27", "embedding": null, "metadata": {"window": "I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question. ", "original_text": "Thanks.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96fcefc1-5b1c-4f7c-8ca4-08cea1414561", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nHi, yeah, thanks for taking my call.  I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c171e3f793eee50f3efcdc6a088a77e807b18683ce06d2d90a59115c5cc4801c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcfb9df1-ff02-486c-ab10-1a6f719e55f6", "node_type": "1", "metadata": {"window": "I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "9a16fe7438d7b121638a84951958cd6e6deb6f70c6f3ca78a087802ade2b0e6e", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2605, "end_char_idx": 2616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcfb9df1-ff02-486c-ab10-1a6f719e55f6": {"__data__": {"id_": "bcfb9df1-ff02-486c-ab10-1a6f719e55f6", "embedding": null, "metadata": {"window": "I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f539f494-9e2a-456d-93c9-ff3e02b9ed27", "node_type": "1", "metadata": {"window": "I just want to follow -up on this negative operating profit leverage question.  I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question. ", "original_text": "Thanks.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e54018f372dc6eb13f8aba439261dca8b2a49079accbfb1bffb36acd16b871b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3441c33c-c8fa-40cb-aaca-6c09bfff7f22", "node_type": "1", "metadata": {"window": "But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n", "original_text": "A \nYeah. "}, "hash": "cd73d518bd9a05277891476134badc9d2ee5b24a7c983e84fabef0cf700af2e0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2616, "end_char_idx": 2977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3441c33c-c8fa-40cb-aaca-6c09bfff7f22": {"__data__": {"id_": "3441c33c-c8fa-40cb-aaca-6c09bfff7f22", "embedding": null, "metadata": {"window": "But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n", "original_text": "A \nYeah. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcfb9df1-ff02-486c-ab10-1a6f719e55f6", "node_type": "1", "metadata": {"window": "I \nmean, I appreciate all the details.  But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "562e6a228635af6adf911071cd185af39c5abb0a7d4531adecb8e154e82fd0c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ff16397-e169-4a0e-8f0f-fb92e453de58", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted. ", "original_text": "Thanks for that question. "}, "hash": "b741f64b0a182340de85e8d2ddbba73a882d15e618558aa69956762745e290e1", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2977, "end_char_idx": 2986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ff16397-e169-4a0e-8f0f-fb92e453de58": {"__data__": {"id_": "4ff16397-e169-4a0e-8f0f-fb92e453de58", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted. ", "original_text": "Thanks for that question. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3441c33c-c8fa-40cb-aaca-6c09bfff7f22", "node_type": "1", "metadata": {"window": "But maybe, Britt, could you unpack the guidance a little bit at the gross margin \nline, particularly as it relates to things like mix and drug pricing and contract renewals, because what I think all of \nus are probably trying to understand is maybe how much of the operating profit contraction  may be the result of a \nweaker gross margin versus lower revenues or incremental expenses related to something like COVID and that \nwill maybe help us better assess how much of the incremental expense is maybe one -time versus ongoing? \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n", "original_text": "A \nYeah. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d342e421c089fd8356453b7a56f765237d916768f57c8325240eda17cc086bd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c5c049d-3851-411c-9bfa-671edcc8386e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities. ", "original_text": "Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points. "}, "hash": "ca92a8bbbb15c4a24b15b7603e6ffce2d25c1c7371a7f48b379d1269328fd0b7", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for that question. ", "start_char_idx": 2986, "end_char_idx": 3012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c5c049d-3851-411c-9bfa-671edcc8386e": {"__data__": {"id_": "1c5c049d-3851-411c-9bfa-671edcc8386e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities. ", "original_text": "Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ff16397-e169-4a0e-8f0f-fb92e453de58", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted. ", "original_text": "Thanks for that question. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e55b3dbbeef3e81060b661e79d7044a1dd55b8b764494df0592021cfe434681f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edc10015-027d-4f57-bdd4-0fcdc897e8fd", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n ", "original_text": "That \nis one of the most severely impacted of our business.  \n \n"}, "hash": "024c84c482e6e798107510f2b0d5b6cd73c16933d228e67aa0d44358bf29f757", "class_name": "RelatedNodeInfo"}}, "text": "Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points. ", "start_char_idx": 3012, "end_char_idx": 3321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edc10015-027d-4f57-bdd4-0fcdc897e8fd": {"__data__": {"id_": "edc10015-027d-4f57-bdd4-0fcdc897e8fd", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n ", "original_text": "That \nis one of the most severely impacted of our business.  \n \n", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c5c049d-3851-411c-9bfa-671edcc8386e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vit alone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities. ", "original_text": "Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5fff96ab54309b52ee3163ef2ee8fe69717fa5cb808528b201e824f28cfe7c7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bc1f067-a961-44da-9799-e803d2fc2ab5", "node_type": "1", "metadata": {"window": "Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted. "}, "hash": "8414c2a69c6e535a9750c19ed53b11546a5441300b807cfa667815d306ded434", "class_name": "RelatedNodeInfo"}}, "text": "That \nis one of the most severely impacted of our business.  \n \n", "start_char_idx": 3321, "end_char_idx": 3385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bc1f067-a961-44da-9799-e803d2fc2ab5": {"__data__": {"id_": "9bc1f067-a961-44da-9799-e803d2fc2ab5", "embedding": null, "metadata": {"window": "Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edc10015-027d-4f57-bdd4-0fcdc897e8fd", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n ", "original_text": "That \nis one of the most severely impacted of our business.  \n \n", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "badafd9a667646108fe064e46954f4c503b1e319106d236ea8cd397835709494", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2878c492-e833-4c4d-bc54-0f3758e845fe", "node_type": "1", "metadata": {"window": "Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n ", "original_text": "So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities. "}, "hash": "caffd8854a3dcec258a84d1883232449ea7f7b885f24150cec5a587e885890b6", "class_name": "RelatedNodeInfo"}}, "text": "And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted. ", "start_char_idx": 3385, "end_char_idx": 3653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2878c492-e833-4c4d-bc54-0f3758e845fe": {"__data__": {"id_": "2878c492-e833-4c4d-bc54-0f3758e845fe", "embedding": null, "metadata": {"window": "Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n ", "original_text": "So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bc1f067-a961-44da-9799-e803d2fc2ab5", "node_type": "1", "metadata": {"window": "Thanks for that question.  Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "819f557887b4c3fb6c925bce528dadaa967082ceda872df1fcf115b34997f59b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28414470-510e-4883-b879-022f38d5378a", "node_type": "1", "metadata": {"window": "That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n "}, "hash": "b44c52b60710e9bca4a54b89c37489233fe61074ab2c406162b3440bd24406f3", "class_name": "RelatedNodeInfo"}}, "text": "So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities. ", "start_char_idx": 3653, "end_char_idx": 3832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28414470-510e-4883-b879-022f38d5378a": {"__data__": {"id_": "28414470-510e-4883-b879-022f38d5378a", "embedding": null, "metadata": {"window": "That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2878c492-e833-4c4d-bc54-0f3758e845fe", "node_type": "1", "metadata": {"window": "Again, what I would come back to here is and I tried to give you a little bit more \ndetail into where we're seeing the impacts on our business, and i n particular, if you just talk about our medical \nbusiness for a moment, that medical business has an adjusted operating profit rate of over 800 basis points.  That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n ", "original_text": "So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1829dc116804e74dcfa81091bb809cd6966efc180d796568abbd0ba771c1e3fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34ce1f04-3358-42d8-bb62-cde5fd8e8b82", "node_type": "1", "metadata": {"window": "And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "67fbebe6ecc8c4a5c9ce4bf7f01c70ead510fd4a88aeeb8f0e2ca7ac5c40854c", "class_name": "RelatedNodeInfo"}}, "text": "This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n ", "start_char_idx": 3832, "end_char_idx": 4014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34ce1f04-3358-42d8-bb62-cde5fd8e8b82": {"__data__": {"id_": "34ce1f04-3358-42d8-bb62-cde5fd8e8b82", "embedding": null, "metadata": {"window": "And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28414470-510e-4883-b879-022f38d5378a", "node_type": "1", "metadata": {"window": "That \nis one of the most severely impacted of our business.  \n \n And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99f077ecdf1bb6e98b5e631b6d889cbb4f1a668acdf7d5399e2c907f98991289", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e0fc8d7-8dce-415b-a137-e2630a3c0709", "node_type": "1", "metadata": {"window": "So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "A \nOperator, we have time for one more question.  \n "}, "hash": "89ba3514118a3c29d26a1e3d73c894cf1b1b53b7ce3740895d8780d187fb7352", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 4014, "end_char_idx": 4359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e0fc8d7-8dce-415b-a137-e2630a3c0709": {"__data__": {"id_": "9e0fc8d7-8dce-415b-a137-e2630a3c0709", "embedding": null, "metadata": {"window": "So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "A \nOperator, we have time for one more question.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34ce1f04-3358-42d8-bb62-cde5fd8e8b82", "node_type": "1", "metadata": {"window": "And we try to give you a little bit mo re detail in the sense that our primary care business where we have lots of \ncapabilities and services that we provide there, about 60% of that medical business is primary care sites, which \nhave been the most severely impacted.  So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4672511c6de98935fe0eb9f02429b8e11c717fae3747b99ebca66c594b04150", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc37033a-3530-463d-975a-a9b31dcbaf64", "node_type": "1", "metadata": {"window": "This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. "}, "hash": "60cda8a2aa244a6acc1e2a9d55229f065294fc01954328342bf619fa8ad2292b", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, we have time for one more question.  \n ", "start_char_idx": 4359, "end_char_idx": 4411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc37033a-3530-463d-975a-a9b31dcbaf64": {"__data__": {"id_": "fc37033a-3530-463d-975a-a9b31dcbaf64", "embedding": null, "metadata": {"window": "This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e0fc8d7-8dce-415b-a137-e2630a3c0709", "node_type": "1", "metadata": {"window": "So what I would say is it's n ot necessarily a cost issue and we do have \nadditional cost for protecting our employees and sanitation and cleaning in our distribution facilities.  This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "A \nOperator, we have time for one more question.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a398aa2cbdad5726ccd93f25332099961f8dec76ddda2fb71c64683d256cb604", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6750f897-96c5-4a26-822e-15e0185d9a9f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q ", "original_text": "That question will come from George Hill with Deutsche Bank.  \n "}, "hash": "9c4f363e35391eeffa243f6ee3bbd2471a645ad4c4825b4b3e1ead13286b98b1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "start_char_idx": 4411, "end_char_idx": 4707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6750f897-96c5-4a26-822e-15e0185d9a9f": {"__data__": {"id_": "6750f897-96c5-4a26-822e-15e0185d9a9f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q ", "original_text": "That question will come from George Hill with Deutsche Bank.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc37033a-3530-463d-975a-a9b31dcbaf64", "node_type": "1", "metadata": {"window": "This is more a \nfirst half mix issue, particularly in our specialty provider businesses and our medical busin ess, which as you know \nhas a higher adjusted operating profit rate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3b4971c736fe443f5c47f568b7fc3941208ad300ecebbd76cbb852e4f76e7d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "779c7869-897e-4bc4-9352-1712c52cfa08", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  "}, "hash": "8726daf8d75fe59623fd9a55d2aab1b7a74df70f71f1941cb0b5fbb441e3d104", "class_name": "RelatedNodeInfo"}}, "text": "That question will come from George Hill with Deutsche Bank.  \n ", "start_char_idx": 4707, "end_char_idx": 4771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "779c7869-897e-4bc4-9352-1712c52cfa08": {"__data__": {"id_": "779c7869-897e-4bc4-9352-1712c52cfa08", "embedding": null, "metadata": {"window": "A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6750f897-96c5-4a26-822e-15e0185d9a9f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q ", "original_text": "That question will come from George Hill with Deutsche Bank.  \n ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0acb5e684d7032277eac950d4fb3efe4bfe568ff987625782b5979b00ce3c24d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c097dc4-9502-447f-9a04-c648048350e0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q ", "original_text": "Q "}, "hash": "b49f59ed435b6cf35c6f4425b80d9da50a7ddb43855741e029e7e214a3389a3d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "start_char_idx": 4771, "end_char_idx": 5098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c097dc4-9502-447f-9a04-c648048350e0": {"__data__": {"id_": "1c097dc4-9502-447f-9a04-c648048350e0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q ", "original_text": "Q ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd763f70-715f-41af-9a49-ce591c476748", "node_type": "4", "metadata": {"page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4af7ee415eab188cdde9ebdcc3942706cbe725c634221dd2a440381c51357ed4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "779c7869-897e-4bc4-9352-1712c52cfa08", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42c690b5a0ac1691cdf0be9fbcb08b2ae8905dd0d58715e3b1dbb5947f7c9dd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82bac935-7c62-467c-97f8-8a87bcb113b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact. ", "original_text": "McKesson Corp.  "}, "hash": "a452984be83239b6ece70208837f4fad98720ea58bf1b494d1243fe958bd5785", "class_name": "RelatedNodeInfo"}}, "text": "Q ", "start_char_idx": 1915, "end_char_idx": 1917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82bac935-7c62-467c-97f8-8a87bcb113b7": {"__data__": {"id_": "82bac935-7c62-467c-97f8-8a87bcb113b7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact. ", "original_text": "McKesson Corp.  ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c097dc4-9502-447f-9a04-c648048350e0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q ", "original_text": "Q ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "482c596d06bcf7c6ffcb93382d7cf91e4a71b7e77b52e3c0190db7977e095eb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d16e22f2-7c00-4e2b-b0b3-d84174564f9f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question. "}, "hash": "180a629f9732371bf31ba152595a343a04ec2a9e556df0a3bca5277c72c3029f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d16e22f2-7c00-4e2b-b0b3-d84174564f9f": {"__data__": {"id_": "d16e22f2-7c00-4e2b-b0b3-d84174564f9f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82bac935-7c62-467c-97f8-8a87bcb113b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact. ", "original_text": "McKesson Corp.  ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f57ac11a16e29c2e400eb391242de92585d546a8103b638b41aff2a3c38f6cc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fc20094-9857-4cfd-a12a-b024e5501e0b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n ", "original_text": "I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time. "}, "hash": "129e729ca9309530073c9af3d1c944682918143cfb2bad3d441a1e8156f2ab2a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question. ", "start_char_idx": 16, "end_char_idx": 241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fc20094-9857-4cfd-a12a-b024e5501e0b": {"__data__": {"id_": "1fc20094-9857-4cfd-a12a-b024e5501e0b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n ", "original_text": "I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d16e22f2-7c00-4e2b-b0b3-d84174564f9f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04c48395c66db4359bb3162c7073c5819322c188349cc1821eb710962c81f3b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4004cdb-598a-431f-8341-3ea1885b3738", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact. "}, "hash": "558b3c9792f79170792ac3fb7a210925375b60644a8b99e6285eb27145ea1fc8", "class_name": "RelatedNodeInfo"}}, "text": "I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time. ", "start_char_idx": 241, "end_char_idx": 343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4004cdb-598a-431f-8341-3ea1885b3738": {"__data__": {"id_": "f4004cdb-598a-431f-8341-3ea1885b3738", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fc20094-9857-4cfd-a12a-b024e5501e0b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n ", "original_text": "I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a16f6287ad606df4f76c4054a5224e637fa41c2c430c399b7fc01d175bf22a3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71daf10b-af13-468e-9737-ea2ca48b099d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers. "}, "hash": "a5e36776c85001a4077a036ce35983de83c9e0d9e64cdd94132548ec380f23d3", "class_name": "RelatedNodeInfo"}}, "text": "You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact. ", "start_char_idx": 343, "end_char_idx": 479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71daf10b-af13-468e-9737-ea2ca48b099d": {"__data__": {"id_": "71daf10b-af13-468e-9737-ea2ca48b099d", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4004cdb-598a-431f-8341-3ea1885b3738", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1396e704699d5c9d09854cd9df448ce1cd65ab15eb9348040c385e413592a7e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98fc8151-9e76-49c0-aac9-0f4f58110303", "node_type": "1", "metadata": {"window": "I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question. ", "original_text": "Thanks.  \n "}, "hash": "abb692511bd2233dcc8dc4273d3906867925018c87f2380e61313cd7cad20951", "class_name": "RelatedNodeInfo"}}, "text": "I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers. ", "start_char_idx": 479, "end_char_idx": 746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98fc8151-9e76-49c0-aac9-0f4f58110303": {"__data__": {"id_": "98fc8151-9e76-49c0-aac9-0f4f58110303", "embedding": null, "metadata": {"window": "I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question. ", "original_text": "Thanks.  \n ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71daf10b-af13-468e-9737-ea2ca48b099d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfeb2a4600f00faeccf46a82d5b6461dc0ad92b4a627f7589d603d289a6c0767", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41889df8-a149-424d-8935-c2919c274dea", "node_type": "1", "metadata": {"window": "You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "a1a8a4cf816b45a05117a59fddef0c47edfb02222bb29ae7443fdd072f8fba03", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 746, "end_char_idx": 757, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41889df8-a149-424d-8935-c2919c274dea": {"__data__": {"id_": "41889df8-a149-424d-8935-c2919c274dea", "embedding": null, "metadata": {"window": "You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98fc8151-9e76-49c0-aac9-0f4f58110303", "node_type": "1", "metadata": {"window": "I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question. ", "original_text": "Thanks.  \n ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a52c9de7c5d5e4b434b0c6a62ab5e8e60a7e63187f4b9e57a8da5086e30eb65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "535e9e5e-51d2-4c78-a4d5-84f0f47945d7", "node_type": "1", "metadata": {"window": "I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact. ", "original_text": "A \nYeah. "}, "hash": "b4ee8c40b94f0208178ef0c03d745544f9db695601e3f00f4ed54c1e24faf11c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 757, "end_char_idx": 1117, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "535e9e5e-51d2-4c78-a4d5-84f0f47945d7": {"__data__": {"id_": "535e9e5e-51d2-4c78-a4d5-84f0f47945d7", "embedding": null, "metadata": {"window": "I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact. ", "original_text": "A \nYeah. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41889df8-a149-424d-8935-c2919c274dea", "node_type": "1", "metadata": {"window": "You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact.  I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af0d6817787a7b44954f611fa84396968129b986199f79eeff0a224be524127b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23d0477c-8fba-45a6-b2a2-fadc46d5c196", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n", "original_text": "Thanks for that question. "}, "hash": "9221ee65b5b12827c5ed226cedef463b5061a99e7f91dd7c3e82a9603706dc71", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1117, "end_char_idx": 1126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23d0477c-8fba-45a6-b2a2-fadc46d5c196": {"__data__": {"id_": "23d0477c-8fba-45a6-b2a2-fadc46d5c196", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n", "original_text": "Thanks for that question. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "535e9e5e-51d2-4c78-a4d5-84f0f47945d7", "node_type": "1", "metadata": {"window": "I guess, as we look at the 2021 margin \nguidance in the drug segment, could you kind of rank order what's driving the margin erosion when we think of \neither customer mix, product mix, VA renewal or COVID, just kind of rank ordering the negative margin mix \ndrivers.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact. ", "original_text": "A \nYeah. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58082d585ef11f0349c041356e5e95268400c7386a966ce0810702f8c66295fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d40bb52-b741-4457-b07e-834864b8ddcb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites. ", "original_text": "Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear. "}, "hash": "4ea976cad45bbdd0d07a2b15af39371afa38fe187cdd25ba4d3dfb7c5ced949d", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for that question. ", "start_char_idx": 1126, "end_char_idx": 1152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d40bb52-b741-4457-b07e-834864b8ddcb": {"__data__": {"id_": "9d40bb52-b741-4457-b07e-834864b8ddcb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites. ", "original_text": "Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23d0477c-8fba-45a6-b2a2-fadc46d5c196", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n", "original_text": "Thanks for that question. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f89f5eb9945e031e5837f94da56572cf095d4ef092a5f0b62dc9c186b92a8581", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ac892e7-88f8-4fdd-886d-b76de1733c3f", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business. ", "original_text": "We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact. "}, "hash": "90fba7b6505fcfa4fc982bd1eb96b878800c7cc21abe5aafccda32771657d23a", "class_name": "RelatedNodeInfo"}}, "text": "Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear. ", "start_char_idx": 1152, "end_char_idx": 1350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ac892e7-88f8-4fdd-886d-b76de1733c3f": {"__data__": {"id_": "1ac892e7-88f8-4fdd-886d-b76de1733c3f", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business. ", "original_text": "We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d40bb52-b741-4457-b07e-834864b8ddcb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites. ", "original_text": "Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "abf6ac3a165c05345c89576b406c54fe068dee6e6547b8fda07c13ccab7bb287", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8266e0dc-a29f-4deb-b445-e4eee1c8f414", "node_type": "1", "metadata": {"window": "Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business. ", "original_text": "Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n"}, "hash": "2111ab5aa40cdf2f1beddb2f8f7817c6615f54e5755cc3ebaa66fa6fc434c250", "class_name": "RelatedNodeInfo"}}, "text": "We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact. ", "start_char_idx": 1350, "end_char_idx": 1515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8266e0dc-a29f-4deb-b445-e4eee1c8f414": {"__data__": {"id_": "8266e0dc-a29f-4deb-b445-e4eee1c8f414", "embedding": null, "metadata": {"window": "Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business. ", "original_text": "Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ac892e7-88f8-4fdd-886d-b76de1733c3f", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business. ", "original_text": "We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71500750eccb46723b7e22749be5e0caa2e7954637242bd1b43505276a5707cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73ee94fa-bb59-4194-a31d-0e12933ff8fc", "node_type": "1", "metadata": {"window": "Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound. ", "original_text": "So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites. "}, "hash": "5141bd43e06943e7fdb9f226146ecaa3fe209167963d201ed05d11218b850ab8", "class_name": "RelatedNodeInfo"}}, "text": "Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n", "start_char_idx": 1515, "end_char_idx": 1666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73ee94fa-bb59-4194-a31d-0e12933ff8fc": {"__data__": {"id_": "73ee94fa-bb59-4194-a31d-0e12933ff8fc", "embedding": null, "metadata": {"window": "Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound. ", "original_text": "So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8266e0dc-a29f-4deb-b445-e4eee1c8f414", "node_type": "1", "metadata": {"window": "Thanks for that question.  Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business. ", "original_text": "Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b8d3a1b55b41965891c5ede76c3cd2f8992a294dc9bbea2ba0999226b097589", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b37887eb-440f-4211-8562-fc7e2783f5ac", "node_type": "1", "metadata": {"window": "We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n ", "original_text": "Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business. "}, "hash": "4a0bc2dd84da061664f1b069217961ed657d1ceb03ca62acb2dac29fce05a211", "class_name": "RelatedNodeInfo"}}, "text": "So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites. ", "start_char_idx": 1666, "end_char_idx": 1855, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b37887eb-440f-4211-8562-fc7e2783f5ac": {"__data__": {"id_": "b37887eb-440f-4211-8562-fc7e2783f5ac", "embedding": null, "metadata": {"window": "We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n ", "original_text": "Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73ee94fa-bb59-4194-a31d-0e12933ff8fc", "node_type": "1", "metadata": {"window": "Again, I would come back to what we're seeing is within our business, our \nspecialties provider businesses are most impacted, so that's certainly having a big impact in the first half of the \nyear.  We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound. ", "original_text": "So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6bf828e7eeafda9f42f8c1380f7bfe6e37aa6ea4968c2f034981105ceb62121", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "112300a6-0dce-450e-82df-a90ffc707539", "node_type": "1", "metadata": {"window": "Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "There's nothing fundamentally or \nstructurally going on within our business. "}, "hash": "2a90f412228edb1747101a3449628eb9a4e4a2c36caa24afa7e23f352837079c", "class_name": "RelatedNodeInfo"}}, "text": "Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business. ", "start_char_idx": 1855, "end_char_idx": 1979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "112300a6-0dce-450e-82df-a90ffc707539": {"__data__": {"id_": "112300a6-0dce-450e-82df-a90ffc707539", "embedding": null, "metadata": {"window": "Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "There's nothing fundamentally or \nstructurally going on within our business. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b37887eb-440f-4211-8562-fc7e2783f5ac", "node_type": "1", "metadata": {"window": "We've called out very similar types of mid -single -digit bran ded price increase rates that we've seen over the \npast couple of years, that's really not an impact.  Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n ", "original_text": "Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9607484bcb118affcf22a657b85d31c7c95567102799fca3fc89464d7d064497", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a7f88ff-28b7-4671-8acc-e89c8466f17f", "node_type": "1", "metadata": {"window": "So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great. ", "original_text": "Our business continues to be very, very fundamentally sound. "}, "hash": "6715481e9e271859b71c85aa3cf11b3a22e171ec1c180bba41218c6f3521c272", "class_name": "RelatedNodeInfo"}}, "text": "There's nothing fundamentally or \nstructurally going on within our business. ", "start_char_idx": 1979, "end_char_idx": 2056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a7f88ff-28b7-4671-8acc-e89c8466f17f": {"__data__": {"id_": "8a7f88ff-28b7-4671-8acc-e89c8466f17f", "embedding": null, "metadata": {"window": "So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great. ", "original_text": "Our business continues to be very, very fundamentally sound. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "112300a6-0dce-450e-82df-a90ffc707539", "node_type": "1", "metadata": {"window": "Renewals are not an impact, we talked about we've been able to \nrenew our \u2013 sort of three of our largest customers without an impact to our guide.  \n \n So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "There's nothing fundamentally or \nstructurally going on within our business. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba1c1b28ad6b7b8c5843a41366d8c9ac5ca17708cd5e8714841056573a42dcd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c35e9b70-def7-450e-943a-0a5abc118b7e", "node_type": "1", "metadata": {"window": "Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you. ", "original_text": "This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n "}, "hash": "df13379107bb3863536899834f53d54935430fcc06da32670719ec2f80fca5b6", "class_name": "RelatedNodeInfo"}}, "text": "Our business continues to be very, very fundamentally sound. ", "start_char_idx": 2056, "end_char_idx": 2117, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c35e9b70-def7-450e-943a-0a5abc118b7e": {"__data__": {"id_": "c35e9b70-def7-450e-943a-0a5abc118b7e", "embedding": null, "metadata": {"window": "Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you. ", "original_text": "This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a7f88ff-28b7-4671-8acc-e89c8466f17f", "node_type": "1", "metadata": {"window": "So I'll just get back to, as you think about where the recovery and the shape of the curve in our business is, most \nseverely impacted is our physician sites, our specialty provider sites.  Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great. ", "original_text": "Our business continues to be very, very fundamentally sound. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e61eb5927f5f2f9f94dfd6bd725ffa941d6bd6efb152d97c83458093a0b98b4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7f89966-17e9-460b-a208-f5fe08ef16c8", "node_type": "1", "metadata": {"window": "There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "b206fcbba99975ea49ee3e56b6b7f53964c20157fd2d9da381b7853efbee54bb", "class_name": "RelatedNodeInfo"}}, "text": "This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n ", "start_char_idx": 2117, "end_char_idx": 2306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7f89966-17e9-460b-a208-f5fe08ef16c8": {"__data__": {"id_": "c7f89966-17e9-460b-a208-f5fe08ef16c8", "embedding": null, "metadata": {"window": "There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c35e9b70-def7-450e-943a-0a5abc118b7e", "node_type": "1", "metadata": {"window": "Those tend to be higher growth and higher \nmargin businesses for us, and that  mix is really what's impacting the business.  There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you. ", "original_text": "This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f20989707ff5ca4be0867f9de86b260dbcd0ed6ca7149a434f100235d9b219bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "caa4dba7-8729-4a56-bf26-1ffee350a239", "node_type": "1", "metadata": {"window": "Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us. ", "original_text": "Great. "}, "hash": "9eb44628020d6a1e457020001e327608936bd13c8e826ec2d6fd7c410a82f0ec", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 2306, "end_char_idx": 2648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "caa4dba7-8729-4a56-bf26-1ffee350a239": {"__data__": {"id_": "caa4dba7-8729-4a56-bf26-1ffee350a239", "embedding": null, "metadata": {"window": "Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us. ", "original_text": "Great. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7f89966-17e9-460b-a208-f5fe08ef16c8", "node_type": "1", "metadata": {"window": "There's nothing fundamentally or \nstructurally going on within our business.  Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9e43dc3c179df5384fd60f65deab10eccd4f17b96ccb6f121e8d1ecaaabf907", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c961ec2-888d-4f46-ab55-044956a27577", "node_type": "1", "metadata": {"window": "This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n", "original_text": "Well, thank you. "}, "hash": "ab54a9ad811822c0bc598598cfb7e7d2207f22d4641fdfa9135da95ca80c9a67", "class_name": "RelatedNodeInfo"}}, "text": "Great. ", "start_char_idx": 2648, "end_char_idx": 2655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c961ec2-888d-4f46-ab55-044956a27577": {"__data__": {"id_": "5c961ec2-888d-4f46-ab55-044956a27577", "embedding": null, "metadata": {"window": "This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n", "original_text": "Well, thank you. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "caa4dba7-8729-4a56-bf26-1ffee350a239", "node_type": "1", "metadata": {"window": "Our business continues to be very, very fundamentally sound.  This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us. ", "original_text": "Great. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbe32419a53123b5166effdcad23ccf5f2f00e342edb3fe639226515c4acf330", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8562874-035c-4e89-92d1-6d5a388b8813", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before. ", "original_text": "Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions. "}, "hash": "c2c1c7354c0c63a8d04ad8035caa8a113bd444e45859564ed02632a7d2e381f8", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you. ", "start_char_idx": 2655, "end_char_idx": 2672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8562874-035c-4e89-92d1-6d5a388b8813": {"__data__": {"id_": "b8562874-035c-4e89-92d1-6d5a388b8813", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before. ", "original_text": "Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c961ec2-888d-4f46-ab55-044956a27577", "node_type": "1", "metadata": {"window": "This is a \nmatter of a temporary decline in revenue and really a mix issue  of where that revenue is coming from, but there's \nnothing fundamentally changing within the business itself.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n", "original_text": "Well, thank you. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a0111d203612f11b8eaa5604606ec35794e8922fd72ec89b1ece9802a568d51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a94582b-e6c6-4479-982e-3bfc3af223c3", "node_type": "1", "metadata": {"window": "Great.  Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before. ", "original_text": "I want to thank Lashana for facilitating this call for us. "}, "hash": "b46fba1608a181c5b3c50d8e009365354cf8db61a62ae75390ed53174945b3cd", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions. ", "start_char_idx": 2672, "end_char_idx": 2794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a94582b-e6c6-4479-982e-3bfc3af223c3": {"__data__": {"id_": "0a94582b-e6c6-4479-982e-3bfc3af223c3", "embedding": null, "metadata": {"window": "Great.  Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before. ", "original_text": "I want to thank Lashana for facilitating this call for us. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8562874-035c-4e89-92d1-6d5a388b8813", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before. ", "original_text": "Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "498434fa6837031069d5268b3691386e27d8fc7264d7d4ffe95a65e463d5e1f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbd901ee-ba40-486d-b214-6040b1b845fc", "node_type": "1", "metadata": {"window": "Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson. ", "original_text": "Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n"}, "hash": "080060c2ef3164039f5e1a3cca76b63c88546e4515af5bb3d7135ba197fb9f10", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank Lashana for facilitating this call for us. ", "start_char_idx": 2794, "end_char_idx": 2853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbd901ee-ba40-486d-b214-6040b1b845fc": {"__data__": {"id_": "bbd901ee-ba40-486d-b214-6040b1b845fc", "embedding": null, "metadata": {"window": "Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson. ", "original_text": "Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a94582b-e6c6-4479-982e-3bfc3af223c3", "node_type": "1", "metadata": {"window": "Great.  Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before. ", "original_text": "I want to thank Lashana for facilitating this call for us. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d84eea0285afed1bb9e42973e51c6836bc165bf9bd9a679b2e9b7ed89616c4b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5851d709-3345-4b60-aea0-30994f9b6c5d", "node_type": "1", "metadata": {"window": "Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay. ", "original_text": "McKesson has navigated challenges many times before. "}, "hash": "7eae3b9a7f541ffca5d6ce6a7fa958b1ab54d3464c6c619cd3604f518f028c44", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n", "start_char_idx": 2853, "end_char_idx": 3071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5851d709-3345-4b60-aea0-30994f9b6c5d": {"__data__": {"id_": "5851d709-3345-4b60-aea0-30994f9b6c5d", "embedding": null, "metadata": {"window": "Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay. ", "original_text": "McKesson has navigated challenges many times before. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbd901ee-ba40-486d-b214-6040b1b845fc", "node_type": "1", "metadata": {"window": "Well, thank you.  Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson. ", "original_text": "Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33b2c38a1a943ff7ea374d07b3dec107d72ed7f05725901b341a9f6eb9155869", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9219269a-978f-44de-81e1-14fc4faa1749", "node_type": "1", "metadata": {"window": "I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n", "original_text": "Our industry and our countries have navigated these \nkinds of challenges many times before. "}, "hash": "a6431553db32c984b9b50d872f9b01a387d09e754ce7c78bb10f5fdca6c9513a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson has navigated challenges many times before. ", "start_char_idx": 3071, "end_char_idx": 3124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9219269a-978f-44de-81e1-14fc4faa1749": {"__data__": {"id_": "9219269a-978f-44de-81e1-14fc4faa1749", "embedding": null, "metadata": {"window": "I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n", "original_text": "Our industry and our countries have navigated these \nkinds of challenges many times before. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5851d709-3345-4b60-aea0-30994f9b6c5d", "node_type": "1", "metadata": {"window": "Thank you, everybody, for your participation today, f or your interest in McKesson and, \ncertainly, your great questions.  I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay. ", "original_text": "McKesson has navigated challenges many times before. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81270e1a696fce3dffac67c382dc0d85e1e06f71d9ce1e3fcf19fbc6afc49ac6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9ffdc95-27a5-4b2e-a6d6-9bddd0effd3f", "node_type": "1", "metadata": {"window": "Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness. ", "original_text": "I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson. "}, "hash": "8e5044545b90f19d9b2fad9f78d164f1287ddc7f959da009201ec12970e93435", "class_name": "RelatedNodeInfo"}}, "text": "Our industry and our countries have navigated these \nkinds of challenges many times before. ", "start_char_idx": 3124, "end_char_idx": 3216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9ffdc95-27a5-4b2e-a6d6-9bddd0effd3f": {"__data__": {"id_": "e9ffdc95-27a5-4b2e-a6d6-9bddd0effd3f", "embedding": null, "metadata": {"window": "Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness. ", "original_text": "I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9219269a-978f-44de-81e1-14fc4faa1749", "node_type": "1", "metadata": {"window": "I want to thank Lashana for facilitating this call for us.  Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n", "original_text": "Our industry and our countries have navigated these \nkinds of challenges many times before. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9268cbc1bf939a7d51ca500796de6fa793cf63b81029989eccf7978e67ef28c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9aa73d85-8784-45f2-bd0f-b1e5c42f3083", "node_type": "1", "metadata": {"window": "McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n ", "original_text": "And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay. "}, "hash": "d50e1b2771d66af91375f2587d56fb2e1295d38a00ee737ea6caf330733580ee", "class_name": "RelatedNodeInfo"}}, "text": "I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson. ", "start_char_idx": 3216, "end_char_idx": 3384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9aa73d85-8784-45f2-bd0f-b1e5c42f3083": {"__data__": {"id_": "9aa73d85-8784-45f2-bd0f-b1e5c42f3083", "embedding": null, "metadata": {"window": "McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n ", "original_text": "And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9ffdc95-27a5-4b2e-a6d6-9bddd0effd3f", "node_type": "1", "metadata": {"window": "Obviously, this was a little \nlonger call than we typically have, but we thought it was very appropriate given the environment to t ry to provide a \nlittle more detail insight into what's going on in the business.  \n \n McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness. ", "original_text": "I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f1f4ef3bf8288aae9e86d19604f076bd28798fc9b651211b8f162f38f98db41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9dec605-db40-4ce5-8ede-bc3d6b9953fb", "node_type": "1", "metadata": {"window": "Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n"}, "hash": "dc6e4a2300489c254ef458e0646629c52a28185a75b7280681d89bd421e662a9", "class_name": "RelatedNodeInfo"}}, "text": "And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay. ", "start_char_idx": 3384, "end_char_idx": 3510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9dec605-db40-4ce5-8ede-bc3d6b9953fb": {"__data__": {"id_": "d9dec605-db40-4ce5-8ede-bc3d6b9953fb", "embedding": null, "metadata": {"window": "Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9aa73d85-8784-45f2-bd0f-b1e5c42f3083", "node_type": "1", "metadata": {"window": "McKesson has navigated challenges many times before.  Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n ", "original_text": "And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4e41dd0e191bc713cf83ed8f06b03bb822cd98e05ae360fe1e0998c9b4918c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c638f8c-948b-425c-a46c-63528e5c3372", "node_type": "1", "metadata": {"window": "I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "On behalf of our team at McKesson, we wish you and your families good health and wellness. "}, "hash": "75778a68be9411c64b23c1c9fd21b0088a43e6e7e05106ab22cb85feeaebdaef", "class_name": "RelatedNodeInfo"}}, "text": "I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n", "start_char_idx": 3510, "end_char_idx": 3641, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c638f8c-948b-425c-a46c-63528e5c3372": {"__data__": {"id_": "6c638f8c-948b-425c-a46c-63528e5c3372", "embedding": null, "metadata": {"window": "I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "On behalf of our team at McKesson, we wish you and your families good health and wellness. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9dec605-db40-4ce5-8ede-bc3d6b9953fb", "node_type": "1", "metadata": {"window": "Our industry and our countries have navigated these \nkinds of challenges many times before.  I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ced3ffac747a44dfb997bc6ca67afb6761cbe289fadb61b0e469c7f8d2ba4bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e4a9d23-ffea-44a2-aa53-82c3ca0ab085", "node_type": "1", "metadata": {"window": "And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "We very much look \nforward to seeing  you soon.  \n "}, "hash": "ab3d8be0c2942c43dbe3a323d8a354865f2ceae63c4117e5c781e932baa10979", "class_name": "RelatedNodeInfo"}}, "text": "On behalf of our team at McKesson, we wish you and your families good health and wellness. ", "start_char_idx": 3641, "end_char_idx": 3732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e4a9d23-ffea-44a2-aa53-82c3ca0ab085": {"__data__": {"id_": "1e4a9d23-ffea-44a2-aa53-82c3ca0ab085", "embedding": null, "metadata": {"window": "And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "We very much look \nforward to seeing  you soon.  \n ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c638f8c-948b-425c-a46c-63528e5c3372", "node_type": "1", "metadata": {"window": "I think it's fair to say, I kn ow I and we all probably take great inspiration \nfrom our frontline healthcare workers and our essential workers like those in McKesson.  And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "On behalf of our team at McKesson, we wish you and your families good health and wellness. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "957425d38540f63d4815ed329e72417ad28d65a84811415e7927e3e952ecf4e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c38784d8-b1b7-404b-b43a-266a70764155", "node_type": "1", "metadata": {"window": "I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. "}, "hash": "b9207fae79b09b6d73f09b56c3c368d275a27b2ef0fe08a19571d8ddcdb220a2", "class_name": "RelatedNodeInfo"}}, "text": "We very much look \nforward to seeing  you soon.  \n ", "start_char_idx": 3732, "end_char_idx": 3783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c38784d8-b1b7-404b-b43a-266a70764155": {"__data__": {"id_": "c38784d8-b1b7-404b-b43a-266a70764155", "embedding": null, "metadata": {"window": "I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e4a9d23-ffea-44a2-aa53-82c3ca0ab085", "node_type": "1", "metadata": {"window": "And I want to thank the \n80,000 members of team McKesson for their dedication and the inspiration they provide me every d ay.  I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "We very much look \nforward to seeing  you soon.  \n ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee00e92859170c02e3555c0d4806959ddb741bf16852919bd34858486c2b5985", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd164616-673b-416d-9e98-ccbf3a099c26", "node_type": "1", "metadata": {"window": "On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n "}, "hash": "0967bdd8aec53378fe524c8d6004dcfaf6bbe32cfe6c23ddae9f169531506229", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "start_char_idx": 3783, "end_char_idx": 4115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd164616-673b-416d-9e98-ccbf3a099c26": {"__data__": {"id_": "bd164616-673b-416d-9e98-ccbf3a099c26", "embedding": null, "metadata": {"window": "On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2d77d038-7df1-4815-8983-173fe11a8a9c", "node_type": "4", "metadata": {"page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbdde3e383504e3c2e421ff77ddcc7b45d7a9d25f74ef4d6ceae25e824d093e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c38784d8-b1b7-404b-b43a-266a70764155", "node_type": "1", "metadata": {"window": "I am \nconfident that we're well positioned to emerge from this experience as a stronger business and in stronger \ncommunities.  \n \n On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ce0f81f09f0d2b638301e2e21b489dda19903ebaa9c9aa0fc9863c423e46356", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a90b037-c9d1-4249-a77c-ed7abddcc737", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  "}, "hash": "38b770e12fc4945f46fe9fa1105e941ef22761895a61384f2847864ed581cf6e", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect, and have a great day.  \n \n \n \n ", "start_char_idx": 4115, "end_char_idx": 4170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a90b037-c9d1-4249-a77c-ed7abddcc737": {"__data__": {"id_": "7a90b037-c9d1-4249-a77c-ed7abddcc737", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9", "node_type": "4", "metadata": {"page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c61fe4b648e4722dd5d4c827f2853d877174b0005f782276d2ee9af9f4d6eb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd164616-673b-416d-9e98-ccbf3a099c26", "node_type": "1", "metadata": {"window": "On behalf of our team at McKesson, we wish you and your families good health and wellness.  We very much look \nforward to seeing  you soon.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "415fe80744b270ad778a0ac0b012f0720cd9ac420cfda667909e1d7290c99f0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46a96516-cdf4-465c-bae0-0ea913268dbb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n"}, "hash": "5f7811008835c1c520c0e34b58b5e541362f9ee59eabec0161f419ef9fbce9bc", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46a96516-cdf4-465c-bae0-0ea913268dbb": {"__data__": {"id_": "46a96516-cdf4-465c-bae0-0ea913268dbb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9", "node_type": "4", "metadata": {"page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c61fe4b648e4722dd5d4c827f2853d877174b0005f782276d2ee9af9f4d6eb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a90b037-c9d1-4249-a77c-ed7abddcc737", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ffc223f6d3b2e928b000d773d579fb384ef132b6c6b117c76720ea27f389fe1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8f632db-36a4-4ce8-8155-268d9085b4c4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. "}, "hash": "8ea268eff2089c80c2d739fa3bb750cf315b6098fecd1d8814af99b406edf38f", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "start_char_idx": 16, "end_char_idx": 403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8f632db-36a4-4ce8-8155-268d9085b4c4": {"__data__": {"id_": "b8f632db-36a4-4ce8-8155-268d9085b4c4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9", "node_type": "4", "metadata": {"page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c61fe4b648e4722dd5d4c827f2853d877174b0005f782276d2ee9af9f4d6eb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46a96516-cdf4-465c-bae0-0ea913268dbb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "original_text": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f005033ef9e6c9633fae6071f6e4939f3051a51d855820054f848e9412bc9b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09245a9f-d6dc-4255-98df-f5866befd3da", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. "}, "hash": "9541162560995cfc4d42729159b07afd3c9848dff3ad80fd8c9bb7cc2b0e0874", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 403, "end_char_idx": 525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09245a9f-d6dc-4255-98df-f5866befd3da": {"__data__": {"id_": "09245a9f-d6dc-4255-98df-f5866befd3da", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9", "node_type": "4", "metadata": {"page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c61fe4b648e4722dd5d4c827f2853d877174b0005f782276d2ee9af9f4d6eb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8f632db-36a4-4ce8-8155-268d9085b4c4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e03e8009426818bf939dc9489548c9973c8a3f60fbed46845d7c923474130101", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9059526b-e876-4cc7-9370-5764cc02425f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor. "}, "hash": "d9d0a62977e693b51bb76c7f9eb7294c1b020a909feaa20cba86e89930679c45", "class_name": "RelatedNodeInfo"}}, "text": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "start_char_idx": 525, "end_char_idx": 818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9059526b-e876-4cc7-9370-5764cc02425f": {"__data__": {"id_": "9059526b-e876-4cc7-9370-5764cc02425f", "embedding": null, "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9", "node_type": "4", "metadata": {"page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c61fe4b648e4722dd5d4c827f2853d877174b0005f782276d2ee9af9f4d6eb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09245a9f-d6dc-4255-98df-f5866befd3da", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fef2a28194460bd5d92fa9588db4a1f45fc45976aa4adb40f2105b0332f94db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e3b5c6c-d951-415f-80db-c83f3b9f0b03", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. "}, "hash": "2c039f8932268cf3fe725e4692f9228ad415248a811d5a15f3dc480b5828a5e2", "class_name": "RelatedNodeInfo"}}, "text": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "start_char_idx": 818, "end_char_idx": 922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e3b5c6c-d951-415f-80db-c83f3b9f0b03": {"__data__": {"id_": "4e3b5c6c-d951-415f-80db-c83f3b9f0b03", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9", "node_type": "4", "metadata": {"page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c61fe4b648e4722dd5d4c827f2853d877174b0005f782276d2ee9af9f4d6eb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9059526b-e876-4cc7-9370-5764cc02425f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "702cd9b88b858dda46df30af2b999c6d5bbbbc156daf8aa6c990c5592151dd4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87b507ed-24a9-4f6e-b1d8-ddab184b1fc0", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. "}, "hash": "dcad480048379c3f99f9271bd5bd90127fd849c4c89108d676add5345fe1a9b3", "class_name": "RelatedNodeInfo"}}, "text": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "start_char_idx": 922, "end_char_idx": 1180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87b507ed-24a9-4f6e-b1d8-ddab184b1fc0": {"__data__": {"id_": "87b507ed-24a9-4f6e-b1d8-ddab184b1fc0", "embedding": null, "metadata": {"window": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9", "node_type": "4", "metadata": {"page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c61fe4b648e4722dd5d4c827f2853d877174b0005f782276d2ee9af9f4d6eb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e3b5c6c-d951-415f-80db-c83f3b9f0b03", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f5071ed62def3d9b3eaff78d29fa76cc3f89ef482e92dd545d0886132f2b3d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39897003-b336-41b9-ac72-5f96121aac1f", "node_type": "1", "metadata": {"window": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. "}, "hash": "68dea3f7c68ad42aef1de3015d8df5455659b0d4cbeeca4cbc6f8f28127097c8", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "start_char_idx": 1180, "end_char_idx": 1264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39897003-b336-41b9-ac72-5f96121aac1f": {"__data__": {"id_": "39897003-b336-41b9-ac72-5f96121aac1f", "embedding": null, "metadata": {"window": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9", "node_type": "4", "metadata": {"page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c61fe4b648e4722dd5d4c827f2853d877174b0005f782276d2ee9af9f4d6eb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87b507ed-24a9-4f6e-b1d8-ddab184b1fc0", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91adc79208d123bf28d38e8b7a6930bc6f7fda24ae4f42b05f336d6c13cadbec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a216387f-c65b-47d3-9d94-c07246b41060", "node_type": "1", "metadata": {"window": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n"}, "hash": "3476ce8ecdd6e7f67578c09c6084b18eb0e42db1f973bfa99283a5fdf0b45605", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 1264, "end_char_idx": 1393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a216387f-c65b-47d3-9d94-c07246b41060": {"__data__": {"id_": "a216387f-c65b-47d3-9d94-c07246b41060", "embedding": null, "metadata": {"window": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9", "node_type": "4", "metadata": {"page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c61fe4b648e4722dd5d4c827f2853d877174b0005f782276d2ee9af9f4d6eb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39897003-b336-41b9-ac72-5f96121aac1f", "node_type": "1", "metadata": {"window": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcd3fbebb8a199850c1f884402def41bd3c19cd56782981b9b10a34257fbaa88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca4680d7-7316-4703-a74e-4590c58f9643", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "5f05868a384c5c6c5f7fd421692c9d87c975e6d4be63eb2488e802eefd36219a", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "start_char_idx": 1393, "end_char_idx": 1556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca4680d7-7316-4703-a74e-4590c58f9643": {"__data__": {"id_": "ca4680d7-7316-4703-a74e-4590c58f9643", "embedding": null, "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9", "node_type": "4", "metadata": {"page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c61fe4b648e4722dd5d4c827f2853d877174b0005f782276d2ee9af9f4d6eb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a216387f-c65b-47d3-9d94-c07246b41060", "node_type": "1", "metadata": {"window": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9be0819919a9616983984f63690a0233da5f8548ae2d6fcdfb989de2b975ac6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52a48bdb-d9cc-48bf-903c-d1bdba829bd2", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n"}, "hash": "889320631137742dc7e3525ea5acad38760b6576d4ea422f02d197146bd91295", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 1556, "end_char_idx": 1991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52a48bdb-d9cc-48bf-903c-d1bdba829bd2": {"__data__": {"id_": "52a48bdb-d9cc-48bf-903c-d1bdba829bd2", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9", "node_type": "4", "metadata": {"page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c61fe4b648e4722dd5d4c827f2853d877174b0005f782276d2ee9af9f4d6eb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca4680d7-7316-4703-a74e-4590c58f9643", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a61d319cf10fb636b82b677dca315012dd0818e39f2d5db8ba5376e28d02d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c4f2d6e-820b-40d1-a74e-43d540357cec", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. "}, "hash": "3fdf2b36046feb6284c1148d34bb681094acd8db3d628729c16b28495a4d4307", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "start_char_idx": 1991, "end_char_idx": 2670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c4f2d6e-820b-40d1-a74e-43d540357cec": {"__data__": {"id_": "4c4f2d6e-820b-40d1-a74e-43d540357cec", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9", "node_type": "4", "metadata": {"page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c61fe4b648e4722dd5d4c827f2853d877174b0005f782276d2ee9af9f4d6eb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52a48bdb-d9cc-48bf-903c-d1bdba829bd2", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ce35ce954ca4529fe2768daedf3dc198b0c565f8c2726b5b95b6ea6c6e694ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dafc6061-f346-45c4-abc6-87520f7acc6d", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. "}, "hash": "c088497918cee5e81435e118a32ce50c9ebc1ccc6e40125d7fc01e1a81088662", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 2670, "end_char_idx": 2859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dafc6061-f346-45c4-abc6-87520f7acc6d": {"__data__": {"id_": "dafc6061-f346-45c4-abc6-87520f7acc6d", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9", "node_type": "4", "metadata": {"page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c61fe4b648e4722dd5d4c827f2853d877174b0005f782276d2ee9af9f4d6eb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c4f2d6e-820b-40d1-a74e-43d540357cec", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "13fccf2f4d2f4e58539874102d9a2063ffddf61b5f55ca9fa22e0ad6def74936", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63282403-6126-40cb-b8e8-4c89ec695768", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "14f74517fe2220a428318ed2e905bb10d0deea546f31b8f529e1880ebb68ff6f", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "start_char_idx": 2859, "end_char_idx": 2937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63282403-6126-40cb-b8e8-4c89ec695768": {"__data__": {"id_": "63282403-6126-40cb-b8e8-4c89ec695768", "embedding": null, "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9", "node_type": "4", "metadata": {"page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c61fe4b648e4722dd5d4c827f2853d877174b0005f782276d2ee9af9f4d6eb4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dafc6061-f346-45c4-abc6-87520f7acc6d", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd27795c95f4f71d7e4e74776c87f93f46e2dbbedd6a908fc4dfe4c3e163c110", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 2937, "end_char_idx": 2959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"b7c79611-c6bb-45cf-83e5-a5be2f4daafb": {"doc_hash": "049e9e165a206257a7e9ed23e9d061ad4b8d3e0db6d3f5d99301f7ac7a01bf2d", "ref_doc_id": "6f04ed7c-eb87-47e3-a52f-ff5878599c6f"}, "7eb581cb-a932-4cd0-8fe2-bda5a78fb20b": {"doc_hash": "7e6f652bce99428d5820d6741626f7d569b7c306431c96f2f10785638f46a576", "ref_doc_id": "6f04ed7c-eb87-47e3-a52f-ff5878599c6f"}, "6c89c7fd-c275-4d4f-8d5e-77a1634e7979": {"doc_hash": "d5c6d6261cf341be62f8edcdee49d6ef26d0260cc60052f1f34644fb2c665d06", "ref_doc_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86"}, "1b01e0b1-88b6-456b-b1d0-8259df38a901": {"doc_hash": "5b0025790e3221d55a4b65b624c5cb003dfa5dcc4ee72763c836f4a0cd0f79cc", "ref_doc_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86"}, "ba6ca4ba-1d79-4842-8103-6af0fb3f2e59": {"doc_hash": "94f0bded5c7e948da54faaa8f010514bef819fa70e2e0f97bced879667573abd", "ref_doc_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86"}, "d2f3facc-2575-456d-bffa-026d8e805347": {"doc_hash": "d699fd833b0b66bd7c2adcb93d1243f1714f9481a213454ca2a3f872d3b2f277", "ref_doc_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86"}, "75c002fc-ed2f-4cb1-a04e-c1b143ed5df7": {"doc_hash": "5e15bc50cb5129440523e1e7117ceaa8d5ad2d2c0525a92e91264db49a924881", "ref_doc_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86"}, "ae3c70d5-727f-4581-8ede-05ed486b3cb5": {"doc_hash": "a17c13d7f9fd1346dd4cc9ea4cb61ea8339579c568ede4a3e656bfd5c5a6d869", "ref_doc_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86"}, "fe025f49-d8d5-439b-bf5d-ef2be25c9906": {"doc_hash": "b0990be691034c20f4c2189d11477061b29484d4610b3229ee6454ed91f959e0", "ref_doc_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86"}, "cbfeb5f4-0307-4c08-9f5b-6b0b5df52191": {"doc_hash": "931bf916722b21055a386c1bb87236bd45333eeda39234d9a65494d27ef00969", "ref_doc_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86"}, "f7ae38a6-0baf-48ec-a00b-75d539f5994a": {"doc_hash": "faa289b8cfd8cf2fc7462ffe623f9763c2021d6d68d02da62929f64e02a2ccca", "ref_doc_id": "7858c473-adea-48b2-9f0e-95b7c72d4c86"}, "71382120-b4fe-48f5-9778-c2dfffe2bcb2": {"doc_hash": "084e5705cad8def207408a78193417e359f874ce4c277d0b102c63bbfec826dc", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "6c6612d8-4df3-4351-ae32-73474482bf42": {"doc_hash": "2f422f49453f4f63dea5db9da490176fa07dc8eb50f2738f758b72efb0b086b2", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "60cbaf52-4cd0-4fd4-b150-daa547d35fec": {"doc_hash": "5bdb632c446b9bec6ef7ff11b812dffc3c7e6cbf9bedfdd3169c229ae7e20aed", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "6d8cfd31-6d03-4de8-a6a5-1bc39788ceb4": {"doc_hash": "94981fd952cb0c16366faa06258a85ff872e0b60ab9cfb973570710bf11a0a13", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "18ba7561-ad5b-4869-8af1-4f26cb0745a6": {"doc_hash": "eb5d7261e693414e2fe63da120ab24bca795619f9eb01e3bb826398ca67d8466", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "918a3d8c-6e42-4eb9-b940-78b64d4e4d59": {"doc_hash": "cfeddfbe2319305ab3feab7a53a64a0e28913988fa351cb269f2345b19947a66", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "167fa8c0-0058-43c9-a472-c2d476b54db3": {"doc_hash": "c1974d3edc6fadb5e02731d0d53ee3d0011bd94ac4c2dd6ea2501ac8eb1a99b5", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "4f7849c6-570f-4d1c-9b36-caaf1711bbf4": {"doc_hash": "6bef7130587d765818432a55cfd0d06a8506398fa4e37bb3d2a95806bf7323b6", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "a9419074-4897-4d89-9dcc-ba2ab64a4eca": {"doc_hash": "8ff8af87d15d0c240c1c9cb007b8f35b203fa2be34fb8423b3aa67ff1d907119", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "2dc63cda-b3c1-4ba6-a36a-7f3fcba146f1": {"doc_hash": "fbed05d416c7b3078471ffa7063f424243e2ea07017b2359d1ebdca6df2475c3", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "e34e6a44-5c14-4080-9936-faaac68ad6f0": {"doc_hash": "fd560e0e87c1024a0ba8b110aad0128d5499880e2f26774b72cd3623498f75be", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "cecb67d2-af9c-40aa-b83b-8b1148e4d91a": {"doc_hash": "753b2c182e065df0e443000256c2829e8655b0a8ea298118afd8b46591565572", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "91dc043f-6fb6-4022-bd27-09d8ee8bfc8e": {"doc_hash": "aadbdd5c6e0a1f030c55bddf61e6ac57497ea445d9ecef77ba08fb419aebb628", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "934877dc-a8a7-418c-beab-7e10dae5755d": {"doc_hash": "1b86af6bfb7478c2e7c9821a3ff6e1fdc8fd31a37ca659bc35f4770943d21371", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "58e6a65a-297a-4f7d-9452-e8c07fb3efd1": {"doc_hash": "3037e845da1a76203b732533a685e25a958447a021edea36f5a1176b204156f4", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "23742ecd-5838-4c06-b187-e877717c6f20": {"doc_hash": "8b0c2d327e78afd46ded1f0a3844e943ec9558ef35cac94692153c7e7ecbd5e9", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "f77f5c64-25f5-4fd3-aa4b-cb69bed4295d": {"doc_hash": "e83ba192972fce93f89e75a1caf7fe7be8d0c4560abc8ed86cf6eaa7def831c0", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "b67a567e-eb2e-4624-8907-7744792a16cb": {"doc_hash": "45d1567cf3f2bfa8176f2194622dc9f3f3ee65d2c6e15a08e24894221d7ee1b7", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "d26dfc13-da6f-4414-9b29-d066e3fdb1fe": {"doc_hash": "3db5df29024c7c96563d0e897ea43cc6263623872b38fb99004316e64c2010e0", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "e21a9c87-2898-4ad0-b0ed-24bda083b839": {"doc_hash": "3bea8d9334f9dd73807a7b57347be2b4b0bcabddb76631b58c21ef298107cc85", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "ef4a4182-d3cc-4e0e-bf15-9f597d9def30": {"doc_hash": "b522d69b98b5fbeb0de0d3be503e3a42cce48f9f08613caca988d813ad1bee9c", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "5f0ffc90-2ac4-45ce-8584-48abc6785d6d": {"doc_hash": "d90061e46e594f9c4532dcd3d586e92d5e6123ee2c39af07ef4fd2a7e24c52c8", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "c7d926d5-dfa1-45d3-bc70-e637e1f9e2fc": {"doc_hash": "626b8e590f0271f98ccd56b327e6dee4c92916d68adec257d6aa3c90ed4be72a", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "c30427c6-fd10-46fb-a44b-250b4c11b3a9": {"doc_hash": "534052d3f30c6a037a438356f4183044297b5907691bccf0892961db29b2c62e", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "1bc48dec-0e91-46aa-8b0f-5b6fe1b4814d": {"doc_hash": "33402ce1ca2dd1f1b56f9de6c842f1903ad32c807841b3b7b9960a96d79d2b81", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "3b06fb94-6db2-49c4-a989-1a7278649f33": {"doc_hash": "16894019f374909551dcec0314da47e4c4413cd3457d94b25eb05d317e86bc4b", "ref_doc_id": "766741af-97b8-41a3-a5b5-80cdcfb8490a"}, "df350493-aeea-4491-b73a-e1305a77d5cb": {"doc_hash": "72ee8eb9b054f7a1a9fce1c0f457fb95a84eb500e349aa46c64ff6e0137b5eaa", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "bfd6fb47-8e86-45e1-87c1-9387eba9bb60": {"doc_hash": "f9cbf90c20eb3e2df087854b0a1040262a73b298bdc599e1fd7d9edb3826e1b0", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "f4461a94-1342-4a28-a2a2-d5dd161e12bd": {"doc_hash": "d0cf19deaa2b137dda8b3c4be1c47f8986a41c549fdaa298dcf6c2319161b6b4", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "81160bc7-49b7-4336-bcb8-91af7b635970": {"doc_hash": "bab09fae8318c2e72d1d3afa5aee367355ab957d2b732a373a29aae0f23e76c9", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "5b587278-45eb-4547-9052-49df994a0877": {"doc_hash": "6807155083b029d16d52f7e57bc3f80fa06466b070f5d293b30acd2e2aac88df", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "b4a8cd3f-963d-48a2-ab04-635fdd79b4e4": {"doc_hash": "58e36901339f9d0199cc770b6c1e6df4ccc6b1dfb84cfe8e4a67163ef093b6c1", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "b2df7a84-d61b-4661-a0b3-ef371d41c733": {"doc_hash": "50f33b20557f6f9e54fe0cbb59f4f4a88b79ddc4566b7b440b933946e28a4f73", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "8ad8dc75-93e9-473e-9ea5-93ae549e614d": {"doc_hash": "5326b14a840cb0944caf39aa95332dc25f5015334de3c8bcf163ad088bf5f849", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "f3f4cdac-f739-482d-83ee-20345c1cc121": {"doc_hash": "69768b861e7c2b2df2e0c74df0b52689d4a1577fb8f111a57e480b5f2e800803", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "0f3aca91-aa79-4398-a6e4-ee6f5bf59896": {"doc_hash": "d582e5e5d908d61d2f474635d4cf1118e894bf40bcdcddcdabba57a12700a412", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "de23220b-30a5-4ef3-974d-4e1037ff7f65": {"doc_hash": "e80a57e4b5cc26dd302fbd187a6bbb0ee24b0f765d6a95ec8840ad339d77f778", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "30a88c4d-9d6c-4e86-9a1a-61e587231664": {"doc_hash": "791f408a51c8f470d510ad5a6ba4ec7d2105d4424baeba42c8cf37887e8c45eb", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "3df04fc2-35fb-482b-8a7b-922aa3487c6d": {"doc_hash": "eb905ef677a3a8a0cf23748579cdfd21f9022456632e2ffdee2eaf7cbfb036eb", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "9990b860-8b84-4611-96df-dde611022e97": {"doc_hash": "2840b0111c1280c7782af87b80cf12e7c58ffbd4e36cc5ee10c605f129922029", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "0a2a01ae-f9e6-412f-9c5f-1a44cafb732d": {"doc_hash": "a69014babfc0ccec15a259d2875d1e91ecb0a8b4f0a47e68ecd32eae692fffc4", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "ef86c74d-efad-44d0-9246-e71f7121c276": {"doc_hash": "e9dd26aa7f1c2e9ba9bf832844c4c088d5dbf404ec6e0fdb44131af7e7ae180f", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "4a2568c0-ce18-4f12-924f-16904eeaa4e8": {"doc_hash": "a760ef66121e00395486034310269b8ab2be6c6f100073933fbe8785df6537b2", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "a81f0956-afc5-40a7-9120-02a163fdffaf": {"doc_hash": "4e19a09a0ae8ec53d3ab97ec7e1b61fa1a6653ea13bed6d6bb58bf962716bef0", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "e3b8a761-8a4c-4b8b-932f-1b7e0b79ddfc": {"doc_hash": "85ac9186aaf58a1a4f044d8354b2447cc363de3545a40bb85e58f9f53a7201f5", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "da7dcadc-fa57-4f9c-af5d-72b1baa5f8dc": {"doc_hash": "c9c49e1cf6e02d5f3738d73c93762a84a48b0292264dcb88ade6a88ea779ba13", "ref_doc_id": "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7"}, "7c2953b5-ba40-4078-b12e-dc29392b20d1": {"doc_hash": "52ace4dde6fea7c931ecd137b4fc18a37d87a55de413bb9e4b5aef08009e403f", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "e1fa504d-fcb8-4cc4-b5f9-4aada49d7dbe": {"doc_hash": "5ef31c69ead0ba96ba0c7591d2e760ec8178fa335003ce6f4efd84128e832ca7", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "dbfd708e-bfb5-4b72-9612-f4db6ccfdd5c": {"doc_hash": "94290289490efa4d576a8bb1cd1bbe64165992dc66e5bf25665ac4846f4868d2", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "3d0795d6-2f36-4928-97e0-f2b61329b32e": {"doc_hash": "c087497f8d404537c430e8e243ce3ceb2a52526cd3c7998c8fb01b64ba626b04", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "c89b3690-432b-40ec-9889-05aee1686fe4": {"doc_hash": "25764da825cfdbbddcf963270141e445c88b33d0bdc68097bb104b8994312dc2", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "96c979e5-f766-41d5-9c0a-56e7cf8ac5c1": {"doc_hash": "f14a69ae2ad1d767e436e8adeb294288fcf989b91a164033f5bf5af1904fb157", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "41068803-b2c0-4461-b178-b0a0d0f62480": {"doc_hash": "9376cce8b311f24208f216d499e274eef943c1446e663c9a75c23b3b96775946", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "9fe51ca0-12e9-43b0-9b2d-30a514a613ec": {"doc_hash": "5c092611a30492acbcd2b191b5c055c8863d5a92ffdd2feb7eba9125bd0d8de4", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "fc3209d2-b9b6-4255-b420-a2526bdade4d": {"doc_hash": "0f13c02ba37c715803c7117e05ccb760ea14edd723f93410f647cbd4a4e5eb86", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "7428bb5f-4b2e-45b0-a3c9-5f66c8b993cb": {"doc_hash": "acd4494ebb936b647a728c94a83117eeebfb49b5bbf448325eda0f80e5fc974d", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "1ddb71c9-b39f-4895-b267-b078b4aef7a2": {"doc_hash": "29dca5999bae9dc91380954597bf2b7752f5201d9346a9066a358ccc40cbb3ab", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "4a10be71-e4dd-4be9-8778-9c5db82f12e0": {"doc_hash": "d9a0e4a1b329a097ada70ef68da5bdab27c2521e874b7066211f1f76258b5744", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "514d4865-431a-4183-a456-e6a55faba191": {"doc_hash": "0ec872449433ad21004f03ff995cf38d4ccb526b2f59c5791a633383d220013e", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "d6ce3d14-0b54-415f-b06f-f82218ef95ae": {"doc_hash": "b208065937dc85c8a16a01ade5c84a413dd0d8d3adf731d60c66ab6e3f35bb77", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "db2abff1-79f5-4bd0-a115-10c7c19b2cca": {"doc_hash": "8d2b7cd4c33ca5af916d37ed25515977a3a406306462de340613e33f420b810a", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "a3bd19a7-c268-4884-8e2d-a8a3f7c4390f": {"doc_hash": "173ee6d87254d88238fbd1e65254b8bdc49183e1fe3a389c731488ffdd74eec0", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "d8302cde-db53-4648-b72c-43e7137ff62a": {"doc_hash": "c73a6593d5836fa89a8bdd82629e79b7f8f99dd41320fbddfe61620ef7c0a0d4", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "a9dd4f86-e787-46f9-993c-eb42f0139467": {"doc_hash": "72695d19862d0c3574914818f0ee9fafeda54c8742811981d9ab53c17acfb828", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "075d7018-7429-4294-92a1-db92e6080569": {"doc_hash": "eb3ef18616af887a16cc74098f03816ea7f604a4bda6a95f8e865e0277e238dc", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "2f1ff1c5-85f6-4830-b2a1-497e332e527f": {"doc_hash": "303e47f46d2ee012d3349dd342bdc33e891c1269f1583e3061da524eed505046", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "c5282f2d-624a-4b2a-9f3f-8850d381cf66": {"doc_hash": "38f3e09bc0afc0dee9323155d022626cc466b240b3411d83337cd3dfb554715d", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "83739e53-e2a6-4b63-be4f-5eb8d2660cd5": {"doc_hash": "e37071d7d55578211063e49ff48c1dc803306393796e3e1c027a8d7334ab3e07", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "37766d81-be37-4a5b-9eb9-5c6566ee589a": {"doc_hash": "6eed47bfdc89dae2a500368b1eff1fd18de8a7070a4be8a62441306859c8d4c0", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "019006a5-44b3-43c3-b449-8cd839cbe692": {"doc_hash": "31ebc6b8d5d7fad9db224dfb0c8c2f4c8f86c118f9d3b01b6012df740b88b56d", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "62a3d3c2-2a8f-4dc4-b392-a7bd4d69d94d": {"doc_hash": "725eb568914f8e58627b4b0aadfa3db2be4cc1879ae2d2fd7a35ac6af4df62ec", "ref_doc_id": "817daef2-2e22-4438-ae95-f06e3f7e02b6"}, "ae07db96-fb7a-4acf-8c4b-9541c78b5dc6": {"doc_hash": "942d992f774679cd0aeaa7d048b9bcd677f82ac1bf9ffc78d020f31127d18735", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "9cba5881-dd10-4460-9bc1-12ecf6265170": {"doc_hash": "1c7b07dd0e5e0cdf074a37e52467215b2bda41a2e2ef552221b39e2f6e5f7fd6", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "8015caaf-488f-4a42-97bb-3c85813f912d": {"doc_hash": "52cf6cdc0e703ed0ad53d329c4157e28da181d00b86dbdefe5ce0ece937cbcea", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "8c729807-428c-40cc-8d22-556ae4a06bb2": {"doc_hash": "f2a3cbe425023995c1f0e57be93c9b8537a2652782fdce9c6934fbb9db968838", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "e7376695-be65-4906-8e83-ad734c867405": {"doc_hash": "2dabaf23be8d40f31d10efc92eedbf6e3f038feedee2543116ef1858565abb4f", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "4bd6deaa-fb4b-4720-9531-d42f5225b07a": {"doc_hash": "a75e48cbe833f260df390c04da5cdf6c4b428978e7216f866763d25d49152db3", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "9b1e0292-c967-4eac-a77a-f21bb50d8c1c": {"doc_hash": "21f6317254c07ba767a29d3cd656d6a6457434e206261d03b14d77a7bff4dc9a", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "3cb6ea31-d193-4ba8-9b9f-b1a26a0308be": {"doc_hash": "4e1750f52c8f5e937927dbeb548507d1333022bb8bf6f19f8c9939477ff5efb4", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "35af83e2-6379-4dcd-b85b-2fd99ede99d8": {"doc_hash": "921a0cda2da4257d1af4f53c8bc52070ec5e331e0fd6420fee1bfcd33ca3461c", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "caca2e71-dcb8-4c2e-bb02-0330c0fdaf08": {"doc_hash": "706a3a16c4264974a91004a3669314ffbc0f80b915d638b67243b4a41e02f9c1", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "4f2e6b80-6f14-4cc2-a011-88071fc600f0": {"doc_hash": "451515d0a61137e12b0ea1507c8cd35c467c4762c1fba08fb542260913e5f236", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "59172798-b18e-4f1f-a0cf-aa1cf26c2b0f": {"doc_hash": "5cdc9ea56440735f4d2c5589265d013342cf635d429568410ddca4137933c70b", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "b5c13d19-1e0d-44b9-a9c6-bd359f0d29fd": {"doc_hash": "104d1da775afee89131510dce108b853ea35584756fe54399b29b8625acfc414", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "e6454d9c-6445-4973-8eb9-7b294d096b37": {"doc_hash": "d1ed9efddee95b3d3c91106efdaa3cb077bf154bc0baaa59d2cc1b4770044ada", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "a26c0bb0-5b4c-4ae5-bc1b-bf26b7194f14": {"doc_hash": "efbfbad75972d08db7690b6565a7d7c5e8f2cad18530a17a0595ebbd64c37d95", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "6533b011-b609-4371-86db-5a9962bf3a7e": {"doc_hash": "67a0ddf00bb04e0c29c97e306ed6099cc6dea7662cdc217e4a7fc2d3ead2c2cd", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "a510d8be-4530-4358-8b8e-e37a3305ed92": {"doc_hash": "987c00b76b4c2a9802ff36c0979d18727a1cd247c63467d20ec0265e4b636903", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "db0ea668-7b93-4dfb-8fcb-9283ddc5fa29": {"doc_hash": "4e1219188d92d2eb62141f13c32bfd68b08061d9767756cc43c1d57e5c0ac012", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "a022dc64-989c-4bcc-a73a-ac95738f99b9": {"doc_hash": "a0e1c8cb6f07ceb652d1a2c6a7eb713018aa93e40014e9239fdc5b145da9d1fd", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "85498caa-4623-4572-b8dd-1162d99cb016": {"doc_hash": "72b374dafb360b856a90e790fb404507414828024e8654f2faa35885c95fcee9", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "41840264-35ff-4881-82bd-74f1d09e3d0e": {"doc_hash": "413e4d60a2983bc6264d65e91747cb60772106faef70110011cb17f59df025c8", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "2ad62c32-a357-4e42-95f7-d6ca8f648abf": {"doc_hash": "b67d1ec7ae83d8db2878f476cbf5887e589442880c52ebe8bf7192e87b36cf3c", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "4ed6816c-dae1-4767-9229-89f747e38d6b": {"doc_hash": "01514d9b6d7a96d4b02c33474a04966b500f8c5bdecab29421b5a0faf599eb02", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "cb583725-963a-4577-a27f-a25d35291f6e": {"doc_hash": "3b6541d20356beb8a4a859694fea6f5d0cc1daa59d36a7bc9c6d78f6b1478a2a", "ref_doc_id": "ba158130-c643-44e1-9024-e87d5258ad90"}, "4931c29c-e08c-4027-b2a9-c690cf4dff8f": {"doc_hash": "77bf73d078b305217c64f1376d661ffe6e3efef42485f96192596bce09f38d0c", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "2f63b4a6-c656-4f57-ab27-195ac1acdd5d": {"doc_hash": "83da1769452b72961c2dc23f42ec6789bee01107385531b75416098ed080fd12", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "7e0ff743-eeab-42a2-9192-659b218a417b": {"doc_hash": "ffdf72ec3912f1a858bee78d42e17277eeddf844f4a8cff6fb8252f27d020f3a", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "9215cf5a-1823-499b-a5dd-cd7b4126da0f": {"doc_hash": "5c03058f907c4d4ed52c448e8f4d7ae91db51ef1317f17a2da0cb4c45408c514", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "cd873e80-31db-4440-a825-8c5f9890ad5d": {"doc_hash": "8e6c1251c2353776092f6575e17b2e84998be67c45643eda68b0e1e04ea1c5c8", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "03ddb6fa-b1e7-4d70-8b6c-983602e51c27": {"doc_hash": "713a841149857d75672ccf282df2d0f6c5d4891594764f1f7e3be110cab3dbe5", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "a51764fd-9db6-4cc5-af38-5fcb0834ba1f": {"doc_hash": "4422a754ba6fd6d48ccc3828a964844fcd9d8d8970900f84eac23fb87836d720", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "d8914b61-7de5-479e-81f4-23d08e42c5fe": {"doc_hash": "3cb4d084e24c152edc5f23e0a86292b7fd7bda629b0886b2fb6dfda922899f00", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "ba574bf3-7a0b-435e-aef2-3f33da8f3bd6": {"doc_hash": "f2acc816650bb51d497d2347b4675f8f11d72cb83074eb44dceaa62b2331f05b", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "48d77a27-edb1-41df-a109-c3cd1871d347": {"doc_hash": "52a22ea608d7363a0097b4402e4270fb482239d3037f1b431b1b07f549c6000f", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "7f30e7ab-b265-45e2-9599-cac53f8d2c9d": {"doc_hash": "e9b77c949eff0b8b3579fbd5050be0653bd47daafd63a97ef4e54bbb90fcf07d", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "866b83b2-7277-4b69-ac78-516cd6313309": {"doc_hash": "c0d25a55341ec7b845c9937336758c32a57513da756ba1fc96e72793b6337a1c", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "6242b55d-e7ae-45ec-ad71-236b86fab9af": {"doc_hash": "11bfd82d70ab1685228ebaaec850b30fa54786efa1ca603699697c4ed8eb5037", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "6a180024-5c0b-42ee-bacd-3e58581d9fe2": {"doc_hash": "1ce91d7fef17a2d438137119b99412392422c38b0d052e7933b0419c822234b5", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "ace7233c-1f5d-4c74-892d-0f56fc7bf6b8": {"doc_hash": "0b97c7b7d3434fde00666fd5750e5d2b7af02950737f22f9c04f18efaeda369f", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "efcb04de-312d-4028-ba03-7e2721924e4a": {"doc_hash": "576795cfe5c2c14bed2a4e7a517775eb2fc2f0eaa9452eecf11054f1c4393885", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "74b5514b-f115-4460-8a41-876631f4fc42": {"doc_hash": "0c7fab281695021862b829ef7a7bb4cb0a6237a51542b072d11e9360d5bda6f6", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "24269b3b-2e65-48f3-816d-dda28b137f49": {"doc_hash": "434f76ce14259807d6f7df175f7c81591544d6c48ad58706a1623795b0a4778f", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "e94c4b7b-be3a-40e2-b270-10089b2200d8": {"doc_hash": "c04f5216c0d003aec96156fed9a51e6082f435e62d70498ee6d4a9cd6ee40e52", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "4111a34f-7778-4528-9fb3-024fa46b2cf3": {"doc_hash": "fbd20a05ef46cd34b6f15a8feb7b5697548af102a1414335ffcda8ac16113ee7", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "ebaa484b-304f-4dd0-93e9-a1d764933c34": {"doc_hash": "80971cc276e66d9010f537ef81bc4c7495afca2a985f769d0b480b946a4a5b60", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "9c39aa7d-20df-4ce7-83a1-b00cdd67e158": {"doc_hash": "cdb8dab67c49ae3db9ebe84ff35cdb9dd0a88b63120fd0916cea638ec646d8e4", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "9780a963-0a2e-44cb-a7fe-1bcfe9953f07": {"doc_hash": "1d5cf6813c93e7284f7354f164e6de31fc835ae98d2f78cc452a478f411c211a", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "828a863b-67ba-4771-8502-fb2e9f5a78cc": {"doc_hash": "27788b76b6e61021a39a768ccdd35deb55df7cc3b9cba6d2866094cd469b6473", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "24183efe-5b45-4362-a9e7-821e650ccb06": {"doc_hash": "b00409fd4648960e63fd59d87ecbd49d4ea5275e15c3bf8ba86e3e7209decfaf", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "10596699-8392-46aa-88a7-17b1db1268ef": {"doc_hash": "7048e7159ca7945b1fe3420f25387ebad0f1eabedb3bdff6a45e0c9b4344e28b", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "3513aaaf-c37e-4bd6-ade6-14f1a57edbe8": {"doc_hash": "e99c582896b15b1906dbebd0a1e202ffbe4f37a5c87f38aa53cea064a50be619", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "7bbe7586-2618-4b8d-a11c-7cc3faaa25d7": {"doc_hash": "ba1153e4edb98414307546702ad67796fc23a50a9de66a1f22d87961436c05af", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "acb0a9cd-7baa-429a-8af7-ec1e1191ccc7": {"doc_hash": "156647c2f0f0553d7a5acd0486060d4b9e4c37aab1b7649af0127c2f6621df79", "ref_doc_id": "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d"}, "84a71180-722b-4731-a2dc-e0704d6000cb": {"doc_hash": "7132f33ed2bc42b32ff52cc71cf5ee88546f75a180a94f839654790540564e11", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "24a9032c-f97e-446f-bc1c-13b330227f5e": {"doc_hash": "d0adea614e3dfada445f27b70eb02ce34a8685eae77b6063d5e58a0e253b1ed0", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "d55efcb8-954c-4417-b433-198093413dee": {"doc_hash": "756bb5ad2d688caa61e3a01100bf4e2557aacca568787c110f25b853d8dca918", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "8fd95920-3e06-4b66-a7a4-8c4d252fa2ec": {"doc_hash": "9c85f99757188ab2bcaa5f8a083d72a3c3f0268331e52db484a0dafb655604e6", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "40aedd49-44d6-4544-a2ab-8bc4030d0feb": {"doc_hash": "8f76adee2bdf2cb4a60aafef846f7b658fcb6a9f09832bf354d5ae55758a5056", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "64af0dce-d020-4ae8-a5a2-e446080b252d": {"doc_hash": "4a7015b915ed71cb2685d4bf90c1a5b5a2a250c737ec268aab019584e71201cd", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "fc2f5ea9-16b9-4195-8a4f-a4ab5df205a9": {"doc_hash": "d1fc366b14d13122ba99c0fe369d7dbfb082bc6c8fd92cd763a5e81228f4da7f", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "aed7fb18-dc88-4102-890e-0645de59e386": {"doc_hash": "d5a95491725e42d634331d7359b723b4f21d77a9aba4a93f14acbf3a7203d661", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "4a359667-ed2a-4445-8f70-7c0b7f0098b2": {"doc_hash": "025686745d2d2e0b7d74e71ce7c2ad08336ce607688e22f5420b76a6c7a2f673", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "53270696-5b2d-45ba-9e08-67e34bd7edce": {"doc_hash": "7dcf2c831547fcb00bc2bc3c1312d86249e5bfcc09a73ecc140e90b9d9fe29d4", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "454dd243-6e81-4969-8029-34c283ebc31c": {"doc_hash": "c9548fd0eca50bb5d8e97e4d127ba7994105735a51ed4039c8d29679b4e2e0b5", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "3367c7c0-2581-4933-89d9-aa85a212767e": {"doc_hash": "c40390368eddbf3f6566fc2ed34e4fbb5b6c7687cb6e7f0504c7a8c126ae2217", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "7517c4d2-1ec6-4cbd-b66c-b2f03ef09e46": {"doc_hash": "3076cf49188362a711a32ba9395e62aca7b1d7274567eaa29e0db8b6f563e749", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "9c6cfe42-b566-4ce7-9a6e-0b0302404ebe": {"doc_hash": "74b6bf3e46d965426e1399b7409117d06bde3519c46b764d10caf5f0b321ae6f", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "f432ea9c-2cf1-45c4-b2f8-61d21dcfdf28": {"doc_hash": "59e39750ee05fdfede78d9e64594dde1a77b92f0fc5589e4f2ccfb156f2d40d4", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "d88250dd-ae0a-4c71-a11c-14ff840916fb": {"doc_hash": "bf63af8f0d495f65c336659f4ce427573ed62549e8c7b9fba9ed4c0ac0f25e89", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "8d763cf7-b575-4d19-8c33-0514706be632": {"doc_hash": "1952aead0ba432557f70652e59c7957b642feb485cf58b37c6cdeaf9097382b4", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "eb3c88ff-ddaf-4b93-9908-25029b7a8f5a": {"doc_hash": "41c58528ce80ca0e89542fff8fc34bbec558e9e516514e32c4f60909828874f8", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "5902bef1-65e2-403f-a277-45fb43fa1682": {"doc_hash": "30137dd59966117e0f8a3cb59711e3c92db046e8d25ec9f740549955a766f6b8", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "2751e32a-a0bd-4f65-99e1-900ebac181d1": {"doc_hash": "3044f364fbce45638a946cf0bbae1bf5afdd044e138dc189d7f41fe11013c997", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "ba0a9ae0-0b72-453f-864c-0018f796aa83": {"doc_hash": "0fb5729876371765d9ccf97aef01dc6b7a8fb5290e0ca962de9d59c4e73915b3", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "a6a74a3e-413b-4473-9b17-126edfdad713": {"doc_hash": "71cca94c2d9fda91527b5b99e8d1324de52dd42aa619a6fea5c065a4670b61c3", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "e0171365-b4e4-4f79-84ed-4b31cdd2b75f": {"doc_hash": "edd8568a278272158d6a5b8f5d174ccb84ef915a9e365e1d9d3d91b468ad4688", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "e4032980-8916-4bec-ba63-fbb0697c56dc": {"doc_hash": "1ca82f2dfaa6c5f354e833a28fa46f6603aaeb9529180ad93e47a4557b6d7c49", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "81129022-b37a-4cb7-99fc-68a91c9dcd0f": {"doc_hash": "de631289bfbbb822a77ed6db4b7109349cc4bdbf8b9dd1e51c2e6795ca499450", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "8237e4f5-b5af-47f0-baf7-42e2fdf19b9c": {"doc_hash": "9929fae70652f7ec2352fbff8df3438d3f0df888aed6f902ace7bf40776f6e44", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "159faf0c-e2e5-4e24-a1ec-edbf82db6a0b": {"doc_hash": "957a56da5d3a3f9be946b57c79d76ef6bb144700855848bfdba846fd9ee3ba7a", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "4444c764-47fe-46b1-b16c-503dee7bb431": {"doc_hash": "0986b6797adc2b5cc65be54ff965cf1e175f407e28d94b5b0e139758642afd2a", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "19623459-80de-4eb4-b9a5-51afedfbb7ed": {"doc_hash": "1c75748bd8c9c63825d288c44c8e4cec69faa059220d2165a24625ca8c7d3669", "ref_doc_id": "f0bc6e76-1162-49d9-9ef7-e56943372fe7"}, "fe18e34a-5259-4f42-b64f-6e4933c9f77d": {"doc_hash": "68ac62081c18cf09d50f9e43ce693b946f9665b4ca41b3debb470b97aa6aca2e", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "d6facb89-9895-42df-b558-2919db2033c9": {"doc_hash": "5092005fa872794b0a54c6da3118520a49cf36cf0edc1cc62394316d36b4ccbf", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "2e034c0d-ff09-403c-ad40-ed06f3528f71": {"doc_hash": "108e1595b6c3e560f618a403ce369f7c728842b9ca508470246757beaedc50fe", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "b0120357-8781-49ea-8c83-84e4fac644f1": {"doc_hash": "0966ce2a778a93741a496d21a7bb65da80a0e17529f690d1237c36867019755c", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "6c40d299-5ccc-40fb-b3e5-591eee596b65": {"doc_hash": "c14b51ad370a795b642ed330ab49a457f466299a0712a8569d9697b7badb1d3e", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "9fb805a9-54b9-45b8-9ac0-661820f522ef": {"doc_hash": "742e7070b70429efc464eba49871803ff3e2f7123e23fa15ce84d876132ecd5b", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "14716f82-b1ba-4d9e-9d6e-9ee1813c860c": {"doc_hash": "f459601e4c00ee08817c950f77c83d67fc4d178ff5a1579a0dedbc5ab2129f88", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "17d1a355-d23e-4d81-9d76-c392eca52b2b": {"doc_hash": "f2ea0543719b460b16fec86b51029c6e575166633b0ede2e42a15e71bc18c973", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "80a7ddbd-b8e4-4e31-b575-7169c2f7b2fb": {"doc_hash": "50b9c675d9319b91092e72e86f6691bdffa519def5282aaebc07d75a907bf984", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "630bc1be-2c3c-4d95-bc0c-2834a0a175c5": {"doc_hash": "6f1ec650c6dc636b0879e6c0eafe6b74ac56a9c2e5d9dc24ee682593a82b1b41", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "4aa0dc88-8364-4b5c-9606-70a4659f90a5": {"doc_hash": "1e4cbae937d7bfe56387b31730fc8cff94f967fe81788fdf94f6bc8bfda2b125", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "2f98a661-9fc1-4522-87b2-5e9174cbb433": {"doc_hash": "8aaf0678f58213ed0bfa10dda42ad60c7efb50aab3062c3c8155a6a045f8d2ed", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "c0a8ccc3-de4d-42f0-8aa3-8e4b5c56ef70": {"doc_hash": "5afbc13f8bf1065a48a390ab26990a2a98a7ce12d19076cb835a90a68f296819", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "a9769874-1e19-4d22-9fde-c6b7aa661cdc": {"doc_hash": "64dfbbd394c6c23a93dd498394700f9a53ed8333fe10c548ed6dfeb6e62ba58d", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "cc0f5645-dc7f-4d82-86cd-d7d7d1950816": {"doc_hash": "9cc0c9efbae468033425ca42f9b44c1b79228f05157e319cc0b7da257cbff261", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "60e003bf-2d06-475a-be11-eb5e9a4f96e1": {"doc_hash": "6866af0f5864385124a317975598dec747c02cdeb547f3436e9c2e566cd1200b", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "91f0d58a-6060-4e50-9729-4c9900aadbbb": {"doc_hash": "316c74d6967a6e7e2784e1cd48228a6245358409840dc43dab0cb31e77ac4b81", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "093b9008-0910-46ff-bcc2-3a2bd2c9500a": {"doc_hash": "0b01371b94bf21e9adbb77d0d5850f986f62a0054a5590d2d628e0f4c2cd7d88", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "7ef81b63-419d-4143-bd71-0d5e1d3013ae": {"doc_hash": "4b26a43906ddb8fa20a7e85bedcf102384105b8ac57e01751454fc95483b1579", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "dda89814-4db8-4cfb-996f-258d6f81ee11": {"doc_hash": "8b3eb173f4d2609c71b83195a527ba0451459b33c44c5f858f2a0d2dadeaa4f4", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "81dd87e5-f9e2-4b47-b8bb-9fda74e8d6a5": {"doc_hash": "05c3bf7ee0720e52abc2f383d978d0032eca352405627cbe3b484c059563edc0", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "a6039336-dd47-43f4-a05e-71ab7adfa8eb": {"doc_hash": "37d174ce369014aca9d109e12946c10c11076a094d65c30216f75f30b73f2b87", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "bd5cd663-3d4c-4a2d-a282-a1a513aaf467": {"doc_hash": "7c2ec29d0083ab43ab90325744ebe605b563a294190d9a921af3860a4d72469e", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "fa94fcd8-1e33-48a1-82f4-88fce2a22969": {"doc_hash": "087c29a6e53c4a11a8a2cd4048b12f7cfc3dff683096018242dc76bd4c3a87d0", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "4be1f3a4-1135-407e-b1f5-b7fb566a4a83": {"doc_hash": "1f2391973c8787c5c738e685f80479dc91cf8fd6024d88c675c57dfaeacf84d1", "ref_doc_id": "65fb4206-1b4d-40c3-86d8-c46eab526ce9"}, "a41ad611-721a-4b68-8f76-1aa42f1f4eee": {"doc_hash": "0f9a9addef05b01f6f2e1e1d85e0d1ae1d66756b59815000f4c62cde8b56b1cd", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "a9a4387c-6a12-4401-ba1c-3cb60dcb1505": {"doc_hash": "7d4b6b750a1ce13b194099ff100c4da092f1a181352516e89c34cf3887c008b2", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "b5b1e5d7-cf12-480d-a391-dec3f4b80a5b": {"doc_hash": "a8012e7c71ffc99766a084300b24b7be40da47f9b3d0dfee9426a459d2bc8179", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "8784bdff-c5db-4937-aba1-8c5f6e7b92bf": {"doc_hash": "47b50899ca176d87fc87f8487cfc7c3cb53065d617b6efdd1d70c5306ba6bcb9", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "8f8c5862-3381-48b2-b997-a16ee39e2b2f": {"doc_hash": "5990c6a44b192dc0714d9f77e04a54875561fdef9be35be0b8d0d9db54bc6236", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "8ada6c77-2474-45a5-b314-1d74c16e3945": {"doc_hash": "ce58895dc32dd7672f48044caaedc25249d01de1b1863cbad0851b9599a3f892", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "e36bcd9e-78ed-42f9-a8f0-2d717d62ebd3": {"doc_hash": "324d7e8c5da3d91edd4b69c82fbf161e4fcd73c3e2a5efff564d7c8784b86610", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "8e0d9e10-4284-477d-a373-b479f8b8052c": {"doc_hash": "3af77971c83f8b01fd6178470f9affb89f4f500d34a01e99487b08313a72704c", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "a7b74bf8-e21e-435e-8a87-a0c1ef8cc9b7": {"doc_hash": "2a9d694b6a1b0ab093c38b0aa4010a6cc83b2663f03b97932476ada97a0c6610", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "7e5665e1-82f0-428c-a97c-9d43196cd612": {"doc_hash": "dbda45a3809437aa395807b5a2543d6319dbe99986f40551949859e5c9068f2f", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "0918980c-32a2-4c07-8c3f-0944eb562ad9": {"doc_hash": "3263f9c50c5371f0df49788d190653d8a5f763e07934433894ea475573147cac", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "9dee559c-7bcb-4eda-b67a-8303a1a220d4": {"doc_hash": "a80c5791087e21ae4c4eb51e50876f3adc099a663765276dd9684ab61bbdb80d", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "4a6fb73a-b4e5-4613-b40f-76b9c3459135": {"doc_hash": "cf93d617aa3fe22151b7f74fdfd1a7eecd1b17ba00ff94e8e87969b3fd651916", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "98914559-8af2-4c0e-9b0a-59c2a00c974f": {"doc_hash": "8be434def4fe3b74ccbd78a0adadf83071a0dc1c84a5cb9d42f4ed366b6e963f", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "288ad1a4-608c-4779-b4f5-91d84f4cb9e0": {"doc_hash": "34ac2c5c8849677c819df732d3fffb6a9c70c83ed44b5d6fac4c2b97d287339a", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "bb933ca9-2565-46f1-aeb3-b3dd15fb8f4e": {"doc_hash": "ccd5293a14aaa7b25d4ccb047376e888a0a31a6b6cd77e1f6b025ee5864eeef4", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "8b838e76-55d6-47b1-866a-d8812ec7389b": {"doc_hash": "76d8c72b70dd87b234b99eb9b5b195566f09bad355104949887ccfd3e6d2f09e", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "132da3f8-e279-4c2c-ac1f-c10c5cef8e56": {"doc_hash": "f04a24adfc68348d5c3721f531dcdcd4248ff5a0911e3eff99061cb38dfa92c6", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "64c51b1f-4de4-4a17-a597-595c70d6b62e": {"doc_hash": "d297377c7599a60675e61bc22617eb5be7331d5526d9cd30387a51df6a8e4769", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "d4a34552-24d9-4712-bd3e-9eb8d0e32db9": {"doc_hash": "415b0ba74a939be7bdd82dce05a6735713a6f4f652a32ebb85ea7e76ccb94809", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "9b41ea45-e8eb-4dc9-83c2-7fe6ba05b2ac": {"doc_hash": "c896e820b99e056bc5f5c78f12a6d37bc41ba8598fbc5b02f39403e81e70db8e", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "7be277d7-959c-452e-bb8d-6bebb744ed05": {"doc_hash": "30af866920190b1bb422e2497aa49da5c527eb575ad7e330cc8944c0b687154d", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "40aa555f-f376-4c43-a19c-9dbf30fe5ce6": {"doc_hash": "d4232c642a7b53746148ba04b956b81269ac6b2d40a608e5af18cf3faf279cf0", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "8a55a092-0aa5-4ce8-9e1a-97384d10cbfa": {"doc_hash": "35fde11876c05c30d6924337226d747db3e0bae1123cf038f4bba7d7e45ee785", "ref_doc_id": "04caef37-b299-40a1-88af-be38492b51c2"}, "f486db4f-ff5a-4517-abd7-f4a144987b94": {"doc_hash": "8f29bb712e383840d01e337270e6d7832cd172d5a53ec2b9a1403099af29e3ad", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "36fcf97a-aa4d-4dab-a0e8-aceb9ca94bae": {"doc_hash": "3402e8196e8a3481922d10ae7264c70d987b7c8d2dbb4598f4e56e531d2d0453", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "78f19231-88c6-4c1e-a5b9-1bbaf4442c46": {"doc_hash": "526ba19b6958c3790de3c185dbb401c01cb39c2ce6dee59ae10741a13e81d417", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "30c33ad0-1328-438e-9b82-41a8bccafd24": {"doc_hash": "d26274635897db4664e3837c63a8fe14ce27db2b3222a2ad23da74a4de9cf219", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "80c4152b-2556-46b9-b4df-5fdb4afd9a5a": {"doc_hash": "608e1741f13048583e70260b854d63939c54fee37fd955f9190cc486abb77a62", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "165d1f1a-1ed1-49aa-9a63-2a3610b2ea7d": {"doc_hash": "d67c559aecce5f3cace2165e37911aad90d93595d2d157cc958034f3343d2ad5", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "e3a5b55d-b6bb-4349-a4a7-c7528cdbdb4c": {"doc_hash": "fe2d02514f0cd9c7b5017b6b39f8eb8c0477d6733e3821ac34393fd7e6a6fcc3", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "449f8d6a-5021-4ad1-bebd-8d7cca57174f": {"doc_hash": "bac184641ce5066395e9a59462eda2451c40ecd7ae9b41afeb81b387c0266348", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "d58cb710-f8d9-405b-9863-d6ebcf32863f": {"doc_hash": "ed18d580a152da6dfc46a2a31c3022619d674a2bbbee27a0d0c3789a9576446f", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "0cd29a46-575d-43fc-b647-bfcc3a43ebee": {"doc_hash": "589102dd3a758f577c6d91fc9d367be8204226abe9c5948e5522f40c2caa6ce8", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "3d10edaa-921c-4271-802a-c95d51052d04": {"doc_hash": "c5a6653e094fc34117bcd44694806515dd9596b54eb019b17a2b5be410201d24", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "6733e202-61c0-4f52-9009-afb747bbcc74": {"doc_hash": "5b15f2e9cc8458e3aea0d03f198d3271610af3507893db5daea260192317ad86", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "fbff924c-69ee-4ff4-89ee-3d30028b416d": {"doc_hash": "b8a1baac1bd7705b2f6d7d1d166636851d2d43ec150dcbeccffad909e7a74f34", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "3c6719c0-fd95-4153-bb54-ecf2b2f92636": {"doc_hash": "c59e098f5e56960cc32f610ddbb09eb31249c9ec238e580613eaea87b917da19", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "f21f40f2-3fcb-4d43-a8b2-de01ee63c8f7": {"doc_hash": "d7e496ab68d4e9dab3bcde7fe7b4dbc0f991c41a9e25fb88eb15f0eaa23f4d1b", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "16bb928a-83d4-4afd-bba5-e62701195b44": {"doc_hash": "0ec81415e64f190b69db9486276f87cceaaa27393c28ac902e37c7d6c785194a", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "cd029429-c7e2-4e3c-9906-409f4ac577a4": {"doc_hash": "d0c3dbacaa3b6f6ccf2023ccbbf275cfa63b7483a4a38910f7ec795584b8e5fa", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "054f1e4d-fb63-48df-bb8a-ccfbf23c21fe": {"doc_hash": "423a129603de3df19080d2122983c6dd88c58dac9fa950f32f912492521fa2f3", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "3033c553-d58d-4425-b23b-fea32c2c9d26": {"doc_hash": "04636abd9d4eef5a770232b179fdd5c864715a5c0e6ee1f197db75538a7147f4", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "81bb7834-9a58-42ae-bb62-e4ec12e5c5fd": {"doc_hash": "bf3324848b67dce1e5d300387fffe9d8bb29d8f92f9e037719c24c3384ccebb7", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "7c0dca00-0d14-41f0-a71e-9ed3d60ac95d": {"doc_hash": "b11353f48fbd99bdd3a39bf5f5f31af0452455905b2b19ca577f46d19263ee3a", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "bcfdbbcf-6691-462e-89fa-ac59c04570a6": {"doc_hash": "09079a0bc8f232d58badc1bd1bfa4e48a8aca6c625b1969878fbc0df46599901", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "a5ba8673-4013-4964-8277-3cae99ff2465": {"doc_hash": "db5592adea7b1622ad2e7bda5f66ee35990158874195d4034cb180c720baa6d4", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "3ec7c61f-6c07-44c6-ae59-0e42d9089096": {"doc_hash": "ef68c10669f2082acd7d7ddb81cbfd5ee962e2ccd8c576a2911cc01e89cb5c7b", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "439e3cff-b9fb-4251-8508-7b1ea09aabc2": {"doc_hash": "045975838e742669ef2109bab6fda118d264ecff80b7717f493c9c00f2b2fe67", "ref_doc_id": "c299a84c-c422-4443-85c7-4a8b016785fc"}, "ee1fbfc5-a9dc-4ac4-939c-6eb33f1c88a2": {"doc_hash": "583ef2880835bbd03324756f9ddd3a6548c58fc3dae9d5482c56fbe299ad4d22", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "81f1b4fd-049f-456b-ae93-81aad0996f1f": {"doc_hash": "d0cf01d02e08a33e123ed60d917d421479950fca021b713488268a7576db52f8", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "31a1ec8c-8cc7-4053-b362-f0336331441f": {"doc_hash": "1f0df94fdb3747060766a3d2f48566b1767835b7b292668512507e101ddbeba8", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "513681dc-6454-49b8-844a-d6b1d4d2dded": {"doc_hash": "87c9e06df9ea6b7e4d21ac5c317d22ea676b71f2b53a3387734b76f64b7c67fd", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "1e86f018-fab3-4201-90bd-0f7eba5f93b8": {"doc_hash": "2731a533a9fee6525b96979d001e47891377341c87ffed17b8c987fafe2c93f0", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "3b97047f-ef3d-444c-bee0-332f5745e0d7": {"doc_hash": "f6f4f02188b67a605205dec5c5cd352d0020cb0c101eb13c73c4efa577857ff0", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "1bcb6550-d84f-4d04-8973-41e0579f2e41": {"doc_hash": "65406032c43a9ef4543723b8019be1be68dbdee274aa8aa4be595be36e3792d3", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "f340c165-778e-46e9-bcae-8618e25db32d": {"doc_hash": "6eb70a4f9645603274bfc5bb626134d4147d32a6a24c4c478edc31e783a48c05", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "058d286e-5ed2-4a35-917d-66b2e795600d": {"doc_hash": "20c74d7299285ca6178e4fbcc05a0ed3855b4180ce93f6a53f298114dfdafc05", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "bebc3b2b-e825-4077-b284-3a116b6e4b6f": {"doc_hash": "3a0520ff86d4d8556b8f5d6e87b9e51263b253390f3f6711b7dcfa2512f9a767", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "e2bbd195-a774-44d0-a45a-2dd4a51283d3": {"doc_hash": "87778461558e15060ad64b1c614d6fe82028185b5defee46f0da1392f4dd6c7a", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "d0d90c94-c30d-4437-9a62-a15bc78087f0": {"doc_hash": "06aa4de2ac144243d2da21cde47d7c0efd097d82c894de8617a99c5b094cc35c", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "e2f7aa14-6dc8-43ce-8352-4150a8b59fc9": {"doc_hash": "b88dfa2f137141a31ab4cb43599060fcf1caa9f90efe87de137c9864493f0fa9", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "88b1f3d6-61f4-48f3-a783-62f2537bb9d4": {"doc_hash": "60676314876e5d77c723610478a7393e4ca45cb59c04135d1aca0548f87e339c", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "c1749adc-4f4d-4dac-95bc-f4606f10388b": {"doc_hash": "7769aaa5e32f88961f6bf04c876a119812e4202d1425cb0da446ca70981d66c2", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "ad8f6c34-de72-439d-9444-537511ed460b": {"doc_hash": "7bb7419936596c6ee7f2919e5d77e9a9264cffa3adc43f09dbe90c2b6c0d240e", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "05e6f29e-adb6-40ed-9d3e-8b28b8a7ea6d": {"doc_hash": "a416f2aa8cf0920b2a12bf4ea1fbdf504b312703c992bab2fd9b7a8f1c9610ab", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "446d5929-8c3e-4a8f-90bf-803653e823ae": {"doc_hash": "35acb50015251878e79061550c64c416f2a1b9ad372541cdd01040083c4ff972", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "9e27297a-b36e-4e4c-b18e-94e2fca260d9": {"doc_hash": "e618bb8885d1637d286fc28dc503ffcc341d4090ed01079056230304cd4c03af", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "5d8775dc-2947-410f-bd64-184e4c8861ac": {"doc_hash": "67c8090d3da10fb225d1cf064226e215e45792273b10a714f76059da1809bd6e", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "36f171c5-0237-445f-8d00-c46448870a98": {"doc_hash": "fb57410e5de72f9cf5555dd4b0d234a2d7a6a4f5bea6911456df312818463011", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "8a10c445-4b86-4116-8b12-71e60d59f9b1": {"doc_hash": "41534b75dd5f0a8e2227e812b733e6ba2d0778ba86701899a81f5fcc7ac5dd3f", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "f0a6d80c-2928-4d88-8b42-810c5bdd4035": {"doc_hash": "9e3b274b831763d7be27bea9931e69b9e05a6171b50203e9e4a8ed435fd81259", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "e5cd1a9a-d5e0-4018-af76-7464c6c59bb5": {"doc_hash": "3e24df0dc7347ecc02069e520e650d19289abc6dd2df275c147bc1f7259a425f", "ref_doc_id": "a8b93ffe-a33c-4096-a69a-4394749e6ab1"}, "4a42de16-e166-4114-8e89-b0293de60d48": {"doc_hash": "4848dea9ddd85c30e4cd8a419aed254539ea92bbe58fecb1c4d0ba41f8cb8b3c", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "846b67f4-3204-4c3c-9bdf-a900810929f6": {"doc_hash": "7d7a51a00a72696c0a3f469a8687ae711eca33dbf4d82229d6683be10286b112", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "58959bb7-1eda-462b-b80b-3ecdeb3ff8d8": {"doc_hash": "088d0b4d35d7920561645d36266fa74effd53846b361986a881dc5e76359c874", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "1f6ccce7-0ac8-4383-bb50-bdd01cd156b1": {"doc_hash": "c74e0c13e53f6068a17d2835ec39bebaaf4456994f62d7d0ba092bf68ce63cd1", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "3f3f67b4-69b7-441c-a1d7-d0df2e52faed": {"doc_hash": "92f189f9ff5e0638b49e0e6e9b55255c39ddc00175f16aa21fca48c02f847b8a", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "057f7d9f-2696-4123-a8a6-baeb8e5d8584": {"doc_hash": "df0014aaea574310ddb780e8bf7921325abcc6ca2bfde4f6c7604256db53acd6", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "6ab51ef8-94f7-4291-894c-38bb7078ad17": {"doc_hash": "1d6a9fae6d4d8baad6187f0452b88d9ed82ac095cda8b9d639f1c3268135b961", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "23fba246-fcdc-415c-a659-f225a589eaa0": {"doc_hash": "c9178ede57e990794f8f257cb6baf1607dee7f8ff3e16dc20f886b65416bbbab", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "40e366f6-f73e-4faf-8e9d-77e7f01fbffe": {"doc_hash": "b2d839ab118c5cd980079fddb414af2e1bb2d673496a58e070764a4731cad78f", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "38a37ddf-057e-4291-94fb-47ddf6634ae0": {"doc_hash": "f5de9f92efd1ac776e8e4cbc5d6294da86afc6129abc2e13e6432dd942acd6b1", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "015ee6ed-7bd0-47b3-8a7d-d277c0d84b85": {"doc_hash": "9a8c0657d0e6cb20354bf4ca9ab54d7c5934d1639ebeacdccd1259acdc6ed4c4", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "a97dab4b-9a50-462e-b1dd-27ada54c7517": {"doc_hash": "05e750e897e18584593b5c2a3775db9bd59d4dc2931016bfcabc316744e059af", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "b2cdc94a-971a-4509-816f-5b0c053d30e3": {"doc_hash": "ddc39a6fd6be59282b0e1d6db33364b4b2293f395aa34d92d50f4252beb82996", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "a84dd63a-bfbd-4d40-8742-cdd2dacd4671": {"doc_hash": "e9e7f52a855e559ad10e70b0b0dfeb94f8a771475998ab1ada68d7ccb1dbb975", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "f700825c-cdaa-439e-be70-9d63cb62cc45": {"doc_hash": "f68d28d5482b6328e7cab3710f311f20290b9994704bbf74854f843ef476b490", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "0015d1fb-de9e-4c69-8053-8404e48cb132": {"doc_hash": "fc3b30d0d37a0f77a9f76727be199bc7395598575a7ee5a3846de0ec0624d5cd", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "35325eae-0493-4a01-a2c3-bc6315cf53dd": {"doc_hash": "54b665b3994585c09fc6977814f27e78805a39e3a612a4574388d0d9f83d11c7", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "f451f7bf-7c1a-4500-9560-beab9c5eb9b1": {"doc_hash": "f23a92898e4f7948bf02d9c3c53d9f2e6273d01eba1f72bbb66a05207e746484", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "e3e4a87f-9b6c-4411-83a1-ed97a9690f86": {"doc_hash": "e233bb87e05a5b6d620f372e27ba9827814e25abd9b29bcb7db4a875f6726700", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "1dd014a0-f86f-4413-88ed-030edbebf15f": {"doc_hash": "fa69ba33cf244a332e2ba763931369f7c45819c79c66fd61bb6342540379f8eb", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "079cea04-75c8-4e21-95f0-3cbe7b41daac": {"doc_hash": "2f0bc08d174461725b81697bdbf687dcb1d3d1dea8b0fcde2a002113ef7f4a4f", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "ef954b44-3ba5-4d6e-bb17-2669f7a4b6df": {"doc_hash": "c15393edf8993ecc707a1c782e6748620372b7fd5e37edd8230c0b3c1eda76f0", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "17a620ff-3244-4f9d-8d39-bcdfb5988fec": {"doc_hash": "e50b23b8c1fa6011a7208c1d7ffe4f0c6054d43ad6b151a2566dba76006b04ec", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "27f02176-3fe2-460f-9609-d69e869ad7b1": {"doc_hash": "a1d834843d5c6c44a926c8f155e36a6f6cf2d258f82ffbcb8d040cf516af0f49", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "66e17b00-7c03-4b09-a41f-9642d62e0c15": {"doc_hash": "b372ecc2b72a48604aefaaaea3b016feaf20baa519a7eb7b249e4e3c8eaa12c3", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "7b8649f8-501a-403e-889c-9368786063c9": {"doc_hash": "a2aaefff0ca6957851a389bfc7b9fc8b9794bac2f7cd4a81349193f9d5e3eaab", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "5a2cfc02-99e2-48b9-8346-fdbdac67bb68": {"doc_hash": "1fe12cfc53afdd40f5ca21235aea1102b67586b4a8c413273ce2fe840a9bd953", "ref_doc_id": "0ab2c5a2-204e-46fd-bb9e-ea344815cecf"}, "2721e56b-3f49-4d7c-adb4-73bc0ec82b4a": {"doc_hash": "ea186ebf0b5507b4845b0dfa531041b16e188b84f3534609abb880a9eb95a03d", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "d169cbf1-2cfa-4ff4-8441-6ff32b1f6b3f": {"doc_hash": "2b9c2191644181f957424f4dde0c773e144fa8c868cb899138487824631a68df", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "b6311aef-cbbf-474f-9dc5-f3efce9d56f5": {"doc_hash": "4df9f864a84fe8c194c3f9543f88a8815be77388eab54b08f5ac5373c0c4f10b", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "3b0724c1-a96d-4133-b3dd-737e585ee5e4": {"doc_hash": "7475b88b82442c36a8baf49607f75d99a95f0cb9a62b16ec46625204639769ba", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "5c659796-8a54-47b7-8b5a-68b25f0fb4af": {"doc_hash": "dabd2b7c45324b6f23fa850c03dc848597dd1e5547253c95f4dbde83d0981181", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "38ba0d18-d177-4ff0-a59d-44d5a14470d3": {"doc_hash": "fc202def4d0b0284ef6a4356d0304cec4f7278af9f2c9e03193323bccd7a98bd", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "2186c5c6-700a-4096-9888-f72978c10ab2": {"doc_hash": "5ad28309d5ddcda96469a6b07f3cf1ebb2d5da9b8c3edff6092f80b6f036bfcb", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "8231e4c9-c80c-46a3-8924-cc48086e0b35": {"doc_hash": "4b5d5e3cb28fb0859840919bf30fed565dbe9cdecdf6561593c1666234349db7", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "677137f4-d321-42e3-b0b9-d240925954e9": {"doc_hash": "576d6b0f120158f543e0f767368e854e5bf313fe933a468fb7ddc746b1ae509d", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "ebbbf499-0edc-4cca-91ae-5c05053a5313": {"doc_hash": "862fb77f6f905cebd03861879db6c9b1ee527307165280b4fe379ea735cb36d8", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "c26b7fae-c59c-43d3-acc0-9e2dfac47d66": {"doc_hash": "334c9031e8613e25e530b28deb87eddde33008c3deaf13f2027b1d6a84873126", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "ce145d13-8247-4fb9-828d-4be326dcec3e": {"doc_hash": "ebc304a7635f574ee303b341e8a81a85bd1a125f9bc0ca8f0bb96612327584b8", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "f9e95e3f-4979-490a-95d1-d8ba6c05a599": {"doc_hash": "9d7e1e046661d3d65301e25f517f2533a968d2de22f8c5c007ffaf1dbf3d3f58", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "ed42014f-e7bb-44b6-b2a3-d916e11485e7": {"doc_hash": "286ff0e930e66bfbbe155392c1dd4cf2edbd47fdcb49b69621bfedb8d22ec17a", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "a260604d-844c-4aee-91f3-98732f92921e": {"doc_hash": "20d42da09894215cff6a398d43473cbba2bb398a9efa3b44e4e1e5563f021c47", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "400fcf58-8ae6-4de1-bad1-2ddaf7b4292c": {"doc_hash": "6eef9badda4d90abf6e6529ed085e87794457fb0defbdc5e6f63ff80bcf244ef", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "69e19d4e-5da6-46a7-b1d6-63d805229e72": {"doc_hash": "98d271a0fa96a02c26008db2a2f5743ea3b2cdb473593ecff56a8f6527e9f21e", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "7e4f1a28-417d-4993-9274-0bafd04dacb6": {"doc_hash": "438792acc5666732a2e84b697f65506730a1d8097e6247fdafb4539d2c6fdb2d", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "681ed4e4-49e2-4ffa-aac4-b69cbd0323c2": {"doc_hash": "77252be0aeb681e424d685c1b1be015c72ed08127b741b2a02c8274de6d72b42", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "621fd28c-c351-4310-ad8c-af508dec22b9": {"doc_hash": "c11ec95fb1acdafbc795bb0fe46bcc21e27cf6866845aeabc0fb333ec1b0ce04", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "10a07395-a181-496d-b6b6-737d2a4197a4": {"doc_hash": "0d4a3f7cff6bb352cf87c6e19d1034e5ac1b07470a6c5f7e2ef39de97e07cb4d", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "2ac1c582-ca6d-4e7e-b453-49b429bca17a": {"doc_hash": "27cb4d1841389daa123fe50482c0740bb5b7929809950faf10c890b6766023c9", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "e76963b3-2ca6-45dc-a86e-36cde6ce7793": {"doc_hash": "927c5bc95871d6da14b3746dd24907d6e2a290b9bfbc68ab97d75356c65862ec", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "9e2fec4a-a165-410b-9e4c-e3b8f7ae3b6c": {"doc_hash": "e26ffa4aa56d447be329e3d8267f914abf4114737ce65571fcfbe670ad801bf6", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "9f2f81e0-5e7b-4279-b59b-bdf0daef745a": {"doc_hash": "9928a25537e5712b00a33de0e340b86c78340f4f4c2d925e9cedf396b2d2d1ec", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "67e45273-8e78-420a-9b5d-7ff28fe63d20": {"doc_hash": "f48e4e9d56ab5707c60c540606372260ad99b77279d38f5f4a32145b807e5cad", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "41e5bff8-bd01-49f5-a591-eb972de6e9db": {"doc_hash": "1c8d2c8705f692c299b463b738215d5661e1b594e4faaa79ccf1cd0f5c2f8d4a", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "649a368b-2b9b-4500-a204-1041b9dda045": {"doc_hash": "8bb048a614fbbd4ec56474f77ca984b057c5553a966545b33c7c6c27af57439f", "ref_doc_id": "5bcbcb7f-5250-4acd-8d01-d272e9881076"}, "31b48097-120a-416e-a6ab-2e7feeed7eb1": {"doc_hash": "abe000ea0acee18b9756ff5ae76838bcd242592239052f992e1bfcebffba183c", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "e69ef688-9dd5-456b-8bb0-bb3876ebc954": {"doc_hash": "45de1c67ed12903fad0dd45eb7c9f573e6878f2ac0cdba7000279bfe00fcdea3", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "32886407-b972-4930-a843-fa2f01c634b7": {"doc_hash": "023f87dc5f1006536dca92b314ef9eca6265731210fb5536fa3e32b6b8694b2e", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "7c438c0c-5083-442c-9b0a-5310c6976406": {"doc_hash": "8304fc81145b289cf5a5243a034a75dc04978dc42cab06f304d9f97beff104b6", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "583d99f7-116d-4361-8ce3-af44d3d43b4f": {"doc_hash": "24be8ebe266e325debd83f46beb8657b9c8337f5dadb81e6865476c01f0da156", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "843a9229-dddf-401b-812e-40d6bf75fedb": {"doc_hash": "55e900f042f2e721346bb724f8baf870b5a565ddef319b2fe8f1995dda9ea187", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "7d8272e9-9bb4-47df-8620-de052cfba731": {"doc_hash": "13b11870c5a699c6ccc8e0a31748303ebef6bc952e8bc7a8b298155171229f86", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "025f9a1d-0a3a-4113-9d09-b9e5a8ad8c0c": {"doc_hash": "75232b603f694e2904714acb50eafac52cfcbdbbd365a695b02e865f74fa54a8", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "8399e1e4-8da5-4534-be61-aeebf3dda126": {"doc_hash": "d548e7fd60c3afa5927c1d5e97194223f29e87c9491a54616e0a4a856efa0c57", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "06c93e77-720f-4931-8fed-6a2eaff1c5e8": {"doc_hash": "3e93566001910468c19e882555e113d5851fde49369807abadb95501b71df156", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "5012c8b3-9818-4221-ba41-f60e91c47623": {"doc_hash": "1815e790f69d3a67f156dd2904d1c4a47e0169da567459c309a9c509901bad93", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "d6fb4bc9-4b10-4e08-8f36-34d1108a818d": {"doc_hash": "727afe593aaf3442d8ad3103425a0e671b8b76d6b42cf394ab21b63baf39c6b3", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "850ff376-7cd1-43c5-a0d8-60984ad0ee46": {"doc_hash": "194b05c226d318f31161d2fb444a1883a5ac92deef0df09b7237e6b4870a73a1", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "4422178d-2827-4b0a-b60a-9067d0435f93": {"doc_hash": "0fd1dc40de0dc465036e5ff7c2515be2d211111eb8aff43411d1dd06005a07bb", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "6ca07e66-b45b-408e-a353-77e2e42b0813": {"doc_hash": "152d628e8d5541b97d0ebf3287ca9ce0e138e517be9169e281a1bc344799e169", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "1a99a648-2ab5-429d-bc51-14bd10317ab4": {"doc_hash": "027246747d59fa1e239842b9c1536a6f991674ccda6838d65c7b8ca154cbd65e", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "9e583ddf-0787-4cb3-9481-7f05460f2e9c": {"doc_hash": "619baaba9b26349686eb5aa515b8965a981d04585f07796c45cbc90484e65a81", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "707da978-0b5d-4a02-8ddb-b4dcc84a674f": {"doc_hash": "4212e3deb33d517f6c3332d91e6c0444bc347bb96080589389004750aa583078", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "b021ed42-6176-48a4-b30a-2a6cc6aab861": {"doc_hash": "a790946ff073f683585f038649cf7a15352fb15fc03d33ce637db132e4bc44cf", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "fbba4852-72fc-4919-804e-052a7809be34": {"doc_hash": "b32ab7dc1ddc375878c3586e29c34811851a10e7edf8447f062f4aeafa28407e", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "2aebbc35-99e7-40a3-a94a-29f12901e924": {"doc_hash": "deafb7b81fec49df1a3c8ba260831f0c7f675693a631ad64df8ca66ed8d63416", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "e12dbb4f-f69d-4dc8-a367-c9f03dfe297f": {"doc_hash": "b7b57430f909d3c4dd9ea30a38e5ecdd6e6dd12da967bc00703db885f051b2f0", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "32fd3f07-26d6-4c5b-9baa-854cb40619ea": {"doc_hash": "fdcd2543d8437088eb8fd04c35b0e7bb7c0828731cf277ae37277c069297e575", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "3bcb2ec5-89cb-4a46-abe1-42f394ad5898": {"doc_hash": "507a3dfb8da5276d5c617ececfda1a9a07f68174a127c582489704c358ba0097", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "47e10057-506c-43af-9783-4ba65e4b3d28": {"doc_hash": "ca8091ebf31fc3666e78966541e25c25a9713219f65180024209c66c60e07784", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "6e4da976-11a6-4279-a38c-931acd976f9c": {"doc_hash": "23e2edf1fae8c80fb4d9102f4a1b6ff480f8939f28f14effbb60ac07436a9c88", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "68f79454-7cd4-43ab-a099-b10fdad9510e": {"doc_hash": "ac12c81da80c1e0af1a66e23f4cefa88db511e60d66df3f881613c421ce7b0f3", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "97e15171-e5a4-4380-b314-52ed3e73d9d3": {"doc_hash": "0307dbe4a6e5d8df32ebfcb60895842261dd1dbfa734bb510698099781b23ca2", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "00af09c8-306b-4a40-bc74-508d9d892850": {"doc_hash": "58393c3e4f09e2d68a68744cf725e409b96618b827ee31d64ee18f159bd38f7d", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "9037e3f0-e3b6-4435-9f31-0de67f4da045": {"doc_hash": "d7c4c9944cc0b014ae3ce7263b557f1f49a1deb69cb4b669dfcc00a7baf07bf1", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "98aa52b0-9440-4f73-8b70-c211d78b7dd7": {"doc_hash": "d21b23e95a599083d139ac1b2a1cd1fbf7de3774f883ff02605e5b461928cc7d", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "7ccfad84-6b86-4c21-9cac-443f62361898": {"doc_hash": "710b637a2b9b5ae6e25d68ea49075873ebcb5053ba8fb278470d91be94a138fd", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "ed001328-46d0-42dd-962f-16b547d47620": {"doc_hash": "de2782083237d47cf15e5f0b48fb4ef63c9778c33f2ba0cc32baaca6f952e90e", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "9f9b7154-f200-4d93-806f-bd92a6a4f8dd": {"doc_hash": "cc39eb84d2f02f202fdc96fe8f7e55615570708cd7645863235e94a92cd85a35", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "8ee42c6b-8f17-4f20-92eb-e9763cba6dfb": {"doc_hash": "3e3f3ed71b9e7e9b0cf1abe1cdafd3ae81c82abf62414c739a83a689fac6c04a", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "c485b85e-248d-4dd0-9a20-e143cfcf455d": {"doc_hash": "413dd90e233320f461989a5d1b1f8e053fd111dc52a8b7e55a8f175fe11d55af", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "426115cd-d5a6-45d6-8604-7c84efe165b0": {"doc_hash": "5018394a2728550853228f8e4266cf29499b2cf64183e3be5a1cfb7f8d5a55ff", "ref_doc_id": "3ea971a9-2198-49d7-a2b0-287e4504f6e8"}, "4b9a8655-230c-479f-a967-a32979c308b5": {"doc_hash": "fb3fc28695b64bddc8695001b305afef7ff8f8e3193b40d4c8aa8642f0f305fe", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "e8eace5e-4056-4088-af0d-28b6a3bf7d19": {"doc_hash": "76d37dbd047eb81f0ad02da9ba681c46f8f40ff41ae82222e19f0762825e94c8", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "df437714-f292-47c4-a473-e321da3c0194": {"doc_hash": "6e767274b33f51d2fcea5489db64bca7238f2660c5152bb6e2e986c4dbc93b3b", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "1e170744-9b1c-4b0d-8853-9a096c18265d": {"doc_hash": "0cd19527a7e23203391c6e4d835ffb8e8ee526ce6d5d54d19bed6a4dd43719c3", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "0eeffd25-67c8-43ed-b479-9061a94120fe": {"doc_hash": "b337c5b66f4fe797cc206ebb08cb4ed64252290579de2a8b4941102c13585b07", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "8955d631-73e4-4f30-9c58-185cc3e5c6bc": {"doc_hash": "bc76c84e5b91ed1ffd06feb7c5c06f4c261217b75c03eaf908424a8ff3f4bed6", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "23a3975e-d1a1-45a6-9a56-80941342e9e3": {"doc_hash": "466eb634cb2a79d892706df267271860f6869fe2d4ef7eb0e377c186d96fec1c", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "b75d76d5-6994-40dd-8bd5-6ce9fa4e9bc2": {"doc_hash": "08f4af30a83757dae1ceecb1d9fef9d642daa3b319bdebb516dbfaadd9f9327f", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "18586dfa-29ce-4226-9bd4-4b538be84659": {"doc_hash": "a03a623d78acc08d6f3e2e17b4a985d9b9b5edfb30ba2f2c33f8893be6603117", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "7cb2f251-0d0e-4fb8-90e6-ab17ed25da85": {"doc_hash": "c5016770ef73b2246e45a9c66914dee2d3c4d036c8347b54cb6ec6f9b8bc9078", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "11ba0ee9-69e0-43bd-a77e-f833089bcedd": {"doc_hash": "2d2623aa93d3cc9ca3b536c645e94b35775225fffde2896175baf74185311f4d", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "9f6f2139-2aaa-4ee9-bbe4-d2d71d780dd9": {"doc_hash": "3c32d02d62ede56f50fdd735c0c3bf2cfcebd01c104ef86ec8dbe76999344071", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "a9a589b2-c404-4c4f-aa6e-37e4c7101db4": {"doc_hash": "acc04c7efd5a0d6df8b450b2e797d042f67939dcff0e5e6d5f5de644a1ad7e2a", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "e38748d4-1513-49de-9c58-adb80253906a": {"doc_hash": "0c3c51435a70c3c657127576f7250aae21834a9ffceed7c68a7fae753932d485", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "ac03ce8f-5daf-45e0-b3e2-df08d50b5584": {"doc_hash": "eac2610f6b46ed9e709439c1e50cd0c3fb30a660ff28992e383c5b9d7276f8c3", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "98860d03-4def-4f85-b26a-807ad786caa9": {"doc_hash": "9db39779530b3a8c16d6fa261c526f15d6519bbface7f50535b361eea25a8564", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "4103e707-ab0f-4c8d-9c5a-767adc602a4b": {"doc_hash": "0b7ca422dbf91572a0bdbe265fc720b76094905b650347a76a513f1279c91fb3", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "224c93ef-4fdc-4659-af8b-cedb6cc2b543": {"doc_hash": "68b5dc6f480bc647ad00d569a11f39beb66c299ab3c13809da63ec34ab9ef151", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "7fd5f7ba-545c-461b-b040-2b0414e4d76f": {"doc_hash": "5afc972864d61f135bc094ca1123e43a389c1b2593851048924602c2b34c2139", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "e0f4f223-fcfa-4131-b5df-b5ea72b88651": {"doc_hash": "d8af6a1fc1aad50909c972862b331724514136513fdbedc4174234c574448a38", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "2d736201-e4d0-415c-b3b6-6a92d8626c38": {"doc_hash": "f0a884b9f0b58df997d156e4815bfed77f386a2ff6233b4c66b1f702cd875f4a", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "6ef1749f-c68c-456e-b898-e437fdc3e37b": {"doc_hash": "73627cf63783f45a0490ddf1d469bc3eaf4d011cd4046629efae99ecc56f6756", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "dfd28e99-529b-4695-bcff-e4de21215b1d": {"doc_hash": "7ac147c524cbf307efa744dc32203d4cd5d46ee6fd6d32a9c14c9075c8afed45", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "2c6698b3-1895-40d5-b0be-652b95f9b61b": {"doc_hash": "59c1160925c4906bb69998a644b7bcba8a023e74e2d11eae8b157cfd784875f1", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "b2ff70c8-14ab-4e4c-8995-dd53f995bbe3": {"doc_hash": "1ad9b0d2a197623b80891d39cc94ae3c41276219374f15fb7bb970277176a4ea", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "aff7ef72-5a4e-485f-ab78-35cd71276ab0": {"doc_hash": "439f2d6c7b4edb25273990ac0489a7b8813e1107e64fe8d1344cf561e4154661", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "e87bc492-8c38-4be3-8985-ecef045adc83": {"doc_hash": "5a589acf9faa268e24851b8f6748219a684323dd14bb23fb96b29638bf2b8adc", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "5821e655-1a69-4c49-b6c3-569123350724": {"doc_hash": "235a8be241633ea0ea7b7e681e6ce347a4482d246829dcfaa85ff82fde67878c", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "87f29cbb-ca92-43d9-b8ed-6e868195e0b4": {"doc_hash": "87e54252c145f137b240836187eceb65134bd9d62f6e5f6dffd6e71ed2ebedb8", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "d586f839-6d88-456b-8f90-e475d576882e": {"doc_hash": "2e421cc9e1b588cc4d93811c763f5a40188a6735750e1b3563b2f85af47e6150", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "b90322a8-08e1-4a42-891d-8007a8e4f638": {"doc_hash": "9226c54c718ab28faec25cb5243c3749e72d2508517b35ffab9a0afefc07aeeb", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "14e768ac-d2ac-4bbd-9125-4d29d1cbf325": {"doc_hash": "0cb48963af4ab59a853f31e4779eba609e03c063a09e26fd5dd40f1bc7ce8a83", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "3bdeafe5-a558-4974-bff1-692c238f10ce": {"doc_hash": "801c49c1117adc15df6330b99d1d57a0b481ee5d789790e4f77c0861269d05d7", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "d80a3b49-6546-4de7-beaa-69408a48de34": {"doc_hash": "21d186cd5d117af0bc44e66e00dc919c6b2abfec741c231aff591ec0cc17091e", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "65926d6e-e8c7-449a-95f3-fca012f67efe": {"doc_hash": "c536ae3979ca2d8029f8034eec0b36d1d35c59670ad2b4be855d2d968721a5bf", "ref_doc_id": "92c62c48-d292-4190-87e0-026a2232d32c"}, "610dad96-61cf-4603-9698-e0a9e12b7efc": {"doc_hash": "39fcc60fb6f1349274db2db7c0070af7446afed604a49474c9bf9ba27b6890a9", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "3571846f-ffc3-49e7-95b3-9de314528912": {"doc_hash": "67beb659c81302a8ba0b8f71dcf066302c64b3aee5c1a8d6782ce8e00a31f2ba", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "3ac13c6f-1aa2-43cf-9928-39f1060129e5": {"doc_hash": "2d1ddce67d65a2d3c57fc2d5eb31030b4d7ccc96b368518c25856255823a7cd4", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "cffc15b8-435e-4af7-b781-7c7043d5937a": {"doc_hash": "d5aac473b834a06d9d6a9749fb6f5042e665abbde28020c7aa52ae73ffeb8a6d", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "65a7fb24-46e2-4130-804f-923f005aba4a": {"doc_hash": "2e8fad4d6b3345c78d266170da0476ee39b19c0899929542b840529fd406d660", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "6648bad6-d685-4807-9eab-51b7038b12ec": {"doc_hash": "badf255d0b62dc701b5c91daa4d4a902f4e904a6cf8da0ba69a82a35ca0151a5", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "cf4b7305-cbdf-470b-8264-755b0903c4e7": {"doc_hash": "f47affd40e48250fa4b36ecd703cc762efe7ff8f14a500da2403d6b6f027011f", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "6367a389-b7dc-4223-8668-2a2815d2058a": {"doc_hash": "313e769d6a59cee9e36086a14a8b9344bfc7f4328dd66e2bfa886021b7bc72c8", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "f1c58d75-9730-4f88-9a63-6526a1a24e3c": {"doc_hash": "c4612a156e8ebf11cfc1da0c4cec3137653e599db4b8a6dec5787ebc3f1c2961", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "d4aa4417-cac3-41af-9615-659dd98e8eb7": {"doc_hash": "942212a705667fa0bd35e13527756cceacab1b6336ece2c2d50e26b5ed02913b", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "831a7db9-5d8c-4e24-8f51-d4d92562844b": {"doc_hash": "fd2d6a4a84fa0b59397353b5656027938b3bd6535e963e67be51dfca57c8263a", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "3b8f3b23-bfde-40a1-9f8a-f94e49c2383f": {"doc_hash": "29942cc8638f1310cc283c67f9f92da5e54d7fbb6e790b655e8db1adb0da301e", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "28285f8c-92bd-44da-90f5-dfcf0bcb8a28": {"doc_hash": "f55d38a3b0097b2c2b56bd29599453da23208357b4217ba8c7bf603620996e45", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "582f6482-9d36-40ba-bc11-ce76bdfb5a4b": {"doc_hash": "95d1691a74cc042f56fb4c20ba658f75d1cd504f16cad9f03759db7c442deb4f", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "22773ebd-6561-481f-b4f8-5a20ae230cdb": {"doc_hash": "99bd92db2d682d148388af5b7326b8c8c09554d882adf708ee6ca48c82f40a4a", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "fa413a45-5990-4aeb-9e6b-225696c5262e": {"doc_hash": "930a28eefdf2cddd9af0532916f6d6a249eb8e8aeb8d2f05baec73ecc453e119", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "0284d63f-f408-4abf-b224-4b26cc183608": {"doc_hash": "40871cd76ca999c2f692bc7cabea06a28ea8d404a35b54e376654ce74f19c7e1", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "bb858e80-24e9-4ae2-9f2c-1bde9b6ba979": {"doc_hash": "469b1f49ad65bd54c2a041a79c51adfbfdba693e29f67a76e050d6fd81629110", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "3081133a-e798-44f3-b915-f785dc833c63": {"doc_hash": "0c4673c3d0ffc5352fad836382dfd0835fe8f0afffedbe16d23bcfa81cff7390", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "16bb211f-e884-46ed-a35f-cbebdbdc9b3c": {"doc_hash": "2757e3aead98ae1c2b223d5278b25e12f94ed7653d0087d0d8ebb6c9d2863fc9", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "a3bfb2f2-547c-45dc-bcdd-3dc37241e05b": {"doc_hash": "ac6370bff90936365fd521ed660473ea7c0684861149218288f19989ea105a9b", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "003b3241-53f2-446a-98aa-f34f5457a837": {"doc_hash": "c72d3b73569999c4a1bebb4fb89a2e2adcec03a08fe94756b1f90a0589f94c33", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "1ee09084-09f1-4f24-bce8-7c23811c8943": {"doc_hash": "5d994cbe7d375271703d1f7fba9ea66a3d7081fd7a7efdbd6f0922126030f81a", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "b915f4b6-2ea9-489a-94c4-912fba0b188b": {"doc_hash": "3ad990630dfa71d86d052f4168ee330cb1c58813352e3c87102eee499a736f94", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "d132cf31-1c1f-4ccd-9b05-f2a1c91b5037": {"doc_hash": "7e67745c96161aaa9d41abf8ab514f53acc80b54c4d80d9050d3a5a5d4073c5b", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "9e0f8bba-bff0-4cf6-8db5-c1a04ee98e30": {"doc_hash": "4d01d06ddc33d9fbc4e2d43b382c25aaac853350896592787e3d2ce84068f2d6", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "1d0d4c17-d2b1-42c0-afaf-eea3c9ad1b42": {"doc_hash": "91d8c324a2baae75991b6244c9e4e59fec803cd01ba6837ef61e892831f53152", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "fea055e6-8234-45b4-93bb-9be9153db4ad": {"doc_hash": "c378cc108e2ada8b90de92c574cf159145fdd6c0b19f7a52d6d20dbd297da376", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "f16dcb49-8a9e-4e57-ad0d-89c2677f6d18": {"doc_hash": "cdd86eba0ee8f66ba5cc64cc8749be585323e03bac6521d623cc8d33c7d354d5", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "19a7fa9f-c2b0-471c-a078-a0546fb0c9bd": {"doc_hash": "ef7381fc50131b60045663597288635b47f781c85ecf21b65605dbb1b9591d8d", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "18900f5a-e98c-4d65-ab4c-7ba413123f2f": {"doc_hash": "2ee1772ccc8d8c9ba6ab05dda72de84109dfc8e7a1151795fa4885765f93fa89", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "5d2d6add-2bef-4939-ae87-1c3dc8ffd9b4": {"doc_hash": "4d7d9ff6e90db47cbfc96d7753b4bf2c214b0567abe93e208fbb9bb278b4df43", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "215a2806-4ed5-4e32-a8f2-4da624d3ec4b": {"doc_hash": "73a8993a0a790796b195a695de334a7a20e65bd93070e1746eb96ceab0f32bfd", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "fe5bc88e-dc46-41f7-8ce7-3321999f80eb": {"doc_hash": "756f9382741ecb084c03e533638d198c778daeab5fc673aaec9df51045362bb4", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "3719a21c-fa7d-4b32-b646-b83a2a14b5c9": {"doc_hash": "5667895b71db25f4df9a5571a03d479b73f44d1f401dec9c560c7b9b797cfe2b", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "a1c7471e-425b-4503-99a2-08bdd622bca7": {"doc_hash": "91b4403844f1edeba19ddd199e0117d9c63e12eb800f0716af69997d942c6ed2", "ref_doc_id": "e01e52ea-8f6b-42da-a3bb-71b7dd842f06"}, "f51d9b03-2b57-4e1b-b00f-8a39e554ad3d": {"doc_hash": "18dd26d1c432663429602189a667d9db3aa0add5252c60d362cea964683da3dd", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "033b8f3f-4590-469a-85f5-3f060bd6f8c3": {"doc_hash": "419ab4f23a4a54a9c875cc79a706ada51998a975902c23d581ddd924784a30b6", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "3a4747ed-aaa5-4c96-8ccd-a9971a508d00": {"doc_hash": "f1043bc5bfc7252853a46d1065b7efcaf5c80727fefdf9b7a7eb6725127054eb", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "fcd58db8-11e0-4e95-85c8-c1e3070d0cec": {"doc_hash": "15bfaf613273f6ea2567bee782774586261fe9cc088cecdf8df0f1e9a167798a", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "6c61e642-e9ee-4736-8233-d9bd75035b70": {"doc_hash": "4a42b846dd08ad9806d63fe6d12346542d566fe86c4ba3a9a0b3ac988f0fca10", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "789c5b58-f635-46e0-817a-322d68bbcf5c": {"doc_hash": "a26908c723a17962705ebc36f659ea5100bf6ff03723d6cca901fe1a2e9a50b9", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "69cf8baf-4b20-4c6c-bfaa-feca59b2c0f5": {"doc_hash": "fefd51396304702dee890c31567539e487b5c26e92014d5dcfae254342bc5310", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "62498967-743d-47f5-b4ae-bb2560ae3edb": {"doc_hash": "309db46b098725db8cab43a40f651dbfb204835b61b157ae90818e8524b3537b", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "1eb63626-8990-41fb-87fe-40b974ac99ef": {"doc_hash": "9a292f2b591773cd27448ab3f5ca222d9e7695476b10814a2a805faf5ffe7a71", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "9645b362-9ba1-4858-ba56-fd503d500b06": {"doc_hash": "1af1e1d391b8b333d26856ea9c532ed22cbd2a1bb2ab91862e99471ab1b669d2", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "3efc9ba8-5399-4fa7-8da0-d2b4dfacb1ec": {"doc_hash": "4cb2af5f6e883c8738a45d52b2104b67a67eb027dc53ba0476114cd3762e598e", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "b49cbecf-666c-45fe-b469-80a4e6f83370": {"doc_hash": "509f7d5de5d72e3e91c9ce6bef62f30b71c64106df129579dfc11002705ebe09", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "5baddf33-75ee-47c1-92c2-42f41ed53b1f": {"doc_hash": "b787e8c21c049663a84e8bba9759d13d6333f2e43746ef30fb7b35b7a8a39193", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "44652fcc-b33e-43a0-a88e-a3237c2fa4fe": {"doc_hash": "ae3c6ab2617161dbfcc8ab75d52de24ef5327fb56c18a38643f4d5e5064d7de6", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "1c1da8b8-a169-4263-b8bb-e5b4c0b4bf75": {"doc_hash": "8a39c9a0f37472da9de1fa40b3ddf29b6c555d21112bc8a5d72a3e786d692554", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "50c941ff-d4b4-4e16-9261-5a1371ec3ab4": {"doc_hash": "009bafe1ef7b64bf563fd69d48ee19dab165bc6c13aeb44d0aada17bb1533447", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "49846bee-dc58-451a-a947-5d3a966a22e9": {"doc_hash": "3e205c7a90d801bc22e10cb8377b3d925a0bb89737d524749cab84aab0a5e4c8", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "c585781c-7e5f-4b3d-a3a1-622f46be57cf": {"doc_hash": "c915832450e4bd2101d61fbeaafb577a33b94031cf4d4efbf3ec0d2cec7e36dc", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "a11814f5-a257-4269-928b-6303049c608d": {"doc_hash": "8910fce72ed9a7622bad86ff24f5e0e26bdb2a18f40f82845c65edf6ae932f66", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "fe384570-c2a2-456e-a936-31d9c7c26150": {"doc_hash": "0cf69a1de4d83493f62a26c8b86f87eabf5f8d4cab4e8a25ab47f1b4faedd4c4", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "9f69109e-a7e0-4337-8b70-600e28cfe5c4": {"doc_hash": "951ef1d26121d47b887ec37574110d50f0c775ef858f53db1f1db2635c95a128", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "39eb0e46-6b32-4070-b9d2-6f66ff7b8796": {"doc_hash": "c7b351707006f79e251e8bc4e1103096f45101b69db2fe7c3ed967a31b63d649", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "1266136b-0f7f-4a4a-844c-1b6fb37f3e60": {"doc_hash": "09594bc8edb08de9213ca9d662c25ac7441b2b6882d4a707890dbfb2975f5241", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "f533a8c9-64f7-46a5-a110-fdfe2272f57d": {"doc_hash": "c71a186fd77b622e942f417be99f08df6d8a07a76011889f5564c25b2dfb4526", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "acb017b6-da4c-4de2-89ff-7c8b35fe10c0": {"doc_hash": "8f3765cba579767f9b83a9253e9422669dc9870dc9f66e7d7e80e152a68eb10a", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "b5bda0c0-726f-4992-93b6-583dad8a6d89": {"doc_hash": "db8be61fee3e8271266324b45b4a676d39dead4d18883fc8adb9a74f9dd4a411", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "1ab69f38-a06f-4cda-a0c5-fbae798e140c": {"doc_hash": "d276d9741eac6ad22b32187bdf3216e4d83702701a5bb8172968fda708f310fa", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "e85725be-dfa1-451a-b144-d057e512d4b6": {"doc_hash": "b3ab3ad30575759a8aa5ddf220670cb26b9cb6b6ad7688ae81e47624d9058e40", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "20d2c88c-247c-403d-b558-c2e03b1598a4": {"doc_hash": "b6d40c75d8e1d0dbd5aa5320a77d1ec192545d14b752db087149597b101b3dde", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "b1b85b3c-fb5f-4fbf-8c00-5bfd22fe7764": {"doc_hash": "454328de3d3c20f70352cab945840727b4a681792df23eecd8317f33c5f8960d", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "1611e406-ec9c-47cf-b741-8e382e203143": {"doc_hash": "66b855b1dac0dd5f547d3a0cacac1139fd601c75e274ce5aaba35b68a14c17cd", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "ae4fd2be-a534-4492-be30-7be7555ad972": {"doc_hash": "08826e7ff17ceb642be8e313dfc0aca0c66c4251b96b6ff3bafa32f4e6dadb7b", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "47d28449-0aca-46fa-941c-61e340e6a3da": {"doc_hash": "bb7c4d8b49c4d69d2268e4c422079b4893846bf041cbab2688bfd77d680c76c5", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "01a4be31-e26a-427e-a3ee-4de52c626579": {"doc_hash": "58495b3e09fdbc2712b3dc9ed252974cd7259f392e1f33dc2e0bf21ac7f09a2e", "ref_doc_id": "ef610940-3921-4423-8958-6c921bf25ccd"}, "493041bd-83d3-4648-87ef-627f6bd0a4e2": {"doc_hash": "67ee94ffdde177ae351dde53cf10dd4bdbcce7d699dbd4fabb5c1e4008785b8b", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "fa68b644-7bdf-486f-8aed-160665ceccb2": {"doc_hash": "8c504c8d476470c3ccfc62b1e906794fd5ee6fac52534c06dc0f8df9642b527c", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "30468a99-f51d-4d87-b9b6-ba37db693cf3": {"doc_hash": "61db4fef8355f3957b49bff30f5fee8843a56bf87817271dbebdb5c0a9f4822c", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "243bf40f-5cbc-4fba-931b-ede6c0b9aa27": {"doc_hash": "ab16d5679154e0a82efc623ff454820e1c73093bdfa8dc0b507810fd162df094", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "b4544173-7b65-4692-ba57-8771c95b85da": {"doc_hash": "c3d48f3329d89305a69aa143f43f973e58ad61f27e00e866f3a9c7660ea436f8", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "20ebc75d-c6a3-45b9-8eff-d623e4e67d2b": {"doc_hash": "23ad744163a5b57cae75f5dde8ccbf46f84de9ecd691c21f2e2268adaa2aaa49", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "ad832d3f-5c43-46c4-9991-5220c34ee0d1": {"doc_hash": "c1c0635114c7f69b6a946f1f51d66c4244c0329caa6a65f2107794185b93bc71", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "931a14a4-e65d-4027-8cc4-d5337a010d74": {"doc_hash": "485390b0e7e917a591dceb61cefa14c01defa00bd3b90e94a0a01f67d4b272de", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "3b82e00d-5d29-4534-9d8e-619c2bbb2c71": {"doc_hash": "769d0fbb9a8a8d49745418b35d35e4f9d300e2f2fcba2a048c30c2aaa9edf576", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "3b348c3c-9713-4c7b-9f81-b4a6084dca34": {"doc_hash": "a11a3e279f62cbddb5d5764aca0e440f4c3c54d68ffb04632b8ec6cc2ebb4c1b", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "a7279c13-7fc9-43b4-a700-06b375b01aaf": {"doc_hash": "21f56739138a7839b870895d1b5176705bdacc75a7c76e4416f21ef251d904f6", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "15fa5889-10b2-47a2-9560-09d3e2ac3aa2": {"doc_hash": "80b24bace7b13d58317d8342eec1be52265dccc216d80e1f2619244ba33da719", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "4a880dea-7944-49a6-a382-448b02f90c43": {"doc_hash": "0d11fc2cace0cc4167cdb5d11c25ea06dc9bfbe504a786362a55ffccb4de867d", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "3af13569-be04-43b1-9796-a139f2b06f9b": {"doc_hash": "b8900c5fa75e19d7f6b257acc9a2d6136e9eed001d911b89dfc99cf8ae4b415a", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "01746f08-a513-4429-85cc-df1798757c0f": {"doc_hash": "be5d7a43ed98657ce8356fe8dbe044d7374da26447c2fb8ea134c23cd48e5f23", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "65bf2359-8e30-42b0-aca5-7dbda8bb18b9": {"doc_hash": "18823b83bf8afad9d0582a31098febbd30db8fb64c8b4bf782792ad67f130e20", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "2f59689f-941e-4d03-8e90-59d2a9507181": {"doc_hash": "22680faa6e1993152f2eab414b55b1aa70c604162d5e0d78ed5b25d1f556d2f0", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "4cce2bcb-cabc-4659-be8e-1974b7e29e71": {"doc_hash": "0b3bc16a047408f1f8a82589dc1d918f3a8621ba4609731060b1ca395988a60c", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "6b3998d9-cdad-4443-b084-0e441a82a9c1": {"doc_hash": "a0a2d692c0a9bf5128882891c67e30d3b4aa3c8739ab80ecaeecf050d7165388", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "e90eb2f7-07e9-4d1f-8534-48040d44b2ba": {"doc_hash": "a1a41f02e443c8218fc4b477747b0b9561ffcfc142bc144ddcb872a84697505d", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "9e3125e5-bc70-4cbf-b928-2537f2df3e2e": {"doc_hash": "c6b9d594f62f940830c994b9bdb79464703cc0ba90eaefaa5ebc92a8b63d3865", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "15f061a5-0898-4fc1-aa6b-55b20c1158a4": {"doc_hash": "6d700af073bd8015cd873e06d19933a79c8f56930cc80e315c847824f95f1afc", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "93718238-1705-4323-9303-f825cb564c96": {"doc_hash": "2721601d1517f4de879d4f86af6ec4b779366743763cffc5af82f386d7686efc", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "f311363c-f86e-48f0-965e-64a4839ed8f8": {"doc_hash": "3284f6c188455c5b94dca0e170229c7fd3b63ddd2cafba947909890b59c24754", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "6b91477d-7375-4a39-b0d8-e4172b29b1d6": {"doc_hash": "02f1f43aac7cac60f1d71bf9782358c1d818c2b4d74f78c782014b25020b8b95", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "ea793e11-d4a1-4d0f-8bb5-d5f51d05e558": {"doc_hash": "5ca8e6a9a72a51927d9028fe0a5d6a29bb67ff00b4c927a43a8ed603c5130cea", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "ba588ef1-d2d0-4c98-9246-746f15815fa4": {"doc_hash": "9eb4691793f91049acb202708634d5f19b539c5c0fdcfc1fcaa6c4128b257bb2", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "1f7aaf34-3b73-4936-9fe2-e5ace0e09f50": {"doc_hash": "214782f558c617cfac483525cb0ebdec4278e1023ee2d54a3e214a6daca603f0", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "cb6c3d80-3952-45c7-87d3-14c4c3f0eb4b": {"doc_hash": "04bd580fd5b65aa2198fb7576038d56c27d46b98801e668f890edad301416901", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "36d8701a-3ffa-4f9f-bdf9-2814e6705e74": {"doc_hash": "e3a285860b1a8fe6be32f10611426ccbda02b04c504141a49d9513de2c0e30bb", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "a773db0f-9f0c-4035-af54-f2b0ec50ea71": {"doc_hash": "20eb93d3b2adefbfd93bb5a83cf051990fcd2d24aa547134ded0342735d0b48c", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "710d771f-d5a0-4fd4-9ce6-abf6c7de77dd": {"doc_hash": "6c2adf7a99d7a5d5101e61e6bd0ad267d6139de65822ded1296fdbd320627698", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "ba28c47a-e011-4cfa-a52f-6e66887da0a0": {"doc_hash": "72aab764faf6c4db36af5605edb671c807234d9cd585e47d5a0de8a6cc866e0b", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "b1b83846-c5d7-47ba-b15b-4e95e48f034f": {"doc_hash": "457a0911f53d06ac5a401ad39f2863fa89a3ec19418b236e1cfc5832aa58216f", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "b2ca0c43-bfba-4ffb-8789-6a95ee5af26c": {"doc_hash": "47c0bedfcca0a639b8008332eee84806eef9d31f4762f87a80ba25216fcbabde", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "9af25d68-f9e4-4f71-8ef4-ae82019c2a39": {"doc_hash": "aa3d9eb7f036e8f9109e9a713a47127cbccd9216a1a8f37681007b6135d45e8b", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "a4654289-7188-4ee8-804a-b8d29224e84f": {"doc_hash": "c166acaab6edbc7be78ffe5e563179ffd815c288f3d6763727a7516cea6b1089", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "1736811d-3b89-479e-b1cd-93622c334845": {"doc_hash": "ea1eb23d4fb4cfe2aa4ece442a9615c3e845a612b639b8e78abb8b266d43ead1", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "75af7e69-1ba9-4e74-988c-e5858129cae5": {"doc_hash": "0987383f743cd779a103baac298f3cb655e6ed877d0ec9c0a673c2624afed471", "ref_doc_id": "0838c5d4-4cb1-437b-8870-2996b067e8aa"}, "d990a539-b066-418a-9505-820ffd73f9de": {"doc_hash": "a122c1a32907a936947d93ac7052bbb385eecc38e7a927dbe2d8557bd0898abf", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "cc757813-0fc8-4145-a320-6ba0c6a781c8": {"doc_hash": "b7b17baf5599504c949a93db6371b56107a7c44b9535d337e508a90e84c31b29", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "d9075f32-c828-4eb5-869f-fd3eff235948": {"doc_hash": "ef2474bce857349e117980e50123a5055ac404a30354b4af8f14c7b760549df3", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "dfbac72d-2b84-4a3a-988c-e20bee728ecf": {"doc_hash": "7050da0b578e7983e2e913d85f5d6f3034dfcc58bce940d6e55b06ccdd63c8f9", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "13eb746d-a7aa-46da-9453-d46441c138bb": {"doc_hash": "3e5df8be714b68690cdd4f80c3ed144bf2a07c7eb5cd95050cd44ef22dc14144", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "f2f4593c-1dde-4f38-9f0f-d9dc0b06ea0d": {"doc_hash": "7581891b3901fcacd77f620bf6037bc8dd3314a0f96a20373998855d5927d1cc", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "192ffac8-602b-4a1b-8277-42b85fdf7cd2": {"doc_hash": "fd4bc930631708879ccf0419134d06fe733aba3bcefcc7247b806d55ec52772e", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "29153c8c-3b4c-455b-9c1c-6e64f6c7d974": {"doc_hash": "1aab6969423bdd471c5b808a9e5e8e9d191f48ba2a0baff7ff08b7a87650176d", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "0be952f3-1fc7-41a6-8767-279a3078d87b": {"doc_hash": "1010f9f442b82426b2b7e6fcaad0726c177abaec105097dd89606791c83f94b6", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "47ad31d5-32ed-45bf-91e4-44a4691a6ac9": {"doc_hash": "1b69f8fd06d2574123d0778fca9882b114576c2a0e913091ae52c3e9aab0826f", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "d56d6d0a-91b8-4de4-8788-02dce0d3b647": {"doc_hash": "ecd6131c99adf0ddbf7b3c3d9952b9f710c7230a2b6a5b693a83d4a4658217fc", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "6d029efc-a78f-42d0-9305-1daca853392a": {"doc_hash": "1f5ec5a067d89d5b8795b2a695a2a1369e939b4ef62da5e8eb8b4b8b66c7b3de", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "8e6da954-4a8f-4cc7-8c92-d630eacd196c": {"doc_hash": "d3ec2087e371aca639a3eee868b52ead0c93190ab4c9d1b6bda7c9c574a0c8a0", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "29f48664-5c0c-4b51-bffb-3e7ba5b09e4e": {"doc_hash": "e2585ee24bddc1f46568bf9314a344eac306c0ccfa51b8a91159da7242eead6d", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "c8940454-451c-46ba-977d-cfdc52754ea0": {"doc_hash": "e8b5d58c5d0efe4129f782f3ff03e576e5ebfa67faee6594f6efbc1e3fb427e6", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "9b28e6d6-58bb-48f1-ac17-187437f17e6f": {"doc_hash": "958af0e6bc2ebb886f55f92c8ed4a327ff48d3a34cd80022ba7ba36ec37b76ed", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "5f479543-3b4b-42f2-b5e0-efa32d56b004": {"doc_hash": "06efcf82cfa11b2426a88e0ec00893b44e08f43ecbaa4d965f492355b7e7cc80", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "139b4aca-d3b5-462c-ba28-91407d1c3a6d": {"doc_hash": "29988aa7f8758e8a25d7ce141102309c7ecc4db8e14ac8d30a2ac8614e63afd7", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "47a397ca-ddcf-4ce1-8408-c7911b2eddf8": {"doc_hash": "65c50d1dd0770e73d5c217e101a4589030bfb1eedd17567a431500e3ac99974e", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "99423f8f-19c1-4f23-828b-edc5537a9d33": {"doc_hash": "04607c294f89aa516dc31e805b5650cf3d26b5d165dd4229b8f3fc7217f27340", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "a7dfd16d-7414-41ce-9ec8-42a53e778330": {"doc_hash": "1622631a0a571de89989a03c91b8bd848d4e69ea03c9ccf377976717ccb735df", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "4a3c004b-e261-4dc6-a223-ca3fe57b6d36": {"doc_hash": "ac232723f4434eacd1e28e48f9634622cafa70290a9b5d7de3d2c03b636abb82", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "0706bfe6-07f8-48a4-b5c8-0858e6c7e633": {"doc_hash": "228101b0d820f589d58529161eddd3e97861e74bbe6981532c9b06b65a5d416b", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "bb80a4d3-fc37-4203-a0a6-3143ebe65430": {"doc_hash": "73894ccfe8f6985ae4e1793e701caf55ca9e11ead463cfabc4c7fbb0ab2c8672", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "94634ae8-ef38-4127-bf77-77d1f6fde289": {"doc_hash": "cc0ab55801c72a87e6620b66240d18d4daa345a439576898949b02965d27c959", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "ea7a3bea-ce1c-4fd2-9b10-007db46d3dc9": {"doc_hash": "30c20d7ade94e67d73fa52c90a3c2d8d13fc673e9460bd1381fe2cb8b4c67edb", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "bfc6ad7b-74d5-4c66-8499-9dd95dd0e037": {"doc_hash": "c399bcc7cb5381ad72cf7519f1f745d0fffb4005cf4783f54e170de59a1a8218", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "c99bc1f3-5116-4c26-bc86-15fd7ed7ee6e": {"doc_hash": "f31c45fe693c0182d7d7d179f378491b456de3aaf4ef126015be06af47065273", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "ffef22b0-4577-47a5-a312-9338bec52383": {"doc_hash": "d611504c519585fc78cd6b2fcdb479c00fefa1d9205ce63d48fa4c78dc5205a9", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "8eb44234-40e6-4420-a36e-65a043726eea": {"doc_hash": "2e1d3e40cd5124c124dda28f18b2eab52f3c234cb41a7c8b9ea24134a4d23a8b", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "16e9a285-b012-455d-b703-697983e30b39": {"doc_hash": "e5c7327b265c4ef23fc525b91fc6362b8555b9994498518a2bfb60fc9dc377af", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "a4e7f027-be24-4932-b012-9277453c5c8b": {"doc_hash": "791929a48cd17b3688742579d9e9441b92ee9a0128b1ff145cc53e002f81fc3c", "ref_doc_id": "0a69cc60-96fd-4db1-bd5a-f58082b8c884"}, "b501238b-80f9-4537-8d96-30a7072b4419": {"doc_hash": "d1c132c53f5ad012a983061f25936960f44dbd090510dd62f0cda178c8d6bc95", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "faa22aeb-f90f-4e06-84f5-976b5ecc1a81": {"doc_hash": "9c92a434fbd27841fd6f94d6c1c933f621709aad6746b4f4ce73de0daf53139a", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "057d371c-72ee-4495-8859-721ac4a47fb8": {"doc_hash": "a503f72f8bccf467719f1ec4d4a3bcc46927fe1b07c438b43b9d5fb115299646", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "518b375f-4ea5-4820-ae5a-01dc936a79d5": {"doc_hash": "02b7fdcbedca9498606f3e14512ec1658d8a022c6e73623cb3361564be912975", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "8dfcfd60-d008-4fc2-92af-fb500ed71998": {"doc_hash": "c91461f2a7a5998a46e71b730d7e0060304801f576863c17cea3849e82d2f5cc", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "cf9fc912-cd61-4e70-a4ff-8f272bd60f0f": {"doc_hash": "b93a4ee40f9b050a7b9eafa305deeef2eff5037d75b77b0d7212cb9cb05bfa38", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "68d1d7ea-2845-4468-98a6-dc3e2fe508a3": {"doc_hash": "4de6293d2e0c6339a2d8641d8e3c3f38c4c7d974bf91c62a298b7b97b0ced5d5", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "612e984e-e512-4900-a5ac-5a89dbde056d": {"doc_hash": "0fb54c04e65c1e76499eb6ff429336b7e75f12ca7c1a2d76205949be4f2d2e0b", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "3f29f2aa-298d-44db-88f6-60bf47898fee": {"doc_hash": "bd1c7a2e8323635ef55573cf239b6b4b90721f5fa92ef341385f62087c37f35c", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "43361eb5-8071-45f8-8c3f-bba2e1ac794d": {"doc_hash": "97ed68314f6f830269747dcda9be5458ffc9b8ede1fcabe931c4180949782cce", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "1f1b5b1f-a4a1-46d7-ac99-71b40733ff02": {"doc_hash": "aea7ad24aa11749bc3545d8424c9c12293d7fcbb61304d600d5e7a4e3dcff38a", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "15d1fa13-1b6c-47b5-b762-c84216fedb60": {"doc_hash": "8d35bef0e0ccbc93b6a16168247527121f2ce1e5f64c4a628b338afc1cef7aa1", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "e81c257f-526f-4677-bf22-60907c0525fe": {"doc_hash": "793ce362495f20eed8983e58fe2c80312e5451ce3d0c2a4fb08ade96f59290e4", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "57f95438-a01d-4234-a875-931f700b3082": {"doc_hash": "5371049b826d426468b366cae2d2dde427b75b82f970e93712514c09b93e3d9a", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "ff96691e-ce10-4258-8046-8b79072e7fbf": {"doc_hash": "997937a61c1dcc148098e167f850af65e9159257016b59fe1abfb7761f4ac0e9", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "0bcec97a-9a9d-4164-8739-58c6f6c50b26": {"doc_hash": "04ba73e0f7b66f4932742b0303996a6ab510a932cb567e786e34a32a7fbe8c09", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "e8697e6e-412d-4069-a047-da82828ce262": {"doc_hash": "d759c7c6be741ec9c1cf30f53f4cde4c20ff5c8a0590dbe968093a081278d5f3", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "d909cc2a-ec42-4ef0-a960-bf477a4704e8": {"doc_hash": "4edaec136182875e5242ac3ef8b1b060780cbe4130f65d3d1ed0df6d470c3d7f", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "9da4b98e-4dfc-43c8-aabd-00b572aec9fb": {"doc_hash": "c4bf2dcc9a3f8bd29f74ac8bf3fa0654dc2aaf4313d7f7985480c645a8b99711", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "a172503e-3c3f-4005-bd61-7a57705031a6": {"doc_hash": "d9e3a77d88f09951b8f51c111efd63ec529947ff36bf55882a355bafeec4424e", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "e83ad6b6-e8b6-4aa5-83fc-dff9d4a838f6": {"doc_hash": "5401cbf786485caf4dde385b09ef919ed2d040ed02ae1a14c1d7784fd11aa1ab", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "c9375c9e-19bd-40b9-adf5-35e77d6bb857": {"doc_hash": "41142c934e6bd8c985b39164f785e8803c8258bddc4f31c7ec72f5de5a258120", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "ee018f74-24a0-415c-b4b0-442ad586988b": {"doc_hash": "094bd998b4f57db36ecde4b81f90b3eb09aaddc19147a74b6fddd1f569d2a806", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "99d3f8f9-fdc1-40df-aa5a-a133ae76cfab": {"doc_hash": "aaa33e9e8b6b0de7a7a32f83d70db43f7997e072abcc8339d754eb852b911dfd", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "84ff0bf7-6005-4f00-b1c8-9156931a3827": {"doc_hash": "33ff9bdf8c9edb8b026aabcdb772eb0735bfdbf7158362159a12a8b5b90fd34c", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "dfbb2a07-3da0-468f-90c6-4f5eef259362": {"doc_hash": "606d87c397640665c5ae4df664d38d18baa523db3670cd8c0dd0f7030730a1fd", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "a4e7e264-9244-43d9-b29c-b5c2d04e33b4": {"doc_hash": "67223ffa089c840cd446b006731ef6cf3a24fec0f3bab3cfac76207115c348f3", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "71448a78-2a33-4d0d-803b-7ea903d38070": {"doc_hash": "84a884579147ec757ee16f9016b44c798c046d3c8158663ca1beb826a798cd11", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "e9306b42-0062-4ee4-9b46-5ee23f48800f": {"doc_hash": "ce1e7555b230a7d6d4c3450335a3dbe0a043a3ce6397bb3f728296204e31b5e0", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "d4946593-def1-44a8-94b4-71e15b7771f4": {"doc_hash": "82d26de2b6b35128c9670b845f2345dcd230ead59cfe9979c396ef7b870a2176", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "1d6ea7bf-8048-43dc-8060-868c4b00c9ad": {"doc_hash": "ec951b46e0a65db8fd0c03f9bcaad8f33c807a1cd8cd993cf2d03622fa8f5344", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "9f42dfac-7ac3-436b-9490-8b07b38479ec": {"doc_hash": "cdfafd0c72c79f6937828f64557545e89e95b66eebe738a71c01e9d5f23e9dc5", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "4624e023-4f18-4260-bc16-1acbc0aff3e2": {"doc_hash": "ee1fdad004a96ab36335ca192c55acbd5ca9429c9abc2f3d6dfb0e1331298479", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "0a335cac-afd1-45c4-8ed6-eee993a7fb04": {"doc_hash": "a22f3243318d4699152d3c4eff7401e743858dd35848e7d809476b31038a2cc2", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "97dfd7fa-32ac-40a8-821f-792cb7331e52": {"doc_hash": "ee86dbc954a023f391946ada15e9c3c417e658b4434b44660bfd526a99452c64", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "d819206c-013c-4902-8fdc-d5b5ff7cef6c": {"doc_hash": "59e53320c5df000bd39b2e6cf81b043e07fe8e40e90d1036893da77b63a11f2c", "ref_doc_id": "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694"}, "564157ba-55a8-42a5-8b58-24bd2f00816a": {"doc_hash": "a35a5355977ec03600e1c4a9bf1c0f02899ce255caee1eeb1f709628bd55ab82", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "fcd67d5b-b2c0-44f6-8a3c-bbca14e611a8": {"doc_hash": "440351ba8cf9cd4c032778b446e1d8655695c185b4cad93705e04de1c7f1a17b", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "8ca0d899-117e-4604-9b5f-55e801fcbd51": {"doc_hash": "704765d25702b553cd6d310daa2d7865b6ccb3a83de49cb5380bfbf45f380797", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "5f3ee4fb-ca60-4376-8ae8-97ddf5ae497d": {"doc_hash": "653081b4fc0e9b430a7199cd8f8ad956270958e09f96ea5e5f881d0577adb9b3", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "da1b334a-39b9-45c7-a135-0608fd84c341": {"doc_hash": "5a141c7ebdd4c0e8a9a55e41c777a5697a3abe0251c2a366b2ce63988ab97f0b", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "8f5ba30f-5e92-40ed-b986-3855eee5d5ac": {"doc_hash": "2451935bc4109db3d8007676c638b85396af21b6c7694901a0d65f27a0bc9b74", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "8a32ed2d-df70-4cd7-9fe4-e143dc008bff": {"doc_hash": "4655c6cdccdac9c5c593de0bbec610a469c966a1f3b236012dcc2e20e71a2199", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "a2785415-ff5f-4018-b1c4-77208b035e07": {"doc_hash": "57e1257a63f6793eb403e428545aa02ee51f8c2bb87630386e2c05f7f1af3fe0", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "fb6ce991-7fe4-44f8-ad8b-185d4953897d": {"doc_hash": "ca7568011caaee9577041e6b5a7b04dacba22c80594831c077df631ac18ae0fe", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "37ba9765-bef6-47c6-80d7-784e44961202": {"doc_hash": "baa8b197198e38b56b5c0843a3b9181ae27601d4cfdea05ddd38074d1a945c02", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "3fce5487-98dd-444e-b8c3-b0b3283164e1": {"doc_hash": "174436d3f545e1c274b63b1c684d8ee4e5bd9f5deb2e3273d00a23b96ec50b27", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "96fcefc1-5b1c-4f7c-8ca4-08cea1414561": {"doc_hash": "c171e3f793eee50f3efcdc6a088a77e807b18683ce06d2d90a59115c5cc4801c", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "f539f494-9e2a-456d-93c9-ff3e02b9ed27": {"doc_hash": "e54018f372dc6eb13f8aba439261dca8b2a49079accbfb1bffb36acd16b871b0", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "bcfb9df1-ff02-486c-ab10-1a6f719e55f6": {"doc_hash": "562e6a228635af6adf911071cd185af39c5abb0a7d4531adecb8e154e82fd0c8", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "3441c33c-c8fa-40cb-aaca-6c09bfff7f22": {"doc_hash": "d342e421c089fd8356453b7a56f765237d916768f57c8325240eda17cc086bd0", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "4ff16397-e169-4a0e-8f0f-fb92e453de58": {"doc_hash": "e55b3dbbeef3e81060b661e79d7044a1dd55b8b764494df0592021cfe434681f", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "1c5c049d-3851-411c-9bfa-671edcc8386e": {"doc_hash": "5fff96ab54309b52ee3163ef2ee8fe69717fa5cb808528b201e824f28cfe7c7b", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "edc10015-027d-4f57-bdd4-0fcdc897e8fd": {"doc_hash": "badafd9a667646108fe064e46954f4c503b1e319106d236ea8cd397835709494", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "9bc1f067-a961-44da-9799-e803d2fc2ab5": {"doc_hash": "819f557887b4c3fb6c925bce528dadaa967082ceda872df1fcf115b34997f59b", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "2878c492-e833-4c4d-bc54-0f3758e845fe": {"doc_hash": "1829dc116804e74dcfa81091bb809cd6966efc180d796568abbd0ba771c1e3fc", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "28414470-510e-4883-b879-022f38d5378a": {"doc_hash": "99f077ecdf1bb6e98b5e631b6d889cbb4f1a668acdf7d5399e2c907f98991289", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "34ce1f04-3358-42d8-bb62-cde5fd8e8b82": {"doc_hash": "e4672511c6de98935fe0eb9f02429b8e11c717fae3747b99ebca66c594b04150", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "9e0fc8d7-8dce-415b-a137-e2630a3c0709": {"doc_hash": "a398aa2cbdad5726ccd93f25332099961f8dec76ddda2fb71c64683d256cb604", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "fc37033a-3530-463d-975a-a9b31dcbaf64": {"doc_hash": "a3b4971c736fe443f5c47f568b7fc3941208ad300ecebbd76cbb852e4f76e7d2", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "6750f897-96c5-4a26-822e-15e0185d9a9f": {"doc_hash": "0acb5e684d7032277eac950d4fb3efe4bfe568ff987625782b5979b00ce3c24d", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "779c7869-897e-4bc4-9352-1712c52cfa08": {"doc_hash": "42c690b5a0ac1691cdf0be9fbcb08b2ae8905dd0d58715e3b1dbb5947f7c9dd2", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "1c097dc4-9502-447f-9a04-c648048350e0": {"doc_hash": "482c596d06bcf7c6ffcb93382d7cf91e4a71b7e77b52e3c0190db7977e095eb9", "ref_doc_id": "dd763f70-715f-41af-9a49-ce591c476748"}, "82bac935-7c62-467c-97f8-8a87bcb113b7": {"doc_hash": "f57ac11a16e29c2e400eb391242de92585d546a8103b638b41aff2a3c38f6cc2", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "d16e22f2-7c00-4e2b-b0b3-d84174564f9f": {"doc_hash": "04c48395c66db4359bb3162c7073c5819322c188349cc1821eb710962c81f3b8", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "1fc20094-9857-4cfd-a12a-b024e5501e0b": {"doc_hash": "a16f6287ad606df4f76c4054a5224e637fa41c2c430c399b7fc01d175bf22a3b", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "f4004cdb-598a-431f-8341-3ea1885b3738": {"doc_hash": "1396e704699d5c9d09854cd9df448ce1cd65ab15eb9348040c385e413592a7e6", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "71daf10b-af13-468e-9737-ea2ca48b099d": {"doc_hash": "cfeb2a4600f00faeccf46a82d5b6461dc0ad92b4a627f7589d603d289a6c0767", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "98fc8151-9e76-49c0-aac9-0f4f58110303": {"doc_hash": "8a52c9de7c5d5e4b434b0c6a62ab5e8e60a7e63187f4b9e57a8da5086e30eb65", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "41889df8-a149-424d-8935-c2919c274dea": {"doc_hash": "af0d6817787a7b44954f611fa84396968129b986199f79eeff0a224be524127b", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "535e9e5e-51d2-4c78-a4d5-84f0f47945d7": {"doc_hash": "58082d585ef11f0349c041356e5e95268400c7386a966ce0810702f8c66295fb", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "23d0477c-8fba-45a6-b2a2-fadc46d5c196": {"doc_hash": "f89f5eb9945e031e5837f94da56572cf095d4ef092a5f0b62dc9c186b92a8581", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "9d40bb52-b741-4457-b07e-834864b8ddcb": {"doc_hash": "abf6ac3a165c05345c89576b406c54fe068dee6e6547b8fda07c13ccab7bb287", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "1ac892e7-88f8-4fdd-886d-b76de1733c3f": {"doc_hash": "71500750eccb46723b7e22749be5e0caa2e7954637242bd1b43505276a5707cb", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "8266e0dc-a29f-4deb-b445-e4eee1c8f414": {"doc_hash": "0b8d3a1b55b41965891c5ede76c3cd2f8992a294dc9bbea2ba0999226b097589", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "73ee94fa-bb59-4194-a31d-0e12933ff8fc": {"doc_hash": "b6bf828e7eeafda9f42f8c1380f7bfe6e37aa6ea4968c2f034981105ceb62121", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "b37887eb-440f-4211-8562-fc7e2783f5ac": {"doc_hash": "9607484bcb118affcf22a657b85d31c7c95567102799fca3fc89464d7d064497", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "112300a6-0dce-450e-82df-a90ffc707539": {"doc_hash": "ba1c1b28ad6b7b8c5843a41366d8c9ac5ca17708cd5e8714841056573a42dcd6", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "8a7f88ff-28b7-4671-8acc-e89c8466f17f": {"doc_hash": "e61eb5927f5f2f9f94dfd6bd725ffa941d6bd6efb152d97c83458093a0b98b4e", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "c35e9b70-def7-450e-943a-0a5abc118b7e": {"doc_hash": "f20989707ff5ca4be0867f9de86b260dbcd0ed6ca7149a434f100235d9b219bf", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "c7f89966-17e9-460b-a208-f5fe08ef16c8": {"doc_hash": "b9e43dc3c179df5384fd60f65deab10eccd4f17b96ccb6f121e8d1ecaaabf907", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "caa4dba7-8729-4a56-bf26-1ffee350a239": {"doc_hash": "cbe32419a53123b5166effdcad23ccf5f2f00e342edb3fe639226515c4acf330", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "5c961ec2-888d-4f46-ab55-044956a27577": {"doc_hash": "3a0111d203612f11b8eaa5604606ec35794e8922fd72ec89b1ece9802a568d51", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "b8562874-035c-4e89-92d1-6d5a388b8813": {"doc_hash": "498434fa6837031069d5268b3691386e27d8fc7264d7d4ffe95a65e463d5e1f1", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "0a94582b-e6c6-4479-982e-3bfc3af223c3": {"doc_hash": "d84eea0285afed1bb9e42973e51c6836bc165bf9bd9a679b2e9b7ed89616c4b2", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "bbd901ee-ba40-486d-b214-6040b1b845fc": {"doc_hash": "33b2c38a1a943ff7ea374d07b3dec107d72ed7f05725901b341a9f6eb9155869", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "5851d709-3345-4b60-aea0-30994f9b6c5d": {"doc_hash": "81270e1a696fce3dffac67c382dc0d85e1e06f71d9ce1e3fcf19fbc6afc49ac6", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "9219269a-978f-44de-81e1-14fc4faa1749": {"doc_hash": "c9268cbc1bf939a7d51ca500796de6fa793cf63b81029989eccf7978e67ef28c", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "e9ffdc95-27a5-4b2e-a6d6-9bddd0effd3f": {"doc_hash": "6f1f4ef3bf8288aae9e86d19604f076bd28798fc9b651211b8f162f38f98db41", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "9aa73d85-8784-45f2-bd0f-b1e5c42f3083": {"doc_hash": "fe4e41dd0e191bc713cf83ed8f06b03bb822cd98e05ae360fe1e0998c9b4918c", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "d9dec605-db40-4ce5-8ede-bc3d6b9953fb": {"doc_hash": "1ced3ffac747a44dfb997bc6ca67afb6761cbe289fadb61b0e469c7f8d2ba4bf", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "6c638f8c-948b-425c-a46c-63528e5c3372": {"doc_hash": "957425d38540f63d4815ed329e72417ad28d65a84811415e7927e3e952ecf4e9", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "1e4a9d23-ffea-44a2-aa53-82c3ca0ab085": {"doc_hash": "ee00e92859170c02e3555c0d4806959ddb741bf16852919bd34858486c2b5985", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "c38784d8-b1b7-404b-b43a-266a70764155": {"doc_hash": "1ce0f81f09f0d2b638301e2e21b489dda19903ebaa9c9aa0fc9863c423e46356", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "bd164616-673b-416d-9e98-ccbf3a099c26": {"doc_hash": "415fe80744b270ad778a0ac0b012f0720cd9ac420cfda667909e1d7290c99f0b", "ref_doc_id": "2d77d038-7df1-4815-8983-173fe11a8a9c"}, "7a90b037-c9d1-4249-a77c-ed7abddcc737": {"doc_hash": "0ffc223f6d3b2e928b000d773d579fb384ef132b6c6b117c76720ea27f389fe1", "ref_doc_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9"}, "46a96516-cdf4-465c-bae0-0ea913268dbb": {"doc_hash": "2f005033ef9e6c9633fae6071f6e4939f3051a51d855820054f848e9412bc9b1", "ref_doc_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9"}, "b8f632db-36a4-4ce8-8155-268d9085b4c4": {"doc_hash": "e03e8009426818bf939dc9489548c9973c8a3f60fbed46845d7c923474130101", "ref_doc_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9"}, "09245a9f-d6dc-4255-98df-f5866befd3da": {"doc_hash": "1fef2a28194460bd5d92fa9588db4a1f45fc45976aa4adb40f2105b0332f94db", "ref_doc_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9"}, "9059526b-e876-4cc7-9370-5764cc02425f": {"doc_hash": "702cd9b88b858dda46df30af2b999c6d5bbbbc156daf8aa6c990c5592151dd4e", "ref_doc_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9"}, "4e3b5c6c-d951-415f-80db-c83f3b9f0b03": {"doc_hash": "9f5071ed62def3d9b3eaff78d29fa76cc3f89ef482e92dd545d0886132f2b3d6", "ref_doc_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9"}, "87b507ed-24a9-4f6e-b1d8-ddab184b1fc0": {"doc_hash": "91adc79208d123bf28d38e8b7a6930bc6f7fda24ae4f42b05f336d6c13cadbec", "ref_doc_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9"}, "39897003-b336-41b9-ac72-5f96121aac1f": {"doc_hash": "dcd3fbebb8a199850c1f884402def41bd3c19cd56782981b9b10a34257fbaa88", "ref_doc_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9"}, "a216387f-c65b-47d3-9d94-c07246b41060": {"doc_hash": "d9be0819919a9616983984f63690a0233da5f8548ae2d6fcdfb989de2b975ac6", "ref_doc_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9"}, "ca4680d7-7316-4703-a74e-4590c58f9643": {"doc_hash": "b6a61d319cf10fb636b82b677dca315012dd0818e39f2d5db8ba5376e28d02d4", "ref_doc_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9"}, "52a48bdb-d9cc-48bf-903c-d1bdba829bd2": {"doc_hash": "6ce35ce954ca4529fe2768daedf3dc198b0c565f8c2726b5b95b6ea6c6e694ea", "ref_doc_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9"}, "4c4f2d6e-820b-40d1-a74e-43d540357cec": {"doc_hash": "13fccf2f4d2f4e58539874102d9a2063ffddf61b5f55ca9fa22e0ad6def74936", "ref_doc_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9"}, "dafc6061-f346-45c4-abc6-87520f7acc6d": {"doc_hash": "bd27795c95f4f71d7e4e74776c87f93f46e2dbbedd6a908fc4dfe4c3e163c110", "ref_doc_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9"}, "63282403-6126-40cb-b8e8-4c89ec695768": {"doc_hash": "a0543db933f37ae28abdc4ae5881c728561c63dcd89b679b0f70eadaffed1de3", "ref_doc_id": "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9"}}, "docstore/ref_doc_info": {"6f04ed7c-eb87-47e3-a52f-ff5878599c6f": {"node_ids": ["b7c79611-c6bb-45cf-83e5-a5be2f4daafb", "7eb581cb-a932-4cd0-8fe2-bda5a78fb20b"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n20-May -2020  \nMcKesson Corp.   (MCK ) \nQ4 2020 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n20-May -2020  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "7858c473-adea-48b2-9f0e-95b7c72d4c86": {"node_ids": ["6c89c7fd-c275-4d4f-8d5e-77a1634e7979", "1b01e0b1-88b6-456b-b1d0-8259df38a901", "ba6ca4ba-1d79-4842-8103-6af0fb3f2e59", "d2f3facc-2575-456d-bffa-026d8e805347", "75c002fc-ed2f-4cb1-a04e-c1b143ed5df7", "ae3c70d5-727f-4581-8ede-05ed486b3cb5", "fe025f49-d8d5-439b-bf5d-ef2be25c9906", "cbfeb5f4-0307-4c08-9f5b-6b0b5df52191", "f7ae38a6-0baf-48ec-a00b-75d539f5994a"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "766741af-97b8-41a3-a5b5-80cdcfb8490a": {"node_ids": ["71382120-b4fe-48f5-9778-c2dfffe2bcb2", "6c6612d8-4df3-4351-ae32-73474482bf42", "60cbaf52-4cd0-4fd4-b150-daa547d35fec", "6d8cfd31-6d03-4de8-a6a5-1bc39788ceb4", "18ba7561-ad5b-4869-8af1-4f26cb0745a6", "918a3d8c-6e42-4eb9-b940-78b64d4e4d59", "167fa8c0-0058-43c9-a472-c2d476b54db3", "4f7849c6-570f-4d1c-9b36-caaf1711bbf4", "a9419074-4897-4d89-9dcc-ba2ab64a4eca", "2dc63cda-b3c1-4ba6-a36a-7f3fcba146f1", "e34e6a44-5c14-4080-9936-faaac68ad6f0", "cecb67d2-af9c-40aa-b83b-8b1148e4d91a", "91dc043f-6fb6-4022-bd27-09d8ee8bfc8e", "934877dc-a8a7-418c-beab-7e10dae5755d", "58e6a65a-297a-4f7d-9452-e8c07fb3efd1", "23742ecd-5838-4c06-b187-e877717c6f20", "f77f5c64-25f5-4fd3-aa4b-cb69bed4295d", "b67a567e-eb2e-4624-8907-7744792a16cb", "d26dfc13-da6f-4414-9b29-d066e3fdb1fe", "e21a9c87-2898-4ad0-b0ed-24bda083b839", "ef4a4182-d3cc-4e0e-bf15-9f597d9def30", "5f0ffc90-2ac4-45ce-8584-48abc6785d6d", "c7d926d5-dfa1-45d3-bc70-e637e1f9e2fc", "c30427c6-fd10-46fb-a44b-250b4c11b3a9", "1bc48dec-0e91-46aa-8b0f-5b6fe1b4814d", "3b06fb94-6db2-49c4-a989-1a7278649f33"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Q4 Earnings Call.  Today's conference is being recorded.  At this time, I'd like \nto turn the call over to Holly Weiss. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "33bd0018-0ca7-4bd3-9031-f9e3c92fa3a7": {"node_ids": ["df350493-aeea-4491-b73a-e1305a77d5cb", "bfd6fb47-8e86-45e1-87c1-9387eba9bb60", "f4461a94-1342-4a28-a2a2-d5dd161e12bd", "81160bc7-49b7-4336-bcb8-91af7b635970", "5b587278-45eb-4547-9052-49df994a0877", "b4a8cd3f-963d-48a2-ab04-635fdd79b4e4", "b2df7a84-d61b-4661-a0b3-ef371d41c733", "8ad8dc75-93e9-473e-9ea5-93ae549e614d", "f3f4cdac-f739-482d-83ee-20345c1cc121", "0f3aca91-aa79-4398-a6e4-ee6f5bf59896", "de23220b-30a5-4ef3-974d-4e1037ff7f65", "30a88c4d-9d6c-4e86-9a1a-61e587231664", "3df04fc2-35fb-482b-8a7b-922aa3487c6d", "9990b860-8b84-4611-96df-dde611022e97", "0a2a01ae-f9e6-412f-9c5f-1a44cafb732d", "ef86c74d-efad-44d0-9246-e71f7121c276", "4a2568c0-ce18-4f12-924f-16904eeaa4e8", "a81f0956-afc5-40a7-9120-02a163fdffaf", "e3b8a761-8a4c-4b8b-932f-1b7e0b79ddfc", "da7dcadc-fa57-4f9c-af5d-72b1baa5f8dc"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nclock to maintain McKesson's operations and support our cu stomers and frontline caregivers during these \nchallenging times.  \n \n I want to particularly recognize our colleagues, who are on our front lines, like those in our distribution centers, in \nour pharmacies in Canada and Europe, supporting community practices an d our transportation professionals, \nyour commitment to making it happen, going the extra mile for our customers and rallying around one another in \nthese times, it's \u2013 well, it's just what makes McKesson's culture so special that makes me incredibly proud t o be \npart of team McKesson.  \n \n As one of the largest healthcare companies in the world, we have and we will continue to play an essential role in \naddressing the COVID -19 pandemic. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "817daef2-2e22-4438-ae95-f06e3f7e02b6": {"node_ids": ["7c2953b5-ba40-4078-b12e-dc29392b20d1", "e1fa504d-fcb8-4cc4-b5f9-4aada49d7dbe", "dbfd708e-bfb5-4b72-9612-f4db6ccfdd5c", "3d0795d6-2f36-4928-97e0-f2b61329b32e", "c89b3690-432b-40ec-9889-05aee1686fe4", "96c979e5-f766-41d5-9c0a-56e7cf8ac5c1", "41068803-b2c0-4461-b178-b0a0d0f62480", "9fe51ca0-12e9-43b0-9b2d-30a514a613ec", "fc3209d2-b9b6-4255-b420-a2526bdade4d", "7428bb5f-4b2e-45b0-a3c9-5f66c8b993cb", "1ddb71c9-b39f-4895-b267-b078b4aef7a2", "4a10be71-e4dd-4be9-8778-9c5db82f12e0", "514d4865-431a-4183-a456-e6a55faba191", "d6ce3d14-0b54-415f-b06f-f82218ef95ae", "db2abff1-79f5-4bd0-a115-10c7c19b2cca", "a3bd19a7-c268-4884-8e2d-a8a3f7c4390f", "d8302cde-db53-4648-b72c-43e7137ff62a", "a9dd4f86-e787-46f9-993c-eb42f0139467", "075d7018-7429-4294-92a1-db92e6080569", "2f1ff1c5-85f6-4830-b2a1-497e332e527f", "c5282f2d-624a-4b2a-9f3f-8850d381cf66", "83739e53-e2a6-4b63-be4f-5eb8d2660cd5", "37766d81-be37-4a5b-9eb9-5c6566ee589a", "019006a5-44b3-43c3-b449-8cd839cbe692", "62a3d3c2-2a8f-4dc4-b392-a7bd4d69d94d"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nand to bring some comfort and sense of calm to their families.  We increased funding to our Take Care of Our \nOwn Fund to help with expenses such as child care, groceries, housing and utilities.  And we increased our \nFoundation funding to support our communities in their time of great need, including donations to support local \nfood b anks in communities where McKesson distribution centers are located around the US.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ba158130-c643-44e1-9024-e87d5258ad90": {"node_ids": ["ae07db96-fb7a-4acf-8c4b-9541c78b5dc6", "9cba5881-dd10-4460-9bc1-12ecf6265170", "8015caaf-488f-4a42-97bb-3c85813f912d", "8c729807-428c-40cc-8d22-556ae4a06bb2", "e7376695-be65-4906-8e83-ad734c867405", "4bd6deaa-fb4b-4720-9531-d42f5225b07a", "9b1e0292-c967-4eac-a77a-f21bb50d8c1c", "3cb6ea31-d193-4ba8-9b9f-b1a26a0308be", "35af83e2-6379-4dcd-b85b-2fd99ede99d8", "caca2e71-dcb8-4c2e-bb02-0330c0fdaf08", "4f2e6b80-6f14-4cc2-a011-88071fc600f0", "59172798-b18e-4f1f-a0cf-aa1cf26c2b0f", "b5c13d19-1e0d-44b9-a9c6-bd359f0d29fd", "e6454d9c-6445-4973-8eb9-7b294d096b37", "a26c0bb0-5b4c-4ae5-bc1b-bf26b7194f14", "6533b011-b609-4371-86db-5a9962bf3a7e", "a510d8be-4530-4358-8b8e-e37a3305ed92", "db0ea668-7b93-4dfb-8fcb-9283ddc5fa29", "a022dc64-989c-4bcc-a73a-ac95738f99b9", "85498caa-4623-4572-b8dd-1162d99cb016", "41840264-35ff-4881-82bd-74f1d09e3d0e", "2ad62c32-a357-4e42-95f7-d6ca8f648abf", "4ed6816c-dae1-4767-9229-89f747e38d6b", "cb583725-963a-4577-a27f-a25d35291f6e"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nIn fiscal 2020, we transformed our operating model through initiatives like our Spend Smart prog ram and \ncentralizing functional services across North America and in Europe.  Evidence of our success in rationalizing \ncosts and streamlining back office functions is also reflected in our positive European segment fiscal 2020 results.  \n \n Our Canadian busines s successfully streamlined its organization structure to better serve our retail and wholesale \noperations customers. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "9c4fd393-1fd4-452d-b32c-00e2f25e0c0d": {"node_ids": ["4931c29c-e08c-4027-b2a9-c690cf4dff8f", "2f63b4a6-c656-4f57-ab27-195ac1acdd5d", "7e0ff743-eeab-42a2-9192-659b218a417b", "9215cf5a-1823-499b-a5dd-cd7b4126da0f", "cd873e80-31db-4440-a825-8c5f9890ad5d", "03ddb6fa-b1e7-4d70-8b6c-983602e51c27", "a51764fd-9db6-4cc5-af38-5fcb0834ba1f", "d8914b61-7de5-479e-81f4-23d08e42c5fe", "ba574bf3-7a0b-435e-aef2-3f33da8f3bd6", "48d77a27-edb1-41df-a109-c3cd1871d347", "7f30e7ab-b265-45e2-9599-cac53f8d2c9d", "866b83b2-7277-4b69-ac78-516cd6313309", "6242b55d-e7ae-45ec-ad71-236b86fab9af", "6a180024-5c0b-42ee-bacd-3e58581d9fe2", "ace7233c-1f5d-4c74-892d-0f56fc7bf6b8", "efcb04de-312d-4028-ba03-7e2721924e4a", "74b5514b-f115-4460-8a41-876631f4fc42", "24269b3b-2e65-48f3-816d-dda28b137f49", "e94c4b7b-be3a-40e2-b270-10089b2200d8", "4111a34f-7778-4528-9fb3-024fa46b2cf3", "ebaa484b-304f-4dd0-93e9-a1d764933c34", "9c39aa7d-20df-4ce7-83a1-b00cdd67e158", "9780a963-0a2e-44cb-a7fe-1bcfe9953f07", "828a863b-67ba-4771-8502-fb2e9f5a78cc", "24183efe-5b45-4362-a9e7-821e650ccb06", "10596699-8392-46aa-88a7-17b1db1268ef", "3513aaaf-c37e-4bd6-ade6-14f1a57edbe8", "7bbe7586-2618-4b8d-a11c-7cc3faaa25d7", "acb0a9cd-7baa-429a-8af7-ec1e1191ccc7"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nOur fiscal 2021 outlook of $13.95 to $14.75 of adjusted earnings per diluted share factors in several \nmacroeconomic and business -specific assumptions.  Britt is going to take you through th e detailed assumptions of \nour outlook, but let me comment on why I remain confident now more than ever in McKesson's future.  \n \n We have proven our resiliency and natural ability to lead during times of crisis such as H1N1, SARS, the \nrecession of 2008 -2009. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f0bc6e76-1162-49d9-9ef7-e56943372fe7": {"node_ids": ["84a71180-722b-4731-a2dc-e0704d6000cb", "24a9032c-f97e-446f-bc1c-13b330227f5e", "d55efcb8-954c-4417-b433-198093413dee", "8fd95920-3e06-4b66-a7a4-8c4d252fa2ec", "40aedd49-44d6-4544-a2ab-8bc4030d0feb", "64af0dce-d020-4ae8-a5a2-e446080b252d", "fc2f5ea9-16b9-4195-8a4f-a4ab5df205a9", "aed7fb18-dc88-4102-890e-0645de59e386", "4a359667-ed2a-4445-8f70-7c0b7f0098b2", "53270696-5b2d-45ba-9e08-67e34bd7edce", "454dd243-6e81-4969-8029-34c283ebc31c", "3367c7c0-2581-4933-89d9-aa85a212767e", "7517c4d2-1ec6-4cbd-b66c-b2f03ef09e46", "9c6cfe42-b566-4ce7-9a6e-0b0302404ebe", "f432ea9c-2cf1-45c4-b2f8-61d21dcfdf28", "d88250dd-ae0a-4c71-a11c-14ff840916fb", "8d763cf7-b575-4d19-8c33-0514706be632", "eb3c88ff-ddaf-4b93-9908-25029b7a8f5a", "5902bef1-65e2-403f-a277-45fb43fa1682", "2751e32a-a0bd-4f65-99e1-900ebac181d1", "ba0a9ae0-0b72-453f-864c-0018f796aa83", "a6a74a3e-413b-4473-9b17-126edfdad713", "e0171365-b4e4-4f79-84ed-4b31cdd2b75f", "e4032980-8916-4bec-ba63-fbb0697c56dc", "81129022-b37a-4cb7-99fc-68a91c9dcd0f", "8237e4f5-b5af-47f0-baf7-42e2fdf19b9c", "159faf0c-e2e5-4e24-a1ec-edbf82db6a0b", "4444c764-47fe-46b1-b16c-503dee7bb431", "19623459-80de-4eb4-b9a5-51afedfbb7ed"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me state at the beginning of this call, we expect the business will deliver growth in adjusted income from  \noperations and adjusted earnings per diluted share in the second half of the fiscal year as compared to 2020 \nwhen setting aside the fiscal 2020 contribution from our prior equity stake in Change Healthcare.  \n \n Let's turn now to review of our fiscal 2020 res ults.  McKesson posted a solid close to fiscal 2020 with full year \nadjusted earnings per diluted share of $14.95. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "65fb4206-1b4d-40c3-86d8-c46eab526ce9": {"node_ids": ["fe18e34a-5259-4f42-b64f-6e4933c9f77d", "d6facb89-9895-42df-b558-2919db2033c9", "2e034c0d-ff09-403c-ad40-ed06f3528f71", "b0120357-8781-49ea-8c83-84e4fac644f1", "6c40d299-5ccc-40fb-b3e5-591eee596b65", "9fb805a9-54b9-45b8-9ac0-661820f522ef", "14716f82-b1ba-4d9e-9d6e-9ee1813c860c", "17d1a355-d23e-4d81-9d76-c392eca52b2b", "80a7ddbd-b8e4-4e31-b575-7169c2f7b2fb", "630bc1be-2c3c-4d95-bc0c-2834a0a175c5", "4aa0dc88-8364-4b5c-9606-70a4659f90a5", "2f98a661-9fc1-4522-87b2-5e9174cbb433", "c0a8ccc3-de4d-42f0-8aa3-8e4b5c56ef70", "a9769874-1e19-4d22-9fde-c6b7aa661cdc", "cc0f5645-dc7f-4d82-86cd-d7d7d1950816", "60e003bf-2d06-475a-be11-eb5e9a4f96e1", "91f0d58a-6060-4e50-9729-4c9900aadbbb", "093b9008-0910-46ff-bcc2-3a2bd2c9500a", "7ef81b63-419d-4143-bd71-0d5e1d3013ae", "dda89814-4db8-4cfb-996f-258d6f81ee11", "81dd87e5-f9e2-4b47-b8bb-9fda74e8d6a5", "a6039336-dd47-43f4-a05e-71ab7adfa8eb", "bd5cd663-3d4c-4a2d-a282-a1a513aaf467", "fa94fcd8-1e33-48a1-82f4-88fce2a22969", "4be1f3a4-1135-407e-b1f5-b7fb566a4a83"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFourth quarter adjusted gross profit was up 7% year -over-year, led by growth in our Medical Surgical and U.S. \n Pharmaceutical and Specialty Solutions segments.  Fourth quarter adjusted operating expenses increased 8% \nyear-over-year, driven by increased investmen ts to support future growth in our oncology and specialty \nbusinesses, technology infrastructure and the previously mentioned one -time expenses during the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "04caef37-b299-40a1-88af-be38492b51c2": {"node_ids": ["a41ad611-721a-4b68-8f76-1aa42f1f4eee", "a9a4387c-6a12-4401-ba1c-3cb60dcb1505", "b5b1e5d7-cf12-480d-a391-dec3f4b80a5b", "8784bdff-c5db-4937-aba1-8c5f6e7b92bf", "8f8c5862-3381-48b2-b997-a16ee39e2b2f", "8ada6c77-2474-45a5-b314-1d74c16e3945", "e36bcd9e-78ed-42f9-a8f0-2d717d62ebd3", "8e0d9e10-4284-477d-a373-b479f8b8052c", "a7b74bf8-e21e-435e-8a87-a0c1ef8cc9b7", "7e5665e1-82f0-428c-a97c-9d43196cd612", "0918980c-32a2-4c07-8c3f-0944eb562ad9", "9dee559c-7bcb-4eda-b67a-8303a1a220d4", "4a6fb73a-b4e5-4613-b40f-76b9c3459135", "98914559-8af2-4c0e-9b0a-59c2a00c974f", "288ad1a4-608c-4779-b4f5-91d84f4cb9e0", "bb933ca9-2565-46f1-aeb3-b3dd15fb8f4e", "8b838e76-55d6-47b1-866a-d8812ec7389b", "132da3f8-e279-4c2c-ac1f-c10c5cef8e56", "64c51b1f-4de4-4a17-a597-595c70d6b62e", "d4a34552-24d9-4712-bd3e-9eb8d0e32db9", "9b41ea45-e8eb-4dc9-83c2-7fe6ba05b2ac", "7be277d7-959c-452e-bb8d-6bebb744ed05", "40aa555f-f376-4c43-a19c-9dbf30fe5ce6", "8a55a092-0aa5-4ce8-9e1a-97384d10cbfa"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nFinishing our business review with Other, revenues were $2.9 billion for the quarter, up 3%.  On an FX -adjusted \nbasis, revenues were up 4%, driven primar ily by growth in the Canadian and MRxTS businesses.  \n \n Adjusted operating profit was $242 million for the quarter, down 6% on both the reported and FX -adjusted basis, \ndriven primarily by a lower equity contribution from the company's investment in Change Hea lthcare, partially \noffset by organic growth in the MRxTS business.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c299a84c-c422-4443-85c7-4a8b016785fc": {"node_ids": ["f486db4f-ff5a-4517-abd7-f4a144987b94", "36fcf97a-aa4d-4dab-a0e8-aceb9ca94bae", "78f19231-88c6-4c1e-a5b9-1bbaf4442c46", "30c33ad0-1328-438e-9b82-41a8bccafd24", "80c4152b-2556-46b9-b4df-5fdb4afd9a5a", "165d1f1a-1ed1-49aa-9a63-2a3610b2ea7d", "e3a5b55d-b6bb-4349-a4a7-c7528cdbdb4c", "449f8d6a-5021-4ad1-bebd-8d7cca57174f", "d58cb710-f8d9-405b-9863-d6ebcf32863f", "0cd29a46-575d-43fc-b647-bfcc3a43ebee", "3d10edaa-921c-4271-802a-c95d51052d04", "6733e202-61c0-4f52-9009-afb747bbcc74", "fbff924c-69ee-4ff4-89ee-3d30028b416d", "3c6719c0-fd95-4153-bb54-ecf2b2f92636", "f21f40f2-3fcb-4d43-a8b2-de01ee63c8f7", "16bb928a-83d4-4afd-bba5-e62701195b44", "cd029429-c7e2-4e3c-9906-409f4ac577a4", "054f1e4d-fb63-48df-bb8a-ccfbf23c21fe", "3033c553-d58d-4425-b23b-fea32c2c9d26", "81bb7834-9a58-42ae-bb62-e4ec12e5c5fd", "7c0dca00-0d14-41f0-a71e-9ed3d60ac95d", "bcfdbbcf-6691-462e-89fa-ac59c04570a6", "a5ba8673-4013-4964-8277-3cae99ff2465", "3ec7c61f-6c07-44c6-ae59-0e42d9089096", "439e3cff-b9fb-4251-8508-7b1ea09aabc2"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe take a long -term approach to our businesses.  And although the COVID -19 pandemic presents a near -term \nheadwind, we believe this  to be temporary.  The underlying fundamentals of our business remains stable and on \nsolid footing as evidenced by our Q4 and full year results for fiscal 2020.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a8b93ffe-a33c-4096-a69a-4394749e6ab1": {"node_ids": ["ee1fbfc5-a9dc-4ac4-939c-6eb33f1c88a2", "81f1b4fd-049f-456b-ae93-81aad0996f1f", "31a1ec8c-8cc7-4053-b362-f0336331441f", "513681dc-6454-49b8-844a-d6b1d4d2dded", "1e86f018-fab3-4201-90bd-0f7eba5f93b8", "3b97047f-ef3d-444c-bee0-332f5745e0d7", "1bcb6550-d84f-4d04-8973-41e0579f2e41", "f340c165-778e-46e9-bcae-8618e25db32d", "058d286e-5ed2-4a35-917d-66b2e795600d", "bebc3b2b-e825-4077-b284-3a116b6e4b6f", "e2bbd195-a774-44d0-a45a-2dd4a51283d3", "d0d90c94-c30d-4437-9a62-a15bc78087f0", "e2f7aa14-6dc8-43ce-8352-4150a8b59fc9", "88b1f3d6-61f4-48f3-a783-62f2537bb9d4", "c1749adc-4f4d-4dac-95bc-f4606f10388b", "ad8f6c34-de72-439d-9444-537511ed460b", "05e6f29e-adb6-40ed-9d3e-8b28b8a7ea6d", "446d5929-8c3e-4a8f-90bf-803653e823ae", "9e27297a-b36e-4e4c-b18e-94e2fca260d9", "5d8775dc-2947-410f-bd64-184e4c8861ac", "36f171c5-0237-445f-8d00-c46448870a98", "8a10c445-4b86-4116-8b12-71e60d59f9b1", "f0a6d80c-2928-4d88-8b42-810c5bdd4035", "e5cd1a9a-d5e0-4018-af76-7464c6c59bb5"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe assume modest recovery begins in our fiscal second quarter and that this recovery progres ses into the back \nhalf of the fiscal year, with the business returning to adjusted income from operations and adjusted earnings per \ndiluted share growth in the second half of the fiscal year.  For a full list of fiscal 2021 assumptions, please refer to \nslides 12 through 14 in our supplemental slide presentation.  \n \n Rather than outlining each assumption, I'll instead walk you through the key items, starting with the segments. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "0ab2c5a2-204e-46fd-bb9e-ea344815cecf": {"node_ids": ["4a42de16-e166-4114-8e89-b0293de60d48", "846b67f4-3204-4c3c-9bdf-a900810929f6", "58959bb7-1eda-462b-b80b-3ecdeb3ff8d8", "1f6ccce7-0ac8-4383-bb50-bdd01cd156b1", "3f3f67b4-69b7-441c-a1d7-d0df2e52faed", "057f7d9f-2696-4123-a8a6-baeb8e5d8584", "6ab51ef8-94f7-4291-894c-38bb7078ad17", "23fba246-fcdc-415c-a659-f225a589eaa0", "40e366f6-f73e-4faf-8e9d-77e7f01fbffe", "38a37ddf-057e-4291-94fb-47ddf6634ae0", "015ee6ed-7bd0-47b3-8a7d-d277c0d84b85", "a97dab4b-9a50-462e-b1dd-27ada54c7517", "b2cdc94a-971a-4509-816f-5b0c053d30e3", "a84dd63a-bfbd-4d40-8742-cdd2dacd4671", "f700825c-cdaa-439e-be70-9d63cb62cc45", "0015d1fb-de9e-4c69-8053-8404e48cb132", "35325eae-0493-4a01-a2c3-bc6315cf53dd", "f451f7bf-7c1a-4500-9560-beab9c5eb9b1", "e3e4a87f-9b6c-4411-83a1-ed97a9690f86", "1dd014a0-f86f-4413-88ed-030edbebf15f", "079cea04-75c8-4e21-95f0-3cbe7b41daac", "ef954b44-3ba5-4d6e-bb17-2669f7a4b6df", "17a620ff-3244-4f9d-8d39-bcdfb5988fec", "27f02176-3fe2-460f-9609-d69e869ad7b1", "66e17b00-7c03-4b09-a41f-9642d62e0c15", "7b8649f8-501a-403e-889c-9368786063c9", "5a2cfc02-99e2-48b9-8346-fdbdac67bb68"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs a reminder, fiscal 2020 results i nclude our investment in Change Healthcare, which included $253 million in \nadjusted equity income in fiscal 2020.  Excluding the Change Healthcare results in the prior year for comparison \npurposes, we expect that adjusted operating profit within Other will be flat to down 5% for the full year, but it is \nexpected to increase greater than 10% in the second half of the fiscal year as the businesses within Other return \nto normal volumes.  \n \n Now, let me turn to the consolidated view. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "5bcbcb7f-5250-4acd-8d01-d272e9881076": {"node_ids": ["2721e56b-3f49-4d7c-adb4-73bc0ec82b4a", "d169cbf1-2cfa-4ff4-8441-6ff32b1f6b3f", "b6311aef-cbbf-474f-9dc5-f3efce9d56f5", "3b0724c1-a96d-4133-b3dd-737e585ee5e4", "5c659796-8a54-47b7-8b5a-68b25f0fb4af", "38ba0d18-d177-4ff0-a59d-44d5a14470d3", "2186c5c6-700a-4096-9888-f72978c10ab2", "8231e4c9-c80c-46a3-8924-cc48086e0b35", "677137f4-d321-42e3-b0b9-d240925954e9", "ebbbf499-0edc-4cca-91ae-5c05053a5313", "c26b7fae-c59c-43d3-acc0-9e2dfac47d66", "ce145d13-8247-4fb9-828d-4be326dcec3e", "f9e95e3f-4979-490a-95d1-d8ba6c05a599", "ed42014f-e7bb-44b6-b2a3-d916e11485e7", "a260604d-844c-4aee-91f3-98732f92921e", "400fcf58-8ae6-4de1-bad1-2ddaf7b4292c", "69e19d4e-5da6-46a7-b1d6-63d805229e72", "7e4f1a28-417d-4993-9274-0bafd04dacb6", "681ed4e4-49e2-4ffa-aac4-b69cbd0323c2", "621fd28c-c351-4310-ad8c-af508dec22b9", "10a07395-a181-496d-b6b6-737d2a4197a4", "2ac1c582-ca6d-4e7e-b453-49b429bca17a", "e76963b3-2ca6-45dc-a86e-36cde6ce7793", "9e2fec4a-a165-410b-9e4c-e3b8f7ae3b6c", "9f2f81e0-5e7b-4279-b59b-bdf0daef745a", "67e45273-8e78-420a-9b5d-7ff28fe63d20", "41e5bff8-bd01-49f5-a591-eb972de6e9db", "649a368b-2b9b-4500-a204-1041b9dda045"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nWe also remain committed to returning capital to our shareholders through a modest yet growing dividend and \nshare buybacks.  And I would remind you that we  currently have $1.5 billion remaining on our share repurchase \nauthorization.  \n \n We've maintained our investment grade credit rating, which underpins our financial flexibility and our ability to \naccess the long -term debt and commercial paper markets. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "3ea971a9-2198-49d7-a2b0-287e4504f6e8": {"node_ids": ["31b48097-120a-416e-a6ab-2e7feeed7eb1", "e69ef688-9dd5-456b-8bb0-bb3876ebc954", "32886407-b972-4930-a843-fa2f01c634b7", "7c438c0c-5083-442c-9b0a-5310c6976406", "583d99f7-116d-4361-8ce3-af44d3d43b4f", "843a9229-dddf-401b-812e-40d6bf75fedb", "7d8272e9-9bb4-47df-8620-de052cfba731", "025f9a1d-0a3a-4113-9d09-b9e5a8ad8c0c", "8399e1e4-8da5-4534-be61-aeebf3dda126", "06c93e77-720f-4931-8fed-6a2eaff1c5e8", "5012c8b3-9818-4221-ba41-f60e91c47623", "d6fb4bc9-4b10-4e08-8f36-34d1108a818d", "850ff376-7cd1-43c5-a0d8-60984ad0ee46", "4422178d-2827-4b0a-b60a-9067d0435f93", "6ca07e66-b45b-408e-a353-77e2e42b0813", "1a99a648-2ab5-429d-bc51-14bd10317ab4", "9e583ddf-0787-4cb3-9481-7f05460f2e9c", "707da978-0b5d-4a02-8ddb-b4dcc84a674f", "b021ed42-6176-48a4-b30a-2a6cc6aab861", "fbba4852-72fc-4919-804e-052a7809be34", "2aebbc35-99e7-40a3-a94a-29f12901e924", "e12dbb4f-f69d-4dc8-a367-c9f03dfe297f", "32fd3f07-26d6-4c5b-9baa-854cb40619ea", "3bcb2ec5-89cb-4a46-abe1-42f394ad5898", "47e10057-506c-43af-9783-4ba65e4b3d28", "6e4da976-11a6-4279-a38c-931acd976f9c", "68f79454-7cd4-43ab-a099-b10fdad9510e", "97e15171-e5a4-4380-b314-52ed3e73d9d3", "00af09c8-306b-4a40-bc74-508d9d892850", "9037e3f0-e3b6-4435-9f31-0de67f4da045", "98aa52b0-9440-4f73-8b70-c211d78b7dd7", "7ccfad84-6b86-4c21-9cac-443f62361898", "ed001328-46d0-42dd-962f-16b547d47620", "9f9b7154-f200-4d93-806f-bd92a6a4f8dd", "8ee42c6b-8f17-4f20-92eb-e9763cba6dfb", "c485b85e-248d-4dd0-9a20-e143cfcf455d", "426115cd-d5a6-45d6-8604-7c84efe165b0"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nAs we talked about, we expect that to continue to improve throughout the year.  And as we get to the back half of \nthe year, that gradual improvement throughout each quarter will lead us to g et back to growth for the second half \nof the year.  And so I think that as you think about this, there's going to be gradual improvement across each \nquarter. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "92c62c48-d292-4190-87e0-026a2232d32c": {"node_ids": ["4b9a8655-230c-479f-a967-a32979c308b5", "e8eace5e-4056-4088-af0d-28b6a3bf7d19", "df437714-f292-47c4-a473-e321da3c0194", "1e170744-9b1c-4b0d-8853-9a096c18265d", "0eeffd25-67c8-43ed-b479-9061a94120fe", "8955d631-73e4-4f30-9c58-185cc3e5c6bc", "23a3975e-d1a1-45a6-9a56-80941342e9e3", "b75d76d5-6994-40dd-8bd5-6ce9fa4e9bc2", "18586dfa-29ce-4226-9bd4-4b538be84659", "7cb2f251-0d0e-4fb8-90e6-ab17ed25da85", "11ba0ee9-69e0-43bd-a77e-f833089bcedd", "9f6f2139-2aaa-4ee9-bbe4-d2d71d780dd9", "a9a589b2-c404-4c4f-aa6e-37e4c7101db4", "e38748d4-1513-49de-9c58-adb80253906a", "ac03ce8f-5daf-45e0-b3e2-df08d50b5584", "98860d03-4def-4f85-b26a-807ad786caa9", "4103e707-ab0f-4c8d-9c5a-767adc602a4b", "224c93ef-4fdc-4659-af8b-cedb6cc2b543", "7fd5f7ba-545c-461b-b040-2b0414e4d76f", "e0f4f223-fcfa-4131-b5df-b5ea72b88651", "2d736201-e4d0-415c-b3b6-6a92d8626c38", "6ef1749f-c68c-456e-b898-e437fdc3e37b", "dfd28e99-529b-4695-bcff-e4de21215b1d", "2c6698b3-1895-40d5-b0be-652b95f9b61b", "b2ff70c8-14ab-4e4c-8995-dd53f995bbe3", "aff7ef72-5a4e-485f-ab78-35cd71276ab0", "e87bc492-8c38-4be3-8985-ecef045adc83", "5821e655-1a69-4c49-b6c3-569123350724", "87f29cbb-ca92-43d9-b8ed-6e868195e0b4", "d586f839-6d88-456b-8f90-e475d576882e", "b90322a8-08e1-4a42-891d-8007a8e4f638", "14e768ac-d2ac-4bbd-9125-4d29d1cbf325", "3bdeafe5-a558-4974-bff1-692c238f10ce", "d80a3b49-6546-4de7-beaa-69408a48de34", "65926d6e-e8c7-449a-95f3-fca012f67efe"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nas a company to take those actions.  Obviously, as we look to the year coming ahead, there will be some \nincremental expense to support social distancing, workplace reengineering, protection of customers and \nemployees, and we'll be cont inued to be committed to make whatever investments we need to take care of them.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e01e52ea-8f6b-42da-a3bb-71b7dd842f06": {"node_ids": ["610dad96-61cf-4603-9698-e0a9e12b7efc", "3571846f-ffc3-49e7-95b3-9de314528912", "3ac13c6f-1aa2-43cf-9928-39f1060129e5", "cffc15b8-435e-4af7-b781-7c7043d5937a", "65a7fb24-46e2-4130-804f-923f005aba4a", "6648bad6-d685-4807-9eab-51b7038b12ec", "cf4b7305-cbdf-470b-8264-755b0903c4e7", "6367a389-b7dc-4223-8668-2a2815d2058a", "f1c58d75-9730-4f88-9a63-6526a1a24e3c", "d4aa4417-cac3-41af-9615-659dd98e8eb7", "831a7db9-5d8c-4e24-8f51-d4d92562844b", "3b8f3b23-bfde-40a1-9f8a-f94e49c2383f", "28285f8c-92bd-44da-90f5-dfcf0bcb8a28", "582f6482-9d36-40ba-bc11-ce76bdfb5a4b", "22773ebd-6561-481f-b4f8-5a20ae230cdb", "fa413a45-5990-4aeb-9e6b-225696c5262e", "0284d63f-f408-4abf-b224-4b26cc183608", "bb858e80-24e9-4ae2-9f2c-1bde9b6ba979", "3081133a-e798-44f3-b915-f785dc833c63", "16bb211f-e884-46ed-a35f-cbebdbdc9b3c", "a3bfb2f2-547c-45dc-bcdd-3dc37241e05b", "003b3241-53f2-446a-98aa-f34f5457a837", "1ee09084-09f1-4f24-bce8-7c23811c8943", "b915f4b6-2ea9-489a-94c4-912fba0b188b", "d132cf31-1c1f-4ccd-9b05-f2a1c91b5037", "9e0f8bba-bff0-4cf6-8db5-c1a04ee98e30", "1d0d4c17-d2b1-42c0-afaf-eea3c9ad1b42", "fea055e6-8234-45b4-93bb-9be9153db4ad", "f16dcb49-8a9e-4e57-ad0d-89c2677f6d18", "19a7fa9f-c2b0-471c-a078-a0546fb0c9bd", "18900f5a-e98c-4d65-ab4c-7ba413123f2f", "5d2d6add-2bef-4939-ae87-1c3dc8ffd9b4", "215a2806-4ed5-4e32-a8f2-4da624d3ec4b", "fe5bc88e-dc46-41f7-8ce7-3321999f80eb", "3719a21c-fa7d-4b32-b646-b83a2a14b5c9", "a1c7471e-425b-4503-99a2-08bdd622bca7"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nOperator : Your next question will come from the line of Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you for the details and for your efforts.  A questio n on MedSurg, the metric on 60% of this being provider \nfocused was helpful. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ef610940-3921-4423-8958-6c921bf25ccd": {"node_ids": ["f51d9b03-2b57-4e1b-b00f-8a39e554ad3d", "033b8f3f-4590-469a-85f5-3f060bd6f8c3", "3a4747ed-aaa5-4c96-8ccd-a9971a508d00", "fcd58db8-11e0-4e95-85c8-c1e3070d0cec", "6c61e642-e9ee-4736-8233-d9bd75035b70", "789c5b58-f635-46e0-817a-322d68bbcf5c", "69cf8baf-4b20-4c6c-bfaa-feca59b2c0f5", "62498967-743d-47f5-b4ae-bb2560ae3edb", "1eb63626-8990-41fb-87fe-40b974ac99ef", "9645b362-9ba1-4858-ba56-fd503d500b06", "3efc9ba8-5399-4fa7-8da0-d2b4dfacb1ec", "b49cbecf-666c-45fe-b469-80a4e6f83370", "5baddf33-75ee-47c1-92c2-42f41ed53b1f", "44652fcc-b33e-43a0-a88e-a3237c2fa4fe", "1c1da8b8-a169-4263-b8bb-e5b4c0b4bf75", "50c941ff-d4b4-4e16-9261-5a1371ec3ab4", "49846bee-dc58-451a-a947-5d3a966a22e9", "c585781c-7e5f-4b3d-a3a1-622f46be57cf", "a11814f5-a257-4269-928b-6303049c608d", "fe384570-c2a2-456e-a936-31d9c7c26150", "9f69109e-a7e0-4337-8b70-600e28cfe5c4", "39eb0e46-6b32-4070-b9d2-6f66ff7b8796", "1266136b-0f7f-4a4a-844c-1b6fb37f3e60", "f533a8c9-64f7-46a5-a110-fdfe2272f57d", "acb017b6-da4c-4de2-89ff-7c8b35fe10c0", "b5bda0c0-726f-4992-93b6-583dad8a6d89", "1ab69f38-a06f-4cda-a0c5-fbae798e140c", "e85725be-dfa1-451a-b144-d057e512d4b6", "20d2c88c-247c-403d-b558-c2e03b1598a4", "b1b85b3c-fb5f-4fbf-8c00-5bfd22fe7764", "1611e406-ec9c-47cf-b741-8e382e203143", "ae4fd2be-a534-4492-be30-7be7555ad972", "47d28449-0aca-46fa-941c-61e340e6a3da", "01a4be31-e26a-427e-a3ee-4de52c626579"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks very much and good morning.  Brian, can you give us an update on where you are as far as an opioid \npotential settlement?  I know we talked about the framework, which was several months ago. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "0838c5d4-4cb1-437b-8870-2996b067e8aa": {"node_ids": ["493041bd-83d3-4648-87ef-627f6bd0a4e2", "fa68b644-7bdf-486f-8aed-160665ceccb2", "30468a99-f51d-4d87-b9b6-ba37db693cf3", "243bf40f-5cbc-4fba-931b-ede6c0b9aa27", "b4544173-7b65-4692-ba57-8771c95b85da", "20ebc75d-c6a3-45b9-8eff-d623e4e67d2b", "ad832d3f-5c43-46c4-9991-5220c34ee0d1", "931a14a4-e65d-4027-8cc4-d5337a010d74", "3b82e00d-5d29-4534-9d8e-619c2bbb2c71", "3b348c3c-9713-4c7b-9f81-b4a6084dca34", "a7279c13-7fc9-43b4-a700-06b375b01aaf", "15fa5889-10b2-47a2-9560-09d3e2ac3aa2", "4a880dea-7944-49a6-a382-448b02f90c43", "3af13569-be04-43b1-9796-a139f2b06f9b", "01746f08-a513-4429-85cc-df1798757c0f", "65bf2359-8e30-42b0-aca5-7dbda8bb18b9", "2f59689f-941e-4d03-8e90-59d2a9507181", "4cce2bcb-cabc-4659-be8e-1974b7e29e71", "6b3998d9-cdad-4443-b084-0e441a82a9c1", "e90eb2f7-07e9-4d1f-8534-48040d44b2ba", "9e3125e5-bc70-4cbf-b928-2537f2df3e2e", "15f061a5-0898-4fc1-aa6b-55b20c1158a4", "93718238-1705-4323-9303-f825cb564c96", "f311363c-f86e-48f0-965e-64a4839ed8f8", "6b91477d-7375-4a39-b0d8-e4172b29b1d6", "ea793e11-d4a1-4d0f-8bb5-d5f51d05e558", "ba588ef1-d2d0-4c98-9246-746f15815fa4", "1f7aaf34-3b73-4936-9fe2-e5ace0e09f50", "cb6c3d80-3952-45c7-87d3-14c4c3f0eb4b", "36d8701a-3ffa-4f9f-bdf9-2814e6705e74", "a773db0f-9f0c-4035-af54-f2b0ec50ea71", "710d771f-d5a0-4fd4-9ce6-abf6c7de77dd", "ba28c47a-e011-4cfa-a52f-6e66887da0a0", "b1b83846-c5d7-47ba-b15b-4e95e48f034f", "b2ca0c43-bfba-4ffb-8789-6a95ee5af26c", "9af25d68-f9e4-4f71-8ef4-ae82019c2a39", "a4654289-7188-4ee8-804a-b8d29224e84f", "1736811d-3b89-479e-b1cd-93622c334845", "75af7e69-1ba9-4e74-988c-e5858129cae5"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I might just add that our guidance really assumes that healthcare demand will return. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "0a69cc60-96fd-4db1-bd5a-f58082b8c884": {"node_ids": ["d990a539-b066-418a-9505-820ffd73f9de", "cc757813-0fc8-4145-a320-6ba0c6a781c8", "d9075f32-c828-4eb5-869f-fd3eff235948", "dfbac72d-2b84-4a3a-988c-e20bee728ecf", "13eb746d-a7aa-46da-9453-d46441c138bb", "f2f4593c-1dde-4f38-9f0f-d9dc0b06ea0d", "192ffac8-602b-4a1b-8277-42b85fdf7cd2", "29153c8c-3b4c-455b-9c1c-6e64f6c7d974", "0be952f3-1fc7-41a6-8767-279a3078d87b", "47ad31d5-32ed-45bf-91e4-44a4691a6ac9", "d56d6d0a-91b8-4de4-8788-02dce0d3b647", "6d029efc-a78f-42d0-9305-1daca853392a", "8e6da954-4a8f-4cc7-8c92-d630eacd196c", "29f48664-5c0c-4b51-bffb-3e7ba5b09e4e", "c8940454-451c-46ba-977d-cfdc52754ea0", "9b28e6d6-58bb-48f1-ac17-187437f17e6f", "5f479543-3b4b-42f2-b5e0-efa32d56b004", "139b4aca-d3b5-462c-ba28-91407d1c3a6d", "47a397ca-ddcf-4ce1-8408-c7911b2eddf8", "99423f8f-19c1-4f23-828b-edc5537a9d33", "a7dfd16d-7414-41ce-9ec8-42a53e778330", "4a3c004b-e261-4dc6-a223-ca3fe57b6d36", "0706bfe6-07f8-48a4-b5c8-0858e6c7e633", "bb80a4d3-fc37-4203-a0a6-3143ebe65430", "94634ae8-ef38-4127-bf77-77d1f6fde289", "ea7a3bea-ce1c-4fd2-9b10-007db46d3dc9", "bfc6ad7b-74d5-4c66-8499-9dd95dd0e037", "c99bc1f3-5116-4c26-bc86-15fd7ed7ee6e", "ffef22b0-4577-47a5-a312-9338bec52383", "8eb44234-40e6-4420-a36e-65a043726eea", "16e9a285-b012-455d-b703-697983e30b39", "a4e7f027-be24-4932-b012-9277453c5c8b"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nimpacts the FY 2021 guidance for the European segment, Germany generally included or excluded from the \nEuropean guidanc e. \n \nAnd then second, I guess, whether Germany is in there or not, I guess, what really sticks out to me is that the \nmagnitude of the expected decline in operating profit in Europe, minus 20% to minus 25% relative to the revenue \nguide, 0% to minus 5%, 6% out a little bit, suggesting some notable negative operating leverage in Europe versus \nsome of the other segments.  Any color on the dynamics there would help as well.  Thanks.  \n ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a34c8b69-9faa-4ad3-bc7e-03bf54e5e694": {"node_ids": ["b501238b-80f9-4537-8d96-30a7072b4419", "faa22aeb-f90f-4e06-84f5-976b5ecc1a81", "057d371c-72ee-4495-8859-721ac4a47fb8", "518b375f-4ea5-4820-ae5a-01dc936a79d5", "8dfcfd60-d008-4fc2-92af-fb500ed71998", "cf9fc912-cd61-4e70-a4ff-8f272bd60f0f", "68d1d7ea-2845-4468-98a6-dc3e2fe508a3", "612e984e-e512-4900-a5ac-5a89dbde056d", "3f29f2aa-298d-44db-88f6-60bf47898fee", "43361eb5-8071-45f8-8c3f-bba2e1ac794d", "1f1b5b1f-a4a1-46d7-ac99-71b40733ff02", "15d1fa13-1b6c-47b5-b762-c84216fedb60", "e81c257f-526f-4677-bf22-60907c0525fe", "57f95438-a01d-4234-a875-931f700b3082", "ff96691e-ce10-4258-8046-8b79072e7fbf", "0bcec97a-9a9d-4164-8739-58c6f6c50b26", "e8697e6e-412d-4069-a047-da82828ce262", "d909cc2a-ec42-4ef0-a960-bf477a4704e8", "9da4b98e-4dfc-43c8-aabd-00b572aec9fb", "a172503e-3c3f-4005-bd61-7a57705031a6", "e83ad6b6-e8b6-4aa5-83fc-dff9d4a838f6", "c9375c9e-19bd-40b9-adf5-35e77d6bb857", "ee018f74-24a0-415c-b4b0-442ad586988b", "99d3f8f9-fdc1-40df-aa5a-a133ae76cfab", "84ff0bf7-6005-4f00-b1c8-9156931a3827", "dfbb2a07-3da0-468f-90c6-4f5eef259362", "a4e7e264-9244-43d9-b29c-b5c2d04e33b4", "71448a78-2a33-4d0d-803b-7ea903d38070", "e9306b42-0062-4ee4-9b46-5ee23f48800f", "d4946593-def1-44a8-94b4-71e15b7771f4", "1d6ea7bf-8048-43dc-8060-868c4b00c9ad", "9f42dfac-7ac3-436b-9490-8b07b38479ec", "4624e023-4f18-4260-bc16-1acbc0aff3e2", "0a335cac-afd1-45c4-8ed6-eee993a7fb04", "97dfd7fa-32ac-40a8-821f-792cb7331e52", "d819206c-013c-4902-8fdc-d5b5ff7cef6c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThanks, Ricky, for that question.  Let me start with your first question and then let Brian take it from there.  From a \ngeneric perspective, we continue to have a very strong sourcing organization, which has really benefited us well \nas we've gone through this period. ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "dd763f70-715f-41af-9a49-ce591c476748": {"node_ids": ["564157ba-55a8-42a5-8b58-24bd2f00816a", "fcd67d5b-b2c0-44f6-8a3c-bbca14e611a8", "8ca0d899-117e-4604-9b5f-55e801fcbd51", "5f3ee4fb-ca60-4376-8ae8-97ddf5ae497d", "da1b334a-39b9-45c7-a135-0608fd84c341", "8f5ba30f-5e92-40ed-b986-3855eee5d5ac", "8a32ed2d-df70-4cd7-9fe4-e143dc008bff", "a2785415-ff5f-4018-b1c4-77208b035e07", "fb6ce991-7fe4-44f8-ad8b-185d4953897d", "37ba9765-bef6-47c6-80d7-784e44961202", "3fce5487-98dd-444e-b8c3-b0b3283164e1", "96fcefc1-5b1c-4f7c-8ca4-08cea1414561", "f539f494-9e2a-456d-93c9-ff3e02b9ed27", "bcfb9df1-ff02-486c-ab10-1a6f719e55f6", "3441c33c-c8fa-40cb-aaca-6c09bfff7f22", "4ff16397-e169-4a0e-8f0f-fb92e453de58", "1c5c049d-3851-411c-9bfa-671edcc8386e", "edc10015-027d-4f57-bdd4-0fcdc897e8fd", "9bc1f067-a961-44da-9799-e803d2fc2ab5", "2878c492-e833-4c4d-bc54-0f3758e845fe", "28414470-510e-4883-b879-022f38d5378a", "34ce1f04-3358-42d8-bb62-cde5fd8e8b82", "9e0fc8d7-8dce-415b-a137-e2630a3c0709", "fc37033a-3530-463d-975a-a9b31dcbaf64", "6750f897-96c5-4a26-822e-15e0185d9a9f", "779c7869-897e-4bc4-9352-1712c52cfa08", "1c097dc4-9502-447f-9a04-c648048350e0"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   22 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI did talk about the fact that we've implemented mitigation plans across all of our businesses and across all of our \ndifferent cost categories, and this is an extension of what we're already working on with our cost savings program. \n So we're certainly making great progress on that.  We do have some things in our structure that will rem ain the \nsame year -over-year in our material, like the opioids litigation -related costs, which we expect to continue to be \n$150 million.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "22", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "2d77d038-7df1-4815-8983-173fe11a8a9c": {"node_ids": ["82bac935-7c62-467c-97f8-8a87bcb113b7", "d16e22f2-7c00-4e2b-b0b3-d84174564f9f", "1fc20094-9857-4cfd-a12a-b024e5501e0b", "f4004cdb-598a-431f-8341-3ea1885b3738", "71daf10b-af13-468e-9737-ea2ca48b099d", "98fc8151-9e76-49c0-aac9-0f4f58110303", "41889df8-a149-424d-8935-c2919c274dea", "535e9e5e-51d2-4c78-a4d5-84f0f47945d7", "23d0477c-8fba-45a6-b2a2-fadc46d5c196", "9d40bb52-b741-4457-b07e-834864b8ddcb", "1ac892e7-88f8-4fdd-886d-b76de1733c3f", "8266e0dc-a29f-4deb-b445-e4eee1c8f414", "73ee94fa-bb59-4194-a31d-0e12933ff8fc", "b37887eb-440f-4211-8562-fc7e2783f5ac", "112300a6-0dce-450e-82df-a90ffc707539", "8a7f88ff-28b7-4671-8acc-e89c8466f17f", "c35e9b70-def7-450e-943a-0a5abc118b7e", "c7f89966-17e9-460b-a208-f5fe08ef16c8", "caa4dba7-8729-4a56-bf26-1ffee350a239", "5c961ec2-888d-4f46-ab55-044956a27577", "b8562874-035c-4e89-92d1-6d5a388b8813", "0a94582b-e6c6-4479-982e-3bfc3af223c3", "bbd901ee-ba40-486d-b214-6040b1b845fc", "5851d709-3345-4b60-aea0-30994f9b6c5d", "9219269a-978f-44de-81e1-14fc4faa1749", "e9ffdc95-27a5-4b2e-a6d6-9bddd0effd3f", "9aa73d85-8784-45f2-bd0f-b1e5c42f3083", "d9dec605-db40-4ce5-8ede-bc3d6b9953fb", "6c638f8c-948b-425c-a46c-63528e5c3372", "1e4a9d23-ffea-44a2-aa53-82c3ca0ab085", "c38784d8-b1b7-404b-b43a-266a70764155", "bd164616-673b-416d-9e98-ccbf3a099c26"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   23 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nHey, good morning, guys, and thanks for taking my question.  I thought Glen had just kind of stormed it, but I will \ndive in on the US margin guide one more time.  You guys called ou t in Q4 that branded generic conversions, \nwhich we normally think of as a tailwind to margins or a positive impact. ", "original_text": "McKesson Corp.  ", "page_label": "23", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "fb2eccc6-1b3e-4a3a-a9b1-c70b4591eaf9": {"node_ids": ["7a90b037-c9d1-4249-a77c-ed7abddcc737", "46a96516-cdf4-465c-bae0-0ea913268dbb", "b8f632db-36a4-4ce8-8155-268d9085b4c4", "09245a9f-d6dc-4255-98df-f5866befd3da", "9059526b-e876-4cc7-9370-5764cc02425f", "4e3b5c6c-d951-415f-80db-c83f3b9f0b03", "87b507ed-24a9-4f6e-b1d8-ddab184b1fc0", "39897003-b336-41b9-ac72-5f96121aac1f", "a216387f-c65b-47d3-9d94-c07246b41060", "ca4680d7-7316-4703-a74e-4590c58f9643", "52a48bdb-d9cc-48bf-903c-d1bdba829bd2", "4c4f2d6e-820b-40d1-a74e-43d540357cec", "dafc6061-f346-45c4-abc6-87520f7acc6d", "63282403-6126-40cb-b8e8-4c89ec695768"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ4 2020 Earnings Call  Corrected Transcript  \n20-May-2020   \n \n1-877-FACTSET   www.callstreet.com   24 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  ", "page_label": "24", "file_name": "MCK-Q4-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q4-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 400367, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}